<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>exh_21.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">EXHIBIT 2.1</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">AGREEMENT AND PLAN OF MERGER</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">by and among</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Sucampo pharmaceuticals,
inc.,</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">SABER MERGER SUB, INC.,</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">VTESSE INC.</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">and,</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">SOLELY IN ITS CAPACITY as
COMPANY EQUITYHOLDER REPRESENTATIVE,</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Fortis Advisors LLC</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Dated as of MARCH 31, 2017</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 81%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle; text-align: center; width: 9%">Page</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-weight: bold; vertical-align: middle; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">ARTICLE I</TD>
    <TD STYLE="text-align: left">THE MERGER</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">1.1</TD>
    <TD STYLE="text-align: left">Effective Time of the Merger</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">1.2</TD>
    <TD STYLE="text-align: left">Closing</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">1.3</TD>
    <TD STYLE="text-align: left">Effects of the Merger</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">1.4</TD>
    <TD STYLE="text-align: left">Directors and Officers of the Surviving Corporation</TD>
    <TD STYLE="text-align: center">2</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">ARTICLE II</TD>
    <TD STYLE="text-align: left">CONVERSION OF SECURITIES</TD>
    <TD STYLE="text-align: center">2</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">2.1</TD>
    <TD STYLE="text-align: left">Conversion of Capital Stock</TD>
    <TD STYLE="text-align: center">2</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">2.2</TD>
    <TD STYLE="text-align: left">Payment Fund</TD>
    <TD STYLE="text-align: center">5</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">2.3</TD>
    <TD STYLE="text-align: left">Dissenting Shares</TD>
    <TD STYLE="text-align: center">7</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">2.4</TD>
    <TD STYLE="text-align: left">Company Equityholder Representative</TD>
    <TD STYLE="text-align: center">7</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">2.5</TD>
    <TD STYLE="text-align: left">Treatment of Company Equity Awards</TD>
    <TD STYLE="text-align: center">12</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">2.6</TD>
    <TD STYLE="text-align: left">Closing Cash Consideration Adjustment</TD>
    <TD STYLE="text-align: center">13</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">2.7</TD>
    <TD STYLE="text-align: left">Allocation Schedule; Payments of Future Contingent Payments</TD>
    <TD STYLE="text-align: center">17</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">2.8</TD>
    <TD STYLE="text-align: left">Earn-Out Consideration</TD>
    <TD STYLE="text-align: center">17</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">2.9</TD>
    <TD STYLE="text-align: left">Non-Transferability</TD>
    <TD STYLE="text-align: center">21</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">2.10</TD>
    <TD STYLE="text-align: left">Withholding Rights</TD>
    <TD STYLE="text-align: center">23</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">2.11</TD>
    <TD STYLE="text-align: left">Priority Review Voucher</TD>
    <TD STYLE="text-align: center">23</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">2.12</TD>
    <TD STYLE="text-align: left">Taking of Necessary Action; Further Action</TD>
    <TD STYLE="text-align: center">24</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">ARTICLE III</TD>
    <TD STYLE="text-align: left">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</TD>
    <TD STYLE="text-align: center">24</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.1</TD>
    <TD STYLE="text-align: left">Organization, Standing and Power</TD>
    <TD STYLE="text-align: center">25</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.2</TD>
    <TD STYLE="text-align: left">Capitalization</TD>
    <TD STYLE="text-align: center">25</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.3</TD>
    <TD STYLE="text-align: left">Subsidiaries</TD>
    <TD STYLE="text-align: center">26</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.4</TD>
    <TD STYLE="text-align: left">Authority; No Conflict; Required Filings and Consents</TD>
    <TD STYLE="text-align: center">28</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.5</TD>
    <TD STYLE="text-align: left">Financial Statements</TD>
    <TD STYLE="text-align: center">28</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.6</TD>
    <TD STYLE="text-align: left">Absence of Certain Changes</TD>
    <TD STYLE="text-align: center">29</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.7</TD>
    <TD STYLE="text-align: left">No Undisclosed Liabilities</TD>
    <TD STYLE="text-align: center">29</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.8</TD>
    <TD STYLE="text-align: left">Taxes</TD>
    <TD STYLE="text-align: center">29</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.9</TD>
    <TD STYLE="text-align: left">Owned and Leased Real Properties</TD>
    <TD STYLE="text-align: center">33</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.10</TD>
    <TD STYLE="text-align: left">Intellectual Property</TD>
    <TD STYLE="text-align: center">33</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.11</TD>
    <TD STYLE="text-align: left">Contracts</TD>
    <TD STYLE="text-align: center">37</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center"></TD></TR></TABLE>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center; width: 10%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 81%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.12</TD>
    <TD STYLE="text-align: left">Litigation</TD>
    <TD STYLE="text-align: center">40</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.13</TD>
    <TD STYLE="text-align: left">Environmental Matters</TD>
    <TD STYLE="text-align: center">40</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.14</TD>
    <TD STYLE="text-align: left">Employee Benefit Plans</TD>
    <TD STYLE="text-align: center">41</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.15</TD>
    <TD STYLE="text-align: left">Compliance With Laws</TD>
    <TD STYLE="text-align: center">43</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.16</TD>
    <TD STYLE="text-align: left">Permits</TD>
    <TD STYLE="text-align: center">43</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.17</TD>
    <TD STYLE="text-align: left">Regulatory Matters</TD>
    <TD STYLE="text-align: center">44</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.18</TD>
    <TD STYLE="text-align: left">Insurance</TD>
    <TD STYLE="text-align: center">44</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.19</TD>
    <TD STYLE="text-align: left">Brokers</TD>
    <TD STYLE="text-align: center">46</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.20</TD>
    <TD STYLE="text-align: left">Labor and Employment</TD>
    <TD STYLE="text-align: center">46</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.21</TD>
    <TD STYLE="text-align: left">Title to Personal Properties</TD>
    <TD STYLE="text-align: center">46</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.22</TD>
    <TD STYLE="text-align: left">Transactions with Affiliates</TD>
    <TD STYLE="text-align: center">48</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.23</TD>
    <TD STYLE="text-align: left">Bank Accounts</TD>
    <TD STYLE="text-align: center">48</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.24</TD>
    <TD STYLE="text-align: left">Total Assets</TD>
    <TD STYLE="text-align: center">48</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">3.25</TD>
    <TD STYLE="text-align: left">No Other Representations or Warranties</TD>
    <TD STYLE="text-align: center">48</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">ARTICLE IV</TD>
    <TD STYLE="text-align: left">REPRESENTATIONS AND WARRANTIES OF THE BUYER AND THE TRANSITORY SUBSIDIARY</TD>
    <TD STYLE="text-align: center">49</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">4.1</TD>
    <TD STYLE="text-align: left">Organization, Standing and Power</TD>
    <TD STYLE="text-align: center">49</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">4.2</TD>
    <TD STYLE="text-align: left">Authority; No Conflict; Required Filings and Consents</TD>
    <TD STYLE="text-align: center">49</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">4.3</TD>
    <TD STYLE="text-align: left">Buyer Capitalization</TD>
    <TD STYLE="text-align: center">50</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">4.4</TD>
    <TD STYLE="text-align: left">SEC Documents; Financial Statements</TD>
    <TD STYLE="text-align: center">51</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">4.5</TD>
    <TD STYLE="text-align: left">Litigation</TD>
    <TD STYLE="text-align: center">51</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">4.6</TD>
    <TD STYLE="text-align: left">Operations of the Transitory Subsidiary</TD>
    <TD STYLE="text-align: center">51</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">4.7</TD>
    <TD STYLE="text-align: left">Financing</TD>
    <TD STYLE="text-align: center">51</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">4.8</TD>
    <TD STYLE="text-align: left">Brokers</TD>
    <TD STYLE="text-align: center">52</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">4.9</TD>
    <TD STYLE="text-align: left">Registration Eligibility</TD>
    <TD STYLE="text-align: center">52</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">4.10</TD>
    <TD STYLE="text-align: left">No Other Representations or Warranties</TD>
    <TD STYLE="text-align: center">52</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">ARTICLE V</TD>
    <TD STYLE="text-align: left">COVENANTS OF THE COMPANY</TD>
    <TD STYLE="text-align: center">52</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">5.1</TD>
    <TD STYLE="text-align: left">Conduct of Business of the Company</TD>
    <TD STYLE="text-align: center">52</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">5.2</TD>
    <TD STYLE="text-align: left">Restrictions on Conduct of Business of the Company</TD>
    <TD STYLE="text-align: center">52</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">5.3</TD>
    <TD STYLE="text-align: left">No Solicitation</TD>
    <TD STYLE="text-align: center">55</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">5.4</TD>
    <TD STYLE="text-align: left">Stockholder Consent or Approval</TD>
    <TD STYLE="text-align: center">55</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">5.5</TD>
    <TD STYLE="text-align: left">Access to Information</TD>
    <TD STYLE="text-align: center">55</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center"></TD></TR></TABLE>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center; width: 10%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 81%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">5.6</TD>
    <TD STYLE="text-align: left">280G Matters</TD>
    <TD STYLE="text-align: center">56</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">5.7</TD>
    <TD STYLE="text-align: left">Interim Financial Reports</TD>
    <TD STYLE="text-align: center">56</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">ARTICLE VI</TD>
    <TD STYLE="text-align: left">ADDITIONAL AGREEMENTS</TD>
    <TD STYLE="text-align: center">57</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">6.1</TD>
    <TD STYLE="text-align: left">Closing Efforts; Legal Conditions to the Merger; Third-Party Consents</TD>
    <TD STYLE="text-align: center">57</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">6.2</TD>
    <TD STYLE="text-align: left">Public Disclosure</TD>
    <TD STYLE="text-align: center">59</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">6.3</TD>
    <TD STYLE="text-align: left">Indemnification of Directors and Officers</TD>
    <TD STYLE="text-align: center">59</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">6.4</TD>
    <TD STYLE="text-align: left">Notification of Certain Matters</TD>
    <TD STYLE="text-align: center">60</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">6.5</TD>
    <TD STYLE="text-align: left">Employee Matters</TD>
    <TD STYLE="text-align: center">60</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">6.6</TD>
    <TD STYLE="text-align: left">Tax Matters</TD>
    <TD STYLE="text-align: center">61</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">6.7</TD>
    <TD STYLE="text-align: left">Registration of Buyer Common Stock</TD>
    <TD STYLE="text-align: center">63</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">6.8</TD>
    <TD STYLE="text-align: left">NASDAQ Notification</TD>
    <TD STYLE="text-align: center">68</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">6.9</TD>
    <TD STYLE="text-align: left">Product Regulatory Meetings</TD>
    <TD STYLE="text-align: center">68</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">6.10</TD>
    <TD STYLE="text-align: left">FIRPTA Certificate</TD>
    <TD STYLE="text-align: center">68</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">ARTICLE VII</TD>
    <TD STYLE="text-align: left">CONDITIONS TO MERGER</TD>
    <TD STYLE="text-align: center">69</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">7.1</TD>
    <TD STYLE="text-align: left">Conditions to Each Party&rsquo;s Obligation To Effect the Merger</TD>
    <TD STYLE="text-align: center">69</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">7.2</TD>
    <TD STYLE="text-align: left">Additional Conditions to Obligations of the Buyer and the Transitory Subsidiary</TD>
    <TD STYLE="text-align: center">69</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">7.3</TD>
    <TD STYLE="text-align: left">Additional Conditions to Obligations of the Company</TD>
    <TD STYLE="text-align: center">71</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">ARTICLE VIII</TD>
    <TD STYLE="text-align: left">INDEMNIFICATION</TD>
    <TD STYLE="text-align: center">71</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">8.1</TD>
    <TD STYLE="text-align: left">Indemnification by Company Equityholders</TD>
    <TD STYLE="text-align: center">71</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">8.2</TD>
    <TD STYLE="text-align: left">Indemnification by the Buyer</TD>
    <TD STYLE="text-align: center">73</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">8.3</TD>
    <TD STYLE="text-align: left">Claims for Indemnification</TD>
    <TD STYLE="text-align: center">73</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">8.4</TD>
    <TD STYLE="text-align: left">Survival</TD>
    <TD STYLE="text-align: center">75</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">8.5</TD>
    <TD STYLE="text-align: left">Limitations</TD>
    <TD STYLE="text-align: center">75</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">8.6</TD>
    <TD STYLE="text-align: left">No Right of Contribution</TD>
    <TD STYLE="text-align: center">77</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">8.7</TD>
    <TD STYLE="text-align: left">Effect of Investigation; Reliance</TD>
    <TD STYLE="text-align: center">77</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">8.8</TD>
    <TD STYLE="text-align: left">Manner of Payment; Release of Escrow</TD>
    <TD STYLE="text-align: center">78</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">8.9</TD>
    <TD STYLE="text-align: left">Right to Satisfy Indemnification Claims by Reducing Future Contingent Payments</TD>
    <TD STYLE="text-align: center">78</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">8.10</TD>
    <TD STYLE="text-align: left">Treatment of Indemnification Payments</TD>
    <TD STYLE="text-align: center">79</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">ARTICLE IX</TD>
    <TD STYLE="text-align: left">TERMINATION AND AMENDMENT</TD>
    <TD STYLE="text-align: center">79</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">9.1</TD>
    <TD STYLE="text-align: left">Termination</TD>
    <TD STYLE="text-align: center">79</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">9.2</TD>
    <TD STYLE="text-align: left">Effect of Termination</TD>
    <TD STYLE="text-align: center">80</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center"></TD></TR></TABLE>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center; width: 10%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 81%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">9.3</TD>
    <TD STYLE="text-align: left">Fees and Expenses</TD>
    <TD STYLE="text-align: center">80</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">9.4</TD>
    <TD STYLE="text-align: left">Amendment</TD>
    <TD STYLE="text-align: center">80</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">9.5</TD>
    <TD STYLE="text-align: left">Extension; Waiver</TD>
    <TD STYLE="text-align: center">80</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">ARTICLE X</TD>
    <TD STYLE="text-align: left">DEFINITIONS</TD>
    <TD STYLE="text-align: center">81</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">10.1</TD>
    <TD STYLE="text-align: left">Definitions</TD>
    <TD STYLE="text-align: center">81</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">ARTICLE XI</TD>
    <TD STYLE="text-align: left">MISCELLANEOUS</TD>
    <TD STYLE="text-align: center">100</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">11.1</TD>
    <TD STYLE="text-align: left">Notices</TD>
    <TD STYLE="text-align: center">100</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">11.2</TD>
    <TD STYLE="text-align: left">Entire Agreement</TD>
    <TD STYLE="text-align: center">101</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">11.3</TD>
    <TD STYLE="text-align: left">No Third-Party Beneficiaries</TD>
    <TD STYLE="text-align: center">102</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">11.4</TD>
    <TD STYLE="text-align: left">Assignment</TD>
    <TD STYLE="text-align: center">102</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">11.5</TD>
    <TD STYLE="text-align: left">Severability</TD>
    <TD STYLE="text-align: center">102</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">11.6</TD>
    <TD STYLE="text-align: left">Counterparts and Signature</TD>
    <TD STYLE="text-align: center">102</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">11.7</TD>
    <TD STYLE="text-align: left">Interpretation</TD>
    <TD STYLE="text-align: center">103</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">11.8</TD>
    <TD STYLE="text-align: left">Governing Law; Waiver of Jury Trial</TD>
    <TD STYLE="text-align: center">103</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">11.9</TD>
    <TD STYLE="text-align: left">Remedies</TD>
    <TD STYLE="text-align: center">103</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">11.10</TD>
    <TD STYLE="text-align: left">Submission to Jurisdiction</TD>
    <TD STYLE="text-align: center">104</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">11.11</TD>
    <TD STYLE="text-align: left">Disclosure Schedules</TD>
    <TD STYLE="text-align: center">104</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: center">11.12</TD>
    <TD STYLE="text-align: left">Waiver of Conflicts Regarding Representation; Non-Assertion of Attorney-Client Privilege</TD>
    <TD STYLE="text-align: center">104</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: -1.25in; margin: 0pt 0.5in 0pt 1.25in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>


<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: middle">
    <TD STYLE="width: 13%">Exhibit A</TD>
    <TD STYLE="width: 87%">Form of Written Consent</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit B-1</TD>
    <TD>Form of Optionholder Notice</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit B-2</TD>
    <TD>Form of Option Cancellation Agreement</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit C-1</TD>
    <TD>Illustrative Closing Cash Consideration Statement</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit C-2</TD>
    <TD>Illustrative Allocation Schedule</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit D</TD>
    <TD>Form of Information Statement</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit E</TD>
    <TD>Form of Certificate of Merger</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit F</TD>
    <TD>Form of Escrow Agreement</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit G-1</TD>
    <TD>Form of Investor Questionnaire</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit G-2</TD>
    <TD>Form of Letter of Transmittal</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit G-3</TD>
    <TD>Form of Lock-Up Agreement</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Schedule 1.1(b)</TD>
    <TD>Key Stockholders</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Schedule 2.8(b)</TD>
    <TD>Current Phase 3 Clinical Trial</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Schedule 7.1(g)</TD>
    <TD>Required Consents</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Schedule 11.7</TD>
    <TD>Additional Disclosures</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Company Disclosure Schedule<BR>
Buyer Disclosure Schedule</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>AGREEMENT AND PLAN OF MERGER</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">THIS AGREEMENT AND PLAN OF MERGER (this &ldquo;<U>Agreement</U>&rdquo;)
is entered into as of March 31, 2017, by and among Sucampo Pharmaceuticals, Inc., a Delaware corporation (the&nbsp;&ldquo;<U>Buyer</U>&rdquo;),
Saber Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Buyer (the &ldquo;<U>Transitory Subsidiary</U>&rdquo;),
Vtesse Inc., a Delaware corporation (the&nbsp;&ldquo;<U>Company</U>&rdquo;), and, solely in such Person&rsquo;s capacity as the
representative of the Company Equityholders, Fortis Advisors LLC, a Delaware limited liability company (the &ldquo;<U>Company Equityholder
Representative</U>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Boards of Directors of the Buyer, the Transitory Subsidiary and the Company deem it advisable and in the best interests of each
corporation and their respective stockholders that the Buyer acquire the Company through the merger of the Transitory Subsidiary
with and into the Company in accordance with the terms of this Agreement and the DGCL, as a result of which the Company shall become
a wholly owned direct subsidiary of the Buyer.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly
following the execution and delivery of this Agreement and on the date hereof, the Company will deliver to the Buyer the Written
Consent in the form attached hereto as <U>Exhibit A</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrently
with the execution and delivery of this Agreement, the Company is delivering to the Buyer joinder agreements (the &ldquo;<U>Joinder
Agreements</U>&rdquo;) and Investor Questionnaires executed by each Key Stockholder.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In consideration of the foregoing and the respective
representations, warranties, covenants and agreements set forth below, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Buyer, the Transitory Subsidiary, the Company and, solely in such Person&rsquo;s
capacity as the Company Equityholder Representative, the Company Equityholder Representative agree as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>ARTICLE
I</B></FONT><BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>THE MERGER</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effective Time of the Merger</U>. Subject to the provisions of this Agreement, prior to the Closing, the Buyer and the
Company shall jointly prepare or cause to be prepared the Certificate of Merger, and, immediately following the Closing, the Surviving
Corporation shall cause the Certificate of Merger to be filed with the Secretary of State of the State of Delaware and shall make
all other filings or recordings required under the DGCL in order to give effect to the Merger. The Merger shall become effective
at the Effective Time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">1.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing</U>. The Closing shall take place at 10:00&nbsp;a.m., Eastern Time, on the Closing Date at the offices of Wilmer
Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, Massachusetts 02109, unless another date, place or time is agreed
to in writing by the Buyer and the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">1.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effects of the Merger</U>. At the Effective Time (a) the separate existence of the Transitory Subsidiary shall cease
and the Transitory Subsidiary shall be merged with and into the Company and the Company shall continue as the Surviving Corporation
and (b) the Company Certificate of Incorporation shall be amended and restated in its entirety to read as set forth on Exhibit
A to the Certificate of Merger. In addition, subject to <U>Section 6.3(a)</U>, the by-laws of the Surviving Corporation, immediately
following the Effective Time, shall be the by-laws of the Transitory Subsidiary as in effect immediately prior to the Effective
Time, except that all references to the name of the Transitory Subsidiary therein shall be deemed amended to refer to the name
of the Surviving Corporation. The Merger shall have the effects set forth in Section&nbsp;259 of the DGCL.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">1.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Directors and Officers of the Surviving Corporation</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The directors of the Transitory Subsidiary immediately prior to the Effective Time shall be the initial directors of the
Surviving Corporation, each to hold office in accordance with the certificate of incorporation and by-laws of the Surviving Corporation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The officers of the Transitory Subsidiary immediately prior to the Effective Time shall be the initial officers of the Surviving
Corporation, each to hold office in accordance with the certificate of incorporation and by-laws of the Surviving Corporation.</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>ARTICLE
II</B></FONT><BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>CONVERSION OF SECURITIES</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conversion of Capital Stock</U>. At the Effective Time, by virtue of the Merger and without any action on the part of
the Buyer, the Company, any holder of Company Stock or any other Person:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Capital Stock of the Transitory Subsidiary</U>. Each share of the common stock, $0.001 par value per share, of the Transitory
Subsidiary that is issued and outstanding as of immediately prior to the Effective Time shall be converted into and become one
(1) fully paid and nonassessable share of common stock, $0.001 par value per share, of the Surviving Corporation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cancellation of Treasury Stock and Buyer-Owned Stock</U>. Each share of Company Stock that is owned by the Company as
treasury stock and each share of Company Stock that is owned by the Buyer, the Transitory Subsidiary or any other Subsidiary of
the Buyer as of immediately prior to the Effective Time shall be cancelled and shall cease to exist and no payment or consideration
shall be delivered in exchange therefor.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conversion of Company Stock</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each share of Company Series A Preferred Stock that is issued and outstanding as of immediately prior to the Effective Time
(other than (A) shares of Company Series A Preferred Stock referenced in <U>Section 2.1(b)</U> and (B) Dissenting Shares) shall
be converted into the right of the holder thereof to receive: (1) the Series A Original Issue Price, plus (2) the Per Share Closing
Consideration, plus (3) the applicable Per Share Future Contingent Consideration, Per Share Expense Fund Distribution and Per Share
Escrow Distribution with respect to each Future Contingent Payment that becomes payable pursuant to the terms of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each share of Company Common Stock that is issued and outstanding as of immediately prior to the Effective Time (other than
(A) shares of Company Common Stock referenced in <U>Section 2.1(b)</U> and (B) Dissenting Shares) shall be converted into the right
of the holder thereof to receive: (1) the Per Share Closing Consideration, plus (2) the applicable Per Share Future Contingent
Consideration, Per Share Expense Fund Distribution and Per Share Escrow Distribution with respect to each Future Contingent Payment
that becomes payable pursuant to the terms of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing Payment Certificate; Closing Date Payments</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On the date hereof, the Company shall deliver to the Buyer the Closing Payment Certificate, including the Allocation Schedule
attached thereto.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On the Closing Date (or later, in the case of clause (D)), the Buyer shall make the following payments, in each case in
the respective amounts set forth in the Closing Payment Certificate:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>to the Surviving Corporation&rsquo;s payroll account, by wire transfer of immediately available funds, the portion of the
Closing Cash Consideration payable to the holders of Company Options pursuant to <U>Section 2.5(a)</U> for payment to such holders
of Company Options in accordance with <U>Section 2.5(d)</U>;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>to the Escrow Agent, by wire transfer of immediately available funds, the Escrow Amount to be deposited into the Escrow
Account;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(C)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>to the Company Equityholder Representative, by wire transfer of immediately available funds, the Company Equityholder Representative
Expense Amount;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(D)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>when and to the extent set forth in the Estimated Closing Cash Consideration Statement, to each Person (or to the Surviving
Corporation&rsquo;s payroll account for distribution to such Person) specified in the Closing Payment Certificate as a recipient
of payments in respect of Unpaid Company Transaction Expenses or Indebtedness, by wire transfer of immediately available funds,
the amount payable to such Person as specified in the Closing Payment Certificate; and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(E)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>to the Exchange Agent, by wire transfer of immediately available funds, the Closing Cash Consideration, less any such amounts
payable to holders of Company Options in respect of such Company Options pursuant to <U>Section 2.5(a)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Subject to the last paragraph of this <U>Section
2.1(d)</U>, at such time as the Closing Cash Consideration is paid to a Company Equityholder, the Buyer shall instruct its exchange
agent to issue to such Company Equityholder such Company Equityholder&rsquo;s allocable share of the Buyer Common Stock Consideration
(in electronic form as uncertificated securities, all or a portion of which may be shares of treasury stock held by the Buyer)
in accordance with the Closing Payment Certificate (and the Buyer shall issue such instructions to its exchange agent as provided
in this <U>Section 2.1(d)(ii)(F)</U>).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Notwithstanding anything in this Agreement to
the contrary, with respect to any shares of Buyer Common Stock issuable in connection with the payment of the Buyer Common Stock
Consideration, if the Company Equityholder entitled to receive such shares is not an &ldquo;accredited investor&rdquo; for purposes
of Regulation D under the Securities Act (as determined in the Buyer&rsquo;s sole but reasonable discretion), the Buyer may elect
to pay in cash the amount of consideration otherwise attributable to such shares (in lieu of issuing such shares).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Escrow</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At Closing, the Buyer will (in accordance with <U>Section&nbsp;2.1(d)(ii)(B)</U>) deliver to the Escrow Agent the Escrow
Amount to be held in escrow pursuant to the Escrow Agreement and to be disbursed in accordance with the terms of this Agreement
and the Escrow Agreement. The Escrow Account, together with any interest and earnings thereon, shall be held by the Escrow Agent
and released by the Escrow Agent to the Surviving Corporation, the Exchange Agent or the Buyer, as applicable, in accordance with
the terms of the Escrow Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any portion of the Escrow Fund disbursed pursuant to the Escrow Agreement for the benefit of the Company Equityholders shall
be disbursed in accordance with this <U>Section 2.1(e)(ii)</U> and the Allocation Schedule. A portion of such disbursed amount
equal to the applicable Per Share Escrow Distribution that is payable in respect of each share of Company Stock converted pursuant
to <U>Section 2.1(c)</U> shall be paid by the Escrow Agent to the Exchange Agent pursuant to the terms of the Escrow Agreement
for payment to the holder thereof. A portion of such disbursed amount equal to the applicable Per Share Escrow Distribution that
is payable in respect of each Company Option shall be paid by the Escrow Agent to the Buyer or the Surviving Corporation pursuant
to the terms of the Escrow Agreement for payment to the holder thereof through the Buyer&rsquo;s or the Surviving Corporation&rsquo;s
payroll (which amount shall be paid by the Buyer or the Surviving Corporation to such holder on the first payroll payment date
after the Buyer&rsquo;s or the Surviving Corporation&rsquo;s receipt of such amount; <U>provided</U> that if the Buyer or Surviving
Corporation received such amount fewer than five (5) Business Days prior to such payroll payment date, the amount shall be paid
on the next payroll payment date, and in each case shall be subject to any applicable withholding as provided in <U>Section 2.10</U>).
For the avoidance of doubt, the Buyer shall (in accordance with the Allocation Schedule) cause (A) the Surviving Corporation to
use any funds distributed to the Surviving Corporation pursuant to this <U>Section 2.1(e)(ii)</U> and (B)&nbsp;the Exchange Agent
to use any funds distributed to the Exchange Agent pursuant to this <U>Section 2.1(e)(ii)</U> to make the payments provided for
in this <U>Section 2.1(e)(ii)</U>, and such funds shall not be used for any other purpose except as provided in this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certain Adjustments to Per Share Amounts</U>. All per share amounts payable to the Company Equityholders pursuant to
this <U>Article II</U> shall be adjusted, as applicable and appropriate, to reflect fully the effect of any reclassification, stock
split, reverse split, stock dividend (including any dividend or distribution of securities convertible into Company Stock), reorganization,
recapitalization or other like change with respect to Company Stock occurring (or for which a record date is established) after
the date of this Agreement and prior to the Effective Time; <U>provided</U> that, in accordance with <U>Sections 5.1</U> and <U>5.2</U>,
the Company shall not permit any such event to occur without the prior written consent of the Buyer.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fractional Shares</U>. Notwithstanding any other provision of this Agreement, no fractional shares of Buyer Common
Stock shall be issued in exchange for any Company Stock or Company Equity Awards, and no holder of any of the foregoing shall be
entitled to receive a fractional share of Buyer Common Stock. In the event that any holder of Company Stock or Company Equity Awards
would otherwise be entitled to receive a fractional share of Buyer Common Stock (after aggregating all shares and fractional shares
of Buyer Common Stock issuable to such holder), then such holder shall be paid an amount in Dollars (without interest) determined
by multiplying (i) the Buyer Stock Price by (ii) the fraction of a share of Buyer Common Stock to which such holder would otherwise
be entitled, in which case Buyer shall make available to the Exchange Agent the amount of cash necessary to make such payments.
The parties acknowledge that payment of cash consideration in lieu of issuing fractional shares of Buyer Common Stock was not separately
bargained for consideration but represents merely a mechanical rounding off for purposes of simplifying the problems that would
otherwise be caused by the issuance of fractional shares of Buyer Common Stock.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment Fund</U>. The procedures for exchanging outstanding shares of Company Stock for the consideration to be paid
to the holders of such Company Stock in connection with the Merger are as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exchange Agent</U>. On the Closing Date, the Buyer shall (in accordance with <U>Section 2.1(d)(ii)(E)</U>) deposit the
Payment Fund with the Exchange Agent for payment to the Company Stockholders in accordance with this <U>Section 2.2</U>, the Allocation
Schedule and an Exchange Agent Agreement between the Buyer and the Exchange Agent. The Buyer shall cause the Exchange Agent to,
pursuant to irrevocable instructions from the Buyer in accordance with the Exchange Agent Agreement and the Allocation Schedule,
deliver the Closing Cash Consideration out of the Payment Fund. The Buyer shall take all actions necessary to ensure that, at the
time such payment is to be made in accordance with this Agreement, subject to <U>Section 2.2(d)</U>, the Payment Fund includes
sufficient cash to satisfy the Buyer&rsquo;s obligation to pay the Closing Cash Consideration (to the extent to be paid by the
Exchange Agent). The Payment Fund shall not be used for any purpose other than as specified in this <U>Section 2.2(a)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exchange Procedures</U>. Prior to the Closing, the Company shall deliver to each holder of record of a Certificate (i)&nbsp;a
Letter of Transmittal, which, among other things, shall include a general release of claims, a consent to the holdback of the Escrow
Amount and the Company Equityholder Representative Expense Amount and a consent to indemnification obligations of the Company Stockholders,
(ii) a Lock-Up Agreement (if such holder is receiving shares of Buyer Common Stock), (iii) an Investor Questionnaire and (iv)&nbsp;instructions
for effecting the surrender of such Certificate in exchange for the applicable Aggregate Consideration that is or may become payable
with respect thereto pursuant to the terms of this Agreement; <U>provided</U> that the Buyer shall assist the Company in developing
arrangements for the delivery of such materials at Closing to holders of Company Stock to facilitate the payment of Aggregate Closing
Consideration to such stockholders as promptly as practicable following the Effective Time. Upon surrender of a Certificate for
cancellation to the Exchange Agent and delivery of a duly executed Letter of Transmittal (including the applicable Tax forms required
thereby), Lock-Up Agreement (if such holder is receiving shares of Buyer Common Stock) and Investor Questionnaire, the Buyer shall
cause the Exchange Agent to pay promptly (and in any event within three (3) Business Days) to the holder of such Certificate in
exchange therefor cash in an amount equal to the Aggregate Closing Consideration payable in respect of the shares of Company Stock
represented by such Certificate, as determined in accordance with <U>Section 2.1</U> and reflected on the Allocation Schedule.
In the event of a transfer of ownership of Company Stock which is not registered in the transfer records of the Company, the applicable
Aggregate Closing Consideration may be paid to a Person other than the Person in whose name the Certificate so surrendered is registered,
if such Certificate is presented to the Exchange Agent, accompanied by all documents required to evidence and effect such transfer
and by evidence that any applicable stock transfer Taxes have been paid. Until surrendered as contemplated by this <U>Section&nbsp;2.2(b)</U>,
each Certificate shall be deemed at all times after the Effective Time to represent only the right to receive upon such surrender
the applicable Aggregate Closing Consideration and the applicable portion of the Future Contingent Payments that become payable
pursuant to this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Further Ownership Rights in Company Stock</U>. All consideration paid following the surrender for exchange of Certificates
evidencing shares of Company Stock (including any Future Contingent Payments payable with respect thereto) in accordance with the
terms hereof shall be deemed to have been paid in satisfaction of all rights pertaining to such shares of Company Stock, and from
and after the Effective Time there shall be no further registration of transfers on the stock transfer books of the Surviving Corporation
of the shares of Company Stock which were outstanding as of immediately prior to the Effective Time. If, after the Effective Time,
Certificates are presented to the Surviving Corporation or the Exchange Agent for any reason, they shall be cancelled and exchanged
as provided in this <U>Article II</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Payment Fund</U>. Any amount deposited with the Exchange Agent on account of the Payment Fund that remains
undistributed to the holders of Company Stock six (6) months after the later of (i) the Effective Time or (ii) such time that such
amount is so deposited shall be delivered to the Buyer (subject to abandoned property, escheat or similar Law), upon the Buyer&rsquo;s
demand, and any holder of Company Stock who is entitled to such amount under this <U>Section 2.2</U> shall be entitled to receive
such amount from the Buyer.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Liability</U>. To the extent permitted by applicable Law, none of the Buyer, the Transitory Subsidiary, the Company,
the Surviving Corporation or the Exchange Agent shall be liable to any Company Equityholder for any amount delivered to a public
official pursuant to any applicable abandoned property, escheat or similar Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Lost Certificates</U>. If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit
of that fact and a customary indemnification of the Company and the Buyer in a form reasonably satisfactory to the Buyer and the
Exchange Agent by the Person claiming such Certificate to be lost, stolen or destroyed and the posting of a bond as may be required
by the Buyer or the Exchange Agent, the Buyer shall cause the Exchange Agent to issue in exchange for such lost, stolen or destroyed
Certificate the Aggregate Consideration deliverable in respect thereof pursuant to this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">2.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Dissenting Shares</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary contained in this Agreement, Dissenting Shares shall not be converted into or represent
the right to receive any portion of the Aggregate Consideration in accordance with <U>Section 2.1</U>, but shall be entitled only
to such rights as are granted by the DGCL to a holder of Dissenting Shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If any Dissenting Shares shall lose their status as such (through failure to perfect or otherwise), then, as of the later
of the Effective Time or the date of loss of such status, such shares shall automatically be converted into and shall represent
only the right to receive any portion of the Aggregate Consideration otherwise payable in respect thereof pursuant to this Agreement,
without interest thereon, upon surrender of the Certificate formerly representing such shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall give the Buyer (i) prompt notice of any written demand for appraisal received by the Company prior to
the Effective Time pursuant to the DGCL, any withdrawal of any such demand and any other demand, notice or instrument delivered
to the Company prior to the Effective Time pursuant to the DGCL that relates to such demand and (ii) the opportunity to participate
in all negotiations and proceedings with respect to any such demand, notice or instrument. The Company shall not settle or make
any payment or settlement offer prior to the Effective Time with respect to any such demand, notice or instrument unless the Buyer
shall have given its written consent to such settlement, payment or settlement offer, which consent shall not be unreasonably withheld,
conditioned or delayed.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">2.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Company Equityholder Representative</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>By their execution of a Letter of Transmittal or Option Cancellation Agreement, as applicable, approval of the Merger and
adoption of this Agreement and/or their acceptance of any consideration pursuant to this Agreement, and without any further action
on the part of any Company Equityholder or the Company, the Company Equityholders hereby irrevocably (subject only to <U>Section
2.4(f)</U>) appoint the Company Equityholder Representative as the representative, attorney-in-fact and exclusive agent of the
Company Equityholders in connection with the transactions contemplated by this Agreement, the Exchange Agent Agreement and the
Escrow Agreement and in any litigation or arbitration involving this Agreement, the Exchange Agent Agreement or the Escrow Agreement.
In connection therewith, the Company Equityholder Representative is authorized to do or refrain from doing all further acts and
things, and to execute all such documents as the Company Equityholder Representative shall deem necessary or appropriate, and shall
have the power and authority to:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>act for some or all of the Company Equityholders with regard to all matters pertaining to this Agreement, the Exchange Agent
Agreement or the Escrow Agreement;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>act for the Company Equityholders to transact matters of litigation;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>execute and deliver all amendments, waivers, ancillary agreements, certificates and documents that the Company Equityholder
Representative deems necessary or appropriate in connection with the consummation of the transactions contemplated by this Agreement,
the Exchange Agent Agreement or the Escrow Agreement, including delivering any update to or correction, amendment or modification
of the Allocation Schedule permitted by <U>Section 2.7(a)</U>;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>receive funds, make payments of funds, and give receipts for funds;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>do or refrain from doing, on behalf of the Company Equityholders, any further act or deed that the Company Equityholder
Representative deems necessary or appropriate in the Company Equityholder Representative&rsquo;s discretion relating to the subject
matter of this Agreement, the Exchange Agent Agreement, the Company Equityholder Representative Engagement Agreement or the Escrow
Agreement, in each case as fully and completely as the Company Equityholders could do if personally present;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(vi)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>give and receive all notices required to be given or received by the Company Equityholders under this Agreement, the Exchange
Agent Agreement or the Escrow Agreement;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(vii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>give any written direction to the Exchange Agent or the Escrow Agent;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(viii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>agree to, negotiate and/or comply with the determination of the Final Closing Cash Consideration and the Final Closing Cash
Consideration Adjustment pursuant to <U>Section 2.6</U>;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ix)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>agree to, negotiate, enter into settlements and compromises and/or comply with arbitration awards and court orders with
respect to claims relating to the Earn-Out Consideration or the Priority Review Voucher Payment or claims for indemnification made
by the Buyer under <U>Article VIII</U>; and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(x)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>receive service of process in connection with any claims under this Agreement, the Exchange Agent Agreement and/or the Escrow
Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Notwithstanding the foregoing, the Company Equityholder
Representative shall have no obligation to act on behalf of the Company Equityholders, except as expressly provided herein, in
the Escrow Agreement and in the Company Equityholder Representative Engagement Agreement, and, for the avoidance of doubt, there
are no obligations of the Company Equityholder Representative in any ancillary agreement, schedule, exhibit or the Company Disclosure
Schedule.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All decisions and actions of the Company Equityholder Representative on behalf of the Company Equityholders shall be deemed
to be facts ascertainable outside of the Merger Agreement and shall be binding upon all Company Equityholders, and no Company Equityholder
shall have the right to object, dissent, protest or otherwise contest the same. All defenses which may be available to any Company
Equityholder to contest, negate or disaffirm the action of the Company Equityholder Representative taken in good faith under this
Agreement, the Escrow Agreement or the Company Equityholder Representative Engagement Agreement are waived.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At the Effective Time, the Buyer shall pay the Company Equityholder Representative Expense Amount to the Company Equityholder
Representative as set forth in <U>Section 2.1(d)(ii)(C)</U>, which Company Equityholder Representative Expense Amount shall be
maintained by the Company Equityholder Representative in a segregated account and shall be used (i) for the purposes of paying
directly or reimbursing the Company Equityholder Representative for any Company Equityholder Representative Expenses incurred pursuant
to this Agreement, the Escrow Agreement or any Company Equityholder Representative Engagement Agreement, or (ii) as otherwise determined
by the Advisory Group. The Company Equityholder Representative is not providing any investment supervision, recommendations or
advice and shall have no responsibility or liability for any loss of principal of the Company Equityholder Representative Expense
Amount other than as a result of its gross negligence or willful misconduct. The Company Equityholder Representative is not acting
as a withholding agent or in any similar capacity in connection with the Company Equityholders and has no Tax reporting or income
distribution obligations. The Company Equityholders will not receive any interest on the Company Equityholder Representative Expense
Amount and assign to the Company Equityholder Representative any such interest. Subject to Advisory Group approval, the Company
Equityholder Representative may contribute funds to the Company Equityholder Representative Expense Amount from any consideration
otherwise distributable to the Company Equityholders. The Company Equityholder Representative shall be reimbursed for reasonable
out-of-pocket expenses incurred in the performance of the Company Equityholder Representative&rsquo;s duties (including the reasonable
fees and expenses of counsel) under this Agreement, the Escrow Agreement, the Exchange Agent Agreement and the Company Equityholder
Representative Engagement Agreement from the Company Equityholder Representative Expense Amount and, if the remaining Company Equityholder
Representative Expense Amount is insufficient to pay such expenses, from the first proceeds from Future Contingent Payments otherwise
available for distribution to the Company Equityholders. Upon the determination of the Company Equityholder Representative that
retaining any portion of the Company Equityholder Representative Expense Amount is no longer necessary, the Company Equityholder
Representative shall deliver any then remaining portion of the Company Equityholder Representative Expense Amount (the &ldquo;<U>Company
Equityholder Representative Account Payment</U>&rdquo;) to the Exchange Agent, which the Buyer shall cause promptly to pay (i)
a portion thereof equal to the applicable Per Share Expense Fund Distribution that is represented by each share of Company Stock
converted pursuant to <U>Section 2.1(c)</U> to the Exchange Agent for payment to the holder thereof and (ii) a portion thereof
equal to the applicable Per Share Expense Fund Distribution that is represented by each Company Option to the Buyer or the Surviving
Corporation for payment to the holder thereof (which amount shall be paid by the Buyer or the Surviving Corporation to such holder
on the first payroll payment date after the Buyer&rsquo;s or the Surviving Corporation&rsquo;s receipt of such amount; <U>provided</U>
that if the Buyer or Surviving Corporation received such amount fewer than five (5) Business Days prior to such payroll payment
date, the amount shall be paid on the next payroll payment date, and in each case shall be subject to any applicable withholding
as provided in <U>Section 2.10</U>). The Company Equityholder Representative shall hold, invest, reinvest and disburse the Company
Equityholder Representative Expense Amount in trust for all of the Company Equityholders, and the Company Equityholder Representative
Expense Amount shall not be used for any other purpose and shall not be available to the Buyer to satisfy any claims hereunder.
The Company Equityholder Representative Expense Amount shall be treated as having been received and voluntarily set aside by the
Company Equityholders at the time of Closing (and, for the avoidance of doubt, Tax withholding with respect to such deemed receipt
by any Company Equityholder shall be satisfied from such Company Equityholder&rsquo;s respective share of the Aggregate Closing
Consideration and shall not reduce the Company Equityholder Representative Expense Amount).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company Equityholder Representative shall act for the Company Equityholders on all of the matters set forth in this
Agreement, the Exchange Agent Agreement and the Escrow Agreement in the manner the Company Equityholder Representative believes
to be in the best interest of the Company Equityholders. The Company Equityholder Representative shall be entitled to: (i) rely
upon the Allocation Schedule, (ii) rely upon any signature believed by it to be genuine, and (iii) reasonably assume that a signatory
has proper authorization to sign on behalf of the applicable Company Equityholder or other party. The Company Equityholder Representative
is authorized to act on behalf of the Company Equityholders notwithstanding any dispute or disagreement among the Company Equityholders.
In taking any action as Company Equityholder Representative, the Company Equityholder Representative may rely conclusively, without
any further inquiry or investigation, upon any certification or confirmation, oral or written, given by any Person whom the Company
Equityholder Representative reasonably believes to be authorized thereunto. The Company Equityholder Representative may, in all
questions arising hereunder, rely on the advice of counsel, and the Company Equityholder Representative shall not be liable to
any of the parties hereto or to any Company Equityholder for anything done, omitted or suffered in good faith by the Company Equityholder
Representative based on such advice. The Company Equityholder Representative undertakes to perform such duties and only such duties
as are specifically set forth in this Agreement and no implied covenants or obligations shall be read into this Agreement against
the Company Equityholder Representative. Certain Company Equityholders have entered into an engagement agreement with the Company
Equityholder Representative (the &ldquo;<U>Company Equityholder Representative Engagement Agreement</U>&rdquo;) to provide direction
to the Company Equityholder Representative in connection with its services under this Agreement, the Escrow Agreement and the Company
Equityholder Representative Engagement Agreement (such Company Equityholders, including their individual representatives, collectively
hereinafter referred to as the &ldquo;<U>Advisory Group</U>&rdquo;). Neither the Company Equityholder Representative nor its members,
managers, directors, officers, contractors, agents and employees nor any member of the Advisory Group (collectively, the &ldquo;<U>Company
Equityholder Representative Group&rdquo;</U>), shall have any liability to any of the parties hereto or the Company Equityholders
for any act done or omitted hereunder as Company Equityholder Representative while acting in good faith. The Company Equityholder
Representative Group shall be indemnified, defended and held harmless by the Company Equityholders, on a several and not joint
basis, from and against any loss, liability, claims, damages, fees, costs, judgments, fines or amounts paid in settlement or expense
(including fees, disbursements and costs of counsel and other skilled professionals and in connection with seeking recovery from
insurers) (collectively, the &ldquo;<U>Company Equityholder Representative Expenses</U>&rdquo;) incurred in good faith on the part
of the Company Equityholder Representative and arising out of or in connection with the acceptance or administration of the Company
Equityholder Representative&rsquo;s duties hereunder, under the Escrow Agreement, under the Exchange Agent Agreement or under the
Company Equityholder Representative Engagement Agreement. Any such claim for indemnification shall be satisfied first from any
then available portion of the remaining Company Equityholder Representative Expense Amount and, if such amount is insufficient
to satisfy any such loss, liability or expense, from the first proceeds from Future Contingent Payments otherwise available for
distribution to the Company Equityholders or by a claim against the Company Equityholders (with each Company Equityholder liable
for such Company Equityholder&rsquo;s Pro Rata Share of the applicable Per Share Future Contingent Consideration, Per Share Expense
Fund Distribution and Per Share Escrow Distribution of any such claim that is represented by such Company Equityholder&rsquo;s
Company Stock and Company Options). The Company Equityholders acknowledge that the Company Equityholder Representative shall not
be required to expend or risk its own funds or otherwise incur any financial liability in the exercise or performance of any of
its powers, rights, duties or privileges or pursuant to this Agreement, the Escrow Agreement or the transactions contemplated hereby.
Furthermore, the Company Equityholder Representative shall not be required to take any action unless the Company Equityholder Representative
has been provided with funds, security or indemnities which, in its determination, are sufficient to protect the Company Equityholder
Representative against the costs, expenses and liabilities which may be incurred by the Company Equityholder Representative in
performing such actions.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event the Company Equityholder Representative becomes unable to perform the Company Equityholder Representative&rsquo;s
responsibilities hereunder or resigns from such position, the Company Equityholders (acting by a written instrument signed by holders
of Company Stock who held, as of immediately prior to the Effective Time, a majority (by voting power) of the then outstanding
shares of Company Stock) shall select another representative to fill the vacancy of the Company Equityholder Representative, and
such substituted representative shall be deemed to be the Company Equityholder Representative for all purposes of this Agreement.
The Company Equityholder Representative may be removed only upon delivery of written notice to the Buyer signed by Persons who,
as of immediately prior to the Effective Time, held a majority (by voting power) of the then outstanding shares of Company Stock.
The immunities and rights to indemnification shall survive the resignation or removal of the Company Equityholder Representative
or any member of the Advisory Group and the Closing and/or any termination of this Agreement and the Escrow Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For all purposes of this Agreement:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Buyer shall be entitled to rely conclusively on the instructions and decisions of the Company Equityholder Representative
as to the settlement of any disputes or claims under this Agreement, or any other actions required or permitted to be taken by
the Company Equityholder Representative hereunder, and no party hereunder or any Company Equityholder shall have any cause of action
against the Buyer for any action taken by the Buyer, the Surviving Corporation or any of their Affiliates in reliance upon the
instructions or decisions of the Company Equityholder Representative;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the provisions of this <U>Section 2.4</U> are independent and severable, are irrevocable (subject only to <U>Section 2.4(f)</U>)
and coupled with an interest and shall be enforceable notwithstanding any rights or remedies that any Company Equityholder may
have in connection with the transactions contemplated by this Agreement; and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the provisions of this <U>Section 2.4</U> shall survive the death, incompetence, bankruptcy or liquidation of any Company
Equityholder or any delivery of an assignment of any Company Equityholder&rsquo;s interest in the Escrow Fund and all actions of
the Company Equityholder Representative taken hereunder, under the Escrow Agreement or under the Company Equityholder Representative
Engagement Agreement be binding upon the executors, heirs, legal representatives, personal representatives, successor trustees
and successors of each Company Equityholder as if expressly confirmed and ratified in writing by such Company Equityholder, and
any references in this Agreement to a Company Equityholder shall mean and include the successors to the rights of each applicable
Company Equityholder hereunder, whether pursuant to testamentary disposition, the Laws of descent and distribution or otherwise.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">2.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Treatment of Company Equity Awards</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Company Option will be continued, assumed or substituted for by the Buyer or the Company as part of the Merger. As of
immediately prior to the Effective Time, each Company Option that is then outstanding (whether such Company Option is vested or
unvested, but not to the extent it has theretofore been exercised) shall vest in full and be converted, in settlement and cancellation
thereof, into the right to receive the Per Share Option Consideration with respect to each share of Company Common Stock underlying
such Company Option, subject to the conditions set forth in <U>Section 2.5(d)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Company Restricted Stock Award will be continued, assumed or substituted for by the Buyer or the Company as part of the
Merger. As of immediately prior to the Effective Time, each Company Restricted Stock Award that is unvested in whole or in part
shall vest in full (and all shares of Company Common Stock previously issued in connection with such Company Restricted Stock Award
shall be converted pursuant to <U>Section 2.1(c)(iii)</U>), subject to the conditions set forth in <U>Section 2.5(d)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Promptly (and in any event within five (5) Business Days) after the date hereof (but, notwithstanding the foregoing, no
later than the Closing Date), the Company shall deliver to each holder of Company Equity Awards a notice describing the treatment
of such Company Equity Awards pursuant to <U>Section 2.5(a)</U> and the deadline for exercising such Company Options, in the form
attached hereto as <U>Exhibit B-1</U> (&ldquo;<U>Optionholder Notice</U>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the Buyer&rsquo;s receipt from a holder of Company Options of a duly-executed (i) Lock-Up Agreement (if such
holder is receiving shares of Buyer Common Stock), (ii) Investor Questionnaire and (iii) Option Cancellation Agreement in the form
attached hereto as <U>Exhibit B-2</U> (an &ldquo;<U>Option Cancellation Agreement</U>&rdquo;), the Buyer shall, or shall cause
the Surviving Corporation to pay, as promptly as practicable through its payroll (and in any event no later than the next payroll
date of the Buyer or the Surviving Corporation that occurs at least five (5) Business Days following later of (x) the Closing Date
or (y) the date upon which the Buyer receives from the applicable holder of Company Options the documents described in clauses
(i) - (iii) above) to each holder of Company Options, with respect to each share of Company Common Stock underlying such Company
Option, the Per Share Closing Option Consideration, subject to any applicable withholding as provided in <U>Section 2.10</U>, in
accordance with the Allocation Schedule. The Buyer shall pay, or shall cause the Surviving Corporation to pay, through its payroll
(no later five (5) Business Days after the Closing with respect to holders of Company Options who have delivered Option Cancellation
Agreements by the Closing Date or, otherwise (but subject to delivery of an Option Cancellation Agreement by the applicable holder),
no later than the next payroll date of the Buyer or the Surviving Corporation that occurs at least five (5) Business Days following
the payment of a Future Contingent Payment to the Company Stockholders), to each holder of Company Options, with respect to each
share of Company Common Stock underlying such Company Option, the applicable Per Share Future Contingent Consideration, Per Share
Expense Fund Distribution and Per Share Escrow Distribution, subject to any applicable withholding as provided in <U>Section 2.10</U>,
in accordance with the Allocation Schedule.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall, prior to the Effective Time, take or cause to be taken all actions necessary to cause the termination
of the Company Stock Plan without further obligation or liability to Buyer or its Affiliates.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">2.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing Cash Consideration Adjustment</U>. The Estimated Closing Cash Consideration and the Final Closing Cash Consideration
Adjustment shall be determined as set forth below in this <U>Section 2.6</U>:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Estimated Closing Cash Consideration</U>. On the date hereof, the Company shall deliver to the Buyer a statement setting
forth the Company&rsquo;s estimate of the amount of Closing Cash Consideration, including each component thereof (such amount,
the &ldquo;<U>Estimated Closing Cash Consideration</U>&rdquo; and such statement, the &ldquo;<U>Estimated Closing Cash Consideration
Statement</U>&rdquo;). The Estimated Closing Cash Consideration Statement and each component thereof shall be prepared and calculated
in accordance with GAAP (applied on a basis consistent with the preparation of the Company Financial Statements) and in a manner
consistent with the methodology and format set forth in the illustrative example of the Estimated Closing Cash Consideration Statement
attached hereto as <U>Exhibit C-1</U> (the &ldquo;<U>Illustrative Closing Cash Consideration Statement</U>&rdquo;). Notwithstanding
the foregoing, the Illustrative Closing Cash Consideration Statement shall be, and shall constitute the Company&rsquo;s delivery
of, the Estimated Closing Cash Consideration Statement. During the period beginning on the date of delivery of the Estimated Closing
Cash Consideration Statement by the Company until the Closing Date, the Company shall consult with the Buyer (including by giving
the Buyer an opportunity to provide comments to the Estimated Closing Cash Consideration Statement), the Company and the Buyer
shall work in good faith to resolve any differences the Company and the Buyer may have with respect to any of the amounts or calculations
set forth in the Estimated Closing Cash Consideration Statement, and the Company will provide the Buyer and its representatives
reasonable access to the work papers and other books and records used in preparing the Estimated Closing Cash Consideration Statement
and upon reasonable notice and during normal business hours, afford the Buyer and its representatives access to the relevant personnel
and its external representatives of the Company to verify the accuracy of such amounts as reasonably requested by the Buyer.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Post-Closing Adjustment</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Before 5:00 p.m., Eastern Time, on the sixtieth (60<SUP>th</SUP>) calendar day after the Effective Time, the Buyer shall
prepare and deliver to the Company Equityholder Representative a statement setting forth the Buyer&rsquo;s calculation of the Closing
Cash Consideration, including each component thereof (such amount, the &ldquo;<U>Preliminary Closing Cash Consideration</U>&rdquo;
and such statement, the &ldquo;<U>Preliminary Closing Cash Consideration Statement</U>&rdquo;) in a manner consistent with the
methodology and format set forth in the Illustrative Closing Cash Consideration Statement. If the Buyer does not deliver the Preliminary
Closing Cash Consideration Statement to the Company Equityholder Representative by 5:00 p.m., Eastern time, on the sixtieth (60<SUP>th</SUP>)
calendar day after the Effective Time, then the Estimated Closing Cash Consideration shall be deemed for all purposes of this Agreement
to be the &ldquo;<U>Final Closing Cash Consideration</U>,&rdquo; the Estimated Closing Cash Consideration Statement shall be deemed
for all purposes of this Agreement to be the &ldquo;<U>Final Closing Cash Consideration Statement</U>&rdquo; and each shall be
final and binding on all parties to this Agreement and on all Company Equityholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Company Equityholder Representative agrees in writing to Buyer&rsquo;s calculation of the Closing Cash Consideration,
as proposed in Buyer&rsquo;s Preliminary Closing Cash Consideration Statement, then such Preliminary Closing Cash Consideration
shall be deemed for all purposes of this Agreement to be the &ldquo;<U>Final Closing Cash Consideration</U>,&rdquo; such Preliminary
Closing Cash Consideration Statement shall be deemed for all purposes of this Agreement to be the &ldquo;<U>Final Closing Cash
Consideration Statement</U>&rdquo; and each shall be final and binding on all parties to this Agreement and on all Company Equityholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Company Equityholder Representative disputes the Preliminary Closing Cash Consideration as shown on Buyer&rsquo;s
Preliminary Closing Cash Consideration Statement, then the Company Equityholder Representative shall deliver to the Buyer within
thirty (30) days after receipt of the Preliminary Closing Cash Consideration Statement a statement setting forth the Company Equityholder
Representative&rsquo;s calculation of the Closing Cash Consideration, including each component thereof (an &ldquo;<U>Objection
Statement</U>&rdquo;). The Buyer and the Company Equityholder Representative shall seek in good faith to resolve such differences
regarding the determination of the Closing Cash Consideration for a period of thirty (30) days after the Buyer&rsquo;s receipt
of the Objection Statement from the Company Equityholder Representative.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Buyer and the Company Equityholder Representative reach a final resolution on the Closing Cash Consideration within
thirty (30) days after the Buyer&rsquo;s receipt of the Objection Statement given by the Company Equityholder Representative (or
within any additional period as mutually agreed to between the Buyer and the Company Equityholder Representative), then the Closing
Cash Consideration agreed upon by the Buyer and the Company Equityholder Representative shall be deemed for all purposes of this
Agreement to be the &ldquo;Final Closing Cash Consideration,&rdquo; the corresponding statement calculating such Closing Cash Consideration
shall be deemed for all purposes of this Agreement to be the &ldquo;Final Closing Cash Consideration Statement&rdquo; and each
shall be final and binding on all parties to this Agreement and on all Company Equityholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Buyer and the Company Equityholder Representative do not reach a final resolution on the Closing Cash Consideration
within thirty (30) days after the Buyer&rsquo;s receipt of the Objection Statement (or within any additional period as mutually
agreed to between the Buyer and the Company Equityholder Representative), then the Buyer and the Company Equityholder Representative
shall be entitled to engage PricewaterhouseCoopers or another nationally recognized auditing firm mutually agreeable to the Buyer
and the Company Equityholder Representative (the &ldquo;<U>Neutral Accountant</U>&rdquo;) to determine, in the manner provided
below, the Closing Cash Consideration, pursuant to an engagement agreement executed by the Company Equityholder Representative,
the Buyer and the Neutral Accountant. The Company Equityholder Representative and the Buyer shall each be entitled to make a presentation
to the Neutral Accountant, pursuant to procedures to be agreed to in good faith among the Company Equityholder Representative,
the Buyer and the Neutral Accountant (or, if they cannot agree on such procedures, pursuant to procedures determined by the Neutral
Accountant), regarding each of their respective calculations of the Closing Cash Consideration; and the Company Equityholder Representative
and the Buyer shall instruct the Neutral Accountant to resolve such differences and determine the Closing Cash Consideration within
twenty (20) Business Days after the completion of such presentations to the Neutral Accountant. Absent fraud or manifest error,
or contravention with clause (C) below, the Neutral Accountant&rsquo;s determination of the Closing Cash Consideration hereunder
shall for all purposes of this Agreement be deemed to be the &ldquo;<U>Final Closing Cash Consideration</U>,&rdquo; the statement
setting forth the Neutral Accountant&rsquo;s calculation thereof shall for all purposes of this Agreement be deemed to be the &ldquo;<U>Final
Closing Cash Consideration Statement</U>&rdquo; and each shall be final and binding on all parties to this Agreement and on all
Company Equityholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(C)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Neutral Accountant shall not be authorized or permitted to: (1) determine any questions or matters whatsoever under
or in connection with this Agreement except for the resolution of differences between the Company Equityholder Representative and
the Buyer regarding the determination of the Closing Cash Consideration in accordance with this <U>Section 2.6</U>; (2) resolve
any such differences by making an adjustment to the Closing Cash Consideration or any component thereof that is outside of the
range defined by amounts as finally proposed by the Buyer in the Preliminary Closing Cash Consideration or the Company Equityholder
Representative in the Objection Statement; or (3) apply any accounting principles, policies, methods, treatments or procedures
other than those that are in accordance with GAAP (applied on a basis consistent with the preparation of the Company Financial
Statements) and consistent with the methodology and format set forth in the Illustrative Closing Cash Consideration Statement.
In determining the Closing Cash Consideration hereunder, the Neutral Accountant shall act as an expert and not as arbitrator.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(D)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The fees and expenses of the Neutral Accountant will be paid by the Company Equityholders (out of the Escrow Fund), on the
one hand, and by the Buyer, on the other hand, according to the degree to which the positions of the respective parties are not
accepted by the Neutral Accountant.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The &ldquo;<U>Final Closing Cash Consideration Adjustment</U>&rdquo; shall be equal to (A) the Final Closing Cash Consideration
(as set forth on the Final Closing Cash Consideration Statement), as finally determined pursuant to this <U>Section 2.6</U>, minus
(B) the Estimated Closing Cash Consideration. For the avoidance of doubt, the Final Closing Cash Consideration Adjustment may be
a positive or negative number. If the Final Closing Cash Consideration Adjustment is less than zero (0), then the Buyer shall be
entitled to receive payment of the Final Closing Cash Consideration Adjustment from any then available Escrow Fund pursuant to
<U>Section 2.1(e)(i)</U>; <U>provided</U> that, if the Final Closing Cash Consideration Adjustment is less than zero (0) by $1,000,000
or more, then the Buyer may elect to setoff against any payment of Earn-Out Consideration that may become payable all or any portion
of the Final Closing Cash Consideration Adjustment. If the Final Closing Cash Consideration Adjustment is greater than zero (0),
then promptly (and in no event later than two (2) Business Days after the date of determination of the Final Closing Cash Consideration):
(1) a portion thereof equal to the Per Share Adjustment Amount that is represented by each share of Company Stock converted pursuant
to <U>Section 2.1(c)</U>, less the portion thereof to be paid to Leerink Partners LLC as set forth on the Allocation Schedule,
shall be paid by the Buyer to the Exchange Agent for payment to the holder thereof, (2) a portion thereof equal to the Per Share
Adjustment Amount that is represented by each Company Option, less the portion thereof to be paid to Leerink Partners LLC as set
forth on the Allocation Schedule, shall be paid by the Buyer or the Surviving Corporation to the holder thereof (which amount shall
be paid by the Buyer or the Surviving Corporation to such holder on the first payroll payment date after the Buyer&rsquo;s or the
Surviving Corporation&rsquo;s receipt of such amount; <U>provided</U> that if the Buyer or Surviving Corporation received such
amount fewer than five (5) Business Days prior to such payroll payment date, the amount shall be paid on the next payroll payment
date, and (3) the portion thereof to be paid to Leerink Partners LLC as set forth on the Allocation Schedule shall be paid by the
Buyer to Leerink Partners LLC, in each case shall be subject to any applicable withholding as provided in <U>Section 2.10</U>).
For the avoidance of doubt, the Buyer shall (in accordance with the Allocation Schedule) cause (x) the Surviving Corporation to
use any funds distributed to the Surviving Corporation pursuant to this <U>Section 2.6(b)(iv)</U> and (y) the Exchange Agent to
use any funds distributed to the Exchange Agent pursuant to this <U>Section 2.6(b)(iv)</U> to make the payments provided for in
this <U>Section 2.6(b)(iv)</U>, and such funds shall not be used for any other purpose.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Buyer shall provide or cause to be provided to the Company Equityholder Representative and its attorneys, accountants
and other agents reasonable access (including electronic access, to the extent available), during normal business hours, to the
applicable books, records, properties and personnel of the Buyer, the Company and the Surviving Corporation for purposes of (A)
evaluating the information in the Preliminary Closing Cash Consideration and the Closing Cash Consideration and (B) preparing any
Objection Statement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(vi)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The parties agree that, except for the rights of the Buyer Indemnified Parties under <U>Section 8.1(c)</U>, the procedures
set forth in this <U>Section 2.6</U> shall be the sole and exclusive method for resolving any disputes with respect to the determination
of the Final Closing Cash Consideration; <U>provided</U> that this provision shall not prohibit the Buyer or the Company Equityholder
Representative from instituting litigation to enforce the ruling of the Neutral Accountant.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">2.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Allocation Schedule; Payments of Future Contingent Payments</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On the date hereof, the Company shall deliver to the Buyer and the Exchange Agent the Allocation Schedule (attached as an
exhibit to the Closing Payment Certificate). The Illustrative Allocation Schedule shall be, and shall constitute the Company&rsquo;s
delivery of, the Allocation Schedule. From time to time after the Effective Time and without limiting the rights of the Buyer Indemnified
Parties under <U>Section 8.1(e)</U>, the Company Equityholder Representative may, by written notice to the Buyer, update, correct
or otherwise amend or modify the Allocation Schedule in any manner that is not otherwise inconsistent with the express provisions
of this <U>Article II</U> and in a manner that will not increase the aggregate consideration that is paid hereunder.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Exchange Agent shall make all payments constituting the Closing Cash Consideration to the applicable Company Stockholders
in accordance with the Allocation Schedule, and the Buyer or the Surviving Corporation shall pay the portion of the Closing Cash
Consideration payable in respect of Company Options pursuant to <U>Section 2.5(a)</U> to the holders thereof in accordance with
the Allocation Schedule (subject to any applicable withholding as provided in <U>Section 2.10</U>).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The portion of each Future Contingent Payment payable in respect of Company Stock shall be paid by the Buyer or the Surviving
Corporation to the Exchange Agent for the benefit of the holders thereof, and the portion of each Future Contingent Payment payable
in respect of Company Options shall be paid (subject to any applicable withholding as provided in <U>Section 2.10</U>) by the Buyer
or the Surviving Corporation to the holders thereof, in each case in accordance with the Allocation Schedule within the time periods
set forth herein for such payments.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The parties understand and agree that (i) the Future Contingent Payments are an integral part of the consideration payable
to the Company Equityholders in connection with the transactions contemplated hereby and shall be payable without offset or counterclaim,
except as otherwise set forth herein, (ii) the Company Equityholders have no rights as a security holder of the Surviving Corporation
or the Buyer as a result of their right to receive the Future Contingent Payments, and (iii) except as otherwise provided in <U>Section
2.8(e)(ii)(C)</U>, no interest is payable as additional consideration with respect to the Aggregate Closing Consideration or any
of the Future Contingent Payments. For the avoidance of doubt, subject to <U>Section 2.8</U>, more than one (1) Future Contingent
Payment may become payable as provided herein.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">2.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Earn-Out Consideration</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company Equityholders shall be entitled, on a Product-by-Product and country-by-country basis, to (i) [****] of annual
calendar year Net Sales of each Product during the applicable Earn-Out Term for such Product in such country that are within the
first [****] of aggregate (in all countries in which the applicable Earn-Out Term(s) for the applicable Product(s) have not ended)
worldwide Net Sales of Products during such calendar year, (ii) [****] of annual calendar year Net Sales of each Product during
the applicable Earn-Out Term for such Product in such country that are within the next [****] of aggregate (in all countries in
which the applicable Earn-Out Term(s) for the applicable Product(s) have not ended) worldwide Net Sales of Products during such
calendar year and (iii) [****] of annual calendar year Net Sales of each Product during the applicable Earn-Out Term for such Product
in such country that are in excess of [****] of aggregate (in all countries in which the applicable Earn-Out Term(s) for the applicable
Product(s) have not ended) worldwide Net Sales of Products during such calendar year (the &ldquo;<U>Earn-Out Consideration</U>&rdquo;).
For the avoidance of doubt, any damages or other monetary awards recovered by the Buyer Group in connection with a proceeding to
address infringement or misappropriation by a third party of any patent relating to the manufacture, use, sale, offer for sale
or importation of a Product, after the payment of any costs or expenses of the party bringing suit, to the extent that is payable
in lieu of lost sales or lost profits for a Product, shall be deemed to be Net Sales for purposes of calculating the Earn-Out Consideration
payable to the Company Equityholders under this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Diligence</U>. Following the Closing, the Buyer shall, and shall cause each applicable member of the Buyer Group to,
use Commercially Reasonable Efforts to (i) prosecute and seek the issuance of a patent covering a Product from any of the patents
listed in <U>Section 3.10(a)</U> of the Company Disclosure Schedule, (ii) seek Orphan Drug Exclusivity for Product(s) in each country
in which such exclusivity is available and in which a member of the Buyer Group commercializes such Product(s), (iii) seek marketing
approval for a Product from the FDA and the EMA, (iv) complete the Current Phase 3 Clinical Trial in accordance with <U>Schedule
2.8(b)</U> attached hereto and (v) commercialize a Product until the end of the applicable Earn-Out Term, in each case with respect
to (i), (ii), (iii), (iv) and (v), to the extent Commercially Reasonable to do so; <U>provided</U> that neither Buyer nor any other
member of the Buyer Group shall have any obligation to take any action to the extent: (1) Buyer or the applicable member of the
Buyer Group is prohibited from doing so by an applicable regulatory authority or by applicable Law; (2) undertaking any trial or
other activity would reasonably be expected to represent an inappropriate risk to patient safety, as reasonably determined by the
Buyer in good faith; or (3) doing so would reasonably be expected to cause significant damage to the overall long-term value of
the Product; <U>provided</U>, <U>further</U>, that, so long as the Buyer is using Commercially Reasonable Efforts to develop or
to commercialize one Product, nothing in this Agreement shall require the Buyer or any other member of the Buyer Group to develop
or to commercialize any other Product; <U>provided</U>, <U>further</U>, that nothing in this Agreement shall require the Buyer
or any other member of the Buyer Group to [****].</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reporting; Meetings</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reporting</U>. From and after the Closing and until such time as all Earn-Out Consideration and the Priority Review Voucher
Payment have been paid by the Buyer pursuant to this <U>Section 2.8</U> or <U>Section 2.11</U>, respectively or until all development
efforts cease in accordance with this Agreement (or in case of the Priority Review Voucher Payment that the Voucher has not been
issued and is not capable of being issued), the Buyer shall provide the Company Equityholder Representative, within [****] days
following (A) as to the [****] ending following the Effective Time, [****] of each such calendar year, and (B) thereafter, [****]
of each such calendar year, with reasonably detailed periodic written reports of the status of activities of the members of the
Buyer Group reasonably pertinent to the Earn-Out Consideration or the Voucher, as applicable, and their then-current plans with
respect to the development and commercialization of the Products that include the following, with respect to the Products and the
Voucher:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the status of planned and ongoing clinical trials, including [****];</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the status of material completed regulatory filings (including applications for manufacturing, marketing and pricing approvals);</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(C)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>material correspondence with Governmental Entities regarding regulatory matters with respect to the Voucher; and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(D)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>other matters relating to the status of the Voucher and the status of development, Regulatory Approval or manufacture of
any Product that would be reasonably likely to materially impact whether and when any Earn-Out Consideration is earned.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Net Sales Reporting, Records and Audits</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Quarterly Net Sales Reports</U>. During the Earn-Out Term, the Buyer shall provide the Company Equityholder Representative,
within [****] days following the end of each calendar quarter, with a Net Sales report setting forth, on an aggregate basis, gross
amounts invoiced on sales of the Products, all deductions subtracted therefrom in calculating Net Sales (on a deduction category-by-deduction
category basis) and Net Sales.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2in; margin: 0pt 0">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Records and Audits</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2.5in; margin: 0pt 0">A.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>During the Earn-Out Term, the Buyer agrees to keep, and to cause all other members of the Buyer Group to keep, full, clear
and accurate records for a minimum period of [****] after the relevant Net Sales occur, setting forth the sales of the Products
in sufficient detail to enable Net Sales to be determined.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2.5in; margin: 0pt 0">B.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Buyer further agrees, upon not less than [****] prior written notice, to permit, and to cause all other members of the Buyer
Group to permit, the books and records relating to such Net Sales to be examined by an independent accounting firm selected by
the Company Equityholder Representative and reasonably acceptable to Buyer for the purpose of verifying reports provided by Buyer
under <U>Section 2.8(c)(ii)(A)</U>. Such audit shall not be performed more frequently than once in any twelve (12)-month period,
and shall be conducted under appropriate confidentiality provisions, for the sole purpose of verifying the accuracy and completeness
of such reports. The independent accounting firm shall have the right to make copies of relevant portions of the audited books
and records; provided that any such copies shall be the confidential information of the applicable member of the Buyer Group and
shall be protected by appropriate confidentiality obligations.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 2.5in; margin: 0pt 0">C.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Such examination is to be made at the expense of the Company Equityholders, except if the results of the audit reveal an
underreporting of Net Sales under this Agreement of [****] or more in any calendar year, in which case reasonable out-of-pocket
audit fees for such examination shall be paid by the Buyer.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Meetings</U>. Following receipt by the Company Equityholder Representative of each such report, (i) the Company Equityholder
Representative may request a meeting with a senior representative of the Buyer designated by Buyer having knowledge thereof (the
&ldquo;<U>Buyer Representative</U>&rdquo;) and (ii) the Buyer Representative shall use diligent efforts to respond in reasonable
detail, during such meeting, telephone conference or video conference if practicable (or, if not then practicable, as soon as practicable
thereafter), to the Company Equityholder Representative&rsquo;s reasonable inquiries, in each case for the purpose of providing
the Company Equityholder Representative with an opportunity to inquire about the content of such report and the efforts, progress
and plans of the Buyer and/or the other members of the Buyer Group relating to the Earn-Out Consideration and to obtaining the
Voucher. If the Company Equityholder Representative so requests a meeting, the Company Equityholder Representative and the Buyer
Representative shall promptly, and in any event not later than [****] following such request, meet in person or by telephone conference
or video conference as mutually agreed by the applicable parties. Nothing in this <U>Section 2.8(c)(iii)</U> shall require the
Buyer Representative to provide more information than the Buyer otherwise is required to provide pursuant to this <U>Section&nbsp;2.8(c)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sale of Product Line</U>. If at any time the Buyer or any of its Affiliates (including the Surviving Corporation) directly
or indirectly consummates a Product Line Sale, then the Buyer shall require, as a condition to the consummation of such Product
Line Sale, that the acquirer assume, in an assumption agreement to which the Company Equityholders are made third party beneficiaries,
the Buyer&rsquo;s remaining obligations under this <U>Section 2.8</U> and under <U>Section 2.11</U>, as applicable. In the event
the acquirer is a publicly traded company with a market capitalization of not less than [****] at the time of such Product Line
Sale, the Buyer shall have no further responsibility or liability for such obligations under this <U>Section 2.8</U> and under
<U>Section 2.11</U> once the acquirer has assumed such obligations as set forth above. In the event of a Product Line Sale to any
other Person, the Buyer shall remain liable for the remaining obligations under this <U>Section 2.8</U> and under <U>Section 2.11</U>
and the Company Equityholder Representative may enforce those obligations directly against the Buyer to the extent such purchaser
shall have not fully performed those obligations within [****] of the date required under this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payments</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Within [****] after the end of each calendar quarter in which Net Sales giving rise to Earn-Out Consideration occur, the
Buyer shall (or shall cause the Surviving Corporation to) pay in cash (A) through its payroll system to the applicable Company
Equityholders in respect of their Company Options the applicable Per Share Future Contingent Consideration attributable to such
Earn-Out Consideration, (B) to the Exchange Agent (for further distribution to the Company Stockholders) the applicable Per Share
Future Contingent Consideration attributable to such Earn-Out Consideration and (C) to Leerink Partners LLC the portion of such
Future Contingent Payments set forth on the Allocation Schedule. Each such payment shall be made in accordance with the Allocation
Schedule.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The parties understand and agree that (A) the Earn-Out Consideration and the Priority Review Voucher Payment are an integral
part of the consideration payable to the Company Equityholders in connection with the transactions contemplated hereby and shall
be payable without setoff or counterclaim, except as otherwise provided herein and (B) the Company Equityholders have no rights
as a security holder of the Surviving Corporation or the Buyer as a result of their right to receive the Earn-Out Consideration
and the Priority Review Voucher Payment.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidentiality</U>. All information provided to the Company Equityholder Representative or any of its representatives
pursuant to this <U>Section 2.8</U> or <U>Section 2.11</U>, whether written or oral, shall be held in confidence by such Person;
<U>provided</U> that the Company Equityholder Representative may disclose such information, in each case on a confidential basis,
to (i) its advisors, employees and consultants and (ii) to any Company Equityholder that is subject to a Joinder Agreement or separate
confidentiality agreement in a form acceptable to the Buyer, including, for the avoidance of doubt, the Advisory Group, and any
such Company Equityholder that is a venture capital fund or other institutional or strategic investor may disclose to its limited
partners such venture capital fund&rsquo;s or other institutional or strategic investor&rsquo;s share of the total Future Contingent
Payments payable or that may become payable under this Agreement and the valuation such venture capital fund has placed on its
expected return from the Merger.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">2.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Transferability</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The right of any Company Equityholder to receive any amounts with respect to the Earn-Out Consideration or any other Future
Contingent Payment (i) shall not be evidenced by a certificate or other instrument, (ii) shall not be assignable or otherwise transferable
by such Company Equityholder other than (A) on death by will or intestacy, (B) pursuant to a court order, (C) by operation of Law
(including a consolidation or merger), (D) to or for the benefit of any spouse, children, parents, uncles, aunts, siblings, grandchildren
(collectively, &ldquo;<U>Approved Relatives</U>&rdquo;) or to a trust established solely for the benefit of such Company Equityholder
and/or his or her Approved Relatives; <U>provided</U> that such transferee shall, as a condition to such transfer, deliver to the
Buyer, the Company and following the Closing, the Surviving Corporation a written instrument confirming that such transferee shall
be bound by all of the terms and conditions of this Agreement or (E) without consideration in connection with the dissolution,
liquidation or termination of any corporation, limited liability company, partnership or other entity or (F) in the case of Earn-Out
Consideration only to an Earn-Out Consideration Purchaser and (iii) does not represent any right other than the right to receive
Future Contingent Payments. Any attempted transfer of the right to any amounts with respect to a Future Contingent Payment by any
holder thereof (other than as specifically permitted by the immediately preceding sentence) shall be null and void.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company Equityholder Representative on behalf of all Company Equityholders who elect to be included in such sale (the
&ldquo;<U>Participating Equityholders</U>&rdquo;) may negotiate and consummate the sale of all right, title and interest of all
such Participating Equityholders to receive any Earn-Out Consideration under this Agreement to a single Earn-Out Consideration
Purchaser (the &ldquo;<U>Earn-Out Sale</U>&rdquo;); <U>provided</U> that the Earn-Out Consideration Purchaser shall agree with
the Buyer in writing, as a condition to the sale, to be bound by the terms and conditions of this Agreement, including all indemnity
obligations of Participating Equityholders, and shall agree to the confidentiality provisions in <U>Section 2.8(f)</U> of this
Agreement. The Buyer shall, upon the request of the Company Equityholder Representative, cooperate in good faith with the Company
Equityholders, at no expense or current or future liability to the Buyer (including any obligation to enter into any agreement
or make any representation or warranty), in the execution and delivery of such documents as shall reasonably be required to consummate
the Earn-Out Sale (and the Company Equityholder Representative shall reimburse Buyer for all reasonable third party costs incurred
by Buyer in connection with such transaction); <U>provided</U> that (i) the manner, timing and disclosures relating to the Earn-Out
Sale and right to participate in the Earn-Out Sale shall be conducted in compliance with all applicable Laws, and (ii) the Company
Equityholder Representative shall provide Buyer a draft of the document used to solicit Participating Equityholders to participate
in the proposed Earn-Out Sale, and, in the case of each of (i) and (ii), shall be subject to the prior written approval of the
Buyer (such approval not to be unreasonably withheld, delayed or conditioned).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary in this Agreement:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Earn-Out Consideration Purchaser shall be entitled to receive the information set forth in <U>Section 2.8(c)(i)(A)</U>
and the Net Sales reports pursuant to <U>Section 2.8(c)(ii)</U>; <U>provided</U> that neither the Earn-Out Consideration Purchaser
nor, as of the consummation of a sale or other transfer to an Earn-Out Consideration Purchaser, any Company Equityholder (or the
Company Equityholder Representative, on behalf of any Company Equityholder), shall be entitled to any other reports pursuant to
<U>Section 2.8(c)(i)</U> (other than <U>Section 2.8(c)(i)(A)</U> with respect to the Earn-Out Consideration Purchaser) or otherwise
or to participate in any meetings or request additional information pursuant to <U>Section 2.8(c)(iii)</U> or otherwise, except
that Earn-Out Consideration Purchaser (in substitution of the Company Equityholder Representative and not in addition to) shall
be entitled to audit the books and records of the Buyer Group relating to Net Sales, to the extent the Company Equityholder Representative
is entitled to do so pursuant to <U>Section 2.8(c)</U>;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>neither the Earn-Out Consideration Purchaser nor, as of and following the consummation of the Earn-Out Sale any Company
Equityholder (or the Company Equityholder Representative, on behalf of any Company Equityholder) shall have any rights under <U>Section
2.8(b)</U>, and neither the Buyer nor any other member of the Buyer Group shall have any obligation under <U>Section 2.8(b)</U>
from and after the consummation of the Earn-Out Sale;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Earn-Out Consideration Purchaser shall be entitled to directly enforce the payment of the Earn-Out Consideration;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Company Equityholders shall be entitled to consummate one transaction with one Earn-Out Consideration Purchaser, and
none of the Company Equityholders or the Company Equityholder Representative shall have any further right to enter into any further
transaction with an Earn-Out Consideration Purchaser;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>each Participating Equityholder shall, severally and not jointly, in accordance with such Participating Equityholder&rsquo;s
pro rata share of the proceeds from any Earn-Out Sale (or, if the Company Equityholders have not yet elected whether to be Participating
Equityholders, each Company Equityholder shall, severally and not jointly, in accordance with such Company Equityholder&rsquo;s
Pro Rata Share), indemnify the Buyer Indemnified Parties in respect of, and hold them harmless against and reimburse them for,
any Damages suffered, incurred or sustained by any Buyer Indemnified Party resulting from or arising out of any Earn-Out Sale (or
proposed Earn-Out Sale), including with respect to (A) the manner, timing and disclosure of the offering and sale thereof, (B)
any claims by the Earn-Out Consideration Purchaser or (C) otherwise in connection with the exercise by any Company Equityholder
of its rights under, or the breach of, <U>Section 2.9(b)</U> or this <U>Section 2.9(c)</U>, in each case, except to the extent
resulting from the breach of this Agreement by a Buyer Indemnified Party.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">2.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Withholding Rights</U>. Each of the Exchange Agent, the Buyer, the Escrow Agent and the Surviving Corporation (and any
payroll agent) shall be entitled to deduct and withhold from any consideration otherwise payable pursuant to this Agreement to
the Company Equityholders such amounts as it is required to deduct and withhold with respect to the making of such payment under
the Code, or any other applicable U.S., state, local or non-U.S. Law. To the extent that amounts are so deducted or withheld by
the Exchange Agent, the Buyer, the Escrow Agent or the Surviving Corporation (or any payroll agent), as the case may be, such withheld
amounts shall be (i) remitted by the Exchange Agent, the Buyer, the Escrow Agent or the Surviving Corporation, as the case may
be, to the applicable Person, and (ii) to the extent remitted, treated for all purposes of this Agreement as having been paid to
such Company Equityholder in respect of which such deduction and withholding was made by the Exchange Agent, the Buyer, the Escrow
Agent or the Surviving Corporation (or any payroll agent), as the case may be. Any withholding made at Closing with respect to
a Company Equityholder&rsquo;s deemed receipt of its proportionate share of the Company Equityholder Representative Expense Amount
shall be satisfied from such Company Equityholder&rsquo;s share of the Closing Cash Consideration and any withholding made at Closing
that is attributable to a payment of Buyer Common Stock Consideration to a Company Equityholder shall be satisfied from the applicable
Company Equityholder&rsquo;s share of Closing Cash Consideration.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">2.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Priority Review Voucher</U>. The Buyer acknowledges that under applicable Law as of the date hereof and as currently
interpreted a Voucher may be obtained if approval of an NDA for a Product by the FDA for pediatric Niemann-Pick Disease, Type C
is the first approval obtained for such Product in the United States. If the Buyer obtains approval of an NDA for a Product by
the FDA for pediatric Niemann-Pick Disease, Type C as the first approval for such Product in the United States, the Buyer shall
request a Voucher in such NDA submission if the voucher program remains in effect at the time of such NDA approval. If the Buyer
obtains such Voucher, and if (a) the Buyer elects to use such Voucher for one of its or any of its Affiliates&rsquo; products,
then upon such election Buyer shall provide written notification thereof to the Company Equityholder Representative and, within
[****], pay to the Company Equityholders [****] of the Deemed Proceeds attributable to such Voucher or (b) the Buyer elects to
sell such Voucher to a third party, then, within [****] after the Buyer receives proceeds of such sale, the Buyer shall pay to
the Company Equityholders [****] of the net proceeds of such sale, in each case after deducting all transaction costs incurred
by the Buyer in connection with the sale of the Voucher, including legal fees, advisor fees, and all Taxes in connection therewith,
including Income Taxes paid or payable by the Buyer as a result of the sale of the Voucher (it being understood that, unless the
Buyer and the Company Equityholder Representative agree otherwise, the Buyer shall make multiple payments pursuant to this clause
(b) to the extent the Buyer receives proceeds in more than one increment). The Buyer shall pay to Leerink Partners LLC the portion
of each such payment otherwise due to the Company Equityholders, as set forth on the Allocation Schedule. The Company Equityholders
shall be entitled to only one payment (or a series of related payments as contemplated by the parenthetical in the previous sentence)
pursuant to either clause (a) or (b) of the prior sentence (as applicable, the &ldquo;<U>Priority Review Voucher Payment</U>&rdquo;).
For the avoidance of doubt, if there is a change in applicable Law such that the Buyer is not permitted to sell the Voucher to
a third party and the Buyer does not elect to use the Voucher as contemplated by clause (a) above, then no payment shall be due
under this <U>Section 2.11</U>. In the case of the sale of such Voucher to a third party, (i) the amount of Income Taxes paid or
payable by the Buyer as a result of the sale of the Voucher shall be determined by [****], (ii) the amount of income recognized
shall not be reduced by [****], (iii) the amount of Income Taxes shall not be reduced by [****], (iv) the reduction in any tax
attribute (such as a Tax credit or net operating loss) of the Buyer as a result of the sale of such Voucher shall be deemed to
be [****], (v) the Buyer&rsquo;s tax basis in such Voucher shall be assumed to be [****], and (vi) the Tax rate applied to such
income as calculated shall be [****]. The Buyer shall pay, or shall cause the Surviving Corporation to pay, the Priority Review
Voucher Payment (if payable) in cash (i) to the applicable Company Equityholders in respect of their Company Options the applicable
Per Share Future Contingent Consideration attributable to the Priority Review Voucher Payment and (ii) to the Exchange Agent (for
further distribution to the Company Stockholders) the applicable Per Share Future Contingent Consideration attributable to the
Priority Review Voucher Payment. As provided in <U>Section 2.8(d)</U>, the provisions of this <U>Section 2.11</U> shall apply to
the use or sale of a Voucher by a transferee (or any of its Affiliates) in a Product Line Sale if the Voucher is obtained after
the consummation of the Product Line Sale. If a Product Line Sale is consummated after a Voucher has been obtained and the Buyer
has not made the Priority Review Voucher Payment prior to the consummation of such Product Line Sale, then the Voucher shall be
deemed to have the value allocated to it by the parties to such transaction, which value shall not be less than the Deemed Proceeds
(as if clause (a) above were applicable, but taking into account Income Taxes payable by the Buyer or its Affiliates in connection
with such transaction).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">2.12<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Taking of Necessary Action; Further Action</U>. If at or any time after the Effective Time any further action is necessary
or desirable to vest the Buyer with control over, and to vest, perfect, or confirm of record or otherwise in the Surviving Corporation
any and all right, title and possession to, all assets, property, rights, privileges, powers and franchises of the Company, the
officers and directors of the Surviving Corporation and the Buyer shall, in the name of their respective corporations or otherwise,
be fully authorized to take all such lawful and necessary action.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>ARTICLE
III</B></FONT><BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company represents and warrants to the Buyer
that the statements contained in this <U>Article III</U> are true and correct, except as set forth herein or in the Company Disclosure
Schedule.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Organization, Standing and Power</U>. The Company is a corporation duly organized, validly existing and in good standing
under the Laws of the State of Delaware, has all requisite corporate power and authority to own, lease and operate its properties
and assets and to carry on its business as conducted on the date of this Agreement. The Company is duly qualified to do business
and is in good standing as a foreign corporation in each jurisdiction in which the character of the properties it owns, operates
or leases or the nature of its activities makes such qualification necessary, except for such failures to be so organized, qualified
or in good standing that, individually or in the aggregate, would not reasonably be expected to have a Company Material Adverse
Effect. The Company has made available to the Buyer copies of its Organizational Documents as in effect on the date of this Agreement,
any actions by the Company&rsquo;s board of directors, any committee thereof or stockholders and minutes of all meetings of the
Company&rsquo;s board of directors, any committee thereof and stockholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Capitalization</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The authorized capital stock of the Company, as of the date of this Agreement, consists of 59,667,594 shares of Company
Common Stock and 42,547,398 shares of Company Preferred Stock, of which 42,547,398 shares are designated as Company Series A Preferred
Stock. As of the date of this Agreement, there are outstanding 10,039,998 shares of Company Common Stock and 42,547,395 shares
of Company Series A Preferred Stock. <U>Section 3.2(a)</U> of the Company Disclosure Schedule sets forth a complete and accurate
list, as of the date of this Agreement, of all outstanding shares of Company Stock indicating the names of the holders thereof
and the number of shares and class of Company Stock held by each such holder. Each class of the Company&rsquo;s capital stock is
entitled to the rights and privileges set forth in the Company Certificate of Incorporation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 3.2(b) of the Company Disclosure Schedule sets forth a complete and accurate list, as of the date of this Agreement,
of all outstanding Company Equity Awards, indicating with respect to each such Company Equity Award the name of the holder thereof,
the number of shares of Company Common Stock subject to such Company Equity Award, whether any Company Option is an incentive stock
option under Section 422 of the Code, the date of grant and, if applicable, the exercise or measurement price thereof. The Company
has made available to the Buyer a complete and accurate copy of the Company Stock Plan and the standard form of award agreement
evidencing Company Equity Awards, including copies of any individual award agreement that differs in any material respect from
the Company&rsquo;s standard form of award agreement. No Company Options have been granted with an exercise price that was less
than the fair market value of the Company&rsquo;s Common Stock on the date of grant or are otherwise subject to Section 409A of
the Code. No Company Restricted Stock Awards have been granted at a price (whether paid by the recipient or recognized as compensation)
that was less than the fair market value of the Company&rsquo;s Common Stock on the date of grant or are otherwise subject to Section
409A of the Code. The Company has provided the Buyer with a copy of all third-party valuation reports, or internal reports prepared
for purposes of valuing the Company&rsquo;s Common Stock and used in connection with establishing the exercise price for Company
Options.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except (i) as set forth in this <U>Section 3.2</U>, (ii) as reserved for future grants under the Company Stock Plan and
(iii) for the conversion provisions set forth in the Company Certificate of Incorporation, (A) there are no Equity Interests of
any class of the Company, or any security exchangeable into or exercisable for such Equity Interests, issued, reserved for issuance
or outstanding, including phantom equity, (B) there are no bonds, debentures, notes or other Indebtedness having the right to vote,
consent along with or convert into Equity Interests of the Company and (C) there are no options, warrants, equity securities, calls,
rights, conversion rights, preemptive rights, co-sale rights, rights of first refusal or similar rights, commitments or agreements
to which the Company is a party or by which the Company is bound obligating the Company to issue, exchange, transfer, deliver or
sell, or cause to be issued, exchanged, transferred, delivered or sold, additional shares of capital stock or other Equity Interests
of the Company or any security or rights convertible into or exchangeable or exercisable for any such shares or other Equity Interests,
or obligating the Company to grant, extend, otherwise modify or amend or enter into any such option, warrant, Equity Interest,
call, right, conversion right, preemptive right, co-sale right, right of first refusal or similar right, commitment or agreement.
Except as set forth in this <U>Section 3.2</U>, as of the date of this Agreement, the Company does not have any outstanding equity
compensation or equity-based compensation. Except for the Company Certificate of Incorporation, the Company is not a party to or
bound by any agreements with respect to the voting (including voting trusts and proxies) or sale or transfer of any shares of capital
stock or other Equity Interests of the Company. There are no existing rights with respect to registration of any Equity Interests
of the Company on a public securities exchange. The Company does not hold any Equity Interests in treasury.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All outstanding shares of Company Stock are, and all shares of Company Stock subject to issuance as specified in <U>Section
3.2(b)</U>, upon issuance on the terms and conditions specified in the instruments pursuant to which they are issuable, have been
issued and granted in compliance with all applicable securities Laws will be, duly authorized, validly issued, fully paid and nonassessable
and not subject to or issued in violation of any purchase option, call option, right of first refusal, preemptive right or subscription
right under any provision of the DGCL, the Company&rsquo;s certificate of incorporation or by-laws or any agreement to which the
Company is a party or is otherwise bound.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no obligations, contingent or otherwise, of the Company or any of its Subsidiaries to repurchase, redeem or otherwise
acquire any shares of Company Stock or the capital stock of the Company or any of its Subsidiaries, or make any investment in the
equity securities of any Person.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsidiaries</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 3.3(a) of the Company Disclosure Schedule sets forth, as of the date of this Agreement, for each Subsidiary of the
Company: (i) its name; (ii) the number and type of outstanding Equity Interests and a list of the holders thereof; and (iii) the
jurisdiction of organization. Other than the Subsidiaries listed on Section 3.3(a) of the Company Disclosure Schedule, the Company
does not own, directly or indirectly, any Equity Interests or options to purchase Equity Interests of any other Person. The Company
owns, directly or indirectly, all of the outstanding Equity Interests of each Subsidiary, free and clear of all Liens other than
Permitted Liens. Except as disclosed in Section 3.3(a) of the Company Disclosure Schedule, (A) there are no preemptive rights or
other similar rights in respect of any Equity Interests in any Subsidiary of the Company, (B) there are no Liens, other than Permitted
Liens, on the ownership, transfer or voting of any Equity Interests in any Subsidiary of the Company, (C) except for the transactions
contemplated by this Agreement, there is no agreement, or provision in the Organizational Documents of any Subsidiary of the Company,
which obligates the Company or any of its Subsidiaries to purchase, redeem or otherwise acquire, or make any payment (including
any dividend or distribution) in respect of, any Equity Interest in any Subsidiary of the Company and (D) there are no existing
rights with respect to registration of any Equity Interests in any Subsidiary of the Company on a public securities exchange. All
issued and outstanding Equity Interests of each Subsidiary are validly issued, fully paid and non-assessable and not subject to
or issued in violation of any purchase option, call option, right of first refusal, preemptive right or subscription right under
any applicable Law, organizational document of such Subsidiary or any agreement to which such Subsidiary is a party or is otherwise
bound. There are no Equity Interests of any class of any Subsidiary of the Company, or any security exchangeable into or exercisable
for such Equity Interests, issued, reserved for issuance or outstanding, and there are no options, warrants, equity securities,
calls, rights, commitments or agreements to which any Subsidiary of the Company is a party or by which such Subsidiary is bound
obligating such Subsidiary to issue, exchange, transfer, deliver or sell, or cause to be issued, exchanged, transferred, delivered
or sold, additional shares of capital stock or other Equity Interests of such Subsidiary or any security or rights convertible
into or exchangeable or exercisable for any such shares or other Equity Interests, or obligating such Subsidiary to grant, extend,
otherwise modify or amend or enter into any such option, warrant, Equity Interest, call, right, commitment or agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Subsidiary of the Company is a corporation or similar entity duly organized, validly existing and in good standing
(to the extent such concepts are applicable) under the laws of the jurisdiction of its incorporation. Each Subsidiary of the Company
has all requisite corporate (or similar) power and authority to own, lease and operate its properties and assets and to carry on
its business as conducted as of the date of this Agreement, and is duly qualified to do business and is in good standing as a foreign
corporation (to the extent such concepts are applicable) in each jurisdiction where the character of its properties owned, operated
or leased or the nature of its activities makes such qualification necessary, except for such failures to be so organized, qualified
or in good standing that, individually or in the aggregate, would not reasonably be expected to have a Company Material Adverse
Effect.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has made available to the Buyer complete and accurate copies of the Organizational Documents of each Subsidiary
of the Company, any actions by the board of directors or similar governing body of such Subsidiary, any committee thereof or equityholders
and minutes of all meetings of any of the foregoing.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company Subsidiaries have no revenue, activities or liabilities, other than those that are incidental to their existence
as legal entities.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authority; No Conflict; Required Filings and Consents</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has all requisite corporate power and authority to enter into this Agreement and, subject to receipt of the
Company Stockholder Approval, to consummate the transactions contemplated by this Agreement. The board of directors of the Company
has (i) deemed the Merger advisable and in the best interests of the Company and its stockholders, (ii) approved this Agreement
and the Merger in accordance with the DGCL upon the terms and subject to the conditions set forth herein and (iii) recommended
the adoption of this Agreement by the stockholders of the Company. The execution and delivery of this Agreement and the consummation
of the transactions contemplated by this Agreement by the Company have been duly authorized by all necessary corporate action on
the part of the Company, subject only to the required receipt of the Company Stockholder Approval. This Agreement has been duly
executed and delivered by the Company and constitutes the valid and binding obligation of the Company, enforceable against the
Company in accordance with its terms, subject to the Bankruptcy and Equity Exception.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The execution and delivery of this Agreement by the Company does not, and the consummation by the Company of the transactions
contemplated by this Agreement will not, (i)&nbsp;conflict with, or result in any violation or breach of, the Organizational Documents
of the Company or any of its Subsidiaries, (ii)&nbsp;conflict with, or result in any violation or breach of, or constitute (with
or without notice or lapse of time, or both) a default (or give rise to a right of termination, cancellation or acceleration of
any obligation or loss of any material benefit) under, require a consent, waiver, or delivery of notice under, require the payment
of a penalty under or result in the imposition of any Liens, other than Permitted Liens, on the Company&rsquo;s or any of its Subsidiaries&rsquo;
assets under, any of the terms, conditions or provisions of any Company Material Contract, or (iii)&nbsp;subject to obtaining the
Company Stockholder Approval and compliance with the requirements specified in clauses (i) through (iii) of <U>Section 3.4(c)</U>,
conflict with or violate any Law applicable to the Company or any of its Subsidiaries or any of its or their respective properties
or assets.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No consent, approval, license, permit, order or authorization of, or registration, declaration, notice or filing with, any
Governmental Entity is required by or with respect to the Company or any of its Subsidiaries in connection with the execution and
delivery of this Agreement by the Company or the consummation by the Company of the transactions contemplated by this Agreement,
except for the filing of the Certificate of Merger with the Delaware Secretary of State.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Financial Statements</U>. The Company has made available to the Buyer the Company Financial Statements. The Company Financial
Statements were prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated therein and with
each other and fairly present, in all material respects, the consolidated financial condition of the Company and its Subsidiaries
at the dates therein indicated and the consolidated results of operations and cash flows of the Company and its Subsidiaries for
the periods therein specified, except that the Company Financial Statements described in clause (b) of the definition thereof do
not contain footnotes and are subject to normal year-end adjustments that would not reasonably be expected to be material to the
Company. The Company makes and keeps books, records and accounts which, in reasonable detail, accurately and fairly reflect, in
all material respects, the transactions and dispositions of its assets. The Company has not identified and has no Knowledge of
(a) any significant deficiency or material weakness in the internal accounting controls utilized by the Company, (b)&nbsp;any common
law fraud, whether or not material, that involves the management of the Company or any other current or former employee, consultant,
contractor or director of the Company who has a role in the preparation of financial statements or the internal accounting controls
utilized by the Company or (c)&nbsp;any claim or allegation regarding any of the foregoing.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Absence of Certain Changes</U>. Except as otherwise contemplated or permitted by this Agreement, since December 31, 2016,
there has not been any Change that has had a Company Material Adverse Effect. Except as otherwise contemplated or permitted by
this Agreement, since December 31, 2016, neither the Company nor any of its Subsidiaries has not taken or omitted to take any action
that, if taken after the date hereof, would constitute a breach of <U>Sections 5.1</U> or <U>5.2</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Undisclosed Liabilities</U>. Except as may be disclosed in the Company Disclosure Schedule or in the Company Balance
Sheet and except for (a) liabilities incurred in the ordinary course of business consistent in all material respects with past
practice after the date of the Company Balance Sheet and which are not, individually or in the aggregate, material in amount, (b)
liabilities incurred pursuant to or in connection with the execution, delivery or performance of this Agreement that will be paid
at or prior to Closing, and (c) liabilities arising under contracts (i) set forth on the Company Disclosure Schedule and (ii) not
required to be set forth on the Company Disclosure Schedule, in each case in the ordinary course of business that are not required
by GAAP to be reflected on a balance sheet (in each case, none of which results from, arises out of, relates to, is in the nature
of, or was caused by any breach of contract, breach of warranty, tort, infringement or violation of Law or allegation of any of
the foregoing), the Company and its Subsidiaries do not have any liabilities, obligations, or commitments of any nature (whether
absolute, accrued, matured or unmatured, fixed or contingent).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Taxes</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each of the Company and its Subsidiaries has filed on a timely basis all income and other material Tax Returns that it was
required to file, and all such Tax Returns are true, complete and correct in all material respects. Each of the Company and its
Subsidiaries has paid on a timely basis all income and other material Taxes due and owing by the Company or its Subsidiary.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All Taxes that the Company or any Subsidiary is or was required by applicable Law to withhold or collect in connection with
any amounts paid or owing to any employee, independent contractor, customer, creditor, stockholder, or other third party have been
duly withheld or collected and, to the extent required, have been paid to the appropriate Governmental Entity, and the Company
and each of its Subsidiaries have complied in all material respects with any reporting requirements under applicable Law relating
to such Taxes.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any Subsidiary of the Company is or has ever been a member of an affiliated group with which it
has filed (or been required to file) consolidated, combined, unitary or similar Tax Returns, other than a group of which the common
parent is the Company. With the exception of customary commercial leases or contracts that are not primarily related to Taxes entered
into in the ordinary course of business (such contracts, &ldquo;<U>Ordinary Commercial Agreements</U>&rdquo;) and liabilities thereunder,
neither the Company nor any of its Subsidiaries (i) has any liability under Treasury Regulation Section 1.1502-6 (or any comparable
or similar provision of federal, state, local or foreign Law), as a transferee or successor or pursuant to any contractual obligation
or any applicable Law for any Taxes of any Person other than the Company or any of its Subsidiaries, or (ii) is a party to or bound
by any Tax indemnity, Tax sharing, Tax allocation or similar agreement with any third party relating to allocating, indemnification
or sharing the payment of, or liability for, Taxes.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has made available to the Buyer complete and correct copies of all federal, state, local and foreign income
Tax Returns and all other material Tax Returns of the Company or any of its Subsidiaries for all taxable periods ending on or after
December 31, 2012, and all examination reports, audits, non-routine enquiries or discoveries of, and any statements of deficiencies
or other assessments, notices or claims in respect of Tax assessed against or agreed to by the Company or any of its Subsidiaries
with respect to such taxable periods.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No examination, audit or other proceeding relating to any Tax Return of the Company or any Subsidiary of the Company by
any Governmental Entity is currently in progress or to the Knowledge of the Company, pending, nor has the Company or any of its
Subsidiaries been notified in writing (or to the Knowledge of the Company, orally) of any such examination, audit, or other proceeding
relating to Taxes. There is no Tax deficiency outstanding, assessed or to the Knowledge of the Company, proposed against the Company
or any of its Subsidiaries that has not been paid in full. Neither the Company nor any Subsidiary of the Company has been informed
in writing (or, to the Knowledge of the Company, orally) by any jurisdiction in which the Company or any Subsidiary of the Company
did not file a Tax Return that the jurisdiction believes that the Company or any Subsidiary of the Company was required to file
any Tax Return that was not filed or is subject to Tax in such jurisdiction. Neither the Company nor any Subsidiary of the Company
has (i) waived any statute of limitations with respect to Taxes or agreed to extend the period for assessment or collection of
any Taxes, which waiver or extension is still in effect, (ii) requested or been granted any extension of time within which to file
any Tax Return, which Tax Return has not yet been filed, or (iii) executed or filed any power of attorney with any taxing authority,
which is still in effect.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Buyer, the Company, any Subsidiary of the Company, nor any of their Affiliates will be required to include an
item of income in, or exclude an item of deduction from, taxable income for any Tax period (or portion thereof) ending after the
Closing as a result of any: (i) change in method of accounting, or use of an improper method of accounting, by the Company or any
Subsidiary of the Company, in each case for a Tax period ending on or prior to the Closing Date; (ii) &ldquo;closing agreement&rdquo;
as described in Section 7121 of the Code (or any comparable or similar provisions of applicable Law) executed by the Company or
any Subsidiary of the Company on or prior to the Closing Date; (iii) installment sale or open transaction disposition made by the
Company or any Subsidiary of the Company on or prior to the Closing Date; (iv) prepaid amount received on or prior to the Closing
Date by the Company or any Subsidiary of the Company; or (v) intercompany transactions or excess loss account described in Treasury
Regulations under Section 1502 of the Code (or any corresponding or similar provisions of state, local or foreign income Tax Law)
entered into, or incurred by, the Company or any Subsidiary of the Company, that occurred on or prior to the Closing Date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The unpaid Taxes of the Company and its Subsidiaries (i) did not, as of the date of the Company Balance Sheet, exceed the
reserve for Taxes payable (rather than any reserve for deferred Taxes established to reflect timing differences between book and
Tax income) set forth on the face of the Company Balance Sheet, and (ii) do not exceed that reserve as adjusted for the passage
of time through the Closing Date in accordance with the past custom and practice of the Company and its Subsidiaries in filing
Tax Returns. Since the date of the Company Balance Sheet, neither the Company nor any of its Subsidiaries has incurred any liability
for Taxes outside the ordinary course of business.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any of its Subsidiaries is subject to Tax in any country other than its country of incorporation,
organization or formation by virtue of having employees, a permanent establishment or other place of business in that country.
The Company and its Subsidiaries are, and have been at all relevant times, in substantial compliance with all applicable transfer
pricing laws and regulations, and have maintained all material documentation required (under Section 482 of the Code and any other
applicable federal, state, local or foreign laws and regulations), if any, for all transfer pricing arrangements. The Company and
its Subsidiaries have been in compliance in all material respects with the requirements for any applicable Tax holidays or incentives
that have current applicability to the Company or its Subsidiaries and no such Tax holidays or incentives that have current applicability
to the Company or its Subsidiaries will be jeopardized by the transactions contemplated by this Agreement. The Company has provided
to the Buyer all material documentation relating to any applicable Tax holidays or incentives that have current applicability to
the Company and its Subsidiaries. None of the assets owned by the Company or any of its Subsidiaries are (A) tax-exempt use property
under Section 168(h) of the Code; (B) tax-exempt bond financed property under Section 168(g) of the Code; or (C) treated as owned
by any Person other than the Company or any of its Subsidiaries, as applicable, under Section 168 of the Code.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Other than the Company&rsquo;s interest in the Subsidiaries listed on Section&nbsp;3.3(a) of the Company Disclosure Schedules,
neither the Company nor any of its Subsidiaries has any direct or indirect interest in any trust, partnership, corporation, limited
liability company, or other business entity for U.S. federal income tax purposes. <U>Section 3.8(i)</U> of the Company Disclosure
Schedules indicates the U.S. federal income Tax classification of each of the Subsidiaries of the Company (e.g., domestic corporation,
foreign corporation, domestic partnership, disregarded entity), and except as otherwise indicated on Section 3.8(i) of the Company
Disclosure Schedules, each Subsidiary of the Company has always had such classification and will have such classification until
the Closing.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(j)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any Subsidiary of the Company has been a United States real property holding corporation within
the meaning of Section&nbsp;897(c)(2) of the Code during the applicable period specified in Section&nbsp;897(c)(l)(A)(ii) of the
Code.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(k)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any Subsidiary of the Company has distributed to its shareholders or security holders stock or securities
of a controlled corporation, nor has stock or securities of the Company or any Subsidiary of the Company been distributed, in a
transaction to which Section 355 of the Code.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(l)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no Liens with respect to Taxes upon any of the assets of the Company or any Subsidiary of the Company, other than
with respect to Taxes not yet due and payable.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(m)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any Subsidiary of the Company has engaged in a &ldquo;reportable transaction&rdquo; as defined in
Section 6707A(c)(2) of the Code and Treasury Regulation section 1.6011-4(b)(2). Neither the Company nor any of its Subsidiaries
has applied for or received any private letter ruling from the Internal Revenue Service (or any comparable Tax ruling from any
other Governmental Entity).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(n)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>None of the Company Stock is a &ldquo;covered security&rdquo; within the meaning of Treasury Regulation Section 1.6045-1(a)(15).
A valid election under Section 83(b) of the Code has been made for all Company Restricted Stock Awards. The Company has provided
the Buyer with true, correct and complete copies of all election statements filed under Section 83(b) of the Code and received
by the Company in accordance with Treasury Regulation Section 1.83-2(d).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(o)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Vtesse Europe, Limited is a &ldquo;controlled foreign corporation&rdquo; as defined in Section 957(a) of the Code, has never
been a &ldquo;passive foreign investment company&rdquo; as defined in Section 1297 of the Code, is not a &ldquo;surrogate foreign
corporation&rdquo; as defined in Section 7874(a)(2)(B) of the Code, and is not subject to U.S. federal income Tax under any provision
of the Code. Neither the Company nor any of its Subsidiaries (or beneficial owner thereof) would be required to include any amount
as income under Section 951 of the Code were the taxable year of Vtesse Europe, Limited deemed to close on the Closing Date. As
of the Closing Date, Vtesse Europe, Limited will not hold any assets that constitute U.S. property within the meaning of Section
956 of the Code. Neither the Company nor any of its Subsidiaries has transferred intangible property the transfer of which would
be subject to the rules of Section 367(d) of the Code. Vtesse Europe, Limited has been classified as a corporation for U.S. federal
income tax purposes at all times since its formation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Notwithstanding anything to the contrary in
this Agreement, it is agreed and understood that (i) the representations and warranties of the Company in this <U>Section 3.8</U>
(other than the representations and warranties of the Company in <U>Sections 3.8(c)</U>, <U>(f)</U>, <U>(h)</U>, <U>(i), (k)</U>
and <U>(m)</U>) shall not serve as representations and warranties regarding, or a guarantee of, nor can they be relied upon with
respect to, Taxes attributable to any Tax period (or portion thereof) beginning, or Tax positions taken, after the Closing Date
and (ii) no representations, warranties or guarantees are made with respect to the amount or availability of Tax attributes of
the Company or any Subsidiary in a taxable period that begins after the Closing Date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Owned and Leased Real Properties</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any of its Subsidiaries owns, or has ever owned, any real property or is, or ever has been, obligated
under or a party to, any option, right of first refusal or other contractual right to purchase, acquire, sell, assign or dispose
of any real estate or any portion thereof or interest therein.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 3.9(b) of the Company Disclosure Schedule sets forth a complete and accurate list as of the date of this Agreement
of all Company Leases and the location of the applicable premises. The Company has good and valid leasehold interest in all Company
Leases and the applicable premises. None of the Company, any of its Subsidiaries or, to the Company&rsquo;s Knowledge, any other
party to any Company Lease is in material default under any of the Company Leases. Neither the Company nor any of its Subsidiaries
leases or subleases any real property to any Person. The Company has made available to the Buyer complete and accurate copies of
all Company Leases. With respect to each Company Lease: (i) the Company&rsquo;s possession and quiet enjoyment of the property
under such Company Lease has not been disturbed and there any no disputes with respect to such Company Lease; (ii) no security
deposit or portion thereof deposited with respect to such Company Lease has been applied in respect of a breach or default under
such Company Lease which has not been redeposited in full; (iii) the Company does not owe any brokerage commissions or finder&rsquo;s
fee with respect to such Company Lease; (iv) the Company has not collaterally assigned or granted any other security interest in
such Company Lease or any interest therein; and (v) the Company does not have, and does not in the future expect to have, any monetary
obligations under any Company Lease for improvements or otherwise (except for regularly scheduled payments of rent).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 3.10(a)</U> of the Company Disclosure Schedule sets forth a correct and complete list of all of the following
Intellectual Property, in each case, used in the business of the Company or any of its Subsidiaries and identifying whether such
Intellectual Property is solely owned by the Company, jointly owned with a third party or Third-Party Intellectual Property licensed
by the Company, (i) issued Patents, pending Patent applications and provisional Patent applications, (ii) Trademark registrations
and applications and material unregistered Trademarks, (iii) Copyright registrations and applications and material unregistered
Copyrights, (iv) material Software, and as to each, (v) the jurisdiction in which such item of registered Intellectual Property
has been registered or filed and the applicable registration or serial number; (vi) all owner(s), and, if one or more owner(s)
is not the Company (including any joint owner(s)), (A) the corresponding license agreement pursuant to which the Company has the
right to use such Intellectual Property or (B) any corresponding agreement(s) relating to joint ownership; <U>provided</U>, <U>however</U>,
that <U>Section 3.10(a)</U> of the Company Disclosure Schedule need not include Third-Party Intellectual Property licensed on a
non-exclusive basis and not used in connection with the development of any Product. <U>Section 3.10(a)</U> of the Company Disclosure
Schedule also describes each filing, payment, and action that, to the Company&rsquo;s Knowledge, must be made or taken on or before
the date that is one hundred twenty (120) days after the date of this Agreement in order to maintain each such item of Intellectual
Property that is listed or required to be listed on <U>Section 3.10</U> the Company Disclosure Schedule, and for which the Company
is responsible. Each of the Patents that is solely owned or purported to be solely owned by the Company, and to the Company&rsquo;s
Knowledge each of the Patents set forth on <U>Section 3.10(a)</U> of the Company Disclosure Schedule that is not solely owned or
purported to be solely owned by the Company, properly identifies by name each and every inventor of the claims thereof as determined
in accordance with United States patent law (and the inventors listed in each such Patent collectively constitute the entire inventive
entity, as the term &lsquo;inventive entity&rsquo; is defined and interpreted under United States Patent Law). The Company or its
applicable Subsidiary is the sole and exclusive beneficial and, with respect to applications and registrations (including Patents),
record owner of all of the Intellectual Property items set forth in <U>Section 3.10(a)</U> of the Company Disclosure Schedule that
are solely owned by the Company or purported to be solely owned by the Company free and clear of any encumbrances. All such granted
Intellectual Property rights are subsisting, valid, and enforceable.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has complied in all material respects with all of its obligations and duties to the respective patent, Trademark
and copyright offices, including the duty of candor and disclosure to the U.S. Patent and Trademark Office, and all applicable
Laws, with respect to all Company Intellectual Property.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 3.10(b) of the Company Disclosure Schedule sets forth a true, correct, and complete list of all contracts pursuant
to which the Company or any of its Subsidiaries (i)&nbsp;is granted or obtains or agrees to obtain any license or right to use
any Intellectual Property (other than standard form contracts granting rights to use readily available shrink wrap or click wrap
Software having a replacement cost and annual license fee of less than $10,000 for all such related contracts in the aggregate),
(ii)&nbsp;is restricted in its right to use or register any Intellectual Property or (iii) permits or agrees to permit any other
Person, to use, obtain, enforce, or register any Intellectual Property, including any license agreements, coexistence agreements,
and covenants not to sue, and all contracts that (y) would require the Buyer or any of its Subsidiaries to license, assign, or
make available its Intellectual Property to any other Person, or restrict its use of such Intellectual Property as a result of
the transactions contemplated hereby.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company or its applicable Subsidiary owns, or has a valid right to use, free and clear of all Liens, all Intellectual
Property used or held for use in, or necessary to conduct, the business of the Company, including all rights used in or necessary
to complete development of and commercialize the Product as currently contemplated to be developed and commercialized, including
the manufacture, use, offer for sale, sale, or importation of the Product. No Person has any right of first refusal, option or
other right to acquire any right, title or interest in or to with respect to, any Company Intellectual Property. In each case where
the Company has acquired ownership of Company Intellectual Property from any other Person, the Company has obtained a valid and
enforceable assignment sufficient to irrevocably transfer all rights, title and interest in and to such Company Intellectual Property
to the Company, and the Company has recorded each such assignment with the United States Patent and Trademark Office and/or, where
required by applicable Law, other applicable Governmental Entity.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The conduct of the business of the Company and its Subsidiaries as currently conducted does not, the conduct of such business
as conducted in the past has not and, to the Knowledge of the Company, the development of and commercialization of the Products
as currently contemplated will not, infringe, misappropriate, or otherwise violate, any Person&rsquo;s Intellectual Property, and
there has been no such claim asserted or threatened (including in the form of offers or invitations to obtain a license) in the
past three years against the Company or any of its Subsidiaries or, to the Knowledge of the Company, any other Person.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Knowledge of the Company, no Person is infringing, misappropriating, or otherwise violating any Intellectual Property
owned, used, or held for use by the Company or any of its Subsidiaries, and no such claims have been asserted or threatened against
any Person by the Company or any of its Subsidiaries or, to the Knowledge of the Company, any other Person.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There has been no claim asserted or threatened challenging the scope, validity, or enforceability of, or the Company&rsquo;s
ownership or right to use, any applications or registrations for Patents or Trademarks listed or required to be listed in Section
3.10(a) of the Company Disclosure Schedule. As of the date of this Agreement, the Company has no Knowledge of any information,
facts or circumstances that could reasonably be expected to adversely impact, in any material respect, the ownership, use, patentability,
enforceability or validity of any Company Intellectual Property, including the eventual maturation of pending and/or provisional
Intellectual Property applications into subsisting, valid and enforceable granted Intellectual Property rights. None of the Company
or any of its Subsidiaries has granted any Person any right to control the prosecution or registration of any Intellectual Property
listed in Section 3.10(a) of the Company Disclosure Schedule or to commence, defend, or otherwise control any claim with respect
to any Intellectual Property listed or required to be listed in Section 3.10(a) of the Company Disclosure Schedule.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and its Subsidiaries take reasonable measures to protect the confidentiality of Trade Secrets, including requiring
all Persons having access thereto to execute written non-disclosure agreements. To the Knowledge of the Company, there has not
been any disclosure of any Trade Secret of the Company or any of its Subsidiaries (including any such information of any other
Person disclosed in confidence to the Company) to any Person in a manner that has resulted or could result in the loss of such
Trade Secret or other rights in and to such information.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each current and former employee and other service provider of the Company or any of its Subsidiaries has executed a valid
and enforceable proprietary information and inventions agreement, each of which has been made available to the Buyer and is substantially
in the form made available to the Buyer, and no such Person has excluded works or inventions from his or her assignment of inventions
pursuant to such Person&rsquo;s proprietary information and inventions agreement. Each such Person conceived of, created, developed
or improved Intellectual Property used in the business of the Company or any of its Subsidiaries only while such Person was an
employee or other service provider of the Company and subject to a proprietary information and inventions agreement as described
above and none of such Persons is in violation of such proprietary information and inventions agreement. There are no allegations
that any current or former employee or other service provider (i) misappropriated, infringed or otherwise violated the Intellectual
Property rights or (ii) breached any agreement with, any Person that had previously employed or engaged such Person.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(j)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No current or former partner, director, stockholder, officer, employee or other service provider of the Company or any of
its Subsidiaries will, after giving effect to the transactions contemplated hereby, own, license, or retain any proprietary rights
in any of the Intellectual Property owned, used, or held for use (including for defensive purposes) by the Company or any of its
Subsidiaries.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(k)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No funding, facilities or personnel of any Governmental Entity or academic institution were used, directly or indirectly,
to develop or create, in whole or in part, any Company Intellectual Property and no Governmental Entity or academic institution
has any rights to, ownership of or rights to royalties or other payments from any Company Intellectual Property. Further, the Company
has not licensed or used any Intellectual Property of any Governmental Entity or academic institution, directly or indirectly,
to develop, manufacture or create, in whole or in part, a Product or any Company Intellectual Property rights.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(l)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The execution of this Agreement and consummation of the transactions contemplated by this Agreement (alone or in combination
with any other event) will not result in the loss or impairment of or payment of any additional amounts with respect to, nor require
the consent of any other Person in respect of, the Company&rsquo;s or any of its Subsidiaries&rsquo; right to own, use, or hold
for use any of the Intellectual Property as owned, used, or held for use (including for defensive purposes) as of the date hereof
or the validity, enforceability or registrability of any such Intellectual Property or any priority, duration, scope or effectiveness
with respect thereto.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(m)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to the use of the Software by the Company and its Subsidiaries, (i) no capital expenditures are necessary with
respect to such use other than capital expenditures in the ordinary course of business consistent with the past practice of the
Company and its Subsidiaries, and (ii) none of the Company or any of its Subsidiaries has experienced any material defects in such
Software, including any material error or omission in the processing of any transactions other than defects which have been corrected.
There have been no material security breaches in the Company&rsquo;s or any of its Subsidiaries&rsquo; information technology systems,
and there have been no disruptions in any of the Company&rsquo;s or any of its Subsidiaries&rsquo; information technology systems
that adversely affected the Company&rsquo;s or any of its Subsidiaries&rsquo; business or operations. The Company and its Subsidiaries
have evaluated their disaster recovery and backup needs and have implemented plans and systems that reasonably address their assessment
of risk.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(n)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability
of another Person for infringement, misappropriation or other violation of any Intellectual Property rights and is not contractually
obligated to do so. None of the Company Intellectual Property is subject to any pending or outstanding consent, settlement, injunction,
directive, order, judgment, or other disposition of dispute that adversely impacts or restricts the use, ownership, transfer, registration
or licensing or other disposition of any such Intellectual Property by the Company, or otherwise adversely affects the validity,
scope, use, registrability, or enforceability of any Company Intellectual Property.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(o)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company is, and to the Knowledge of the Company each Person acting on its behalf (including any Third Party Service
Provider, as defined below) is and has been in material compliance with (i) all applicable Laws relating to the privacy, data protection
and security of patient medical records and all other personal information and data, including with respect to the collection or
use, including the storage, sharing, transfer, disposition, protection and processing thereof (including in connection with any
pre-clinical or clinical trials conducted with respect to any Product (collectively, and together with all data and other information
that is subject to any such Laws, &ldquo;<U>Personal Information</U>&rdquo;)), (ii) all privacy, data protection and security policies
of the Company concerning patient medical records and other Personal Information, and (iii) any contractual requirements to which
the Company is subject that relate to any of the foregoing. Neither the Company, nor to the Company&rsquo;s Knowledge, any service
provider of, or other Person acting for or otherwise on behalf of, the Company that may collect, store, process, analyze or otherwise
have access to any pre-clinical or clinical trial data, patient medical records, or any Personal Information or confidential information
of the Company (a &ldquo;<U>Third Party Service Provider</U>&rdquo;), has been subject to any security breaches with respect to
(including any that have resulted in the public disclosure of or any other unauthorized access to) any Personal Information or
any confidential information of the Company. The Company has, and, to the Knowledge of the Company, each of its Third Party Service
Providers has, taken reasonable actions and implemented policies and procedures which, in each case, are reasonably appropriate
to protect and maintain the security of all Personal Information and confidential information of the Company, including from any
unauthorized access or use. There have not been any written or, to the Company&rsquo;s Knowledge, other complaints or notices,
or any audits, proceedings, investigations or claims conducted or asserted, or to the Knowledge of the Company, threatened by any
Governmental Entity or other Person against the Company, and none are pending, regarding any collection, use, storage, disclosure,
transfer or other disposition of any patient medical records or other Personal Information by or on behalf of the Company (including
by any Third Party Service Provider), including in connection with any pre-clinical or clinical trials conducted with respect to
any Product, or the violation of any applicable Laws relating to any of the foregoing.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Contracts</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section&nbsp;3.11(a) of the Company Disclosure Schedule sets forth a complete and accurate list as of the date of this Agreement
of the following contracts and agreements to which the Company or any of its Subsidiaries is a party and under which the Company
or any of its Subsidiaries has any remaining rights or obligations:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any license, sublicense, right to use or other agreement (1) relating to any Company Intellectual Property or (2) pursuant
to which the Company or any of its Subsidiaries is granted a license under, or granted an option to obtain a license under, any
Third-Party Intellectual Property;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any cloud or software as service subscription agreement;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any clinical trial agreement;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any manufacturing or supply agreement with respect to a Product;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any agreement (or group of related agreements) for the lease of tangible property describe in <U>Section 3.21(b)</U>;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(vi)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Company Lease;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(vii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any agreement (or group of related agreements) that the Company expects to involve consideration in the next twelve (12)
months in excess of $100,000;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(viii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any agreement providing for the establishment or operation of a partnership, joint venture or limited liability company;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ix)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any agreement that provides for royalty obligations, &ldquo;earn-outs&rdquo; or other contingent payments;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(x)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any agreement containing covenants of the Company or any of its Subsidiaries that prohibit the Company or any of its Subsidiaries
from competing in any line of business, with any Person, or otherwise restricting their activities in any material respect, in
each case, in geographic area or during any period of time;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(xi)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any agreement (or group of related agreements) under which the Company or any of its Subsidiaries has created, incurred,
assumed or guaranteed (or may create, incur, assume or guarantee) Indebtedness;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(xii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any agreement for the disposition of any portion of the business, stock, or assets of the Company or any of its Subsidiaries
in exchange for consideration having a value excess of $100,000;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(xiii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any agreement for the acquisition of any operating business or the capital stock of any other Person;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(xiv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any collective bargaining agreement or any other agreement with a labor or trade union, labor organization, employee association,
works council, or other employee representative;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(xv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any bonus, incentive compensation, commission, severance, long-term incentive plan, pension, profit sharing retirement or
other form of deferred compensation plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(xvi)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any employment or consulting agreement between the Company or its Subsidiaries and any officer, individual employee or other
person or entity on a full-time, part-time or consulting basis, other at will offers of employment on the Company&rsquo;s standard
form provided to the Buyer that can be terminated by the Company (or the Company&rsquo;s Subsidiary party thereto) on 30 or fewer
days&rsquo; notice without payment by the Company (or such Subsidiary) of any severance;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(xvii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all broker, distributor, dealer, or agency agreements to which the Company is a party;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(xviii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any agreement for the indemnification by the Company of any officer or director or the assumption of any liability of any
officer or director;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(xix)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any agreement that (A) contains a &ldquo;most-favored-nation,&rdquo; &ldquo;best pricing&rdquo; or other similar term or
provision by which another party to such contract or agreement or any other Person is, or could become, entitled to any benefit,
right or privilege which, under the terms of such contract or agreement, must be at least as favorable to such party as those offered
to another Person, (B) grants any rights of first refusal, rights of first negotiations or similar rights to any Person or (C)
includes a standstill provision or minimum purchase condition;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(xx)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any direct or indirect agreement with or involving any Governmental Entity, including any agreement that is a settlement,
conciliation, or similar agreement with any Governmental Entity or that imposes any monetary or other material obligations upon
the Company to any Governmental Entity after the date of this Agreement;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(xxi)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any contract or agreement involving commitments to make capital expenditures in excess of $50,000 individually or $250,000
in the aggregate;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(xxii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any power of attorney granted by the Company that is currently in effect; and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(xxiii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any other agreement that would be a &ldquo;material contract&rdquo; (as such term is defined in Item 601(b)(10) of Regulation
S-K of the Securities and Exchange Commission if the Company were a registrant thereunder).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has made available to the Buyer a complete and accurate copy of each Company Material Contract in effect as
of the date of this Agreement. Each Company Material Contract is in full force and effect and enforceable (subject to the Bankruptcy
and Equity Exception) with respect to the Company or the Subsidiary that is a party thereto and, to the Company&rsquo;s Knowledge,
with respect to each other party thereto. Neither the Company nor the Subsidiary party thereto nor, to the Company&rsquo;s Knowledge,
any other party to any Company Material Contract is in material violation of or in material default under any Company Material
Contract, or has provided or received any written, or to the Company&rsquo;s Knowledge any non-written, notice of any violation,
default or intention to terminate, any Company Material Contract. No event or circumstance has occurred that, with notice or lapse
of time or both, would constitute an event of default under any Company Material Contract or result in a termination thereof (other
than the expiration of any such Company Material Contract in accordance with its terms), or would cause or permit the acceleration
or other changes of any material right or obligation or the loss of any material benefit thereunder (other than in accordance with
its terms).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.12<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Litigation</U>. There is no action, suit, proceeding, claim, arbitration or investigation (a) pending or, to the Knowledge
of the Company, threatened against the Company or any of its Subsidiaries or (b) that challenges, or that may have the effect of
preventing, delaying, making illegal or otherwise interfering with, the Merger or any of the other transactions contemplated by
this Agreement. To the Company&rsquo;s Knowledge, no such action, suit, proceeding, claim, arbitration or investigation has been
threatened against the Company or any of its Subsidiaries. There are no judgments, orders or decrees outstanding against the Company
or any of its Subsidiaries, or any assets owned (or, to the Knowledge of the Company, used by) the Company or any of its Subsidiaries.
To the Knowledge of the Company, no officer or other employee of the Company or any of its Subsidiaries is subject to any order,
writ, injunction, judgment or decree that prohibits such officer or other employee from engaging in or continuing any conduct,
activity or practice relating to the Company&rsquo;s or its Subsidiaries&rsquo; business.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.13<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Environmental Matters</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and its Subsidiaries are in compliance in all material respects with all Environmental Laws, and are not in
violation of, and have not received any written notice alleging any violation by the Company or any of its Subsidiaries with respect
to, or written request for information pursuant to any, Environmental Laws.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Company&rsquo;s Knowledge, the properties operated by the Company and its Subsidiaries or otherwise subject to a
Company Lease (including soils, groundwater, surface water, buildings or other structures) are not contaminated with any Hazardous
Substances in an amount or concentration that would give rise to an obligation to act or disclose that condition under any Environmental
Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and its Subsidiaries have not received a written notice that the Company or any Subsidiary is subject to any
liability for any Hazardous Substance disposal or contamination in violation of any Environmental Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any of its Subsidiaries has released any Hazardous Substance into the environment except (i)&nbsp;in
compliance with Law or (ii)&nbsp;in an amount or concentration that would not reasonably be expected to give rise to any liability
or obligation under any Environmental Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any of its Subsidiaries is named as a party to any orders, decrees or injunctions by any Governmental
Entity addressing liability under any Environmental Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="background-color: white">The Company and its Subsidiaries have obtained and are in material compliance with
all environmental permits necessary for the ownership, lease, operation or use of the business or assets of the Company and its
Subsidiaries, and all such permits are in full force and effect.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The parties agree that the only representations and warranties of
the Company in this Agreement as to any environmental matters or any other obligation or liability with respect to Hazardous Substances
or materials of environmental concern are those contained in this <U>Section&nbsp;3.13</U>. Without limiting the generality of
the foregoing, the Buyer specifically acknowledges that the representations and warranties contained in <U>Sections 3.15</U> and
<U>3.16</U> do not relate to environmental matters.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.14<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Benefit Plans</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 3.14(a) of the Company Disclosure Schedule sets forth a complete and accurate list, as of the date of this Agreement,
of all Company Employee Plans.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to each Company Employee Plan in effect on the date of this Agreement or with respect to which the Company
or any ERISA Affiliate has or may have any liability, the Company has made available to the Buyer a complete and accurate copy
of (i) such Company Employee Plan document (including amendments thereto) or summary of such plan if no plan document, (ii) the
most recent determination or opinion letter received from the IRS, (iii) the three (3) most recent Form 5500 annual reports (including
all applicable attachments) filed with the IRS, if any, (iv) the most recent actuarial valuation report, if applicable, (v) each
trust agreement, group annuity contract and summary plan description as in effect on the date of this Agreement, if any, relating
to such Company Employee Plan, and (vi) all correspondence to or from any Governmental Entity regarding such Company Employee Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Company Employee Plan (and each related trust) complies with and has been administered in all material respects in
accordance with (i) ERISA, (ii) the Code, (iii) all other applicable laws and the regulations thereunder and (iv) its terms.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to each Company Employee Plan, there are no benefit obligations which are unfunded or for which contributions
have not been made, in either case to the extent required by such Company Employee Plan or applicable Law or, to the extent required
by GAAP, properly accrued.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Company Employee Plan that is intended to be qualified under Section 401(a) of the Code has received a determination
or opinion letter from the IRS to the effect that such Company Employee Plan is qualified and the plans and trusts related thereto
are exempt from federal income Taxes under Sections 401(a) and 501(a), respectively, of the Code, or is based on prototype or volume
submitter documents that have received such letter, or the period for obtaining such letter is still open. No such determination
or opinion letter has been revoked and revocation has not been threatened.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company, its Subsidiaries and their respective ERISA Affiliates have never (i) maintained, established, sponsored, participated
in, or been required to contribute to any pension plan subject to Section 412 or 430 of the Code or Title IV of ERISA; (ii) had
any outstanding liabilities under Title IV of ERISA; or (iii) been party to or obligated to contribute to a &ldquo;multiemployer
plan&rdquo; (as described in Section 4001(a)(3) or Section 3(37) of ERISA or to a &ldquo;multiple employer plan&rdquo; within the
meaning of Section 3(40) of ERISA.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>None of the Company Employee Plans promises or provides post-termination medical or other post-termination welfare or other
benefits to any person, except as required by (i) applicable Law, (ii) contractually required subsidies for COBRA coverage during
severance or (iii) the terms of any plan qualified under Section 401(a) of the Code.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither the Company nor any of its Subsidiaries or ERISA Affiliates is a party to any agreement with any director, executive
officer or other employee of the Company or any of its Subsidiaries the benefits of which are triggered by, contingent on, or the
terms of which are altered, upon the occurrence of a transaction involving the Company of the nature of any of the transactions
contemplated by this Agreement or which provide for severance, retention or similar compensation or benefits after the termination
of employment of such director, executive officer or employee.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company its Subsidiaries and ERISA Affiliates are in material compliance with all applicable requirements of the Patient
Protection and Affordable Care Act of 2010, as amended, and all regulations thereunder (together, the &ldquo;<U>ACA</U>&rdquo;),
as well as any similar provisions of state or local law, including all requirements relating to eligibility waiting periods and
the offer of or provision of minimum essential coverage that is compliant with Section&nbsp;36B(c)(2)(C) of the Code and the regulations
issued thereunder to full-time employees as defined in Section 4980H(c)(4) of the Code and the regulations issued thereunder. No
material excise tax or penalty under the ACA, including Sections 4980D and 4980H of the Code, is outstanding, has accrued, or has
arisen with respect to any period prior to the Closing, with respect to any Company Employee Plan. The Company and its Subsidiaries
do not have any unsatisfied obligations to any employees or qualified beneficiaries pursuant to the ACA, or any state or local
Law governing health care coverage or benefits that would result in any liability to the Company and its Subsidiaries. The Company
has maintained all records necessary to demonstrate its compliance with the ACA and any other similar state or local law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(j)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Company Employee Plan that constitutes in any part a nonqualified deferred compensation plan within the meaning of
Section 409A of the Code has been operated and maintained in all material respects in operation and documentary compliance with
Section&nbsp;409A of the Code and all IRS guidance promulgated thereunder, to the extent such section and such guidance have been
applicable to such Company Employee Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(k)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to the Company Employee Plans, (i) there are no actions, suits or claims or other proceedings pending or, to
the Company&rsquo;s Knowledge, threatened, other than routine claims for benefits, (ii) there have been no &ldquo;prohibited transactions&rdquo;
(as that term is defined in Section 406 of ERISA or Section 4975 of the Code) that are non-exempt and likely to result in liability
on the Company or its Subsidiaries, and (iii) all reports, returns and similar documents required to be filed with any Governmental
Entity or distributed to any Company Employee Plan participant have been filed or distributed. With respect to each Company Employee
Plan, no investigation, audit, action or other legal proceeding by the Department of Labor, Internal Revenue Service or any other
Governmental Entity that would, individually or in the aggregate, reasonably be expected to result in material liability to the
Company or any of its Subsidiaries or ERISA Affiliates is in progress (as indicated by notice to the Company) pending or, to the
Knowledge of the Company, threatened. Neither the Company nor any of its Subsidiaries or ERISA Affiliates has any liability by
reason of an individual who performs or performed services for the Company or any of its Subsidiaries or ERISA Affiliates in any
capacity being improperly excluded from participating in a Company Employee Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(l)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No payment or benefit which will or may be made with respect to any &ldquo;disqualified individual&rdquo; (as defined in
Section 280G of the Code and the regulations thereunder) in connection with the consummation of the Merger (either alone or in
combination with any other event) will be characterized as a parachute payment within the meaning of Code Section&nbsp;280G(b)(2).
There is no contract, agreement, plan or arrangement to which the Company or any Company ERISA Affiliates is bound to provide a
gross-up or otherwise reimburse any employee for excise taxes paid pursuant to Section 4999 or 409A of the Code. Neither the execution
or delivery of this Agreement nor the consummation of the Merger, either alone or in combination with any other event, will increase
the benefits or compensation payable under any Company Employee Plan or to any current or former director, officer, employee or
other individual service provider of the Company, or will result in any acceleration of the time of payment, funding or vesting
of any benefits or compensation under any Company Employee Plan or for any current or former director, officer, employee or other
individual service provider of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.15<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance With Laws</U>. The Company and its Subsidiaries have been and are conducting their respective businesses in
compliance in all material respects with all applicable Laws, and neither the Company nor any of its Subsidiaries has received
any written notice alleging, or otherwise have Knowledge of any material violation of any such Laws. Without limiting the foregoing,
(a) none of the Company, its Subsidiaries or any of their directors, officers, employees or agents have, directly or indirectly,
made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any &ldquo;foreign
official&rdquo; (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &ldquo;<U>FCPA</U>&rdquo;)),
foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any official
act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence
to affect any act or decision of a foreign governmental authority, or (iii) securing any improper advantage, in the case of (i),
(ii) and (ii) above in order to assist the Company or any of its Subsidiaries in obtaining or retaining business for or with, or
directing business to, any Person, (b) no such Person has, with respect to the Company and its Subsidiaries, made or authorized
any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained any funds in
violation of any law, rule or regulation, (c) the Company and its Subsidiaries have maintained systems of internal controls (including,
but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA or any other
applicable anti-bribery or anti-corruption law and (d) none of the Company or any of its Subsidiaries is, and, to the Knowledge
of the Company, none of such other Persons is, the subject of any allegation, voluntary disclosure, prosecution or other enforcement
action or, to the Knowledge of the Company, investigation, in each case related to the FCPA or any other anti-corruption law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.16<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Permits</U>. The Company and its Subsidiaries have all Permits necessary for the conduct of their business as presently
conducted and all such Permits are in full force and effect. The Company and its Subsidiaries are in compliance in all material
respects with the terms of such Permits. The Company has not received any written notice or other written communication from any
Governmental Entity regarding (a) any material violation of any such Permit or any failure to comply in a material respect with
any term or requirement of any such Permit or (b) any revocation, withdrawal, suspension, cancellation, termination or material
modification of any such Permit.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.17<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulatory Matters</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and its Subsidiaries are developing, testing, labeling, manufacturing and storing, and at all times has developed,
tested, labeled, manufactured and stored each product candidate of the Company or any of its Subsidiaries in compliance in all
material respects with applicable Law, including the FDA Act and applicable implementing regulations issued by the FDA and any
other applicable Governmental Entities, including, as applicable, those requirements relating to the FDA&rsquo;s current good manufacturing
practices, good laboratory practices, good clinical practices and investigational use, in each case, for a new pharmaceutical product.
The Company and its Subsidiaries have not received written notice of any pending or threatened claim, suit, proceeding, hearing,
enforcement, audit, investigation, arbitration or other action from the FDA or any other Governmental Entity alleging that any
operation or activity of the Company or any of its Subsidiaries is in violation of the FDA Act or the respective counterparts thereof
promulgated by applicable Governmental Entities outside the United States.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and its Subsidiaries have made available to the Buyer complete and correct copies of all governmental authorizations
from the FDA, EMA, and all other applicable comparable foreign Governmental Entities (collectively, the &ldquo;<U>Regulatory Authorities</U>&rdquo;),
held by the Company or any of its Subsidiaries necessary to conduct its business as presently conducted. The Company and its Subsidiaries
hold such authorizations the Regulatory Authorities require for the conduct of its business as currently conducted (collectively,
the &ldquo;<U>Regulatory Permits</U>&rdquo;) and all such Regulatory Permits are in full force and effect. The Company and its
Subsidiaries have filed all required notices and responses to notices, supplemental applications, reports (including all adverse
event/experience reports) and other information with the Regulatory Authorities. Each submission to the Investigational New Drug
applications submitted by or on behalf of the Company or any of its Subsidiaries to the FDA, including all supplements and amendments
thereto was true, complete and correct as of the applicable date of submission.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Company&rsquo;s Knowledge, all preclinical studies and clinical trials, and other studies and tests conducted by
or on behalf of the Company have been, and if still pending are being, conducted in material compliance, to the extent applicable,
with the applicable protocol for such study or trial, good laboratory practices, good clinical practices and all applicable Law,
including the FDA Act. No clinical trial conducted by or on behalf of the Company or any its Subsidiaries has been terminated or
suspended prior to scheduled completion, and neither the FDA nor any other applicable Governmental Entity, clinical investigator
that has participated or is participating in, or institutional review board that has or has had jurisdiction over, a clinical trial
conducted by or on behalf of the Company or any of its Subsidiaries has initiated, or, to the Company&rsquo;s Knowledge, threatened
to initiate, any action to place a clinical hold order on, or otherwise terminate or suspend, any proposed or ongoing clinical
investigation conducted or proposed to be conducted by or on behalf of the Company or any of its Subsidiaries.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and its Subsidiaries are not subject to any investigation that is pending and of which the Company has been
notified in writing or, to the Company&rsquo;s Knowledge, which has been threatened, in each case by (i) the FDA or (ii) the Department
of Health and Human Services Office of Inspector General or Department of Justice pursuant to the Federal Healthcare Program Anti-Kickback
Statute (42 U.S.C. &sect;1320a-7b(b)), the Federal False Claims Act (31 U.S.C. &sect;3729) (known as the &ldquo;<U>Federal False
Claims Act</U>&rdquo;) or any equivalent foreign applicable Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Company&rsquo;s Knowledge, the Company and its Subsidiaries have not submitted any claim for payment to any government
healthcare program in violation of any Laws relating to false claims or fraud, including the Federal False Claim Act or any applicable
state false claim or fraud Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and its Subsidiaries have complied in all material respects with all applicable security and privacy standards
regarding protected health information under (i) the Health Insurance Portability and Accountability Act of 1996, as amended by
the Health Information Technology for Economic and Clinical Health Act of 2009, including the regulations promulgated thereunder
and (ii) any applicable state privacy Laws.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the Company&rsquo;s Knowledge, all manufacturing operations conducted for the benefit of the Company and its Subsidiaries
have been and are being conducted in material compliance with applicable Laws, including, to the extent applicable, the provisions
of the FDA&rsquo;s current good manufacturing practice regulations, and the respective counterparts thereof promulgated by Governmental
Entities in countries outside the United States. To the Company&rsquo;s Knowledge, none of the Company&rsquo;s and its Subsidiaries&rsquo;
contract manufacturers has received a FDA Form 483 or other Governmental Entity notice of inspectional observations, &ldquo;warning
letters&rdquo; or &ldquo;untitled letters&rdquo;, in each case, related to or affecting any of the Company&rsquo;s and its Subsidiaries&rsquo;
products or product candidates.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 3.17(h) of the Company Disclosure Schedule sets forth a list of (i)&nbsp;all recalls, field notifications, investigator
notices, safety alerts, &ldquo;serious adverse event&rdquo; reports or other notices of action relating to an alleged lack of safety
or regulatory compliance issued by the Company (&ldquo;<U>Safety Notices</U>&rdquo;), (ii) the dates such Safety Notices, if any,
were resolved or closed, and (iii) to the Company&rsquo;s Knowledge, any material complaints that are currently unresolved.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>None of the Company or any of its Subsidiaries has committed any act, made any statement or failed to make any statement
that would reasonably be expected to provide a basis for the FDA or any other Governmental Entity to invoke its policy with respect
to &ldquo;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&rdquo; or any such similar policies set forth
in any applicable Laws. None of the Company, its Subsidiaries or, to the Company&rsquo;s Knowledge, any of their officers, employees
or agents, and, in connection with Products, third party suppliers and contractors, has been convicted of any crime or engaged
in any conduct that has resulted, or would reasonably be expected to result, in debarment, disqualification, suspension or exclusion
under applicable Law, including, without limitation, 21 U.S.C. Section 335a. To the Company&rsquo;s Knowledge, no claims, actions,
proceedings or investigations that would reasonably be expected to result in such a material debarment or exclusion of the Company
or any of its Subsidiaries are pending or threatened against the Company, its Subsidiaries or any of their officers, employees
or agents.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(j)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has made available to the Buyer all material written formal communications submitted by or on behalf of the
Company or any of its Subsidiaries to any Regulatory Authority.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.18<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Insurance</U>. Section 3.18 of the Company Disclosure Schedule sets forth <FONT STYLE="background-color: white">a true
and complete list of all current policies of fire, liability, product liability, umbrella liability, real and personal property,
workers&rsquo; compensation, vehicular, directors&rsquo; and officers&rsquo; liability, fiduciary liability, other casualty and
property and other insurance maintained by Company or any of </FONT>its Subsidiaries <FONT STYLE="background-color: white">(the
&ldquo;<U>Insurance Policies</U>&rdquo;), each of which is in full force and effect</FONT>. True and correct copies of such Insurance
Policies have been made available to Buyer. The Company and its Subsidiaries have complied in all material respects with the provisions
of each Insurance Policy. No insurer under any material Insurance Policy has provided written notice to the Company or any of its
Subsidiaries that it has cancelled or generally disclaimed liability under, or increased the premium with respect to, or altered
the coverage under, any such Insurance Policy or indicated any intent to do so or not to renew any such Insurance Policy. All premiums
payable under the Insurance Policies have been paid or accrued, when due or within applicable grace periods. There is no claim
pending under any Insurance Policy as to which coverage has been questioned, denied or disputed by any underwriter of such policy,
or in respect of which any underwriter has reserved its rights.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.19<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Brokers</U>. Except for the fees payable to Leerink Partners LLC, the fees and expenses of which shall be paid in full
at the Closing (as an Unpaid Company Transaction Expense) or prior to the Closing, no agent, broker, investment banker, financial
advisor or other Person is or shall be entitled, as a result of any action, agreement or commitment of the Company or any of its
Subsidiaries, to any broker&rsquo;s, finder&rsquo;s, financial advisor&rsquo;s or other similar fee or commission in connection
with any of the transactions contemplated by this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.20<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Labor and Employment</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 3.20(a)&nbsp;<FONT STYLE="background-color: white">of the Company Disclosure Schedule sets forth a list of all persons
who are employees, independent contractors or consultants of the Company or any of its Subsidiaries as of the date hereof, including
any employee who is on a leave of absence of any nature, paid or unpaid, authorized or unauthorized, and sets forth for each such
individual the following: </FONT>(i) name; (ii) title or position; (iii) the entity or entities by which such individual is employed;
(iv) hire or start date and service date; (v) base salaries or base hourly wage or contract rate; (vi) target bonus rates or target
commission rates and other incentive-based compensation; (vii) accrued but unused vacation or paid time off balance; (viii) active
or inactive status and, if applicable, the anticipated date of return to service; (ix) full-time or part-time status; (x) exempt
or non-exempt status; (xi) employment location; (xii) <FONT STYLE="background-color: white">severance upon termination or upon
the consummation of the transactions contemplated hereby</FONT>; and (xiii) in which Company Employee Plans the individual participates.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No employees of the Company or any of its Subsidiaries are represented by any labor or trade union, works council, employee
association or other employee representative. Neither the Company nor any of its Subsidiaries is a party to, or otherwise subject
to, any collective bargaining agreement or other agreement with a labor or trade union, works council, employee association or
other employee representative. There have been no strikes, lockouts, slow-downs, work stoppages, picketing, or any other manner
of collective labor unrest among the employees of the Company or its Subsidiaries and, during that time, none of the Company, its
Subsidiaries or any ERISA Affiliate has received written or, to the Knowledge of the Company, any other notice, that such actions
have been threatened. As of the date of this Agreement, there are no complaints pending or, to the Company&rsquo;s Knowledge, threatened
against the Company or any of its Subsidiaries or any ERISA Affiliate alleging that any of them has violated any Laws or contracts
that relate to wages, taxes and withholdings related to such wages, hours, employment or termination of employment, employment
policies or practices, paid time off or sick leave, meal and rest breaks, wage statements, leave of absence rights, immigration
Laws, terms and conditions of employment, compensation, labor or employee relations, classification of employees (whether for purpose
of overtime or employee/independent contractor status or otherwise), affirmative action, government contracting, equal employment
opportunity and fair employment practices, workers&rsquo; compensation, unemployment compensation, whistle-blowing, retaliation
or employee safety or health. To the Company&rsquo;s Knowledge, as of the date of this Agreement there is no organizational effort
presently being made or threatened by or on behalf of any labor or trade union, employee association or current or former employee
of the Company or any of <FONT STYLE="background-color: white">its Subsidiaries</FONT> with respect to the Company&rsquo;s employees.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In all countries where the Company&rsquo;s and its Subsidiaries&rsquo; employees are located, the Company and its Subsidiaries
are and have been in compliance in all material respects with all applicable laws respecting employment and employment practices,
terms and conditions of employment, wages and hours, workplace safety, occupational health and safety, vacation pay, overtime pay,
pay equity, notice of termination, immigration, employee privacy, family, medical and other leaves, classification of employees,
consultants and independent contractors, workers&rsquo; compensation and assessments, human rights and nondiscrimination, non-harassment,
and non-retaliation in employment.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and its Subsidiaries do not have any liability as a result of the failure to properly classify applicable persons
as employees, independent contractors, leased employees or as persons exempt from overtime pay. There are no amounts of compensation
outstanding, (including, but not limited to, vacation or paid time off, paid sick leave, bonuses, commissions, or other liabilities
accrued through the date of this Agreement) to any current or former employee, independent contractor or leased employee other
than accrued amounts representing salary, fees, compensation or bonus entitlements not yet due to be paid or for the reimbursement
of legitimate business expenses.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.21<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Title to Personal Properties</U>. The Company and its Subsidiaries have good and marketable title to, or, in the case
of property held under a lease or other contractual obligation, a valid leasehold interest in, or right to use, all of their tangible
assets that are material to the Company and its Subsidiaries, taken as a whole. None of the Company&rsquo;s or its Subsidiaries&rsquo;
material tangible assets are subject to any Lien other than Permitted Liens. Such tangible assets are, in the aggregate, in good
working order (ordinary wear and tear excepted). Section 3.21(b) of the Company Disclosure Schedule sets forth a true, correct
and complete list of all leases of the Company or any of its Subsidiaries for personal property having annual payment obligations
in excess of $10,000, and the items of tangible property subject thereto are in good working order (ordinary wear and tear excepted),
and such property is in all material respects in the condition required of such property by the terms of such lease applicable
thereto.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.22<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transactions with Affiliates</U>. Neither the Company nor any of its Subsidiaries is or has been a debtor or creditor
of, or otherwise party to any contract with or involved in any business arrangement with, any Company Equityholder or any director,
officer or employee of the Company or any of its Subsidiaries (except for amounts due as salaries and bonuses under employment
agreements or employee benefit plans and amounts payable in reimbursement of ordinary expenses) or any of such Person&rsquo;s family
members or Affiliates, and no such Person, or his, her or its family members or Affiliates, owns or has owned any material asset,
tangible or intangible, that is used in the business of the Company or any of its Subsidiaries.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.23<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Bank Accounts</U>. Section&nbsp;3.23 of the Company Disclosure Schedule sets forth a true and complete list of (a) the
name and address of each bank with which the Company or any of its Subsidiaries has an account or safe deposit box, (b) the account
number thereof and (c) the name of each person authorized to draw thereon or have access thereto.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.24<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Total Assets</U>. The total aggregate value of the assets of the Company and its Subsidiaries, as of February 28, 2017
and as of the date hereof, as determined under GAAP is less than $16,200,000.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.25<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Other Representations or Warranties</U>. Except as expressly set forth in this <U>Article III</U>, neither the Company
nor any Person on behalf of the Company has made, nor are any of them making, any representation or warranty, written or oral,
express or implied, at law or in equity, in respect of the Company, its Subsidiaries or the business of the Company and its Subsidiaries
in connection with the Merger or the other transactions contemplated hereby (including with respect to any financial projections),
and any other such representations and warranties are hereby expressly disclaimed. The Buyer acknowledges and agrees that, except
as set forth in this <U>Article III</U>, neither the Buyer nor any of the Buyer&rsquo;s agents, employees or representatives is
relying on any other representation or warranty of the Company or any other Person, including regarding the accuracy or completeness
of any such other representations or warranties or the omission of any material information (including with respect to any financial
projections), regardless of the forum in which such information has been made available (whether through an electronic dataroom,
management presentation or otherwise), whether express or implied, in each case with respect to the Merger and the other transactions
contemplated hereby.</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>ARTICLE
IV</B></FONT><BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>REPRESENTATIONS AND WARRANTIES OF THE BUYER AND THE TRANSITORY SUBSIDIARY</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Buyer and the Transitory Subsidiary represent
and warrant to the Company that the statements contained in this <U>Article IV</U> are true and correct, except as set forth herein
or in the Buyer Disclosure Schedule.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Organization, Standing and Power</U>. Each of the Buyer and the Transitory Subsidiary is a corporation duly organized,
validly existing and in good standing under the Laws of the jurisdiction of its incorporation, has all requisite corporate power
and authority to own, lease and operate its properties and assets and to carry on its business as conducted on the date of this
Agreement, and is duly qualified to do business and, where applicable as a legal concept, is in good standing as a foreign corporation
in each jurisdiction in which the character of the properties it owns, operates or leases or the nature of its activities makes
such qualification necessary, except for such failures to be so qualified or in good standing, individually or in the aggregate,
that would not reasonably be expected to have a Buyer Material Adverse Effect.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authority; No Conflict; Required Filings and Consents</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each of the Buyer and the Transitory Subsidiary has all requisite corporate power and authority to enter into this Agreement
and, subject to the adoption of this Agreement by the Buyer as sole stockholder of the Transitory Subsidiary (which shall occur
immediately after the execution and delivery of this Agreement), to consummate the transactions contemplated by this Agreement.
The board of directors of the Transitory Subsidiary has (i) deemed the Merger advisable and in the best interests of the Transitory
Subsidiary and the Buyer, as the Transitory Subsidiary&rsquo;s sole stockholder, (ii) approved this Agreement and the Merger in
accordance with the DGCL upon the terms and subject to the conditions set forth herein and (iii) recommended the adoption of this
Agreement by the Buyer, as the Transitory Subsidiary&rsquo;s sole stockholder. The execution and delivery of this Agreement and
the consummation of the transactions contemplated by this Agreement by the Buyer and the Transitory Subsidiary have been duly authorized
by all necessary corporate action on the part of each of the Buyer and the Transitory Subsidiary, subject to the adoption of this
Agreement by the Buyer as sole stockholder of the Transitory Subsidiary (which shall occur immediately after the execution and
delivery of this Agreement). This Agreement has been duly executed and delivered by each of the Buyer and the Transitory Subsidiary
and constitutes the valid and binding obligation of each of the Buyer and the Transitory Subsidiary, enforceable against each of
them in accordance with its terms, subject to the Bankruptcy and Equity Exception.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The execution and delivery of this Agreement by each of the Buyer and the Transitory Subsidiary do not, and the consummation
by the Buyer and the Transitory Subsidiary of the transactions contemplated by this Agreement will not, (i)&nbsp;conflict with,
or result in any violation or breach of, the Organizational Documents of the Buyer or the Transitory Subsidiary, (ii)&nbsp;conflict
with, or result in any violation or breach of, or constitute (with or without notice or lapse of time, or both) a default (or give
rise to a right of termination, cancellation or acceleration of any obligation or loss of any material benefit) under, require
a consent, waiver or delivery of notice under, constitute a change in control under, require the payment of a penalty under or
result in the imposition of any Lien on the Buyer&rsquo;s or the Transitory Subsidiary&rsquo;s assets under, any of the terms,
conditions or provisions of any lease, license, contract or other agreement, instrument or obligation to which the Buyer or the
Transitory Subsidiary is a party or by which any of them or any of their properties or assets may be bound or (iii)&nbsp;subject
to the adoption of this Agreement by the Buyer as sole stockholder of the Transitory Subsidiary (which shall occur immediately
after the execution and delivery of this Agreement) and subject to compliance with the requirements specified in clauses (i) and
(ii) of <U>Section 4.2(c)</U>, conflict with or violate any Law applicable to the Buyer or the Transitory Subsidiary or any of
its or their respective properties or assets.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No consent, approval, license, permit, order or authorization of, or registration, declaration, notice or filing (other
than a Current Report on Form 8-K with respect to this Agreement and the transactions contemplated hereby) with, any Governmental
Entity or any stock market or stock exchange on which shares of Buyer common stock are listed for trading is required by or with
respect to the Buyer or the Transitory Subsidiary in connection with the execution and delivery of this Agreement by the Buyer
or the Transitory Subsidiary or the consummation by the Buyer or the Transitory Subsidiary of the transactions contemplated by
this Agreement, except for the filing of the Certificate of Merger with the Delaware Secretary of State.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No vote of the holders of any class or series of the Buyer&rsquo;s capital stock or other securities is necessary for the
consummation by the Buyer of the transactions contemplated by this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Buyer Capitalization</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As of March 27, 2017, the authorized capital of the Buyer consisted of 270,000,000 shares of Buyer Class A Common Stock,
of which 43,635,826 shares were issued and outstanding, and 3,009,942 were held in treasury; 75,000,000 shares of Buyer Class B
Common Stock, none of which were issued and outstanding; and 5,000,000 shares of Buyer Preferred Stock, none of which were issued
and outstanding. The rights, preferences, privileges and restrictions of the capital stock of Buyer are as stated in the Buyer&rsquo;s
certificate of incorporation or otherwise as provided under applicable Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As of March 24, 2017, 9,943,867 shares of Buyer Common Stock were reserved for issuance under the Buyer&rsquo;s 2016 Equity
Incentive Plan, of which 6,401,148 shares were subject to awards with respect to shares of Buyer Common Stock.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All shares of Buyer Common Stock have been duly authorized and validly issued, and are fully paid and non-assessable and
have been issued and granted in all material respects in compliance with all applicable securities Laws. All shares of Buyer Common
Stock which may be issued pursuant to the Merger, will be, when issued in accordance with the terms hereof, voting stock that is
duly authorized, validly issued, fully paid and non-assessable, free and clear of any Liens created by Buyer (for the avoidance
of doubt, excluding Liens arising under applicable securities Laws) and not subject to any preemptive rights created by statute,
the certificate of incorporation or bylaws of Buyer or any contract to which Buyer is a party or by which it is bound and will
have been issued in all material respects in compliance with all applicable securities Laws.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>SEC Documents; Financial Statements</U>. The Buyer has timely filed or furnished all forms, reports, schedules, statements
and other documents required to be filed or furnished by it with the SEC, together with all certifications required pursuant to
the Sarbanes-Oxley Act (these documents, as supplemented or amended since the time of filing, and together with all information
incorporated by reference therein and schedules and exhibits thereto, collectively, the &ldquo;<U>Buyer SEC Reports</U>&rdquo;)
since the end of Buyer&rsquo;s most recent fiscal year. No Subsidiary of Buyer is required to file with or furnish to the SEC any
forms, reports, schedules, statements or other documents. As of their respective filing dates (or if amended, as of the date of
such amendment), each Buyer SEC Report and all Buyer SEC Reports filed after the date hereof but before the Closing complied or,
if filed after the date hereof, will comply in all material respects with the requirements of the Exchange Act or the Securities
Act, as applicable, and the rules and regulations of the SEC promulgated thereunder, and none of the Buyer SEC Reports as of their
respective filing dates contained any untrue statement of a material fact or omitted to state a material fact required to be stated
therein or necessary to make the statements made therein, in light of the circumstances under which they were made, not misleading,
except to the extent amended or superseded by a Buyer SEC Report filed subsequently (but prior to the date hereof). The financial
statements of Buyer, including the notes thereto, included in the Buyer SEC Reports comply as to form in all material respects
with the published rules and regulations of the SEC with respect thereto, have been prepared in accordance with GAAP consistently
applied and Regulation S-X of the SEC (except as may be indicated in the notes thereto or, in the case of unaudited financial statements,
as permitted by Form 10-Q under the Exchange Act) and present fairly, in all material respects, the consolidated financial position
of Buyer and its consolidated subsidiaries at the dates thereof and the consolidated results of its operations, changes in shareholders&rsquo;
equity and cash flows for the periods then ended (subject, in the case of unaudited financial statements, to (i) such exceptions
as may be permitted by Form 10-Q under the Securities Act and (ii) normal year-end adjustments).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Litigation</U>. As of the date hereof, there is no litigation, action, suit, proceeding, claim, arbitration or investigation
pending or, to the knowledge of the Buyer or the Transitory Subsidiary, threatened, against the Buyer or the Transitory Subsidiary,
and neither the Buyer nor the Transitory Subsidiary is subject to any outstanding order, writ, judgment, injunction or decree of
any Governmental Entity that, in either case, would, individually or in the aggregate, reasonably be expected to have a Buyer Material
Adverse Effect.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Operations of the Transitory Subsidiary</U>. The Transitory Subsidiary was formed solely for the purpose of engaging
in the transactions contemplated by this Agreement, has engaged in no other business activities and has conducted its operations
only as contemplated by this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Financing</U>. The Buyer has sufficient funds to make the payments required to be made by it on the Closing Date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Brokers</U>. Except for the fees payable to Jefferies LLC, no agent, broker, investment banker, financial advisor or
other Person is or shall be entitled, as a result of any action, agreement or commitment of the Buyer or any of its Subsidiaries,
to any broker&rsquo;s, finder&rsquo;s, financial advisor&rsquo;s or other similar fee or commission in connection with any of the
transactions contemplated by this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration Eligibility</U>. Buyer is eligible to register for resale the Buyer Common Stock to be issued in the Merger
on Form S-3 promulgated under the Securities Act, as contemplated by <U>Section 6.7</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Other Representations or Warranties</U>. Except as expressly set forth in this <U>Article IV</U>, none of the Buyer,
Transitory Subsidiary or any Person on their behalf has made, nor are any of them making, any representation or warranty, written
or oral, express or implied, at law or in equity in respect of the Buyer, Transitory Subsidiary, the Buyer&rsquo;s other Subsidiaries
or their businesses in connection with the Merger or the other transactions contemplated hereby, and any other such representations
and warranties are hereby expressly disclaimed. The Company and the Company Equityholder Representative (on behalf of all Company
Equityholders) acknowledge and agree that, except as set forth in this <U>Article IV</U>, none of the Company, the Company Equityholder
Representative or any of their agents, employees or representatives is relying on any other representation or warranty of the Buyer,
the Transitory Subsidiary or any other Person, including regarding the accuracy or completeness of any such other representations
or warranties or the omission of any material information, regardless of the forum in which such information has been made available,
whether express or implied, in each case with respect to the Merger and the other transactions contemplated hereby.</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>ARTICLE
V</B></FONT><BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>COVENANTS OF THE COMPANY</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">5.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conduct of Business of the Company</U>. Except (a) as expressly contemplated by this Agreement, (b) as set forth in <U>Section
5.1</U> of the Company Disclosure Schedule, (c) as required by applicable Law or (d) as consented to in writing by the Buyer, during
the Pre-Closing Period, the Company shall, and shall cause each of its Subsidiaries to: (i) carry on its business in the ordinary
course of business consistent with past practices, (ii) use commercially reasonable efforts to preserve intact its present business
organization, and (iii) use commercially reasonable efforts to preserve its relationships with suppliers, distributors, licensors,
licensees and others with whom the Company has contractual relationships.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">5.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions on Conduct of Business of the Company</U>. During the Pre-Closing Period, without limiting the Company&rsquo;s
obligations under <U>Section 5.1</U>, except as set forth in Section 5.2 of the Company Disclosure Schedule the Company shall not
and shall not permit any of its Subsidiaries to do the following without the written consent of the Buyer:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>change or amend the Company Certificate of Incorporation, the Company Bylaws, any other organizational documents of the
Company or any of the organizational documents of the Company&rsquo;s Subsidiaries, or authorize or propose the same;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>split, combine or reclassify any of its capital stock or other Equity Interest; issue or authorize the issuance of any other
securities in respect of, in lieu of or in substitution for shares of its capital stock; declare, set aside, or pay any dividend
or make any distribution (whether in cash or in kind) with respect to any of its or other Equity Interest; or redeem, purchase,
or otherwise acquire, directly or indirectly, any of its capital stock or other Equity Interest (except from former employees in
accordance with agreements in place on the date of this Agreement that provide for the repurchase of shares at their original issue
price in connection with any termination of employment with or services to the Company);</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>issue, deliver, encumber, dispose, transfer or sell, or authorize to issue, deliver, encumber, dispose, transfer or sell,
any shares of its capital stock or other Equity Interest, <U>provided</U>, <U>however</U>, that the Company may issue shares of
Company Common Stock in connection with the exercise of Company Options outstanding as of immediately prior to the date of this
Agreement;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>enter into or adopt any plan or agreement of complete or partial liquidation, restructuring, recapitalization or dissolution,
or file a voluntary petition in bankruptcy or commence a voluntary legal procedure for reorganization, arrangement, adjustment,
release or composition of indebtedness in bankruptcy or other similar Laws now or hereafter in effect;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>incur any Indebtedness (other than borrowings in the ordinary course of business under existing lines of credit), or guarantee
any Indebtedness;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="background-color: white">impose any Lien other than a Permitted Lien on any of the Company properties, capital
stock, or tangible or intangible assets;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>make any capital expenditures, capital additions or capital improvements, in excess of (x) $50,000 individually or (y) $250,000
in the aggregate;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>acquire or agree to acquire by merging with, or by purchasing a portion of the stock or assets of, or by any other manner,
any business or any entity, or invest in, make a loan, advance or capital contribution to, or otherwise acquire the securities
of any other Person (other than advances to employees of the Company in the ordinary course of business and consistent with past
practices);</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(A) initiate any new line of business, (B) make any loan or capital contribution to any Person or (C) otherwise acquire
or agree to acquire any securities or assets that are material, individually or in the aggregate, to the Company;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(j)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>terminate, cancel, amend, waive, modify or fail to maintain, renew or comply with any material Permit;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(k)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>sell, assign or otherwise dispose of, lease or license any properties or assets of the Company;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(l)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(A) sell, assign, transfer, license, abandon or otherwise dispose of any Company Intellectual Property, or (B) acquire,
in-license or otherwise obtain any right, title or interest in or to any pending or issued patent rights, inventions, patent disclosures
or other Intellectual Property from any other Person;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(m)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend or modify in any material respect any Company Material Contract, terminate any Company Material Contract, waive any
material right under a Company Material Contract or enter into or modify any other contract or arrangement such that it would be
a Company Material Contract if entered into or if such modification were in effect as of the date of this Agreement;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(n)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>make, revoke or change any election in respect of Taxes, change an annual Tax accounting period, adopt or change any accounting
method in respect of Taxes, file any amended Tax Return, enter into any closing agreement with respect to Taxes, settle any claim
or assessment in respect of Taxes, surrender or abandon any right to claim a refund of a material amount of Taxes, or consent to
any extension or waiver of the limitation period applicable to any material claim or assessment in respect of Taxes, or take any
position on any Tax Return, take any action or enter into any transaction that would have the effect of increasing the Tax liability
of the Buyer or the Company (or its Subsidiaries) in respect of any Tax period (or portion thereof) beginning after the Closing
Date;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(o)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>make a material change in its accounting principles, methods, policies or practices, unless required under GAAP;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(p)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>except as required by applicable Law, make, or amend, any filings with the FDA, the EMA or any other Regulatory Authority
performing functions similar to those performed by the FDA, the EMA or such other Regulatory Authority;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(q)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(i) other than as required by applicable Law, adopt, establish, enter into, amend or terminate the Company Stock Plan any
Company Employee Plan or any plan, agreement, program, policy, trust, fund or other arrangement with the employees or other service
providers of the Company, (ii) increase the compensation or fringe benefits (including severance, termination, retention and change
of control compensation or benefits) of, or grant any bonus or other incentive compensation to, any current or former employee,
director or officer or other individual service provider of the Company, (iii) grant any severance or termination pay to any current
or former director, officer or employee or other individual service provider of the Company, (iv) terminate the employment of any
Company Employees or (v) except in the ordinary course of business, hire or engage the services of any new employee or other service
provider; <U>provided</U> that the Buyer&rsquo;s consent shall be required with respect to any such hiring or engagement involving
base compensation or payment for services in excess of $100,000 per year;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(r)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>recognize, or enter into any collective bargaining agreement or any other agreement with, a labor or trade union, employee
association, works council, or other employee representative;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(s)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>waive, release, assign, compromise, commence, settle or agree to settle any action, suit, proceeding, claim, arbitration
or investigation pending before any Governmental Entity or any arbitrator against the Company or any of its Subsidiaries; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(t)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>agree or commit to take any of the actions described in clauses &ldquo;(a)&rdquo;&nbsp;through &ldquo;(r)&rdquo; of this
<U>Section 5.2</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">5.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Solicitation</U>. During the Pre-Closing Period, the Company shall not (and shall cause each of its Subsidiaries not
to), and the Company shall not permit its and its Subsidiaries&rsquo; directors, officers, employees and other agents to, directly
or indirectly, (a) solicit, initiate or knowingly encourage any Acquisition Proposal, (b) enter into, continue or otherwise participate
in any discussions or negotiations regarding, or furnish to any Person any information for the purpose of encouraging or facilitating,
or in connection with any Acquisition Proposal, or (c)&nbsp;enter into any agreement, arrangement, understanding or other contract
with any Person the terms of which require it to abandon or terminate the transactions contemplated hereby. The Company shall promptly
(and in all events within one Business Day) inform the Buyer of the identity of any Person making an Acquisition Proposal, or any
inquiry by any Person directed to the Company with respect to or which could lead to any Acquisition Proposal, during the Pre-Closing
Period as well as the nature and material terms of any such Acquisition Proposal and any documents or written correspondence in
connection therewith. The Company shall not provide any information concerning the Company to any party making or considering making
an Acquisition Proposal. The Company shall, concurrently with the execution of this Agreement, require the return or destruction
of any confidential information shared in connection with any terminated discussions or negotiations with respect to any Acquisition
Proposal (to the extent the Company has the right to require such return or destruction). The Company shall (and shall cause each
of its Subsidiaries to), and the Company shall require its and its Subsidiaries&rsquo; directors, officers, employees and other
agents to, immediately cease and cause to be terminated any existing discussions or negotiations with any Persons (other than Buyer)
conducted heretofore with respect to any Acquisition Proposal.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">5.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stockholder Consent or Approval</U>. The Company shall, in accordance with the Company Certificate of Incorporation and
the Company Bylaws and the applicable requirements of the DGCL (including Sections 228 and 262 of the DGCL), (i) solicit the Written
Consent for the adoption of this Agreement and the approval of the Merger and the other transactions contemplated hereby and (ii)
cause a copy of an information statement in the form attached hereto as <U>Exhibit D</U> (the &ldquo;<U>Information Statement</U>&rdquo;)
to be delivered to the physical or electronic address on record for each stockholder of the Company who is entitled to vote upon
adoption of this Agreement. Without limiting the foregoing and notwithstanding anything to the contrary in this Agreement, the
Company shall deliver to the Buyer the Written Consent, together with a certificate executed on behalf of the Company by its corporate
Secretary certifying that such Written Consent reflects the Company Stockholder Approval, within two (2) hours following the execution
of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">5.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Access to Information</U>. During the Pre-Closing Period, the Company shall (and shall cause each of its Subsidiaries
to) afford to the Buyer&rsquo;s officers, employees, accountants, counsel and other representatives, reasonable access, upon reasonable
notice, during normal business hours and in a manner that does not unreasonably disrupt or interfere with business operations,
to all of its facilities, properties, books, contracts, commitments, management personnel and records as the Buyer shall reasonably
request, and, during such period, the Company shall (and shall cause each of its Subsidiaries to) furnish promptly to the Buyer
the information concerning its business, properties, assets and personnel (other than personnel or medical records) as the Buyer
may reasonably request. Any access provided to the Buyer or information provided by the Company or its Subsidiaries shall not constitute
any expansion of or additional representations or warranties of the Company beyond those specifically set forth in this Agreement.
The Buyer will hold any such information which is nonpublic in confidence in accordance with the Confidentiality Agreement. Notwithstanding
the foregoing, the Company and its Subsidiaries shall not be required to provide the Buyer access to or disclose information where
such access or disclosure would, in the Company&rsquo;s reasonable judgment (based on the advice of outside counsel), (a) result
in the loss of any attorney-client privilege; <U>provided</U>, <U>however</U>, that the Company and its Subsidiaries shall provide
the Buyer with a summary of the information to the extent consistent with such privilege and make a commercially reasonable effort
to enter into a joint defense agreement with the Buyer which would allow disclosure of such information, (b) result in the disclosure
of competitively sensitive information in violation of applicable Antitrust Laws, or (c) be prohibited under applicable Law; <U>provided</U>,
<U>however</U>, that the Company and its Subsidiaries shall provide the Buyer with a summary of the information if and to the extent
permitted by such Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">5.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>280G Matters</U>. As soon as possible after the date of this Agreement, and in any event prior to the Effective Time,
the Company shall submit to a stockholder vote the right of any &ldquo;disqualified individual&rdquo; (as defined in Section 280G(c)
of the Code) listed in Section 5.6 of the Company Disclosure Schedule to receive any and all payments (or other benefits) contingent
on the consummation of the transactions contemplated by this Agreement (within the meaning of Section 280G(b)(2)(A)(i) of the Code)
to the extent necessary so that, if such vote is adopted by the Company stockholders in a manner that satisfies the stockholder
approval requirements under Section 280G(b)(5)(B) of the Code and regulations promulgated thereunder, no payment received by such
&ldquo;disqualified individual&rdquo; would be a &ldquo;parachute payment&rdquo; under Section 280G(b) of the Code (determined
without regard to Section&nbsp;280G(b)(4) of the Code). Such vote shall establish the &ldquo;disqualified individual&rsquo;s&rdquo;
right to the payment or other compensation. In addition, the Company shall provide adequate disclosure to Company stockholders
entitled to vote under Section 280G(b)(5)(B) of all material facts concerning all payments that, but for such vote, could be deemed
&ldquo;parachute payments&rdquo; to any such &ldquo;disqualified individual&rdquo; under Section 280G of the Code in a manner that
satisfies Section 280G(b)(5)(B)(ii) of the Code and regulations promulgated thereunder. Prior to the stockholder vote contemplated
by this <U>Section 5.6</U>, the Company shall give the Buyer a reasonable opportunity to review and approve (such approval not
to be unreasonably withheld, delayed or conditioned) its calculations and any document to be delivered to any &ldquo;disqualified
individual&rdquo; or the Company Stockholders in connection with the foregoing.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">5.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Interim Financial Reports</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>During the Pre-Closing Period, within forty (40) days of the end of each calendar month commencing after January 31, 2017,
the Company shall deliver to the Buyer an unaudited consolidated balance sheet and the related consolidated statement of operations
and cash flows of the Company and its Subsidiaries as of and for each such month, in each case prepared in accordance with GAAP.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>During the Pre-Closing Period, in order to assist the Buyer in satisfying the Buyer&rsquo;s reporting obligations under
Rule 3-05 of Regulation S-X, the Company shall, as promptly as practicable and upon reasonable notice, cooperate with the Buyer
to permit Buyer to obtain all information (including drafts and workpapers of the Company&rsquo;s auditor, to the extent available)
reasonably necessary for the Buyer to comply with such reporting obligations and take all other reasonable actions in connection
with the preparation of audited financial information with respect to the Company and its Subsidiaries and Buyer&rsquo;s preparation
of pro forma financial statements for the acquisition of the Company and its Subsidiaries in compliance with Buyer&rsquo;s reporting
obligations under Regulation S-X. The cost of the Company&rsquo;s 2016 audit and obtaining a reliance letter from the Company&rsquo;s
auditors with respect to such audit shall be borne by the Company. All other expenses incurred in connection with such cooperation
shall be borne by the Buyer.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>ARTICLE
VI</B></FONT><BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>ADDITIONAL AGREEMENTS</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">6.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing Efforts; Legal Conditions to the Merger; Third-Party Consents</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the terms hereof, including <U>Section 6.1(b)</U>, the Company and the Buyer shall each:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>use its commercially reasonable efforts to take, or cause to be taken, all actions, and do, or cause to be done, and to
assist and cooperate with the other parties in doing, all things necessary, proper or advisable to consummate and make effective
the transactions contemplated hereby as promptly as practicable, but in no event later than the Outside Date;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>use its commercially reasonable efforts to make, as promptly as practicable, all necessary filings, and thereafter make
any other required submissions, with respect to this Agreement and the Merger required under any applicable Law including complying
with any pre-merger notification requirements under any applicable Antitrust Laws;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>use its commercially reasonable efforts to obtain, as promptly as practicable, from any Governmental Entity or any other
third party any consents, licenses, permits, waivers, approvals, authorizations or orders required to be obtained or made by the
Company or the Buyer (or any of their Subsidiaries), respectively, in connection with the authorization, execution and delivery
of this Agreement and the consummation of the transactions contemplated hereby, it being understood that neither the Company nor
the Buyer (or any of their Subsidiaries) shall be required to make any material payments in connection with the fulfillment of
its obligations under this paragraph; and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>execute or deliver any additional instruments reasonably necessary to consummate the transactions contemplated by, and to
fully carry out the purposes of, this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Company and the Buyer shall cooperate with each other in connection
with the making of all such filings, including providing copies of all such documents to the non-filing party and its advisors
prior to filing and, if requested, accepting reasonable additions, deletions or changes suggested in connection therewith. Except
to the extent prohibited by applicable Law, the Company and the Buyer shall furnish to each other all information required for
any application or other filing to be made pursuant to the rules and regulations of any applicable Law in connection with the transactions
contemplated by this Agreement (which shall be subject to the Confidentiality Agreement or, in the case of information received
by the Company, the Company and its representatives shall maintain such information in strict confidence to the extent not publicly
available (other than through a breach of this provisions by the Company or any of its representatives)). For the avoidance of
doubt, the Buyer and the Company agree that nothing contained in this <U>Section 6.1(a)</U> shall modify or affect their respective
rights and responsibilities under <U>Section 6.1(b)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the terms hereof, the Buyer and the Company agree, and shall cause each of their respective Subsidiaries, to
cooperate and to use their respective commercially reasonable efforts to (i)&nbsp;obtain any government clearances or approvals
required for Closing under applicable Antitrust Laws and (ii) respond to any government requests for information under any Antitrust
Law; <U>provided</U> that neither the Buyer nor the Company shall be required to (A) contest and resist any action, including any
legislative, administrative or judicial action, or seek to have vacated, lifted, reversed or overturned any Antitrust Order that
restricts, prevents or prohibits the consummation of the Merger or any other transaction contemplated by this Agreement under any
Antitrust Law or (B) take any action or accept any condition that (x) is materially adverse to the business or operations of such
party and its Subsidiaries or (y) would require the sale, divestiture or disposition of any material assets, properties or business
held by such party or its Subsidiaries. Except to the extent prohibited by applicable Law, the parties hereto will consult and
cooperate with one another, and consider in good faith the views of one another, in connection with, and provide to the other parties
in advance, any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals made or submitted by
or on behalf of any party hereto in connection with proceedings under or relating to any Antitrust Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Without limiting any of the parties&rsquo; respective obligations set forth in any of <U>Section 6.1(a)</U> and <U>Section
6.1(b)</U>, the Company or the Buyer shall give (or shall cause their respective Subsidiaries to give) any notices to third parties,
and use, and cause their respective Subsidiaries to use, its commercially reasonable efforts to obtain any third party consents
required in connection with the Merger that are (i) necessary with respect to the Company or the Buyer (or their subsidiaries),
respectively, to consummate the transactions contemplated hereby, (ii) with respect to the Company and its Subsidiaries, disclosed
or required to be disclosed in the Company Disclosure Schedule or (iii) required to prevent the occurrence of an event that would
reasonably be expected to have a Company Material Adverse Effect or a Buyer Material Adverse Effect, respectively, prior to or
after the Effective Time, it being understood that neither the Company nor the Buyer shall be required to make any material payments
in connection with the fulfillment of its obligations under this <U>Section&nbsp;6.1(c)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">6.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Public Disclosure</U>. Promptly following the execution of this Agreement, the Buyer and the Company shall issue a joint
press release announcing the execution of this Agreement in such form as shall be mutually agreed upon by the Company and the Buyer.
Except for the foregoing, during the Pre-Closing Period, neither the Company nor the Buyer shall issue any other press release
or make any public statement regarding the Merger or this Agreement, without the prior written consent of the other party, except
as may be required by Law or stock market regulations (including with respect to the Buyer&rsquo;s disclosures relating to this
Agreement and the transactions contemplated hereby as required under the Securities Act), in which case the Buyer or the Company
shall consult with the other party before issuing any other press release or otherwise making any required public statement with
respect to the Merger or this Agreement; <U>provided</U> that any such press release or public statement as may be required by
Law or stock market regulations may be issued without such consultation if the party making the release or statement has used its
commercially reasonable efforts to consult with the other party prior to such release or statement; <U>provided</U>, <U>further</U>,
that the Buyer shall be permitted to make public statements and disclosures consistent with the content of the press release announcing
the transactions contemplated by this Agreement from and after the issuance of such press release.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">6.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification of Directors and Officers</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>From the Effective Time through the sixth (6<SUP>th</SUP>) anniversary of the date on which the Effective Time occurs, each
of the Buyer and the Surviving Corporation shall, subject to the terms, conditions and limitations of the Company Certificate of
Incorporation, the Company Bylaws and the indemnification agreements between the Company and the officers and directors of the
Company set forth on <U>Section 6.3</U> of the Company Disclosure Schedule and in effect as of the date of this Agreement (the
&ldquo;<U>Indemnification Agreements</U>&rdquo;), jointly and severally, indemnify each Company Indemnified Party against all claims,
losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&rsquo; fees and disbursements,
incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative,
arising out of or pertaining to the fact that the Company Indemnified Party is or was an officer or director of the Company or
any of its Subsidiaries or any predecessor thereof, whether asserted or claimed prior to, at or after the Effective Time, to the
fullest extent permitted under the DGCL for officers and directors of Delaware corporations. To the extent permitted under the
DGCL, but subject to the terms, conditions and limitations of the Company Certificate of Incorporation, the Company Bylaws and
the Indemnification Agreements, each Company Indemnified Party will be entitled to advancement of expenses in connection with matters
for which such Company Indemnified Party is eligible to be indemnified pursuant to this <U>Section 6.3(a)</U> from either the Buyer
or the Surviving Corporation promptly after receipt by the Buyer or the Surviving Corporation from the Company Indemnified Party
of a request therefor, subject to the execution by such Company Indemnified Party of appropriate undertakings to repay such advanced
costs and expenses if such Company Indemnified Party is ultimately determined not entitled to be indemnified for such advanced
costs and expenses.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The certificate of incorporation and by-laws of the Surviving Corporation shall contain, and the Buyer shall cause the certificate
of incorporation and by-laws of the Surviving Corporation to so contain, provisions no less favorable with respect to indemnification,
advancement of expenses and exculpation of present and former directors and officers of the Company and its Subsidiaries or any
predecessor thereof than are set forth in the certificate of incorporation and by-laws of the Company immediately prior to the
execution and delivery of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the following sentence, the Surviving Corporation shall, at no expense to the beneficiaries, maintain a six (6)
year extended reporting period endorsement with respect to the Current D&amp;O Insurance (a &ldquo;<U>Reporting Tail Endorsement</U>&rdquo;)
and maintain such endorsement in full force and effect for its full term. Any premium or other cost or expense relating to the
Reporting Tail Endorsement that has not been paid prior to the Effective Time shall constitute Unpaid Company Transaction Expenses.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Buyer, the Surviving Corporation or any of the Company&rsquo;s Subsidiaries (i) shall consolidate with or merge into
any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii) shall
transfer all or substantially all of its properties and assets to any Person, then, and in each such case, proper provisions shall
be made so that the successor and assigns of the Buyer, the Surviving Corporation or such Subsidiary, as the case may be, shall
assume all of the obligations of this <U>Section 6.6</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The provisions of this <U>Section 6.3</U> shall operate for the benefit of, and shall be enforceable by, each of the Company
Indemnified Parties, their heirs and their permitted assigns.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">6.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notification of Certain Matters</U>. During the Pre-Closing Period, the Buyer shall give prompt notice to the Company,
and the Company shall give prompt notice to the Buyer, of (a) the occurrence, or failure to occur, of any event, which occurrence
or failure to occur would reasonably be expected to cause the conditions to Closing set forth in <U>Sections 7.1</U>, <U>7.2(a)</U>
or <U>7.3(a)</U>, as the case may be, not to be satisfied or (b) any failure of the Buyer and the Transitory Subsidiary or the
Company, as the case may be, to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by
it under this Agreement, which failure would reasonably be expected to cause the conditions to Closing set forth in <U>Sections
7.1</U>, <U>7.2(b)</U> or <U>7.3(b)</U>, as the case may be, not to be satisfied. Notwithstanding the above, the delivery of any
notice pursuant to this <U>Section 6.4</U> will not limit or otherwise affect the remedies available hereunder to the party receiving
such notice or the conditions to such party&rsquo;s obligation to consummate the Merger.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">6.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Matters</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Following the Closing, the Buyer shall give each Continuing Employee full credit for prior service with the Company and
its Subsidiaries for purposes of (i) eligibility and vesting under any Buyer Employee Plans and (ii) determination of benefit levels
under any Buyer Employee Plan or policy relating to vacation or severance, in each case for which the Continuing Employee is otherwise
eligible and in which the Continuing Employee is offered participation, but not where such credit would result in a duplication
of benefits. In addition, the Buyer shall use its commercially reasonable efforts to cause to be waived any limitations on benefits
relating to pre-existing conditions to the same extent such limitations are waived under any comparable plan of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall deliver, or cause to be delivered, to the Buyer (unless the delivery is waived in writing by the Buyer),
written evidence, in form and substance reasonably satisfactory to the Buyer, that (A) any 401(k) Plan sponsored or maintained
by the Company or its Subsidiaries or ERISA Affiliates has been terminated effective as of no later than the Business Day before
the Closing Date (consisting of such resolutions of the Company&rsquo;s board of directors or the applicable committee of the Company&rsquo;s
board of directors as are necessary to effect such termination), and (B) the Company has made or will in the next payroll date
following the Closing Date make all necessary payment to fund the contributions: (x)&nbsp;necessary or required to maintain the
tax qualified status of any such 401(k) Plan; (y) for elective deferrals made pursuant to any such 401(k) Plan for the period prior
to termination; and (z) for employer matching contributions (if any) for the period prior to termination.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Nothing in this Agreement shall prohibit the Buyer or any of its Subsidiaries from amending, modifying or terminating, or
shall be construed as an amendment or modification to, any or all compensation or benefit plans, programs, policies, practices,
agreements and arrangements sponsored or maintained by the Company, the Buyer or any of their Subsidiaries, including each Company
Employee Plan and Buyer Employee Plan, and&nbsp;nothing in this Agreement shall require the Buyer or any of its Subsidiaries to
continue any particular compensation or benefit plan, program, policy, practice, agreement or arrangement after the Effective Time
or to employ any particular person on any particular terms. Nothing in this <U>Section 6.5</U> shall give any Company employee
or other third party any right to enforce the provisions of this <U>Section 6.5</U> in their capacity as such.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">6.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Matters</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall prepare and timely file or shall cause to be prepared and timely filed all Tax Returns of the Company
and its Subsidiaries required to be filed (taking into account extensions) prior to the Closing Date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Buyer shall prepare and timely file or shall cause to be prepared and timely filed all other Tax Returns for the Company
and its Subsidiaries (such Tax Returns, to the extent related to a Straddle Period or Pre-Closing Tax Period, &ldquo;<U>Buyer Prepared
Tax Returns</U>&rdquo;). The Buyer shall make all payments required with respect to any such Tax Returns; <U>provided</U>, <U>however</U>,
that the Company Equityholders shall promptly reimburse the Buyer to the extent any payment the Buyer is required to make is a
Pre-Closing Tax.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any Buyer Prepared Tax Return shall be prepared on a basis consistent with the last previous similar Tax Return unless otherwise
required pursuant to applicable Law. The Buyer shall provide the Company Equityholder Representative with a copy of each Buyer
Prepared Tax Return (and such additional information regarding such Tax Return as may reasonably be requested by the Company Equityholder
Representative) for review and comment at least thirty (30) days prior to the filing of such Buyer Prepared Tax Return, in the
case of Income Tax Returns, and in such period of time prior to filing as the Buyer shall reasonably determine to be practicable
in the case of any other Buyer Prepared Tax Return. The Buyer shall consider in good faith all timely received comments of the
Company Equityholder Representative to such Buyer Prepared Tax Returns with respect to Pre-Closing Tax Periods.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Buyer and the Company Equityholders agree that if the Company or any of its Subsidiaries is permitted but not required
under applicable foreign, state or local Tax Laws to treat the Closing Date as the last day of a taxable period, the Buyer and
the Company Equityholders shall treat such day as the last day of a taxable period of the Company or its Subsidiary as applicable.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The portion of any Taxes for a Straddle Period shall be deemed to equal (i) in the case of Taxes that (x) are based upon
or related to income or receipts or (y) imposed in connection with any sale or other transfer or assignment of property, other
than Transfer Taxes, the amount which would be payable if the taxable year ended with the Closing Date, and (ii) in the case of
other Taxes imposed on a periodic basis (including property Taxes), the amount of such Taxes for the entire period multiplied by
a fraction the numerator of which is the number of calendar days in the period ending with and including the Closing Date and the
denominator of which is the number of calendar days in the Straddle Period; <U>provided</U>, <U>however</U>, that appropriate adjustments
shall be made to reflect specific events that can be identified and specifically allocated as occurring on or prior to the Closing
Date or occurring after the Closing Date. For purposes of computing the Taxes attributable to the two portions of a taxable period
pursuant to this <U>Section 6.6(e)</U>, the amount of any item that is taken into account only once for each taxable period (e.g.,
the benefit of graduated tax rates, exemption amounts, etc.) shall be allocated between the two portions of the period in proportion
to the number of days in each portion.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Transactions that occur on the Closing Date but after the Closing and that are not incurred in the ordinary course of business
of the Company shall be considered to be attributable to the period that commences on the day following the Closing Date. The Buyer
agrees to report and to cause to be reported all transactions not in the ordinary course of business, or not specifically contemplated
by this Agreement, occurring on the Closing Date but after the Closing as occurring at the beginning of the following day to the
extent permitted by the next day rule under Treasury Regulation Section 1.1502-76(b)(1)(B).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Buyer will have the responsibility for, and the right to control any audit, litigation or other proceeding with respect
to Taxes or Tax Returns of the Company and its Subsidiaries (each, a &ldquo;<U>Tax Claim</U>&rdquo;); <U>provided</U>, <U>however</U>,
that, with respect to any Tax Claim that relates in whole or in part to any Pre-Closing Tax Period and to Taxes for which the Company
Equityholders may be liable (including pursuant to this Agreement), the Company Equityholder Representative shall have the right
to review in advance and comment upon all submissions made in the course of such Tax Claims (including any administrative appeals
thereof), and the Company Equityholder Representative&rsquo;s consent (not to be unreasonably withheld or delayed) shall be required
for any settlement of such Tax Claims by the Buyer that could reasonably affect the liability of the Company Equityholders pursuant
to this Agreement. Notwithstanding anything to the contrary in this Agreement, the conduct of any Tax Claim shall be governed by
this <U>Section 6.6(g)</U> and not <U>Section 8.3(a)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All Tax allocation, Tax indemnity, Tax sharing or other similar agreements to which the Company or any Subsidiary is a party
or bound by (other than (i) Ordinary Commercial Agreements, and (ii) agreements solely among the Company and its Subsidiaries)
shall be terminated as of the Closing Date and, after the Closing Date, none of the Company or any Subsidiary shall be bound thereby
or have any liability thereunder.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company Equityholder Representative, on behalf of the Company Equityholders, and the Buyer shall each be responsible
for the payment of fifty percent (50%) of any transfer, sales, use, stamp, conveyance, value added, recording, registration, documentary,
filing and other similar Taxes, fees or charges (including, without limitation, notary fees) arising in connection with the consummation
of the transactions contemplated by this Agreement (collectively, &ldquo;<U>Transfer Taxes</U>&rdquo;). The Company Equityholder
Representative and the Buyer shall cooperate in timely making all filings, returns, reports and forms as necessary or appropriate
to comply with the provisions of all applicable Laws in connection with the payment of such Transfer Taxes, and shall cooperate
in good faith to minimize, to the fullest extent possible under such Laws, the amount of any such Transfer Taxes payable in connection
therewith.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(j)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Buyer and the Company Equityholders and their respective Affiliates shall cooperate in the preparation of all Tax Returns
and the conduct of all Tax Claims or other administrative or judicial proceedings relating to the determination of any Tax for
any Tax periods for which one party could reasonably require the assistance of the other party in obtaining any necessary information.
Such cooperation shall include the retention and (upon the other party&rsquo;s request) the provision of records and information
which are reasonably relevant to any such Tax Return, Tax Claim or any tax planning and making employees available on a mutually
convenient basis to provide additional information and explanation of any material provided hereunder.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(k)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Buyer agrees that it will not make any election under Sections 336 or 338 of the Code, or any comparable election under
state or local Law, with respect to the acquisition of the Company pursuant to this Agreement, without the prior written consent
of the Company Equityholder Representative.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">6.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration of Buyer Common Stock</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Buyer shall prepare and file with the SEC a registration statement on Form S-3 (the &ldquo;<U>Form S-3</U>&rdquo;) with
respect to the Company Equityholder&rsquo;s resale of shares of Buyer Common Stock issued to Company Equityholders pursuant to
<U>Sections 2.2(b)</U> and <U>2.5(d)</U> hereunder (the &ldquo;<U>Registrable Stock</U>&rdquo;). Buyer agrees to use its reasonable
best efforts to cause the Form S-3 to become or be declared effective not later than the three (3) month anniversary of the Effective
Time. In connection with the filing of the Form S-3, Buyer agrees to make any other filings with the SEC required to be made prior
to the effectiveness thereof, including, if required, a Current Report on Form&nbsp;8-K with respect to the closing of the Merger
and all financial statements required to be included therein, and such amendments and supplements to the Form S-3, and the prospectus
used in connection with such Form S-3, as may be necessary to comply with the Securities Act to enable the disposition thereunder
of all Registrable Stock covered by the Form S-3. The Company Equityholders holding Registrable Stock are intended third party
beneficiaries of this <U>Section 6.7</U>).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Buyer shall use its reasonable best efforts to maintain the effectiveness of the Form S-3 (and to maintain the current status
of the prospectus or prospectuses contained therein) until all Registrable Stock has been sold pursuant to such registration statement
or may be sold without restriction under Rule 144(b)(i) under the Securities Act. Buyer will notify the Company Equityholder Representative,
promptly after Buyer receives notice thereof, of the time the Form S-3 has been declared effective or a supplement to any prospectus
forming a part of the Form S-3 has been filed.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At least three (3) Business Days prior to the filing of the Form S-3 or any amendments or supplements thereto, or comparable
statements under securities or state &ldquo;blue sky&rdquo; laws of any jurisdiction, or any free writing prospectus related thereto,
or before sending a response to an SEC comment letter related to the Form S-3, Buyer shall furnish to the Company Equityholder
Representative copies of reasonably complete drafts of all such documents proposed to be filed (including all exhibits thereto
and each document incorporated by reference therein to the extent then required by the rules and regulations of the SEC), which
documents will be subject to the review and comment of the Company Equityholder Representative, and Buyer shall consider in good
faith the changes reasonably requested by the Company Equityholder Representative prior to making any such filing.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to the Form S-3 that has been filed pursuant to <U>Section&nbsp;6.7(a)</U>, (i) upon the issuance by the SEC
of any stop order suspending the effectiveness of the Form S-3 or the initiation of any proceedings for that purpose; (ii) if the
Form S-3 or related prospectus or any document incorporated or deemed to be incorporated therein by reference shall contain any
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein not misleading (including, in any such case, as a result of the non-availability of financial statements); or (iii) if,
in the good faith judgment of Buyer&rsquo;s Board of Directors following consultation with legal counsel, it would be detrimental
to Buyer and its stockholders for resales of Registrable Stock to be made pursuant to the Form S-3 because such action would (A)
require premature disclosure of material information that Buyer has a bona fide business purpose for preserving as confidential,
or (B) materially interfere with a significant acquisition, corporate reorganization or other similar transaction involving Buyer,
(I)(1) in the case of clause (ii) above, but subject to clause (iii) above, Buyer shall as promptly as reasonably practicable prepare
and file a post-effective amendment to the Form S-3 or a supplement to the related prospectus so that the Form S-3 or prospectus
does not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein not misleading, and in the case of a post-effective amendment to the Form S-3, use reasonable best
efforts to cause it to become effective as promptly as reasonably practicable and (2) in the case of clause (i) above, use reasonable
best efforts to cause such stop order to be lifted, and (II) Buyer shall give notice in writing to the Company Equityholder Representative
that the availability of the Form S-3 is suspended and, upon receipt of any such notice, each Company Equityholder shall be prohibited
from selling any of the registered Buyer Common Stock pursuant to the Form S-3 until such Company Equityholder or the Company Equityholder
Representative is notified in writing by Buyer of the effectiveness of the post-effective amendment to the Form S-3 provided for
in clause (I) above. In connection with any circumstance covered by clause (iii) above, Buyer shall be entitled to exercise its
rights pursuant to this <U>Section 6.7(d)</U> to suspend the availability of the Form S-3 for no more than thirty (30) consecutive
days, provided that (x) Buyer may not invoke its right more than once (and, in such case, for more than an aggregate of thirty
(30) days) in any 180-day period and (y) Buyer shall not register any securities for its own account or that of any other stockholder
during such thirty (30) day period other than pursuant to a registration relating to the sale of securities to employees of Buyer
or a subsidiary pursuant to a stock option, stock purchase, or similar plan; a registration on any form that does not include substantially
the same information as would be required to be included in the Form S-3 covering the resale of the Registrable Stock; or a registration
in which the only Buyer Common Stock being registered is Buyer Common Stock issuable upon conversion of debt securities that are
also being registered. Buyer shall promptly notify in writing the Company Equityholder Representative upon the receipt of any comment
letter or request by the SEC, state securities authority or other Governmental Entity for amendments or supplements to the Form
S-3 for additional information.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All expenses (other than any underwriting discounts, selling commissions, and stock transfer taxes applicable to the resale
of Registrable Stock) incurred in connection with registrations or filings pursuant to this <U>Section 6.7</U>, including all registration,
filing, and qualification fees; printers&rsquo; and accounting fees; fees and disbursements of counsel for the Buyer shall be borne
and paid by the Buyer. Any underwriting discounts, selling commissions, and stock transfer taxes applicable to the resale of Registrable
Stock that are registered pursuant to this <U>Section 6.7</U> shall be borne and paid by the Company Equityholders pro rata on
the basis of the number of Registrable Stock registered on their behalf.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Buyer&rsquo;s obligations under this <U>Section 6.7</U> are subject to each Company Equityholder compliance with the
following sentence. Each Company Equityholder (i) shall furnish to Buyer such information regarding themselves, their relationship
to the Buyer and its Affiliates, their beneficial ownership of Buyer Common Stock, the Registrable Stock held by them, and the
intended method of disposition of such Registrable Stock as is required to be included under the Securities Act in the Form S-3
(or any amendment thereto) or any prospectus with respect to such Company Equityholder, (ii) shall comply with the prospectus delivery
requirements under the Securities Act in connection with the sale or other distribution of Registrable Stock pursuant to the Form
S-3, and (iii) shall report to Buyer all sales or other distributions by such Company Equityholder of Registrable Stock pursuant
to the Form S-3. No Company Equityholder shall use any free writing prospectus (as defined in Rule 405 under the Securities Act)
in connection with the resale of Registrable Stock without the prior written consent of the Buyer. It shall be a condition precedent
to the obligations of Buyer to take any action pursuant to this <U>Section 6.7</U> with respect to the Registrable Stock of any
selling Company Equityholder that such selling Company Equityholder furnish to Buyer the information required by clause (i) above
within a reasonable time prior to Buyer&rsquo;s obligation to file the Form S-3.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Solely for purposes of <U>Section 6.7</U>, if any Registrable Stock is included in the Form S-3 under this <U>Section 6.7</U>:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the extent permitted by Law, the Buyer will indemnify and hold harmless each selling Company Equityholder, and the partners,
members, officers, directors, and stockholders of each such Company Equityholder; any underwriter (as defined in the Securities
Act) for each such Company Equityholder; and each Person, if any, who controls such Company Equityholder or underwriter within
the meaning of the Securities Act or the Exchange Act, against any Damages to which such Company Equityholder, underwriter, controlling
Person or other aforementioned Person may become subject, under the Securities Act, the Exchange Act or other Law, insofar as such
Damages arise out of or are based upon any untrue statement or alleged untrue statement of a material fact contained in the Form
S-3 or related prospectus or any document incorporated or deemed to be incorporated therein by reference or the omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading
(any such Damages being referred to as &ldquo;<U>S-3 Damages</U>&rdquo;), and the Buyer will pay to each such Company Equityholder,
underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection
with investigating or defending any claim or proceeding from which S-3 Damages may result, as such expenses are incurred; <U>provided</U>,
<U>however</U>, that the indemnity agreement contained in this <U>Section 6.7(g)(i)</U> shall not apply to amounts paid in settlement
of any such claim or proceeding if such settlement is effected without the consent of Buyer, nor shall Buyer be liable for any
S-3 Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity
with written information furnished by or on behalf of the Company Equityholder Representative or any such Company Equityholder,
underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the extent permitted by law, each selling Company Equityholder, severally and not jointly, will indemnify and hold harmless
Buyer, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls
Buyer within the meaning of the Securities Act, legal counsel and accountants for Buyer, any underwriter (as defined in the Securities
Act), any other Company Equityholder selling Registrable Stock in the Form S-3, and any controlling Person of the Buyer, any such
underwriter or other Company Equityholder, against any S-3 Damages, in each case only to the extent that such S-3 Damages arise
out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or
on behalf of such selling Company Equityholder expressly for use in connection with such registration; and each such selling Company
Equityholder will pay to Buyer and each other aforementioned Person any legal or other expenses reasonably incurred thereby in
connection with investigating or defending any claim or proceeding from which S-3 Damages may result, as such expenses are incurred;
<U>provided</U>, <U>however</U>, that the indemnity agreement contained in this <U>Section 6.7(g)(ii)</U> shall not apply to amounts
paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company Equityholder,
which consent shall not be unreasonably withheld; <U>provided</U>, <U>further</U>, that in no event shall the aggregate amounts
payable by any Company Equityholder by way of indemnity or contribution under <U>Sections 6.7(g)(ii)</U> and <U>6.7(g)(iv)</U>
exceed the proceeds from the offering received by such Company Equityholder (net of any underwriting discounts, selling commissions
and stock transfer taxes applicable to the sale of Registrable Stock paid by such Company Equityholder), except in the case of
fraud by such Company Equityholder.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Promptly after receipt by an indemnified party under this <U>Section 6.7(g)</U> of notice of the commencement of any action
(including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will,
if a claim in respect thereof is to be made against any indemnifying party under this <U>Section 6.7(g)</U>, give the indemnifying
party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the
extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given,
and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain
one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party
by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between
such indemnified party and any other party represented by such counsel in such action. The failure to give written notice to the
indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any
liability to the indemnified party under this <U>Section 6.7(g)</U>, to the extent that such failure materially prejudices the
indemnifying party&rsquo;s ability to defend such action. The failure to give written notice to the indemnifying party will not
relieve it of any liability that it may have to any indemnified party otherwise than under this <U>Section 6.7(g)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either:
(i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Section 6.7(g)</U>
but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration
of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding
the fact that this <U>Section 6.7(g)</U> provides for indemnification in such case, or (ii) contribution under the Securities Act
may be required on the part of any party hereto for which indemnification is provided under this <U>Section 6.7(g)</U>, then, and
in each such case, such parties will contribute to the aggregate losses, claims, S-3 Damages, liabilities, or expenses to which
they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each
of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted
in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative
fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the
untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information
supplied by the indemnifying party or by the indemnified party and the parties&rsquo; relative intent, knowledge, access to information,
and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Company Equityholder
will be required to contribute any amount in excess of the public offering price of all such Registrable Stock offered and sold
by such Company Equityholder pursuant to the Form S-3, and (y) no Person guilty of fraudulent misrepresentation (within the meaning
of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent
misrepresentation; and provided further that in no event shall a Company Equityholder&rsquo;s liability pursuant to this <U>Section
6.7(g)(iv)</U>, when combined with the amounts paid or payable by such Company Equityholder pursuant to <U>Section 6.7(g)(ii)</U>,
exceed the proceeds from the offering received by such Company Equityholder (net of any underwriting discounts, selling commissions
and stock transfer taxes applicable to the sale of Registrable Stock paid by such Company Equityholder), except in the case of
fraud by such Company Equityholder.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Through the first anniversary of the Effective Time, (i) Buyer shall make and keep available adequate current public information,
as those terms are understood and defined in Rule 144, at all times after the effective date of the Form S-3 and use reasonable
best efforts to file with the SEC in a timely manner all reports and other documents required of Buyer under the Securities Act
and the Exchange Act, and (ii) Buyer shall furnish to any Company Equityholder, so long as the Company Equityholder owns any Registrable
Stock, forthwith upon request, a written statement by Buyer that it has complied with the reporting requirements of Rule 144, the
Securities Act, and the Exchange Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">6.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>NASDAQ Notification</U>. Buyer shall provide appropriate and timely notification to the NASDAQ Global Market regarding
the issuance of shares of Buyer Common Stock in the Merger.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">6.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Product Regulatory Meetings</U>. During the Pre-Closing Period, the Company shall provide the Buyer with advance notice
of all meetings, conferences, and discussions scheduled with Regulatory Authorities concerning any regulatory matters relating
to any Product not later than five (5) days after the Company receives notice of the scheduling of such meeting, conference, or
discussion. The Buyer shall be entitled to have reasonable representation present at all such meetings; <U>provided</U>, <U>however</U>,
that (a) except with the prior written consent of the Buyer, the Company shall not, at any time following the date of this Agreement,
request any meeting regarding any Product with any Regulatory Authority, (b) the Company shall not accept any such meetings without
prior approval of the Buyer and (c) the Company shall not attend any meetings with Regulatory Authorities regarding any Product
without participation of the Buyer in such meeting. The Company and the Buyer shall use commercially reasonable efforts to agree
in advance on the scheduling of such meetings, conferences and discussions with any Regulatory Authority and on the agenda and
objectives to be accomplished at any such meetings, conferences and discussions. Each party shall provide all such assistance as
is reasonably requested by the other in the preparation and conduct of any such meetings, conferences and discussions, including
any inspections by Regulatory Authorities with respect to any Product. Notwithstanding the foregoing, nothing in this <U>Section
6.9</U> shall prohibit the Company from taking such actions as may be necessary to comply with applicable Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">6.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>FIRPTA Certificate</U>. Prior to the Closing, the Company shall deliver or cause to be delivered to the Buyer a certification
that the shares of Company Stock are not United States real property interests as defined in Section 897(c) of the Code, together
with a notice to the Internal Revenue Service, in accordance with the Treasury Regulations under Sections 897 and 1445 of the Code.</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>ARTICLE
VII</B></FONT><BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>CONDITIONS TO MERGER</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">7.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conditions to Each Party&rsquo;s Obligation To Effect the Merger</U>. The respective obligations of each party to this
Agreement to effect the Merger shall be subject to the satisfaction on or prior to the Closing Date of the following conditions:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stockholder Approval</U>. The Company shall have obtained the Company Stockholder Approval.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governmental Approvals</U>. Other than the filing of the Certificate of Merger with the Delaware Secretary of State (which
shall be filed in accordance with <U>Section&nbsp;1.1</U>), all authorizations, consents, orders or approvals of, or declarations
or filings with, or expirations of waiting periods imposed by, any Governmental Entity in connection with the Merger, the failure
of which to file, obtain or occur would reasonably be expected to be material to the Buyer, the Company and their respective Subsidiaries,
in each case taken as a whole, shall have been filed, been obtained or occurred.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Injunctions</U>. No Governmental Entity of competent jurisdiction shall have enacted, issued, promulgated, enforced
or entered any order, executive order, stay, decree, judgment or injunction (preliminary or permanent) or statute, rule or regulation
which is in effect and which has the effect of making the Merger illegal, otherwise prohibiting consummation of the Merger or imposing
material restrictions on the Buyer or the Surviving Corporation after the Closing.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">7.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Additional Conditions to Obligations of the Buyer and the Transitory Subsidiary</U>. The obligations of the Buyer and
the Transitory Subsidiary to effect the Merger shall be subject to the satisfaction on or prior to the Closing Date of each of
the following additional conditions, each of which may be waived, in writing, exclusively by the Buyer and the Transitory Subsidiary:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties</U>. The representations and warranties of the Company set forth in this Agreement (without
regard to any materiality or Company Material Adverse Effect qualifications contained therein), other than the Company Fundamental
Representations, shall be true and correct as of the date of this Agreement and as of the Closing Date as though made on and as
of the Closing Date, except (i) to the extent such representations and warranties are specifically made as of a particular date,
in which case such representations and warranties shall be true and correct as of such date and (ii) where the failure to be true
and correct has not had and would not reasonably be expected to result in a Company Material Adverse Effect, and the Company Fundamental
Representations (in each case without regard to any materiality or Company Material Adverse Effect qualifications contained therein)
shall be true and correct in all material respects as of the date of this Agreement and as of the Closing Date as though made on
and as of the Closing Date, except (x) to the extent such representations and warranties are specifically made as of a particular
date, in which case such representations and warranties shall be true and correct in all material respects as of such date and
(y) for changes explicitly required by the terms of this Agreement; and the Buyer shall have received a certificate, in a form
reasonably satisfactory to the Buyer, signed on behalf of the Company by an authorized officer of the Company to such effect.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Performance of Obligations of the Company</U>. The Company shall have performed in all material respects all obligations
required to be performed by it under this Agreement on or prior to the Closing Date; and the Buyer shall have received a certificate,
in a form reasonably satisfactory to the Buyer, signed on behalf of the Company by an authorized officer of the Company to such
effect.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Escrow Agreement</U>. The Company Equityholder Representative and the Escrow Agent shall have executed and delivered
to the Buyer the Escrow Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Resignations</U>. The Buyer shall have received a resignation and release letter, effective as of the Closing and in
form and substance reasonably satisfactory to the Buyer, from each director and officer of the Company (other than any such resignations
which the Buyer designates, by written notice to the Company, as unnecessary).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Lock-Up Agreements and Investor Questionnaires</U>. Each Key Stockholder shall have executed and delivered a Lock-Up
Agreement and an Investor Questionnaire, each of which shall be in full force and effect (it being understood and agreed that each
Company Equityholder must execute and deliver an Investor Questionnaire, and each Company Equityholder receiving shares of Buyer
Common Stock in the Merger must execute and deliver a Lock-Up Agreement, in addition to the other documents required by <U>Section&nbsp;2.2(b)</U>,
as a condition to the payment to such Company Equityholder of such Company Equityholder&rsquo;s allocable portion of Aggregate
Consideration, when and to the extent payable hereunder).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Consents and Waivers</U>. The Company shall have provided all necessary notices and obtained all necessary consents listed
on <U>Schedule 7.2(f)</U> (in written form satisfactory to the Buyer) and shall have delivered executed copies of such consents
and waivers to the Buyer.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Material Adverse Effect</U>. No Company Material Adverse Effect shall have occurred since the date of the Agreement;
and the Buyer shall have received a certificate, in a form reasonably satisfactory to the Buyer, signed on behalf of the Company
by an authorized officer of the Company to such effect.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Dissenting Shares</U>. The number of shares of Company Stock that are Dissenting Shares shall be no more than three percent
(3%) of the number of outstanding shares of Company Stock outstanding as of the date of the Written Consent (calculated on an as
converted to common stock basis).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certificate of the Company&rsquo;s Secretary</U>. The Buyer shall have received a certificate, in a form reasonably satisfactory
to the Buyer, signed on behalf of the Secretary of the Company, certifying as to (i)&nbsp;an attached copy of the Company Certificate
of Incorporation, (ii)&nbsp;an attached copy of the Company Bylaws, and stating that the Company Bylaws have not been amended,
modified, revoked or rescinded, (iii)&nbsp;an attached copy of the resolutions of the board of directors of the Company authorizing
and approving the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby,
(iv) an attached copy of a certificate of good standing for the Company issued by the Secretary of State of the State of Delaware
and dated as of a date not more than five (5) Business Days prior to the Closing Date and (v) the fact that none of the foregoing
documents has not been amended, modified, revoked or rescinded in any respect.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">7.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Additional Conditions to Obligations of the Company</U>. The obligation of the Company to effect the Merger shall be
subject to the satisfaction on or prior to the Closing Date of each of the following additional conditions, each of which may be
waived, in writing, exclusively by the Company:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties</U>. The representations and warranties of the Buyer and the Transitory Subsidiary set
forth in this Agreement (without regard to any materiality or Buyer Material Adverse Effect qualifications contained therein),
other than the Buyer Fundamental Representations, shall be true and correct as of the date of this Agreement and as of the Closing
Date as though made on and as of the Closing Date except (i) to the extent such representations and warranties are specifically
made as of a particular date, in which case such representations and warranties shall be true and correct as of such date and (ii)
where the failure to be true and correct has not had and would not reasonably be expected to result in a Buyer Material Adverse
Effect, and the Buyer Fundamental Representations (in each case without regard to any materiality or Buyer Material Adverse Effect
qualifications contained therein) shall be true and correct in all material respects as of the date of this Agreement and as of
the Closing Date as though made on and as of the Closing Date, except (x) to the extent such representations and warranties are
specifically made as of a particular date, in which case such representations and warranties shall be true and correct in all material
respects as of such date and (y) for changes explicitly required by the terms of this Agreement; and the Company shall have received
a certificate, in a form reasonably acceptable to the Company, signed on behalf of the Buyer by an authorized officer of the Buyer
to such effect.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Performance of Obligations of the Buyer and the Transitory Subsidiary</U>. The Buyer and the Transitory Subsidiary shall
have performed in all material respects all obligations required to be performed by them under this Agreement on or prior to the
Closing Date; and the Company shall have received a certificate, in a form reasonably acceptable to the Company, signed on behalf
of the Buyer by an authorized officer of the Buyer to such effect.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Escrow Agreement</U>. The Buyer and the Escrow Agent shall have executed and delivered to the Company the Escrow Agreement.</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>ARTICLE
VIII</B></FONT><BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>INDEMNIFICATION</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification by Company Equityholders</U>. Subject to the terms and conditions of this <U>Article VIII</U>, from and
after the Closing, each Company Equityholder shall, severally and not jointly, in accordance with such Company Equityholder&rsquo;s
Pro Rata Share, indemnify the Buyer and the Surviving Corporation, their respective Affiliates, and each of their respective officers,
directors, employees, stockholders, agents, other representatives, successors and permitted assigns (each a &ldquo;<U>Buyer Indemnified
Party</U>&rdquo;) in respect of, and hold them harmless against and reimburse them for, any Damages suffered, incurred or sustained
by any Buyer Indemnified Party resulting from or arising out of:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the failure of any representation or warranty of the Company contained in this Agreement to be true and correct as of the
date of this Agreement or as of the Closing Date (except to the extent such representation or warranty is specifically made as
of a particular date, in which case the accuracy of such representation or warranty shall be evaluated as of such date) or the
failure of any representation or warranty of the Company contained in any certificate or other instrument delivered hereunder to
be true and correct as of the date of such certificate or other instrument; <U>provided</U> that, solely for the purpose of calculating
the amount of Damages incurred by any Buyer Indemnified Party (and not, for purposes of clarity, determination of any breach or
inaccuracy of any such representation or warranty), any materiality or Company Material Adverse Effect qualifications contained
in any such representation or warranty shall be disregarded for purposes of this <U>Section 8.1(a)</U>;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any failure by the Company or the Company Equityholder Representative to perform any of their respective covenants, obligations
or agreements contained in this Agreement, in the case of the Company, that are required to be performed prior to the Effective
Time;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Unpaid Company Transaction Expenses or Indebtedness of the Company that were not taken into account in the determination
of the Final Closing Cash Consideration;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Pre-Closing Taxes.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the allocation or misallocation of any portion of the Aggregate Consideration and/or the Escrow Amount amongst the Company
Equityholders, including as a result of any inaccuracy or error in the Allocation Schedule as delivered to the Buyer prior to the
Closing in accordance with <U>Section 2.7(a)</U> (without giving effect to any update, correction, amendment or modification to
the Allocation Schedule, as contemplated by <U>Section 2.7(a)</U> with respect to (i) any payment previously made by the Buyer,
or (ii) any payment to be made by Buyer five (5) or fewer Business Days following the Buyer&rsquo;s receipt of such update, correction,
amendment or modification);</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any fraud of the Company or any of its Subsidiaries;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any proceeding in respect of Dissenting Shares and any payments to any Person that was a holder of Company Stock immediately
prior to the Effective Time in respect of such Person&rsquo;s Dissenting Shares, to the extent such payments exceed the amount
to which such Person would have been entitled pursuant to <U>Section 2.1</U> in respect of such Dissenting Shares if such Person
had not exercised appraisal or dissenters rights in respect thereof, and any other claim by a Company Equityholder against the
Buyer, the Surviving Corporation or any of their Affiliates in connection with the transactions contemplated hereby;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any claim by a Company Indemnified Party with respect to the matters addressed in <U>Section 6.3</U>, to the extent not
satisfied by the Reporting Tail Endorsement; and/or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any claim by a current or former holder of Company Stock or Company Equity Awards, or any other Person, seeking to assert,
or based upon: (i) ownership or rights to ownership of any shares of capital stock or other equity securities of the Company, including
any claims for breaches of fiduciary duties owed to such Person in such capacity; or (ii) any rights of a stockholder or other
equity holder (other than, with respect to Company Stockholders identified on the Allocation Schedule, in the case of clauses (i)
and (ii), claims based on the rights of any such Person to receive a portion of the payments contemplated to be made to such Person
hereby as and to the extent set forth herein), including any option, preemptive rights or rights to notice or to vote.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification by the Buyer</U>. Subject to the terms and conditions of this <U>Article&nbsp;VIII</U>, from and after
the Closing, the Buyer shall indemnify the Company Equityholders in respect of, and hold them harmless against and reimburse them
for, any Damages suffered, incurred or sustained by any Company Equityholder resulting from or arising out of:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the failure of any representation or warranty of the Buyer or the Transitory Subsidiary contained in this Agreement to be
true and correct as of the date of this Agreement or as of the Closing Date (except to the extent such representation or warranty
is specifically made as of a particular date, in which case the accuracy of such representation or warranty shall be evaluated
as of such date) or the failure of any representation or warranty of the Buyer contained in any certificate or other instrument
delivered hereunder to be true and correct as of the date of such certificate or other instrument; <U>provided</U> that, solely
for the purpose of calculating the amount of Damages incurred by any Company Equityholder (and not, for purposes of clarity, determination
of any breach or inaccuracy of any such representation or warranty), any materiality or Buyer Material Adverse Effect qualifications
contained in any such representation or warranty shall be disregarded for purposes of this <U>Section 8.2(a)</U>; and/or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any failure by the Buyer or the Transitory Subsidiary to perform any of their respective covenants, obligations or agreements
contained in this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Claims for Indemnification</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Third-Party Actions</U>. All claims for indemnification made under this Agreement resulting from, related to or arising
out of a Third-Party Action against an Indemnified Party shall be made in accordance with the following procedures. An Indemnified
Party shall deliver a Third-Party Claim Notice within [****] after receipt by the Indemnified Party of notice of any Third-Party
Action or, if earlier, upon the assertion of any such claim by a third party (provided that the failure to provide such notice
in a timely manner shall not limit the rights of the Indemnified Party, except to the extent the Indemnifying Party has been prejudiced
by such delay), and shall describe in reasonable detail (to the extent then known by the Indemnified Party) the facts constituting
the basis for such Third-Party Action and the amount of the claimed Damages and shall be accompanied by copies of any relevant
and material documentation submitted by the third party making such third-party claim. At any time after</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0pt; margin: 0pt 0">delivery of such Third-Party
Claim Notice, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of
such Third-Party Action with counsel reasonably satisfactory to the Indemnified Party; <U>provided</U> that (i) the Indemnifying
Party may only assume control of such defense if it acknowledges in writing to the Indemnified Party that any damages, fines, costs
or other liabilities that may be assessed against the Buyer in connection with such Third-Party Action constitute Damages for which
the Indemnified Party shall be indemnified pursuant to this <U>Article VIII</U> and (ii) the Company Equityholder Representative
may not assume control of the defense of any Third-Party Action involving any Governmental Entity or criminal liability or in which
equitable relief, other than incidental equitable relief that is not material to the Buyer or the Surviving Corporation, is sought
against any Buyer Indemnified Party. If the Indemnifying Party does not or is not permitted to assume control of such defense,
the Indemnified Party shall control such defense. The party not controlling such defense may participate therein at its own expense;
<U>provided</U> that if the Indemnifying Party assumes control of such defense and the Indemnified Party reasonably concludes,
based on advice from counsel, that the Indemnifying Party and the Indemnified Party have conflicting interests with respect to
such Third-Party Action, the reasonable fees and expenses of counsel to the Indemnified Party solely in connection therewith shall
be considered &ldquo;Damages&rdquo; for purposes of this Agreement; <U>provided</U>, <U>however</U>, that the foregoing shall not
limit the Indemnified Party&rsquo;s ability to recover its reasonable fees and expenses of counsel if such amounts otherwise are
recoverable Damages under this <U>Article VIII</U>; <U>provided</U>, <U>further</U>, that in no event shall the Indemnifying Party
be responsible for the fees and expenses of more than one (1) counsel for all Indemnified Parties (in addition to one (1) local
counsel for each jurisdiction as necessary). The party controlling such defense shall keep the other party advised of the status
of such Third-Party Action and the defense thereof and shall consider recommendations made by the other party with respect thereto.
The Indemnified Party shall not agree to any settlement of such Third-Party Action without the prior written consent of the Indemnifying
Party (such consent not to be unreasonably withheld, conditioned or delayed). The Indemnifying Party shall not agree to any settlement
of such Third-Party Action that does not include a complete release of the Indemnified Party from all liability with respect thereto
or that imposes any liability or obligation on the Indemnified Party without the prior written consent of the Indemnified Party.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Procedure for Claims Not Involving Third Parties</U>. An Indemnified Party wishing to assert a claim for indemnification
under this <U>Article VIII</U> that does not involve a Third-Party Action shall deliver to the Indemnifying Party a Claim Notice.
To the extent the Indemnifying Party fails to provide a written objection to the matters set forth in the Claim Notice within [****]
following the Indemnifying Party&rsquo;s receipt thereof, the Indemnifying Party shall be deemed to have irrevocably agreed and
consented to the Indemnified Party&rsquo;s positions with respect to such matters.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as otherwise provided in this <U>Section 8.4</U>, the representations and warranties of the Company and the Buyer
set forth in this Agreement shall survive the Closing and the consummation of the transactions contemplated hereby and shall continue
until the date that is [****] following the Closing Date, at which time they shall expire.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Buyer Fundamental Representations and the Company Fundamental Representations shall survive the Closing and the consummation
of the transactions contemplated hereby and shall continue indefinitely; <U>provided</U>, <U>however</U>, that the representations
and warranties set forth in <U>Section 3.8</U> (Taxes) shall survive the Closing until the date that is [****].</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each of the Company Excluded Representations shall survive the Closing and the consummation of the transactions contemplated
hereby and shall continue until [****] following the Closing Date, at which time they shall expire.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All covenants and agreements of the parties contained in this Agreement (A) that are to be performed at or prior to the
Closing shall survive the Closing and the consummation of the transactions contemplated hereby and shall continue until the date
that is [****] following the Closing Date, at which time they shall expire and (B) that are to be performed after the Closing Date
shall survive the Closing and the consummation of the transactions contemplated hereby and shall continue until fully-performed,
at which time it will expire.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to the survival periods specified above, the parties agree that they intend, and hereby contractually agree,
to lengthen or shorten the applicable statute of limitations period with respect to claims relating thereto (and with respect to
the indefinite survival period specified in <U>Section 8.4(b)</U>, the parties intend, and hereby contractually agree, that such
survival period shall be the maximum period during which an action based on a written contract, agreement or undertaking involving
at least $100,000 may be brought pursuant to Section 8106(c), Title 10 of the Delaware Code (10 Del.C. &sect; 8106(c)).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If an indemnification claim is properly asserted in writing pursuant to <U>Section 8.3</U> prior to the expiration of the
survival period applicable to a representation, warranty, covenant or agreement that is the basis for such claim, then such representation,
warranty, covenant or agreement shall survive until, but only for the purpose of, the resolution of such claim.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitations</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary contained in this Agreement:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>except with respect to the Company Excluded Representations (other than the first sentence of <U>Section 3.10(d)</U>), the
Company Fundamental Representations and the Buyer Fundamental Representations (to which the limitation in this <U>Section 8.5(a)(i)</U>
shall not apply), the Buyer Indemnified Parties or the Company Equityholders shall not be entitled to receive any indemnification
pursuant <U>Section 8.1(a)</U> or <U>8.2(a)</U>, respectively, unless and until the aggregate amount of all Damages exceeds [****];</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>except with respect to the Company Excluded Representations and the Company Fundamental Representations (to which the limitation
in this <U>Section&nbsp;8.5(a)(ii)</U> shall not apply), the amount of Damages that may be recovered by the Buyer Indemnified Parties
under <U>Section 8.1(a)</U> shall not exceed [****];</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>except with respect to the Buyer Fundamental Representations (to which the limitation in this <U>Section 8.5(a)(iii)</U>
shall not apply), the Company Equityholders shall not be entitled to receive any indemnification pursuant to <U>Section&nbsp;8.2(a)</U>
in an aggregate amount in excess of [****];</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the case of claims under the Company Excluded Representations, the Buyer Indemnified Parties shall not be entitled to
receive any indemnification pursuant to <U>Section 8.1(a)</U> in an aggregate amount, including amounts under <U>Section 8.1(a)</U>
as a result of the failure of any representation and warranty contained in the Agreement to be true and correct that is subject
to the limitations set forth in <U>Section 8.5(a)(ii)</U>, in excess of [****];</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the case of Excluded Matters, other than claims under the Company Excluded Representations or claims for fraud, the amount
of Damages that may be recovered by the Buyer Indemnified Parties under this <U>Article VIII</U> shall not exceed an amount equal
to [****]; <U>provided</U> that, except as set forth in <U>Section 8.5(a)(vii)</U>, in no event shall the maximum aggregate liability
of a Company Equityholder under this <U>Article VIII</U> exceed [****];</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(vi)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>other than claims for fraud, the amount of Damages that may be recovered by the Company Equityholders under this <U>Article
VIII</U> shall not exceed an amount equal to [****];</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(vii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>for the avoidance of doubt, there shall be no limitation of liability for a Company Equityholder&rsquo;s own fraud; <U>provided</U>
that no Company Equityholder shall have any liability for any fraud on the part of any other Company Equityholder (except to the
extent the Buyer is otherwise entitled under this <U>Article VIII</U> to recover Damages resulting therefrom); and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1.5in; margin: 0pt 0">(viii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Buyer shall only be permitted to recover any Damages directly from any Company Equityholder, if (and subject to the
limitations set forth in this <U>Section 8.5</U>) and only to the extent that the Pro Rata Share of the then available Escrow Fund
(if any) represented by such Company Equityholder&rsquo;s Company Stock and Company Options shall be insufficient to indemnify
fully the Buyer for their Pro Rata Share of such Damages.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The amount of any Damages for which indemnification is provided under this <U>Article VIII</U> shall be reduced by any actual
recoveries by the Indemnified Party under insurance policies or third parties with respect to the subject matter of the applicable
claim; <U>provided</U>, <U>however</U>, that (i) no Indemnified Party shall be required to pursue insurance or other collateral
sources to offset such Damages and (ii) the amount of such reduction shall be reduced by any reasonable costs and expenses incurred
in obtaining such recovery and by the amount of any increase in insurance premiums resulting from making the claim giving rise
to such recovery. In the event that an insurance or other recovery is made by any Indemnified Party with respect to any Damages
for which any such Indemnified Party has been indemnified hereunder, then the Indemnified Party shall promptly pay to the Indemnifying
Party the amount of such recovery, but in no event shall the amount of such payment to the Indemnifying Party exceed the amount
of the indemnification payment made to the Indemnified Party.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except with respect to (i) claims against a Company Equityholder for fraud as provided above, (ii) claims for fraud against
the Buyer, (iii) claims for equitable relief made with respect to breaches of any covenant or agreement contained in this Agreement
or the Escrow Agreement and (iv) disputes regarding the determination of Closing Cash Consideration (which shall be resolved and
paid exclusively in accordance with <U>Section 2.6</U>), from and after the Closing, the rights of the Indemnified Parties under
this <U>Article VIII</U> shall be the sole and exclusive remedies of the Indemnified Parties and their respective Affiliates with
respect to claims under, or otherwise relating to the transactions that are the subject of, this Agreement or the Escrow Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Buyer Indemnified Parties shall not be entitled to make any claim for indemnification with respect to any matter to
the extent it has been taken into account in determining the Aggregate Closing Consideration (including the Closing Cash Consideration).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of this <U>Article VIII</U>, (i)&nbsp;if the Company Equityholders comprise the Indemnifying Party, any references
to the Indemnifying Party (except provisions relating to an obligation to make any payments) shall be deemed to refer to the Company
Equityholder Representative and (ii)&nbsp;if the Company Equityholders comprise the Indemnified Party, any references to the Indemnified
Party (except provisions relating to an obligation to make or a right to receive any payments) shall be deemed to refer to the
Company Equityholder Representative.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All indemnification payments made under this Agreement shall be treated by the parties as an adjustment to the Aggregate
Closing Consideration for Tax purposes to the extent permitted by Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Right of Contribution</U>. Neither the Company Equityholder Representative nor any Company Equityholder shall make
any claim for contribution from the Company or the Surviving Corporation with respect to any indemnity claims arising under or
in connection with this Agreement to the extent that the Company, Surviving Corporation or any Buyer Indemnified Party is entitled
to indemnification hereunder for such claim, and the Company Equityholder Representative, on its own behalf and on behalf of all
Company Equityholders, hereby waives any such right of contribution from the Company or the Surviving Corporation it has or may
have in the future.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Investigation; Reliance</U>. The right to indemnification, payment of Damages or any other remedy will not
be affected by any investigation conducted, or any knowledge acquired (or capable of being acquired) at any time, whether before
or after the execution and delivery of this Agreement, with respect to the accuracy or inaccuracy of or compliance with, any representation,
warranty, covenant or agreement made by the Company or the Buyer or any other matter. The waiver of any condition based on the
accuracy of any such representation or warranty, or on the performance of or compliance with any such covenant or agreement, will
not affect the right to indemnification, payment of Damages, or any other remedy based on any such representation, warranty, covenant
or agreement. No Indemnified Party shall be required to show reliance on any representation, warranty, certificate or other agreement
in order for such Indemnified Party to be entitled to indemnification hereunder.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Manner of Payment; Release of Escrow</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any payment that the Company Equityholders are obligated to make to any Buyer Indemnified Parties pursuant to this <U>Article
VIII</U> shall be made (i) first, to the extent there are sufficient Escrow Funds, by release of such Escrow Funds to the Buyer
Indemnified Parties from the Escrow Account by the Escrow Agent, and the Buyer and the Company Equityholder Representative shall
deliver joint written instructions to the Escrow Agent to such effect, and (ii) second, to the extent the Escrow Funds are insufficient
to pay any remaining sums due, then, at the Buyer&rsquo;s option (in its sole discretion), all or any portion of such payment may
be recovered (x) in cash, directly from the Company Equityholders in accordance with their respective Pro Rata Shares, or (y) in
accordance with <U>Section 8.9</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On the [****] of the Closing Date, the Buyer and the Company Equityholder Representative shall jointly instruct the Escrow
Agent to release the then remaining Escrow Funds (to the extent such funds are not then subject to any claim by the Buyer Indemnified
Parties), less the portion thereof to be paid Leerink Partners LLC as set forth on the Allocation Schedule, to (i) the Exchange
Agent for further distribution to the Company Stockholders in accordance with <U>Section 2.1</U> and (ii) to the Buyer or the Surviving
Corporation for further distribution to the former holders of Company Options in accordance with <U>Section&nbsp;2.5</U>. Buyer
shall pay, or cause the Exchange Agent to pay, the portion thereof to be paid to Leerink Partners LLC set forth on the Allocation
Schedule. Any amounts retained by the Escrow Agent shall be released (to the extent such funds are not utilized to indemnify any
Buyer Indemnified Party) to the Exchange Agent or to the Buyer or the Surviving Corporation, as applicable, in accordance with
the prior sentence upon the final and binding resolution of the claims pending on the [****] of the Closing Date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Right to Satisfy Indemnification Claims by Reducing Future Contingent Payments</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Buyer is expressly authorized, but shall not be obligated, to set off against each Company Equityholder up to [****]
of any Damages for which it is entitled to indemnification hereunder from such Company Equityholder (subject to other provisions
of this <U>Article VIII</U>), with respect to any claim for indemnification pursuant to this <U>Article VIII</U>, against any Future
Contingent Payment.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to <U>Section 8.8</U>, if at the time any Future Contingent Payment is due and payable there shall be any outstanding
demand for indemnification in accordance with this <U>Article VIII</U>, the amount of Damages with respect to which shall not have
been finally determined, then the Buyer shall be entitled, but shall not be required, to withhold from such Future Contingent Payment
the amount of Damages the Buyer Indemnified Party reasonably estimates to be subject to such claim. If the final amount of Damages
for such claim is determined to be less than the amount withheld from such Future Contingent Payment, then the Buyer shall promptly,
and in any event within [****] following the final determination of the amount of such Damages, cause the difference to be delivered
to the Company Equityholders in accordance with this Agreement. If the final amount of Damages for such claim for indemnification
is determined to exceed the amount by which such Future Contingent Payment was reduced for such claim, then the Buyer shall continue
to be entitled to indemnification for the amount of such excess subject to the terms and conditions of this <U>Article&nbsp;VIII</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">8.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Treatment of Indemnification Payments</U>. Following the Closing, any payment made pursuant to this <U>Article VIII</U>
shall be treated by the Buyer, the Surviving Corporation and the Company Equityholders, for federal income Tax and other applicable
Tax purposes, unless otherwise required by applicable Law, as an adjustment to the Aggregate Consideration.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>ARTICLE
IX</B></FONT><BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>TERMINATION AND AMENDMENT</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">9.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>. This Agreement may be terminated at any time prior to the Effective Time (with respect to <U>Sections&nbsp;9.1(b)</U>
through <U>9.1(f)</U>, by written notice by the terminating party to the other party), whether before or, subject to the terms
hereof, after receipt of the Company Stockholder Approval:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by mutual written consent of the Buyer, the Transitory Subsidiary and the Company; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by either the Buyer or the Company if the Merger shall not have been consummated by the Outside Date; <U>provided</U>, <U>however</U>,
that the right to terminate this Agreement under this <U>Section 9.1(b)</U> shall not be available to a party if the failure of
the Merger to have been consummated on or before the Outside Date was primarily due to the failure of such party to perform any
of its material obligations under this Agreement; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by either the Buyer or the Company if a Governmental Entity of competent jurisdiction shall have issued a nonappealable
final order, decree or ruling or taken any other nonappealable final action, in each case having the effect of permanently restraining,
enjoining or otherwise prohibiting the Merger; <U>provided</U>, <U>however</U>, that the right to terminate this Agreement under
this <U>Section 9.1(c)</U> shall not be available to a party if the issuance of such order, decree, ruling or the taking of such
action was primarily due to the failure of such party to perform any of its material obligations under this Agreement; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by the Buyer, if there has been a breach of or failure to perform any representation, warranty, covenant or agreement on
the part of the Company set forth in this Agreement, which breach or failure to perform (i)&nbsp;would cause the conditions set
forth in <U>Sections&nbsp;7.2(a)</U> or <U>7.2(b)</U> not to be satisfied and (ii) shall not have been cured by the earlier of
the Outside Date or 15&nbsp;days following receipt by the Company of written notice of such breach or failure to perform from the
Buyer; <U>provided</U>, <U>however</U>, that the right to terminate this Agreement under this <U>Section 9.1(d)</U> shall not be
available to the Buyer if the Company&rsquo;s breach or failure to perform is the result of the Buyer&rsquo;s or the Transitory
Subsidiary&rsquo;s material breach of any representation, warranty or covenant set forth in this Agreement; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by the Company, if there has been a breach of or failure to perform any representation, warranty, covenant or agreement
on the part of the Buyer or the Transitory Subsidiary set forth in this Agreement, which breach or failure to perform (i) would
cause the conditions set forth in <U>Sections 7.3(a)</U> or <U>7.3(b)</U> not to be satisfied and (ii) shall not have been cured
by the earlier of the Outside Date or 15&nbsp;days following receipt by the Buyer of written notice of such breach or failure to
perform from the Company; <U>provided</U>, <U>however</U>, that the right to terminate this Agreement under this <U>Section 9.1(e)</U>
shall not be available to the Company if the Buyer&rsquo;s or the Transitory Subsidiary&rsquo;s breach or failure to perform is
the result of the Company&rsquo;s material breach of any representation, warranty or covenant set forth in this Agreement; or</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by the Buyer, if the Company Stockholder Approval shall not have been obtained within two (2) hours following the execution
of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">9.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Termination</U>. In the event of the termination of this Agreement as provided in <U>Section 9.1</U>, this
Agreement shall immediately become void and there shall be no liability or obligation on the part of the Buyer, the Company, the
Transitory Subsidiary or their respective officers, directors, stockholders or Affiliates; <U>provided</U>, that (a) any such termination
shall not relieve any party from liability for damages for any willful and intentional breach of this Agreement by another party
prior to such termination and (b) each of this <U>Section 9.2</U> (Effect of Termination), <U>Section 9.3</U> (Fees and Expenses),
<U>Article XI</U> (Miscellaneous) (in each case including the respective meanings ascribed to the related capitalized terms in
<U>Article X</U> (Definitions)) and the Confidentiality Agreement shall remain in full force and effect and survive any termination
of this Agreement. Nothing shall limit or prevent any party from exercising any rights or remedies it may have under <U>Section
11.9</U> in lieu of terminating this Agreement pursuant to <U>Section 9.1</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">9.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fees and Expenses</U>. Except as set forth in this <U>Section 9.3</U> or otherwise in this Agreement (including in <U>Sections
2.1(e)(i)</U>, <U>2.6(b)(v)(D)</U> and <U>6.1(b)</U>), all fees and expenses incurred in connection with this Agreement and the
transactions contemplated hereby shall be paid by the party incurring such fees and expenses, whether or not the Merger is consummated.
The Buyer shall pay all fees and expenses relating to the Escrow Agent and the Exchange Agent.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">9.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment</U>. This Agreement may be amended by the Buyer and the Company, by action taken or authorized by their respective
Boards of Directors, at any time before or after receipt of the Company Stockholder Approval, but, after receipt of the Company
Stockholder Approval no amendment shall be made which by Law requires further approval by such stockholders without such further
approval.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">9.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Extension; Waiver</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At any time prior to the Effective Time the Buyer and the Company may, and at any time after the Effective Time, the Buyer
and the Company Equityholder Representative may, in each case to the extent legally allowed, (i)&nbsp;extend the time for the performance
of any of the obligations or other acts of the other parties hereto, (ii)&nbsp;waive any inaccuracies in the representations and
warranties contained herein or in any document delivered pursuant hereto and (iii)&nbsp;waive compliance with any of the agreements
or conditions contained herein; (b) any agreement on the part of a party hereto to any such extension or waiver shall be valid
only if set forth in a written instrument signed on behalf of such party; (c) such extension or waiver shall not be deemed to apply
to any time for performance, inaccuracy in any representation or warranty, or noncompliance with any agreement or condition, as
the case may be, other than that which is specified in the extension or waiver; and (d) the failure of any party to this Agreement
to assert any of its rights under this Agreement or otherwise shall not constitute a waiver of such rights.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>ARTICLE
X</B></FONT><BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>DEFINITIONS</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">10.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this Agreement, each of the following terms has the meaning set forth below.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Acquisition Proposal</U>&rdquo; means
(a)&nbsp;any proposal or offer for a merger, consolidation, dissolution, sale of material assets outside the ordinary course of
business, stock purchase, recapitalization, share exchange or other business combination involving the Company and its Subsidiaries,
including any contribution or exchange of equity involving the Company, the Company Stockholders and/or any third party, (b)&nbsp;any
proposal for the issuance by the Company of over fifteen percent (15%) of its Equity Interests or (c)&nbsp;any proposal or offer
to acquire in any manner, directly or indirectly, over fifteen percent (15%) of the Equity Interests or total consolidated assets
of the Company, in each case other than the transactions contemplated by this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Advisory Group</U>&rdquo; has the
meaning set forth in <U>Section 2.4(d)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Affiliate</U>&rdquo; means any Person
who is an &ldquo;affiliate&rdquo; of that party within the meaning of Rule 405 promulgated under the Securities Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Aggregate Closing Consideration</U>&rdquo;
means (a) an amount in cash equal to (i) the Base Cash Purchase Price, plus (ii) the Closing Cash (as estimated in the Estimated
Closing Cash Consideration Statement), plus (iii) the portion of the aggregate exercise price of all Company Options outstanding
as of immediately prior to the Effective Time determined by ratably allocating such aggregate exercise price based on proportion
of the Closing Cash Consideration to the Aggregate Closing Consideration, as set forth on the Allocation Schedule, plus (iv) the
amount, if any, by which Closing Net Working Capital is greater than zero (as estimated in the Estimated Closing Cash Consideration
Statement), minus (v) the amount, if any, by which Closing Net Working Capital is less than zero (as estimated in the Estimated
Closing Cash Consideration Statement), minus (vi) the Escrow Amount, minus (vii) the Unpaid Company Transaction Expenses (as estimated
in the Estimated Closing Cash Consideration Statement), minus (viii) the Company Equityholder Representative Expense Amount (as
estimated in the Estimated Closing Cash Consideration Statement) and minus (ix) the Closing Indebtedness (as estimated in the Estimated
Closing Cash Consideration Statement), plus (b) the Buyer Common Stock Consideration, plus the portion of the aggregate exercise
price of all Company Options outstanding as of immediately prior to the Effective Time determined by ratably allocating such aggregate
exercise price based on the proportion of the Buyer Common Stock Consideration to the Aggregate Closing Consideration, as set forth
on the Allocation Schedule.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Aggregate Consideration</U>&rdquo;
means the sum of (a) the Aggregate Closing Consideration, plus (b) any Future Contingent Payments that become payable in accordance
with the terms of this Agreement and the Escrow Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Aggregate Series A Original Issue
Price</U>&rdquo; means the Series A Original Issue Price, multiplied by the number of shares of Company Series A Preferred Stock
outstanding as of immediately prior to the Effective Time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Agreement</U>&rdquo; has the meaning
set forth in the first paragraph of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Allocation Schedule</U>&rdquo; means
a schedule, prepared by the Company in a form consistent with the methodology and format set forth on the illustrative example
of the Allocation Schedule attached hereto as <U>Exhibit C-2</U> and dated as of the Closing Date, setting forth, the Company&rsquo;s
calculation of the Aggregate Consideration, the Aggregate Closing Consideration, the Closing Cash Consideration, the Buyer Common
Stock Consideration, the maximum amount payable with respect to each possible Future Contingent Payment, the Per Share Closing
Consideration (including the portions thereof to be paid in cash and Buyer Common Stock) and the maximum Per Share Future Contingent
Consideration, the maximum Per Share Expense Fund Distribution and the maximum Per Share Escrow Distribution, and for each Company
Equityholder: (a) such Company Equityholder&rsquo;s name, e-mail address and address; (b) the number of shares of each class of
Company Stock held as of the Closing Date by such Company Equityholder with corresponding certificate numbers; (c) to the extent
such Company Equityholder holds shares of Company Series A Preferred Stock, the number of shares of Company Common Stock issuable
upon conversion of the shares of each such series of Company Series A Preferred Stock (assuming such conversion occurs as of immediately
prior to the Effective Time) in accordance with Section 4 of Part B of Article FOURTH of the Company Certificate of Incorporation;
(d)&nbsp;the number of shares of Company Common Stock subject to Company Equity Awards outstanding immediately prior to the Effective
Time (after giving effect to the full acceleration of vesting in connection with the transactions contemplated by this Agreement
or otherwise) held by such Company Equityholder (and, if applicable, the exercise price thereof); (e) whether such Company Equityholder
is an &ldquo;accredited investor&rdquo; for purposes of Regulation D under the Securities Act; (f) the amount to be paid to such
Company Equityholder pursuant to <U>Section&nbsp;2.1(c)</U> and/or pursuant to <U>Section 2.5(a)</U>, in each case including the
Buyer Common Stock Consideration attributable to such Company Equityholder; (g) such Company Equityholder&rsquo;s Pro Rata Share;
(h) the portion of the Aggregate Closing Consideration attributable to such Company Equityholder&rsquo;s Company Stock and Company
Options; (i) the portion of any Future Contingent Payments attributable to such Company Equityholder&rsquo;s Company Stock and
Company Options; (j) whether any Taxes are required to be withheld on any portion of the Aggregate Closing Consideration required
to be paid to such Company Equityholder which are treated as wages for Tax purposes, and if any such Taxes are required to be withheld,
the applicable amount of such Taxes that are required to be withheld; (k)&nbsp;a separate column which indicates whether each Company
Equityholder will be paid by the Exchange Agent or through the Surviving Corporation&rsquo;s payroll; and (l) the portion of each
Future Contingent Payment to be paid to Leerink Partners LLC.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Antitrust Laws</U>&rdquo; means the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, the Sherman Act, as amended, the Clayton Act, the Federal Trade
Commission Act and any other applicable federal, state or foreign Law, regulation or decree designed to prohibit, restrict or regulate
actions for the purpose or effect of monopolization or restraint of trade.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Antitrust Order</U>&rdquo; means any
judgment, injunction, order (whether temporary, preliminary or permanent) or decree issued under or with respect to any Antitrust
Laws.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Bankruptcy and Equity Exception</U>&rdquo;
means the effects of bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of general applicability
relating to or affecting creditors&rsquo; rights and to general equity principles.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Base Cash Purchase Price</U>&rdquo;
means $170,000,000.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Business Day</U>&rdquo; means any
day other than (a) a Saturday or Sunday or (b) a day on which banking institutions located in New York, New York are permitted
or required by Law, executive order or governmental decree to remain closed.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Buyer</U>&rdquo; has the meaning set
forth in the first paragraph of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Buyer Common Stock</U>&rdquo; means
the Class A common stock, $0.01 par value per share, of the Buyer.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Buyer Common Stock Consideration</U>&rdquo;
means 2,782,701 shares of Buyer Common Stock equal to (a) $30,000,000 divided by (b) the Buyer Stock Price. The Buyer Common Stock
Consideration shall be subject to equitable adjustment in the event of any stock split, stock dividend, reverse stock split or
similar event affecting the Buyer Common Stock between the date of this Agreement and the Effective Time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Buyer Disclosure Schedule</U>&rdquo;
means the disclosure schedule delivered by the Buyer to the Company and dated as of the date of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Buyer Employee Plan</U>&rdquo; means
any Employee Benefit Plan for the benefit of, or relating to, any current or former employee of the Buyer or any of its Subsidiaries.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Buyer Fundamental Representations</U>&rdquo;
means the representations and warranties set forth in [<U>****</U>].</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Buyer Group</U>&rdquo; means (a) the
Buyer, the Buyer&rsquo;s Affiliates (excluding Affiliates not involved in the development or commercialization of any Product),
the Surviving Corporation and their direct and indirect Subsidiaries, (b) with respect to the Products, any Person to which any
right in or to any Product, or any of the Intellectual Property covering any Product, is licensed, sublicensed, assigned or transferred
by the Buyer, the Surviving Corporation or their direct or indirect Subsidiaries, (c) with respect to the Products, any Person
to which any right in or to any Product, or any of the Intellectual Property covering any Product, is licensed, sublicensed, assigned
or transferred, directly or through one or more intermediaries, by any Person described in clause (b) above; and (d) with respect
to the Products, any successor or assign of any Person described in clauses (a), (b) or (c) above with respect to such Person&rsquo;s
interest in any Product.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Buyer Indemnified Party</U>&rdquo;
has the meaning set forth in <U>Section 8.1</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Buyer Material Adverse Effect</U>&rdquo;
means any Change that has a material adverse effect on the ability of the Buyer or the Transitory Subsidiary to consummate, including
any Change that results in any material delay in the Buyer&rsquo;s ability to consummate, the transactions contemplated by this
Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Buyer SEC Reports</U>&rdquo; has the
meaning set forth in <U>Section 4.4</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Buyer Stock Price</U>&rdquo; means
$10.7809.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Certificate</U>&rdquo; means a certificate
which as of immediately prior to the Effective Time represented outstanding shares of Company Stock.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Certificate of Merger</U>&rdquo; means
the certificate of merger or other appropriate documents prepared and executed in accordance with Section&nbsp;251(c) of the DGCL,
in the form attached hereto as <U>Exhibit E</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Change</U>&rdquo; means any change,
event, circumstance, condition or development.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Claim Notice</U>&rdquo; means a written
notice which contains (a) a description of the claim for indemnification, a reasonable explanation of the basis therefor and a
description (including the amount) of any Damages incurred by an Indemnified Party, in each case to the extent then known, (b)
a statement that the Indemnified Party is entitled to indemnification under <U>Article&nbsp;VIII</U> and (c) a demand for payment
in the amount of such Damages (to the extent then known).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Closing</U>&rdquo; means the closing
of the transactions contemplated by this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Closing Cash</U>&rdquo; means all
unrestricted cash and cash equivalents held by the Company or any of its Subsidiaries as of 12:01 a.m., Eastern Time, on the Closing
Date, calculated in accordance with GAAP on a basis consistent with the Company&rsquo;s accounting principles, policies, methods,
treatments and procedures used in the preparation of the Company Financial Statements.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Closing Cash Consideration</U>&rdquo;
means the Aggregate Closing Consideration, minus the Buyer Common Stock Consideration.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Closing Date</U>&rdquo; means a date
to be specified by the Buyer and the Company, which shall be no later than the third (3rd) Business Day after the satisfaction
or waiver of the conditions set forth in <U>Article VII</U> (other than the delivery of items to be delivered at the Closing and
other than satisfaction of those conditions that by their nature are to be satisfied at the Closing, it being understood that the
occurrence of the Closing shall remain subject to the delivery of such items and the satisfaction or waiver of such conditions
at the Closing).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Closing Indebtedness</U>&rdquo; means
the aggregate amount of all Indebtedness of the Company and its Subsidiaries outstanding as of 12:01 a.m., Eastern Time, on the
Closing Date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Closing Net Working Capital</U>&rdquo;
means, as of 12:01 a.m., Eastern Time, on April 1, 2017 (or, if the Closing occurs after April 3, 2017 and the Buyer so elects,
as of 12:01 a.m., Eastern Time, on the Closing Date), the current assets of the Company (excluding the Closing Cash), less the
current liabilities of the Company, in each case, calculated in accordance with GAAP on a basis consistent with the Company&rsquo;s
accounting principles, policies, methods, treatments and procedures used in the preparation of the Company Financial Statements
and, in all cases, with the methodology and format set forth in the Illustrative Closing Cash Consideration Statement. The determination
of Closing Net Working Capital shall exclude Closing Cash, Closing Indebtedness, Taxes and Unpaid Company Transaction Expenses.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Closing Payment Certificate</U>&rdquo;
means a certificate, signed on behalf of the Company by the chief financial officer of the Company, which (a) sets forth (i) a
calculation of the Aggregate Series A Original Issue Price, (ii) a calculation of the payments to be made by the Buyer in accordance
with <U>Section 2.1(d)(ii)</U>, (iii) the identity of each Person entitled to a payment pursuant to <U>Section 2.1(d)(ii)</U>,
(iv) the amount due to each such Person and (v) the applicable wire instructions for the account or accounts of such Person and
(b) attaches the Allocation Schedule as a schedule thereto.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>COBRA</U>&rdquo; means the Consolidated
Omnibus Budget Reconciliation Act of 1985, 29&nbsp;U.S.C. &sect;1161 <U>et seq</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Code</U>&rdquo; means the Internal
Revenue Code of 1986, as amended.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Commercially Reasonable Efforts</U>&rdquo;
(or &ldquo;<U>Commercially Reasonable</U>,&rdquo; as the context may require) means, for purposes of <U>Sections 2.8</U> and <U>2.11</U>
of this Agreement, the carrying out of such obligations in a commercially reasonable manner using such diligent and sustained efforts
as are typically used by pharmaceutical companies of the size and resources of the Buyer for comparable activities, taking into
consideration the development and commercialization practices for prescription pharmaceutical products of similar commercial potential
at a similar stage in product lifecycle by such similarly-situated pharmaceutical companies, including with respect to the safety
and efficacy of such product, the risks inherent in the development and commercialization of the product, its competitiveness compared
to alternative third party products, the proprietary position of the product (including scope and duration of relevant patents),
the scope of marketing approval, the regulatory status of the product, whether the product is subject to a clinical hold, recall
or market withdrawal, intellectual property rights with respect to the product, then-prevailing economic and market conditions,
the strategic value of the product to such company, the anticipated profitability of the product (including based on pricing and
reimbursement practices) and the therapeutic use of the product, but excluding from such consideration the obligation to make payment
of any Earn-Out Consideration or the obligation to make the Priority Review Voucher Payment.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company</U>&rdquo; has the meaning
set forth in the first paragraph of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Balance Sheet</U>&rdquo; means
the Company&rsquo;s unaudited consolidated balance sheet as of December 31, 2016.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Bylaws</U>&rdquo; means the
bylaws of the Company, as amended or restated from time to time and in effect immediately prior to the Effective Time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Certificate of Incorporation</U>&rdquo;
means the certificate of incorporation of the Company, as amended or restated from time to time and in effect immediately prior
to the Effective Time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Common Stock</U>&rdquo; means
the common stock, par value $0.001 per share, of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Disclosure Schedule</U>&rdquo;
means the disclosure schedule delivered by the Company to the Buyer and the Transitory Subsidiary and dated as of the date of this
Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Employee Plans</U>&rdquo;
means Employee Benefit Plans for the benefit of, or relating to, any current or former employee, officer or director of the Company
or any of its Subsidiaries, or any beneficiary or dependent thereof or to or under which the Company or any of its Subsidiaries
is obligated to make any contributions or has any liability.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Equity Award</U>&rdquo; means
each Company Option and Company Restricted Stock Award outstanding as of immediately prior to the Effective Time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Equityholder</U>&rdquo; means
any holder of Company Stock or Company Equity Awards as of immediately prior to the Effective Time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Equityholder Representative</U>&rdquo;
has the meaning set forth in the first paragraph of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Equityholder Representative
Account Payment</U>&rdquo; has the meaning set forth in <U>Section 2.4(c)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Equityholder Representative
Engagement Agreement</U>&rdquo; has the meaning set forth in <U>Section 2.4(d)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Equityholder Representative
Expense Amount</U>&rdquo; means $2,352,000.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Equityholder Representative
Expenses</U>&rdquo; has the meaning set forth in <U>Section 2.4(d)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Equityholder Representative
Group</U>&rdquo; has the meaning set forth in <U>Section 2.4(d)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Excluded Representations</U>&rdquo;
means the representations and warranties set forth in <U>Section 3.10</U> (Intellectual Property) and <U>Section 3.17</U> (Regulatory
Matters).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Financial Statements</U>&rdquo;
means (a) the Company&rsquo;s audited consolidated balance sheets as of December 31, 2016 and December 31, 2015 and the related
consolidated statement of operations and cash flows for the years then ended and (b) the Company Balance Sheet and the related
unaudited consolidated statement of operations and cash flows of the Company for the month ended January 31, 2017.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Fundamental Representations</U>&rdquo;
means the representations and warranties set forth in [<U>****</U>].</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Indemnified Party</U>&rdquo;
means each natural person who is now, or has been at any time prior to the date of this Agreement, or who becomes prior to the
Effective Time, a director or officer of the Company or any of its Subsidiaries or any predecessor thereof.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Intellectual Property</U>&rdquo;
means any Intellectual Property owned by the Company or any of its Subsidiaries.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Leases</U>&rdquo; means any
real property leased or subleased by the Company or any of its Subsidiaries.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Material Adverse Effect</U>&rdquo;
means any Change that has had, has or would reasonably be expected to have a material adverse effect on the business, assets, operations,
financial condition or results of operations of the Company and its Subsidiaries, taken as a whole; <U>provided</U>, <U>however</U>,
that none of the following shall constitute, or shall be considered in determining whether there has occurred, a Company Material
Adverse Effect: (a) any Change arising out of or resulting from the pendency or announcement of the transactions contemplated by
this Agreement; (b) Changes in Law, rules or regulations or GAAP or the interpretation or method of enforcement thereof; (c) Changes
in the Company&rsquo;s industry in general in the United States or any country or region in the world; (d) Changes in general economic
or political conditions or the financing or capital markets in general in the United States or any country or region in the world,
or Changes in currency exchange rates; or (e) any earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wild fires or
other natural disasters, weather conditions and other force majeure events in the United States or any other country or region
in the world, terrorism, military action or war (whether or not declared); except to the extent such Changes resulting from, arising
out of or attributable to the matters described in clauses (b), (c), (d) and (e) above have a disproportionate adverse effect on
the Company and its Subsidiaries, taken as a whole, as compared to other similarly situated companies.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Material Contracts</U>&rdquo;
means the contracts listed in <U>Section 3.11(a)</U> of the Company Disclosure Schedule.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Option</U>&rdquo; means an
option to purchase Company Common Stock issued by the Company pursuant to the Company Stock Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Restricted Stock Award</U>&rdquo;
means each award of restricted Company Common Stock that is unvested as of immediately prior to the Effective Time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Series A Preferred Stock</U>&rdquo;
means the Series A preferred stock, $0.001 par value per share, of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Stock</U>&rdquo; means the
Company Common Stock and the Company Series A Preferred Stock.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Stock Plan</U>&rdquo; means
the Company&rsquo;s 2014 Stock Incentive Plan, as amended.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Stockholder</U>&rdquo; means
each holder of Company Stock as of immediately prior to the Effective Time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company Stockholder Approval</U>&rdquo;
means the adoption of this Agreement by the Company&rsquo;s stockholders under the DGCL and the Company&rsquo;s certificate of
incorporation, which stockholders shall constitute at least the Required Stockholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Company&rsquo;s Knowledge</U>,&rdquo;
&ldquo;<U>Knowledge of the Company</U>&rdquo; and words of similar effect means the knowledge of each of the individuals identified
in <U>Section 10.2</U> of the Company Disclosure Schedule, after reasonable inquiry.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Confidentiality Agreement</U>&rdquo;
means the Mutual Confidentiality Agreement, dated as of [****], by and between the Company and the Buyer.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Continuing Employees</U>&rdquo; means
each of the employees of the Buyer or the Surviving Corporation immediately following the Effective Time who shall have been an
employee of the Company or one (1) of its Subsidiaries immediately prior to the Effective Time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Current D&amp;O Insurance</U>&rdquo;
means the current policies of the directors&rsquo; and officers&rsquo; liability insurance maintained by the Company as of the
date of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Current Phase 3 Clinical Trial</U>&rdquo;
means a study of the Product with ClinicalTrials.gov identifier NCT02534844 as modified from time to time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Current Representation</U>&rdquo;
has the meaning set forth in <U>Section 11.12(a)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Damages</U>&rdquo; means all liabilities,
damages, claims, causes of actions, fines, fees, penalties, costs, losses, Taxes and expenses, including reasonable attorneys&rsquo;
fees and expenses, but, unless recoverable in connection with a Third-Party Action, excluding any punitive damages.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Deemed Proceeds</U>&rdquo; means the
amount of proceeds that the Buyer would have received from a sale of a Voucher for an amount equal to [****<U>]</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Designated Person</U>&rdquo; has the
meaning set forth in <U>Section 11.12(a)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>DGCL</U>&rdquo; means the Delaware
General Corporation Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Dissenting Shares</U>&rdquo; means
shares of Company Stock held as of the Effective Time by a Company stockholder who has not voted such shares of Company Stock in
favor of the adoption of this Agreement and with respect to which appraisal shall have been duly demanded and perfected in accordance
with Section 262 of the DGCL and not effectively withdrawn or forfeited prior to the Effective Time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Earn-Out Consideration</U>&rdquo;
has the meaning set forth in <U>Section 2.8</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Earn-Out Consideration Purchaser</U>&rdquo;
means a Person to which the Participating Equityholders assign their rights to receive the remaining Earn-Out Consideration payable
to them.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Earn-Out Sale</U>&rdquo; has the meaning
set forth in <U>Section 2.9(b)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Earn-Out Sale Documents</U>&rdquo;
has the meaning set forth in <U>Section 2.9(b)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Earn-Out Term</U>&rdquo; means, on
a Product-by-Product and country-by-country basis, the period commencing on the date of the First Commercial Sale of such Product
in such country and continuing until the later of (a) the expiration of (or final court or patent office decision declaring invalid
or unenforceable) the last-to-expire Valid Claim that covers the sale of such Product in the applicable country of sale or (b)
the expiration of the last-to-expire applicable Orphan Drug Exclusivity that covers such Product in the applicable country of sale;
provided that the Earn-Out Term will permanently expire on a Product-by-Product and country-by-country basis upon [****]. For purposes
of the definition of &ldquo;Earn-Out Term&rdquo;, a sale of a Third-Party Abbreviated Approval Product imported into the country
of sale, other than through personal importation, importation for investigational use or study (including named patient or compassionate
use) or importation for re-export, shall be considered a sale of such Third-Party Abbreviated Approval Product in such country
of sale, whether or not such Third-Party Abbreviated Approval Product is approved in such country of sale.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Effective Time</U>&rdquo; means the
time at which the Surviving Corporation files the Certificate of Merger with the Secretary of State of the State of Delaware.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>EMA</U>&rdquo; means the European
Medicines Agency and any successor governmental authority having substantially the same function.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Employee Benefit Plan</U>&rdquo; means
any employee benefit plan, agreement, commitment, arrangement, scheme, practice, program or policy providing benefits to any current
or former employee officer or director or any beneficiary or dependent thereof, including but not limited to any &ldquo;employee
pension benefit plan&rdquo; (as defined in Section 3(2) of ERISA), any &ldquo;employee welfare benefit plan&rdquo; (as defined
in Section 3(1) of ERISA), and any deferred compensation, bonus, incentive, commission, profit sharing, equity, employment or consulting,
retention or change in control, educational assistance, loan, vacation, medical, dental, travel, accident, life, disability, pension,
retirement or other insurance arrangement, plan, program, or policy whether written or unwritten and whether or not subject to
ERISA.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Environmental Law</U>&rdquo; means
any United States federal, state or local Law, statute, rule or regulation relating to the environment or occupational health and
safety, including any statute, regulation, administrative decision or order pertaining to (a) treatment, storage, disposal, generation
or transportation of industrial, toxic, infectious, biological, radioactive or hazardous materials or substances or solid, medical,
mixed or hazardous waste; (b) air, water or noise pollution; (c) groundwater or soil contamination; (d) the release or threatened
release into the environment of industrial, toxic, infectious, biological, radioactive or hazardous materials or substances, or
solid, medical, mixed or hazardous waste, including emissions, discharges, injections, spills, escapes or dumping of pollutants,
contaminants or chemicals; (e) the protection of wild life, marine life and wetlands, including all endangered and threatened species;
(f) storage tanks, vessels, containers, abandoned or discarded barrels and other closed receptacles; (g) health and safety of employees
and other persons; or (h) manufacturing, processing, using, distributing, treating, storing, disposing, transporting or handling
of materials regulated under any Law as pollutants, contaminants, toxic, infectious, biological, radioactive or hazardous materials
or substances or oil or petroleum products or solid, medical, mixed or hazardous waste.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Equity Interest</U>&rdquo; means,
with respect to any Person, (a) any share, partnership or membership interest, unit of participation or other similar interest
(however designated) in such Person and (b) any option, warrant, purchase right, conversion right, exchange right or other agreement
which would entitle any other Person to acquire any such interest in such Person (including share appreciation, phantom share,
profit participation or other similar rights).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>ERISA</U>&rdquo; means the Employee
Retirement Income Security Act of 1974, as amended.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>ERISA Affiliate</U>&rdquo; means any
entity that is a member of (a)&nbsp;a controlled group of corporations (as defined in Section&nbsp;414(b)&nbsp;of the Code), (b)&nbsp;a
group of trades or businesses under common control (as defined in Section&nbsp;414(c)&nbsp;of the Code) or (c)&nbsp;an affiliated
service group (as defined under Section&nbsp;414(m)&nbsp;of the Code or the regulations under Section&nbsp;414(o)&nbsp;of the Code),
any of which includes or included the Company or any Subsidiary of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Escrow Account</U>&rdquo; means the
account established pursuant to the Escrow Agreement to hold the Escrow Amount.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Escrow Agent</U>&rdquo; means Wilmington
Trust, National Association, a national association, as escrow agent pursuant to the Escrow Agreement, or any successor escrow
agent pursuant to the Escrow Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Escrow Agreement</U>&rdquo; means
the Escrow Agreement in the form attached hereto as <U>Exhibit F</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Escrow Amount</U>&rdquo; means [****].</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Escrow Fund</U>&rdquo; means, as of
any time, the Escrow Amount, including any interest or other amounts earned thereon prior to such time, less (a) any investment
losses thereon incurred prior to such time and (b) disbursements therefrom prior to such time in accordance with this Agreement
and the Escrow Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Estimated Closing Cash Consideration</U>&rdquo;
has the meaning set forth in <U>Section 2.6(a)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Estimated Closing Cash Consideration
Statement</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.6(a)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Exchange Act</U>&rdquo; means the
Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Exchange Agent</U>&rdquo; means American
Stock Transfer &amp; Trust Company, LLC or another bank or trust company mutually acceptable to the Buyer and the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Exchange Agent Agreement</U>&rdquo;
means an agreement to be entered into prior to the Effective Time by the Exchange Agent, the Buyer and the Company Equityholder
Representative, governing the disbursement of the Payment Fund, on terms reasonably satisfactory to the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Excluded Matters</U>&rdquo; means
a claim for indemnification (a) under the Company Excluded Representations, the Company Fundamental Representations or the Buyer
Fundamental Representations, (b) involving fraud, (c) under <U>Section 8.1</U> (except for claims under <U>Section&nbsp;8.1(a)</U>
to the extent relating to a representation or warranty other than a Company Fundamental Representation or a Company Excluded Representation)
or (d) under <U>Section 8.2</U> (except for claims under <U>Section 8.2(a)</U> to the extent relating to a representation or warranty
other than a Buyer Fundamental Representation).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>FCPA</U>&rdquo; has the meaning set
forth in <U>Section 3.15</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>FDA</U>&rdquo; means the United States
Food and Drug Administration.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>FDA Act</U>&rdquo; means the Federal
Food, Drug and Cosmetic Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Final Closing Cash Consideration</U>&rdquo;
has the meaning set forth in <U>Section 2.6(b)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Final Closing Cash Consideration Adjustment</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.6(b)(iv)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Final Closing Cash Consideration Statement</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.6(b)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>First Commercial Sale</U>&rdquo; means
the first sale by a Selling Person to a third party for end use or consumption of a Product in a country after Regulatory Approval
has been granted with respect to such Product in such country.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Form S-3</U>&rdquo; has the meaning
set forth in <U>Section 6.7(a)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Fully Diluted Shares</U>&rdquo; means
a number of shares of Company Stock equal to (a) the aggregate number of shares of Company Common Stock outstanding as of immediately
prior to the Effective Time (other than the shares of Company Stock to be cancelled in accordance with <U>Section 2.1(b)</U>),
plus (b) the aggregate number of shares of Company Common Stock issuable upon conversion of the Company Series A Preferred Stock
outstanding immediately prior to the Effective Time (assuming such conversion occurs immediately prior to the Effective Time) in
accordance with Section 4 of Part B of Article FOURTH of the Company Certificate of Incorporation, plus (c) the aggregate number
of shares of Company Common Stock subject to Company Options outstanding as of immediately prior to the Effective Time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Future Contingent Payments</U>&rdquo;
means, collectively, (a) any Final Closing Cash Consideration Adjustment that may become payable to Company Equityholders pursuant
to <U>Section 2.6</U>, plus (b) any portion of the Escrow Fund that may become distributable to Company Equityholders pursuant
to this Agreement and the Escrow Agreement, plus (c) any Company Equityholder Representative Account Payment, plus (d) any Earn-Out
Consideration, plus (e)&nbsp;any Priority Review Voucher Payment.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>GAAP</U>&rdquo; means United States
generally accepted accounting principles.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Governmental Entity</U>&rdquo; means
any court, arbitrational tribunal, administrative agency or commission or other governmental or regulatory authority, agency or
instrumentality.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Hazardous Substance</U>&rdquo; means
(a) any substance that is regulated or which falls within the definition of a &ldquo;hazardous substance,&rdquo; &ldquo;hazardous
waste&rdquo; or &ldquo;hazardous material&rdquo; pursuant to any Environmental Law; or (b) any petroleum product or by-product,
asbestos-containing material, polychlorinated biphenyls, radioactive materials or radon.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Illustrative Closing Cash Consideration
Statement</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.6(a)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Income Taxes</U>&rdquo; means Taxes
based on or measured by taxable income, net income, profit or a similar standard.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Indebtedness</U>&rdquo; means, with
respect to any Person, the outstanding principal amount of, and all interest, fees, prepayment premiums, expenses, breakage costs,
indemnities, penalties or other amounts accrued in respect of and all amounts otherwise owing or payable at retirement of, (a)&nbsp;any
indebtedness for borrowed money, (b)&nbsp;any obligation evidenced by bonds, debentures, notes, mortgages, security arrangements,
indentures or other similar instruments, (c)&nbsp;any reimbursement obligation of the Company with respect to letters of credit
(including standby letters of credit to the extent drawn upon), bankers&rsquo; acceptances or similar facilities issued for the
account of the Company, (d) all obligations of the Company as lessee under leases that are required to be recorded as capital leases
in accordance with GAAP, (e) all liabilities or obligations of the Company under any interest rate, currency, swap or other hedging
agreements, (f) all liabilities or obligations of the Company for the deferred purchase price of property or services (including
all earn-out or similar obligations) and (g)&nbsp;any obligation of the type referred to in clauses (a)&nbsp;through (f)&nbsp;of
another Person the payment of which such Person has guaranteed or for such Person is responsible or liable, directly or indirectly,
jointly or severally, as obligor or guarantor.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Indemnified Party</U>&rdquo; means,
subject to <U>Section 8.5(e)</U>, (a) in the case of a claim for indemnification by the Buyer Indemnified Parties, the Buyer Indemnified
Parties and (b) in the case of a claim for indemnification by the Company Equityholders, the Company Equityholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Indemnifying Party</U>&rdquo; means,
subject to <U>Section 8.5(e)</U>, (a) in the case of a claim for indemnification by the Buyer, the Company Equityholders and (b)
in the case of a claim for indemnification by the Company Equityholders, the Buyer.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Insurance Policies</U>&rdquo; has
the meaning set forth in <U>Section 3.18</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Intellectual Property</U>&rdquo; shall
mean all intellectual property and industrial property rights and rights in confidential information of every kind and description
throughout the world, including all U.S. and foreign (i) patents, patent applications, invention disclosures, and all related continuations,
continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof (&ldquo;<U>Patents</U>&rdquo;),
(ii) trademarks, service marks, names, corporate names, trade names, domain names, logos, slogans, trade dress, design rights,
and other similar designations of source or origin, together with the goodwill symbolized by any of the foregoing (&ldquo;<U>Trademarks</U>&rdquo;),
(iii) copyrights and copyrightable subject matter (&ldquo;<U>Copyrights</U>&rdquo;), (iii) rights in computer programs (whether
in source code, object code, or other form), algorithms, databases, compilations and data, technology supporting the foregoing,
and all documentation, including user manuals and training materials, related to any of the foregoing (&ldquo;<U>Software</U>&rdquo;),
(iv) trade secrets and all other confidential information, ideas, know-how, inventions, proprietary processes, formulae, models,
and methodologies (&ldquo;<U>Trade Secrets</U>&rdquo;), (v) rights of publicity, privacy, and rights to personal information, and
(vi) moral rights and rights of attribution and integrity.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>IRS</U>&rdquo; means the Internal
Revenue Service.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Investor Questionnaire</U>&rdquo;
means a questionnaire to be delivered by each Company Equityholder regarding whether it is an &ldquo;accredited investor&rdquo;
for purposes of Regulation D under the Securities Act, substantially in the form attached hereto as <U>Exhibit G-1</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Key Stockholder</U>&rdquo; means each
Company Stockholder identified on <U>Schedule 1.1(b)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Law</U>&rdquo; any United States federal,
state or local or foreign law, common law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation, or
any decree, order, injunction, rule, judgment, consent of or by any Governmental Entity, or any Permit or similar right granted
under any of the foregoing, or any similar provision having the force or effect of law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Letter of Transmittal</U>&rdquo; means
a letter of transmittal in the form attached hereto as <U>Exhibit&nbsp;G-2</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Liens</U>&rdquo; means any mortgage,
security interest, pledge, lien, charge or encumbrance.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Lock-Up Agreement</U>&rdquo; means
the Lock-Up Agreement in the form attached hereto as <U>Exhibit G-3</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Major EU Country</U>&rdquo; means
any of [****].</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Merger</U>&rdquo; means the merger
of the Transitory Subsidiary with and into the Company in accordance with the terms of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>NDA</U>&rdquo; means a New Drug Application
submitted to the FDA.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Net Sales</U>&rdquo; means the gross
amounts invoiced for worldwide sales of the Products by any Person within the Buyer Group (each such Person, a &ldquo;<U>Selling
Person</U>&rdquo;) to a non-Affiliate of the Selling Person, less the following deductions, without duplication, in each case to
the extent specifically related to the Products (and not previously deducted in calculating the amount invoiced or billed) and
incurred by the Selling Person and calculated in a manner consistent with the Selling Person&rsquo;s practices for other products:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[****] discounts and [****] reductions;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[****] Taxes on sales to the extent imposed upon and paid directly with respect to such sales (but excluding [****]);</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[****] costs and other [****] charges specifically relating to the sale and separately stated in the invoice therefor;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>invoiced amounts that are written off as uncollectible, provided that if such amounts are subsequently collected, such amounts
shall again be included in Net Sales;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amounts repaid or credits or allowances taken by reason of [****];</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Taxes on sales or delivery (excluding [****]); and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[****] payments, rebates, credits and discounts mandated by or granted to: [****].</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Notwithstanding anything contained herein, (A)
Net Sales shall not include [****] and (B) sales to a third party [****]. Any [****] will not be deemed a sale or disposition for
calculating Net Sales.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Such amounts shall be determined from the books
and records of the applicable Selling Person, maintained in accordance with GAAP, or other similar generally accepted accounting
principles used by such Selling Person, consistently applied and in accordance with customary industry practices. Sales of the
Products between or among the Selling Persons for resale shall not be included within Net Sales; <U>provided</U>, <U>however</U>,
that any subsequent sale of the Products by any Selling Person to another Person that is not a Selling Person shall be included
within Net Sales. With respect to sales of the Products invoiced in U.S. dollars, Net Sales shall be expressed in U.S. dollars.
With respect to sales of the Products invoiced in currencies other than U.S. dollars, Buyer shall use Buyer&rsquo;s then current
standard exchange rate methodology for the translation of foreign currency sales into U.S. dollars or, in the case of a Selling
Person who is not the Buyer or an Affiliate of the Buyer, such similar methodology of such of such Selling Person, consistently
applied.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Niemann-Pick Disease, Type C</U>&rdquo;
means that certain rare progressive genetic disorder characterized by an inability of the body to transport cholesterol and other
fatty substances (lipids) inside of cells.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Organizational Documents</U>&rdquo;
means, with respect to any Person (other than an individual), (a) the certificate or articles of incorporation or organization
and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed
in connection with the creation, formation or organization of such Person and (b)&nbsp;all by-laws, voting agreements and similar
documents, instruments or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Orphan Drug Exclusivity</U>&rdquo;
means the orphan drug regulatory exclusivity to which qualifying drug products are entitled following marketing approval thereof
in a given country, which extends for a period of (i) seven (7) years in the United States, (ii) ten (10) years in the European
Union or (iii) such time, if any, that is prescribed by Law in any other country of the world, as applicable.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Outside Date</U>&rdquo; means 5:00
pm EDT on April 4, 2017.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Participating Equityholders</U>&rdquo;
has the meaning set forth in <U>Section 2.9(b)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Payment Fund</U>&rdquo; means cash
in an amount sufficient to make payment of the portion of the Closing Cash Consideration to be paid to the Company Stockholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Permit</U>&rdquo; means all permits,
licenses, registrations, certificates, orders, approvals, franchises, variances and similar rights issued by or obtained from any
Governmental Entity (including those issued or required under Environmental Laws and those relating to the occupancy or use of
owned or leased real property).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Permitted Liens</U>&rdquo; means any
(a) mechanic&rsquo;s, materialmen&rsquo;s, landlord&rsquo;s and similar Liens, (b) Liens arising under worker&rsquo;s compensation,
unemployment insurance, social security, retirement and similar legislation, (c) Liens on goods in transit incurred pursuant to
documentary letters of credit, in each case arising in the ordinary course of business, (d) Liens for Taxes not yet due and payable,
and Liens for Taxes which are being contested in good faith and by appropriate proceedings for which appropriate reserves have
been made in accordance with GAAP, (e) Liens relating to capitalized lease financings or purchase money financings that have been
entered into in the ordinary course of business, (f) Liens arising under applicable securities Laws other than as a result of any
noncompliance therewith and (g) Liens arising solely by action of the Buyer.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Per Share Adjustment Amount</U>&rdquo;
means, in the event that the Company Equityholders are entitled to payment pursuant to <U>Section 2.6(b)(iv)</U>, an amount equal
to the Final Closing Cash Consideration Adjustment, divided by the Fully Diluted Shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Per Share Closing Consideration</U>&rdquo;
means an amount equal to (a) the Aggregate Closing Consideration, minus the product of (i) the Series A Original Issue Price, multiplied
by (ii) the number of shares of Company Series A Preferred Stock outstanding as of immediately prior to the Effective Time, divided
by (b) the Fully Diluted Shares (for the avoidance of doubt, to be paid in cash and shares of Buyer Common Stock as provided herein
and in the Allocation Schedule).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 101; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Per Share Closing Option Consideration</U>&rdquo;
means an amount equal to the Per Share Closing Consideration, minus the exercise price per share of the applicable Company Option
(with such exercise price being ratably allocated between cash and shares of Buyer Common Stock as provided herein and in the Allocation
Schedule).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Per Share Escrow Distribution</U>&rdquo;
means, with respect to any share of Company Stock, the Pro Rata Share of (a) the amount of any future distribution of any portion
of the Escrow Fund to the Company Equityholders, less (b) the portion thereof to be paid to Leerink Partners LLC as set forth on
the Allocation Schedule.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Per Share Expense Fund Distribution</U>&rdquo;
means the amount of any future distribution of any portion of the Company Equityholder Representative Expense Amount to the Company
Equityholders, divided by the Fully Diluted Shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Per Share Future Contingent Consideration</U>&rdquo;
means, with respect to any Future Contingent Payment payable to the Company Equityholders, other than any future distribution of
any portion of the Escrow Fund or Company Equityholder Representative Expense Amount, an amount equal to such Future Contingent
Payment, less the portion thereof to be paid to Leerink Partners LLC as set forth on the Allocation Schedule, divided by the Fully
Diluted Shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Per Share Option Consideration</U>&rdquo;
means the Per Share Closing Option Consideration, any applicable Per Share Future Contingent Consideration, Per Share Escrow Distribution
and Per Share Expense Fund Distribution.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Person</U>&rdquo; means any natural
person, firm, limited liability company, general or limited partnership, association, corporation, unincorporated organization,
company, joint venture, trust, Governmental Entity or other entity.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Phase 3 Clinical Trial</U>&rdquo;
means clinical trial(s) of the Products substantially in accordance with <U>Schedule 2.8(b)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Post-Closing Representation</U>&rdquo;
has the meaning set forth in <U>Section 11.12(a)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Pre-Closing Period</U>&rdquo; means
the period commencing on the date of this Agreement and ending at the Effective Time or such earlier date as this Agreement is
terminated in accordance with its terms.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Pre-Closing Tax Period</U>&rdquo;
means any taxable period ending on or before the Closing Date and the portion of any Straddle Period ending on and including the
Closing Date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Pre-Closing Taxes</U>&rdquo; means
(a) the Taxes of the Company or any of its Subsidiaries attributable to or with respect to any Pre-Closing Tax Period, (b) any
liability of the Company or any of its Subsidiaries for Taxes of any Person under Treasury Regulation Section 1.1502-6 or under
any comparable or similar provision of state, local or foreign Law, and any liability of the Company or any Subsidiary as a transferee
or successor, or pursuant to any contractual obligation (other than an Ordinary Commercial Agreement) as a result of any event
or transaction occurring prior to the Closing, (c) any Transaction Payroll Taxes, and (d) any Taxes for which the Company Equityholders
are responsible pursuant to <U>Section 6.6(i)</U>; provided, however, that Pre-Closing Taxes shall not include any Taxes taken
into account in Closing Net Working Capital or as an Unpaid Company Transaction Expense, in each case as finally determined pursuant
to <U>Section 2.6</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 102; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Preliminary Closing Cash Consideration</U>&rdquo;
has the meaning set forth in <U>Section 2.6(b)(i)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Preliminary Closing Cash Consideration
Statement</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.6(b)(i)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Priority Review Voucher Payment</U>&rdquo;
has the meaning set forth in <U>Section 2.11</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Product</U>&rdquo; means (a) a product
for the treatment of Niemann-Pick Disease, Type C, which product&nbsp;(1) contains a mixture of 2-hydroxypropyl-beta-cyclodextrins
having a specific compositional fingerprint and impurity profile as described in the investigational new drug application (IND)
113273 or in any new drug application (NDA), supplemental NDA or amendment thereto referencing data in IND 113273 (&ldquo;<U>VTS-270</U>&rdquo;)
provided that such NDA or supplemental NDA does not require new clinical safety or efficacy data beyond that required for the initial
approval of VTS-270, or (2) any purer formulations of VTS-270 (&ldquo;<U>VTS-27X</U>&rdquo;), and (b) any other product containing
a mixture of 2-hydroxypropyl-beta-cyclodextrins approved pursuant to a supplemental NDA filed with respect to the NDA approved
for VTS-270 or VTS-27X, or any new NDA that references the IND 113273 for which no new clinical safety or efficacy data are required.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Product Line Sale</U>&rdquo; means
a sale, transfer, assignment or license to any third party who is not an Affiliate of the Buyer, that includes all or substantially
all of the rights covering any Product (including any Regulatory Approvals and Company Intellectual Property); <U>provided</U>
that any transaction involving changes in the control of the Buyer shall not be a &ldquo;Product Line Sale&rdquo;.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Pro Rata Share</U>&rdquo; means, with
respect to any Company Equityholder, a fraction, (a) the numerator of which is the amount of the Aggregate Closing Consideration
(for this purpose, without reduction for the Escrow Amount, the Company Equityholder Representative Expense Amount or any required
withholding) to which such Company Equityholder is entitled, and (b)&nbsp;the denominator of which is Aggregate Closing Consideration
(for this purpose, without reduction for the Escrow Amount, the Company Equityholder Representative Expense Amount or any required
withholding).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Registrable Stock</U>&rdquo; has the
meaning set forth in <U>Section 6.7(a)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Regulatory Approval</U>&rdquo; means
any and all approvals, licenses, registrations, permits, notifications and authorizations (or waivers) of any Regulatory Authority
that are necessary for the manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale
or other commercialization of a Product in any country or jurisdiction.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Regulatory Authority</U>&rdquo; has
the meaning set forth in <U>Section 3.17(b)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Reporting Tail Endorsement</U>&rdquo;
has the meaning set forth in <U>Section 6.3(c)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 103; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Required Stockholders</U>&rdquo; means
holders of Company Stock that hold (or, following the Effective Time, that held, as of immediately prior to the Effective Time),
(a) a majority of the outstanding shares of Company Stock and (b) a majority of the outstanding shares of Company Series A Preferred
Stock.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>S-3 Damages</U>&rdquo; has the meaning
set forth in <U>Section 6.7(g)(i)</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>SEC</U>&rdquo; means the Securities
and Exchange Commission.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Securities Act</U>&rdquo; shall mean
the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder, as the same may be amended from time
to time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Series A Original Issue Price</U>&rdquo;
has the meaning set forth in Section 1 of Part B of Article FOURTH of the Company Certificate of Incorporation, as calculated on
a per share basis as of the Effective Time and set forth on the Closing Payment Certificate (for the avoidance of doubt, to be
paid in cash and shares of Buyer Common Stock as provided herein and in the Allocation Schedule).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Straddle Period</U>&rdquo; means any
taxable period that begins on or before the Closing Date and ends after the Closing Date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Subsidiary</U>&rdquo; means, with
respect to any party, any corporation, partnership, trust, limited liability company or other non-corporate business enterprise
in which such party (or another Subsidiary of such party) holds stock or other ownership interests representing (a) more than 50%
of the voting power of all outstanding stock or ownership interests of such entity or (b) the right to receive more than 50% of
the net assets of such entity available for distribution to the holders of outstanding stock or ownership interests upon a liquidation
or dissolution of such entity.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Surviving Corporation</U>&rdquo; means
the Company, as the surviving corporation in the Merger.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Tax</U>&rdquo; or &ldquo;<U>Taxes</U>&rdquo;
means all taxes, charges, fees, levies or other similar assessments or liabilities in the nature of a tax, including all U.S. federal,
state, local or non-U.S. income, gross receipts, corporation, net worth, environmental, capital gains, documentary, recapture,
recording, profits, severance, stamp, occupation, customs duties, ad valorem, premium, value-added, alternative minimum, excise,
real property, personal property, sales, use, services, transfer, withholding, social security, employment, unemployment, escheat,
payroll, franchise, estimated taxes or other tax, governmental fee, governmental assessment or governmental charge of any kind
whatsoever and denominated by any name whatsoever imposed by any Governmental Entity, whether computed on a separate, consolidated,
unitary or combined basis or in any other manner, whether or not disputed, and including any interest, penalties or additions to
tax imposed with respect thereto.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Tax Returns</U>&rdquo; means all reports,
returns, declarations, statements, claim for refund, information return, or other document, including any schedules or attachments
thereto, filed or required to be filed in connection with the determination, assessment or collection of any Tax of any party or
the administration of any Laws relating to Taxes.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 104; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Third-Party Abbreviated Approval Product</U>&rdquo;
means a third party product that is a multicomponent mixture of 2-hydroxypropyl-beta-cyclodextrins as its sole active ingredient
that is either (a) in a non-intrathecal formulation for which Regulatory Approval has been obtained in the applicable country for
treating Niemann-Pick Disease, Type C or for one or more other indications for which published clinical data demonstrating its
efficacy for treating neurological symptoms of Niemann-Pick Disease, Type C is available, or (b) in an intrathecal formulation
for which Regulatory Approval has been obtained in the applicable country for treating Niemann-Pick Disease, Type C or an indication
other than Niemann-Pick Disease, Type C; provided that such third party product is approved through an abbreviated product approval
pathway in which the third party or applicable regulatory authority relies in whole or in part, for purposes of seeking or granting
such approval, on the Regulatory Approval of a Product or data submitted in support of the Regulatory Approval of a Product, such
as 505(j) or 505(b)(2) of the FDA Act or Articles 10(1) and 10(2) of Directive 2001/83/EC, or their successor or equivalent regulations,
in the United States, European Union or other countries or territories.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Third-Party Action</U>&rdquo; means
any claim or the commencement of any action, suit or proceeding relating to a third party claim for which indemnification may be
sought by an Indemnified Party.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Third-Party Claim Notice</U>&rdquo;
means a written notification of the commencement of any Third-Party Action.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Third-Party Intellectual Property</U>&rdquo;
means Intellectual Property which the Company or any of its Subsidiaries is licensed under, or granted an option to obtain a license
under, excluding generally commercially available, off-the-shelf software programs with an annual cost of less than $25,000.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Transaction Payroll Taxes</U>&rdquo;
means any employment or payroll Taxes, whether payable by the Buyer, the Company or any of its Subsidiaries with respect to any
change in control payments or other bonuses or other compensatory payments to employees of the Company or any of its Subsidiaries
in connection with the transactions contemplated by this Agreement that are paid before, on or by and including the second payroll
period occurring after, the Closing Date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Transitory Subsidiary</U>&rdquo; has
the meaning set forth in the first paragraph of this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Unpaid Company Transaction Expenses</U>&rdquo;
means, in each case to the extent such costs and expenses shall not have been paid in full as of immediately prior to the Effective
Time, (a)&nbsp;all third-party costs and expenses of the Company incurred in connection with the negotiation, preparation and execution
of this Agreement and the consummation of the transactions contemplated hereby including fees payable to Leerink Partners LLC and
Wilmer Cutler Pickering Hale and Dorr LLP, (b) all bonuses (including any liabilities of the Company and its Subsidiaries with
respect to any retention or &ldquo;stay&rdquo; bonus), change of control, severance or similar payment obligations that become
due and payable, without the occurrence of any other event, by the Company or any of its Subsidiaries in connection with the consummation
of the transactions contemplated hereby, (c) all Transaction Payroll Taxes, including in connection with the payments described
in clause (b) above and payments to holders of Company Options and Company Restricted Stock Awards contemplated hereby, and (d)
the premium and any other costs or expenses payable in connection with the Reporting Tail Endorsement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 105; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Valid Claim</U>&rdquo; means a claim
of any issued and unexpired United States or foreign patent or patent application which shall not have been abandoned, revoked,
withdrawn, cancelled or disclaimed, nor held invalid or unenforceable by a court of competent jurisdiction or other Governmental
Entity of competent jurisdiction in an unappealed or unappealable decision or admitted to be invalid or unenforceable through reissue,
re-examination or disclaimer or otherwise.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Voucher</U>&rdquo; means a priority
review voucher issued by the FDA or otherwise under the authority of the United States Department of Health and Human Services
to Buyer or its Affiliate(s) as the sponsor of a rare pediatric disease or neglected tropical disease product application related
to the Products, that entitles the holder of such voucher to priority review of a single human drug application submitted under
Section 505(b)(1) or 505(b)(2) of the FDA Act or Section 351(a) of the United States Public Health Service Act, as further defined
in the FDA Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&ldquo;<U>Written Consent</U>&rdquo; means the
Company Stockholder Approval obtained pursuant to executed written consents of the Company&rsquo;s stockholders in lieu of a meeting
executed by each Key Stockholder, adopting this Agreement and approving the Merger and the other transactions contemplated hereby.</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>ARTICLE
XI</B></FONT><BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>MISCELLANEOUS</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i)
one (1) Business Days after being sent by registered or certified mail, return receipt requested, postage prepaid, (ii) one (1)
Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable nationwide overnight courier service
or (iii)&nbsp;on the date (or, the first Business Day following such receipt if the date of such receipt is not a Business Day)
of transmission by e-mail, subject to confirmation of receipt other than by means of automated reply, which the recipient shall
provide promptly upon receipt (it being understood that notice shall be deemed effective on the date (or first Business Day) following
transmission regardless of whether confirmation of receipt is provided on a subsequent date), in each case to the intended recipient
as set forth below, provided that notices to the Company Equityholder Representative shall be delivered solely via facsimile or
transmission by e-mail, subject to confirmation of receipt of such e-mail:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if to the Buyer or the Transitory Subsidiary or (after the Effective Time) the Surviving Corporation, to:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">Sucampo Pharmaceuticals, Inc.<BR>
805 King Farm Boulevard, Suite 550<BR>
Rockville, MD 20850<BR>
Attention: General Counsel<BR>
E-mail: N/A</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in"></P>

<!-- Field: Page; Sequence: 106; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">with a copy to:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">Cooley LLP<BR>
4401 Eastgate Mall<BR>
San Diego, California 92121-1909<BR>
Attention: Barbara Borden</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in; text-indent: 40pt">Christian Plaza</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">E-mail: &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;bborden@cooley.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in; text-indent: 40pt">cplaza@cooley.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in; text-indent: 40pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if (prior to the Effective Time) to the Company, to:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">Vtesse Inc.<BR>
910 Clopper Road, Suite 220S<BR>
Gaithersburg, MD 20878<BR>
Attention: Ben Machielse, CEO<BR>
E-mail: ben@vtessepharma.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">with a copy to:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">Wilmer Cutler Pickering Hale and Dorr LLP<BR>
60 State Street<BR>
Boston, Massachusetts 02109<BR>
Attention: Steven D. Singer</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in; text-indent: 40pt">Gary R. Schall</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">E-mail: steven.singer@wilmerhale.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 160pt; text-indent: -20pt">gary.schall@wilmerhale.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 160pt; text-indent: -20pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if to any Company Equityholder or the Company Equityholder Representative, to:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1.5in">Fortis Advisors LLC<BR>
Attention: Notice Department<BR>
Facsimile No.: (858) 408-1843<BR>
E-mail: <U>notices@fortisrep.com</U></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Any party to this Agreement may change the address
to which notices and other communications hereunder are to be delivered by giving the other parties to this Agreement notice in
the manner herein set forth.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement</U>. This Agreement (including the Company Disclosure Schedule and the Exhibits hereto and the documents
and instruments referred to herein that are to be delivered at the Closing) constitutes the entire agreement among the parties
to this Agreement and supersedes any prior understandings or agreements by or among the parties hereto, or any of them, written
or oral, with respect to the subject matter hereof, and the parties hereto specifically disclaim reliance on any such prior understandings
or agreements to the extent not embodied in this Agreement; <U>provided</U> that the Confidentiality Agreement shall remain in
effect in accordance with its terms.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Third-Party Beneficiaries</U>. Except for the parties hereto, this Agreement is not intended to, and shall not, confer
upon any other Person any rights or remedies hereunder, except for (a) the Company Indemnified Parties, who shall be third-party
beneficiaries of <U>Section 6.3</U>, and (b) the Buyer Indemnified Parties, for purposes of <U>Article VIII</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Assignment</U>. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned
or delegated, in whole or in part, by operation of Law or otherwise by any of the parties hereto without the prior written consent
of the other parties, and any such assignment without such prior written consent shall be null and void, except that the Buyer
or the Transitory Subsidiary may transfer or assign its rights and obligations under this Agreement, in whole or from time to time
in part, (a) to one (1) or more of their Affiliates; <U>provided</U>, that such transfer or assignment shall not relieve the Buyer
or the Transitory Subsidiary of its primary liability for its obligations hereunder or enlarge, alter or change any obligation
of any other party hereto or due to the Buyer or the Transitory Subsidiary or (b) in connection with a Product Line Sale. Subject
to the preceding sentence, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto
and their respective successors and permitted assigns.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction
shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability
of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent
jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making
such determination shall have the power to limit the term or provision, to delete specific words or phrases, or to replace any
invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing
the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the
event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to negotiated in good
faith to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve,
to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts and Signature</U>. This Agreement may be executed in counterparts, each of which shall be deemed an original
but all of which together shall be considered one (1) and the same agreement and shall become effective when counterparts have
been signed by each of the parties hereto and delivered to the other parties, it being understood that all parties need not sign
the same counterpart. This Agreement may be executed and delivered by facsimile or by an electronic scan delivered by electronic
transmission.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Interpretation</U>. Except where expressly stated otherwise in this Agreement, the following rules of interpretation
apply to this Agreement: (a) &ldquo;include,&rdquo; &ldquo;includes&rdquo; and &ldquo;including&rdquo; are not limiting; (b) &ldquo;hereof,&rdquo;
&ldquo;hereto,&rdquo; &ldquo;hereby,&rdquo; &ldquo;herein&rdquo; and &ldquo;hereunder&rdquo; and words of similar import when used
in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement; (c) &ldquo;date of
this Agreement&rdquo; refers to the date set forth in the initial caption of this Agreement; (d) &ldquo;extent&rdquo; in the phrase
&ldquo;to the extent&rdquo; means the degree to which a subject or other thing extends, and such phrase does not mean simply &ldquo;if&rdquo;;
(e)&nbsp;the descriptive headings and table of contents included herein are included for convenience only and shall not affect
in any way the meaning or interpretation of this Agreement or any provision hereof; (f) definitions contained in this Agreement
are applicable to the singular as well as the plural forms of such terms; (g) references to a contract or agreement mean such contract
or agreement as amended or otherwise supplemented or modified from time to time; (h)&nbsp;references to a Person are also to its
permitted successors and assigns; (i) references to an &ldquo;Article,&rdquo; &ldquo;Section,&rdquo; &ldquo;Exhibit&rdquo; or &ldquo;Schedule&rdquo;
refer to an Article or Section of, or an Exhibit or Schedule to, this Agreement; (j) references to &ldquo;$&rdquo; or otherwise
to dollar amounts refer to the lawful currency of the United States; (k) references to a federal, state, local or foreign statute
or Law include any rules, regulations and delegated legislation issued thereunder; and (l) references to accounting terms used
and not otherwise defined herein have the meaning assigned to them under GAAP, applied on a basis consistent with the application
thereof in the financial statements of the applicable Person. When reference is made in this Agreement to information that has
been &ldquo;made available&rdquo; to the Buyer, that shall include information that was (i) contained in the Company&rsquo;s electronic
data room no later than 5:00 p.m., Eastern time, on the second Business Day prior to the date of this Agreement or (ii)&nbsp;set
forth on <U>Schedule 11.7</U>. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto
to express their mutual intent, and no rule of strict construction shall be applied against any party hereto. No summary of this
Agreement prepared by any party shall affect the meaning or interpretation of this Agreement. If any date on which a party is required
to make a payment or a delivery pursuant to the terms hereof is not a Business Day, then such party shall make such payment or
delivery on the next succeeding Business Day. Time shall be of the essence in this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law; Waiver of Jury Trial</U>. This Agreement shall be governed by and construed in accordance with the internal
Laws of the State of Delaware without giving effect to any choice or conflict of Law provision or rule (whether of the State of
Delaware or any other jurisdiction) that would cause the application of Laws of any jurisdictions other than those of the State
of Delaware. Each of the parties irrevocably waives the right to trial by jury in connection with any matter based upon or arising
out of this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as otherwise provided in <U>Section 8.5(e)</U> with respect to the period from and after the Closing, any and all
remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred
hereby, or by Law or equity upon such party, and the exercise by a party of any one (1) remedy will not preclude the exercise of
any other remedy.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were
not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall
be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions
of this Agreement, in each case without posting a bond or undertaking, this being in addition to any other remedy to which they
are entitled at Law or in equity. Each of the parties agrees that it will not oppose the granting of an injunction, specific performance
and other equitable relief on the basis that (i) the party seeking such remedy has an adequate remedy at Law or (ii) an award of
specific performance is not an appropriate remedy for any reason at Law or equity.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Submission to Jurisdiction</U>. Each of the parties to this Agreement (a)&nbsp;consents to submit itself to the exclusive
personal jurisdiction of the Court of Chancery of the State of Delaware, New Castle County, or, if that court does not have jurisdiction,
a federal court sitting in Wilmington, Delaware in any action or proceeding arising out of or relating to this Agreement or any
of the transactions contemplated by this Agreement, (b)&nbsp;agrees that all claims in respect of such action or proceeding may
be heard and determined in any such court, (c) agrees that it shall not attempt to deny or defeat such personal jurisdiction by
motion or other request for leave from any such court and (d)&nbsp;agrees not to bring any action or proceeding arising out of
or relating to this Agreement or any of the transactions contemplated by this Agreement in any other court. Each of the parties
hereto waives any defense of inconvenient forum to the maintenance of any action or proceeding so brought and waives any bond,
surety or other security that might be required of any other party with respect thereto. Any party hereto may make service on another
party by sending or delivering a copy of the process to the party to be served at the address and in the manner provided for the
giving of notices in <U>Section&nbsp;11.1</U>. Nothing in this <U>Section 11.10</U>, however, shall affect the right of any party
to serve legal process in any other manner permitted by Law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure Schedules</U>. The Company Disclosure Schedule and the Buyer Disclosure Schedule shall be arranged in Sections
corresponding to the numbered sections and subsections contained in <U>Article&nbsp;III</U> and <U>Article IV</U>, respectively,
or other relevant Sections of this Agreement, and the disclosure in any section of the Company Disclosure Schedule or Buyer Disclosure
Schedule shall qualify (a) the corresponding Section of this Agreement and (b) the other Sections of this Agreement to the extent
that it is reasonably apparent from a reading of such disclosure that it also qualifies or applies to such other Sections. The
inclusion of any information in the Company Disclosure Schedule or Buyer Disclosure Schedule shall not be deemed to be an admission
or acknowledgment, in and of itself, that such information is required by the terms hereof to be disclosed, is material or is outside
the ordinary course of business.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">11.12<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver of Conflicts Regarding Representation; Non-Assertion of Attorney-Client Privilege</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Effective as of the Closing, the Buyer hereby waives and agrees not to assert, and the Buyer agrees to cause the Surviving
Corporation and each of its Subsidiaries to waive and not to assert, any conflict of interest arising out of or relating to any
representation after the Closing (any &ldquo;<U>Post-Closing Representation</U>&rdquo;) of the Company Equityholder Representative,
any Company Equityholder, any of their respective Affiliates or any officer, employee or director of the Company Equityholder Representative,
any Company Equityholder, the Company or any of its Subsidiaries (any such Person, a &ldquo;<U>Designated Person</U>&rdquo;) in
any matter involving this Agreement or any agreement, certificate, instrument or other document executed or delivered pursuant
to this Agreement or any transaction contemplated hereby or thereby (including any litigation, arbitration, mediation or other
proceeding and including any matter regarding the negotiation, execution, performance or enforceability hereof or thereof) by Wilmer
Cutler Pickering Hale and Dorr LLP and any other legal counsel currently representing any Designated Person in connection with
this Agreement or any agreement, certificate, instrument or other document executed or delivered pursuant to this Agreement or
any transaction contemplated hereby or thereby (including the negotiation, execution or performance hereof or thereof) (the &ldquo;<U>Current
Representation</U>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 110; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 0">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Effective as of the Closing, the Buyer hereby agrees not to control or assert, and the Buyer agrees to cause the Surviving
Corporation and each of its Subsidiaries not to control or assert, any attorney-client privilege, work product protection or other
similar privilege or protection applicable to any communication between any legal counsel and any Designated Person during the
Current Representation in connection with any Post-Closing Representation, including in connection with a dispute with the Buyer,
the Surviving Corporation or any of their respective Affiliates (including, after the Closing, the Company and each of its Subsidiaries),
it being the intention of the parties hereto that, notwithstanding anything to the contrary in <U>Section 1.3</U> or Section 259
of the DGCL, all rights of any Person under or with respect to such attorney-client privilege, work product protection or other
similar privilege or protection, including the right to waive, assert and otherwise control such attorney-client privilege, work
product protection or other similar privilege or protection, shall be (and are hereby) transferred to or retained by (as applicable),
and vested solely in, such Designated Person.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">[<I>Remainder of page intentionally left blank</I>]</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 111; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">IN WITNESS WHEREOF, the Buyer, the Transitory
Subsidiary and the Company have caused this Agreement to be signed by their respective officers thereunto duly authorized as of
the date first written above.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 3in">SUCAMPO PHARMACEUTICALS, INC.</P>

<P STYLE="font-size: 10pt; text-indent: -22.5pt; margin: 0pt 0 0pt 238.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -22.5pt; margin: 0pt 0 0pt 238.5pt">By: &nbsp;&nbsp;&nbsp;<U>/s/ Peter Greenleaf&#9;</U><BR>
Name: Peter Greenleaf<BR>
Title: Chairman and Chief Executive Officer</P>

<P STYLE="font-size: 10pt; text-indent: -22.5pt; margin: 0pt 0 0pt 238.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 3in">SABER MERGER SUB, INC.</P>

<P STYLE="font-size: 10pt; text-indent: -22.5pt; margin: 0pt 0 0pt 238.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -22.5pt; margin: 0pt 0 0pt 238.5pt">By:&nbsp;&nbsp;&nbsp; <U>/s/ Peter Pfreundschuh&#9;</U><BR>
Name: Peter Pfreundschuh<BR>
Title: Chief Financial Officers</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 3in">VTESSE INC.</P>

<P STYLE="font-size: 10pt; text-indent: -22.5pt; margin: 0pt 0 0pt 238.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -22.5pt; margin: 0pt 0 0pt 238.5pt">By:&nbsp;&nbsp;&nbsp; <U>/s/ Ben Machielse&#9;</U><BR>
Name: Ben Machielse<BR>
Title: President &amp; CEO</P>

<P STYLE="font-size: 10pt; text-indent: -22.5pt; margin: 0pt 0 0pt 238.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -22.5pt; margin: 0pt 0 0pt 238.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -22.5pt; margin: 0pt 0 0pt 238.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Fortis Advisors LLC</FONT>,<BR>
solely in such Person&rsquo;s capacity as the<BR>
COMPANY EQUITYHOLDER REPRESENTATIVE</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -22.5pt; margin: 0pt 0 0pt 22.5pt">By: &nbsp;&nbsp;&nbsp;<U>/s/ Richard Fink &#9;</U><BR>
Name: Richard Fink<BR>
Title: Managing Director</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 112; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>OMITTED ATTACHMENTS TO THE ASSET PURCHASE AGREEMENT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">The schedules and certain exhibits to the Agreement and Plan of Merger
have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Sucampo hereby undertakes to provide to the Securities and Exchange
Commission copies of such documents upon request; provided, however, that Sucampo reserves the right to request confidential treatment
for portions of any such documents.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: middle">
    <TD STYLE="width: 13%">Exhibit A</TD>
    <TD STYLE="width: 87%">Form of Written Consent</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit B-1</TD>
    <TD>Form of Optionholder Notice</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit B-2</TD>
    <TD>Form of Option Cancellation Agreement</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit C-1</TD>
    <TD>Illustrative Closing Cash Consideration Statement</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit C-2</TD>
    <TD>Illustrative Allocation Schedule</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit D</TD>
    <TD>Form of Information Statement</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit E</TD>
    <TD>Form of Certificate of Merger</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit F</TD>
    <TD>Form of Escrow Agreement</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit G-1</TD>
    <TD>Form of Investor Questionnaire</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit G-2</TD>
    <TD>Form of Letter of Transmittal</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Exhibit G-3</TD>
    <TD>Form of Lock-Up Agreement</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Schedule 1.1(b)</TD>
    <TD>Key Stockholders</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Schedule 2.8(b)</TD>
    <TD>Current Phase 3 Clinical Trial</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Schedule 7.1(g)</TD>
    <TD>Required Consents</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Schedule 11.7</TD>
    <TD>Additional Disclosures</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Company Disclosure Schedule<BR>
Buyer Disclosure Schedule</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 113; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit A</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Form of Written Consent</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>[</B><I>Omitted pursuant to Item 601(b)(2) of Regulation
S-K</I>]</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0"></P>

<!-- Field: Page; Sequence: 114; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit B-1</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Form of Optionholder Notice</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>[</B><I>Omitted pursuant to Item 601(b)(2) of Regulation
S-K</I>]</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 115; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit B-2</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Form of Option Cancellation Agreement</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 116; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>OPTION CANCELLATION AGREEMENT</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.75pt 0pt 0">This <B>O<FONT STYLE="font-size: 10pt">PTION </FONT>C<FONT STYLE="font-size: 10pt">ANCELLATION
</FONT>A<FONT STYLE="font-size: 10pt">GREEMENT </FONT></B>(this &ldquo;<B><I>Cancellation Agreement</I></B>&rdquo;) is made and
entered into as of<U>&#9;</U>, 2017, by and among <B>S<FONT STYLE="font-size: 10pt">UCAMPO </FONT>P<FONT STYLE="font-size: 10pt">HARMACEUTICALS</FONT>,
I<FONT STYLE="font-size: 10pt">NC</FONT>.</B>, a Delaware corporation (&ldquo;<B><I>Buyer</I></B>&rdquo;), <B>V<FONT STYLE="font-size: 10pt">TESSE
</FONT>I<FONT STYLE="font-size: 10pt">NC</FONT>.</B>, a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), and the
undersigned holder of Company Options (the &ldquo;<B><I>Optionholder</I></B>&rdquo;). Terms not otherwise defined herein shall
have the respective meanings ascribed to them in the Merger Agreement (as defined below). If the terms of this Cancellation Agreement
conflict in any way with the provisions of the Merger Agreement, then the provisions of the Merger Agreement shall control.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>R<FONT STYLE="font-size: 10pt">ECITALS</FONT></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 6pt">A.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Optionholder has executed and delivered this Cancellation Agreement in connection with that certain Agreement and Plan
of Merger, dated as of March 31, 2017, by and among Buyer, <B>S<FONT STYLE="font-size: 10pt">ABER </FONT>M<FONT STYLE="font-size: 10pt">ERGER
</FONT>S<FONT STYLE="font-size: 10pt">UB</FONT>, I<FONT STYLE="font-size: 10pt">NC</FONT>.</B>, a Delaware corporation and a wholly-owned
subsidiary of Buyer (&ldquo;<B><I>Transitory Subsidiary</I></B>&rdquo;), the Company and <B>F<FONT STYLE="font-size: 10pt">ORTIS
</FONT>A<FONT STYLE="font-size: 10pt">DVISORS </FONT>LLC</B>, as the Company Equityholder Representative (the &ldquo;<B><I>Company
Equityholder Representative</I></B>&rdquo;) (the &ldquo;<B><I>Merger Agreement</I></B>&rdquo;), pursuant to which Transitory Subsidiary
will merge with and into the Company (the &ldquo;<B><I>Merger</I></B>&rdquo;) with the Company to survive the Merger and become
a wholly-owned subsidiary of Buyer. A copy of the Merger Agreement is attached hereto as <B><I>Exhibit A</I></B>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 6pt">B.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Optionholder desires to agree to be bound by the terms of the Merger Agreement applicable to Optionholders, including
the escrow and indemnification provisions of the Merger Agreement and the provisions regarding the appointment of the Company Equityholder
Representative pursuant to the authority granted therein, in accordance with the terms of the Merger Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 6pt">C.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Optionholder understands and acknowledges that the Company, Transitory Subsidiary and Buyer are entitled to rely on
(i) the truth and accuracy of the Optionholder&rsquo;s representations contained herein and (ii) Optionholder&rsquo;s performance
of the obligations set forth herein.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>A<FONT STYLE="font-size: 10pt">GREEMENT</FONT></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.9pt 0pt 6pt"><FONT STYLE="font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Cancellation of Options</B>. The Optionholder hereby acknowledges and agrees that, pursuant to the Merger Agreement,
and in accordance with (x) the Option Agreement (as defined on the attached &ldquo;<B><I>Schedule of Ownership</I></B>&rdquo;)
and (y) the 2014 Stock Incentive Plan of the Company (as amended from time to time, the &quot;<B><I>Stock Incentive Plan</I></B>&quot;),
as of the Effective Time: (i) the Options (as defined below) will be cancelled and converted into the right to receive certain
Consideration (as defined below) from the Company, and (ii) the Options will cease to exist and will be automatically cancelled
and retired and the Optionholder will cease to have any rights with respect thereto other than the right to receive such Consideration,
without interest. Pursuant to the Merger Agreement, receipt of such Consideration by the Optionholder with respect to such Options
is subject to the receipt by the Company of this Cancellation Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 5.9pt 0pt 42pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 5.9pt 0pt 42pt"></P>

<!-- Field: Page; Sequence: 117; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 5.9pt 0pt 42pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.9pt 0pt 6pt"><FONT STYLE="font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Consideration</B>. The Optionholder hereby acknowledges termination of, and surrenders for cancellation to the Company,
all of the Optionholder's rights, title, and interest in and to the outstanding, unexercised stock options granted to the Optionholder
to purchase shares of the Company's Common Stock under the Stock Incentive Plan, as identified on the attached Schedule of Ownership
(the &quot;<B><I>Options</I></B>&quot;), effective as of the Effective Time and in exchange for cash and/or shares of Buyer Common
Stock, which shall be calculated and payable as provided in Section 2.5 of the Merger Agreement (the &quot;<B><I>Consideration</I></B>&quot;).
The Optionholder further acknowledges that certain portions of the Consideration are contingent upon the achievement of Company
performance metrics and other contingencies and that the Optionholder may not receive any additional consideration after the consummation
of the Merger. The Consideration shall be subject to any applicableAt any time after withholding and/or taxes. If, however, the Merger is not consummated
for any reason, the Options will not be cancelled, the vesting, if any, of the Options will not accelerate, the Consideration will
not be paid and this Cancellation Agreement will be of no force or effect.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 6pt"><FONT STYLE="font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Acknowledgment of Specified Documents</B>. The Optionholder hereby acknowledges and agrees that (i) the Optionholder
has received a copy of the Optionholder Notice (collectively with this Cancellation Agreement, the &quot;<B><I>Specified Documents</I></B>&quot;)
and has reviewed and understands the matters set forth therein and (ii) the Optionholder has been urged to and has been given the
opportunity to consult with its own legal and tax advisors regarding the legal and tax consequences of the transactions contemplated
by the Merger Agreement. In addition, the Optionholder acknowledges and agrees that by execution and delivery of this Cancellation
Agreement, the Optionholder agrees to be bound and obligated by the terms of the Merger Agreement in the capacity of an Optionholder
to the same extent as if he or she were an original party thereto and further agrees to perform the obligations of an Optionholder
thereunder. In the event of any inconsistency between the terms of this Cancellation Agreement and the terms of the Merger Agreement,
the Merger Agreement shall control.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.7pt 0pt 6pt"><FONT STYLE="font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Payments</B>. The Consideration shall be paid to the Optionholder by the Buyer at the same time as applicable to other
Optionholders under and in accordance with the Merger Agreement through the payroll of the Buyer (or the Surviving Corporation)
or its Subsidiaries irrespective of whether the Optionholder has ceased to be an employee of the Company by the date of payment.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 6pt"><FONT STYLE="font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Waivers</B>. The Optionholder hereby waives all requirements under the Options in respect of (i) any and all notices
required to be given in connection with the transactions contemplated by the Merger Agreement prior to the date hereof, whether
pursuant to the Merger Agreement, any of the other documents contemplated thereby, the Stock Incentive Plan, the Option Agreement,
any other agreement to which the Optionholder is a party or the certificate of incorporation or bylaws of the Company, (ii) any
and all of the Optionholder's rights under each of the agreements to which it is a party with the Company or its Affiliates relating
to its direct ownership of securities issued by the Company, whether or not written, including the Option Agreement and the Stock
Incentive Plan, but not including any continuing rights, if any, under the Merger Agreement, and (iii) all claims based upon or
arising from the Optionholder's ownership of the Options, but not including any continuing rights, if any, under the Merger Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 118; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 5.75pt 0pt 42pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 0"> <FONT STYLE="font-size: 10pt">6.</FONT> <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification Obligations and Joinder to Merger Agreement.</B></P>



<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.7pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Escrow and Indemnification Obligations</B>. The Optionholder hereby acknowledges that the Optionholder has read and understands
the Merger Agreement, including <U>Article II</U> and <U>Article VIII</U> of the Merger Agreement with respect to the payment arrangements,
the Escrow Fund, the Company Equityholder Representative Expense Amount, the Illustrative Allocation Statement, the determination
of the number of shares of Buyer Common Stock to be issued, conditions and provisions relating to the receipt and transfer of Buyer
Common Stock, conditions and provisions relating to the receipt and transfer of Future Contingent Payments (including provisions
related to opting into a potential sale of rights to Future Contingent Payments), indemnification obligations of the Optionholder
and other matters set forth therein, in each case described therein.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.7pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Appointment of Company Equityholder Representative</B>. The Optionholder hereby acknowledges the appointment of the Company
Equityholder Representative as set forth in <U>Section 2.4 </U>of the Merger Agreement and hereby agrees to and ratifies such appointment
in all respects.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.75pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Joinder</B>. The Optionholder agrees that by the execution and delivery of this Cancellation Agreement, the Optionholder
shall be, and hereby agrees to be, bound by <U>Article II</U> and <U>Article VIII</U> (and the defined terms in <U>Article X</U>
relating thereto) of the Merger Agreement solely to the extent such articles are applicable to such Optionholder, as if a signatory
to the Merger Agreement, and the Optionholder shall comply with, and be subject to, all of the terms, conditions, covenants, agreements
and obligations applicable to such Optionholder set forth in <U>Article II </U>and <U>Article VIII </U>of the Merger Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 0"><FONT STYLE="font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Acknowledgment of Escrow Obligations, Expense Amount Obligations, Future Contingent Consideration and Distribution of
Proceeds. </B>The Optionholder understands, agrees to and acknowledges the following:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.75pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On the Closing Date, Buyer shall deliver to the Escrow Agent, as a contribution to the Escrow Fund, the Escrow Amount (in
an aggregate amount of $ [****]), which shall serve as partial security for the Optionholder&rsquo;s Pro Rata Share of the indemnification
obligations of the Company Equityholders pursuant to <U>Article VIII </U>of the Merger Agreement and obligations of the Company
Equityholders with respect to the Final Closing Cash Consideration Adjustment pursuant to <U>Section 2.6(b)(iv) </U>of the Merger
Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.75pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On the Closing Date, Buyer shall deliver to the Company Equityholder Representative the Company Equityholder Representative
Expense Amount (in an aggregate amount of $[****]), which shall serve as a partial source of payment for expenses incurred by the
Company Equityholder Representative pursuant to <U>Section 2.4 </U>of the Merger Agreement and for the possible funding of the
Foundation (as defined below) as set forth in Section 9(f) of this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 119; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.95pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The receipt of the Future Contingent Payments by the Optionholder, if any, including any Final Closing Cash Consideration
Adjustment, any portion of the Escrow Fund, any Company Equityholder Representative Account Payment, any Earn-Out Consideration
and any Priority Review Voucher Payment, are not guaranteed and shall be subject to the terms and conditions set forth in the Merger
Agreement and are subject to setoff pursuant to <U>Section 8.9 </U>of the Merger Agreement with respect to the Optionholder&rsquo;s
Pro Rata Share of the indemnification obligations under <U>Article VIII </U>of the Merger Agreement and to the extent provided
in <U>Section 2.6(b)(iv)</U> of the Merger Agreement with respect to the Optionholder&rsquo;s Pro Rata Share of the Final Closing
Cash Consideration Adjustment.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.65pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Optionholder shall be entitled to the Optionholder&rsquo;s share of any Future Contingent Payments, if any, in the proportions
described in the Allocation Schedule and only as and when such amount or amounts are payable to the Optionholder in accordance
with the provisions of the Merger Agreement and the Escrow Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.85pt 0pt 42pt"><FONT STYLE="font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding the provisions of Section 2.9(a) and (b) of the Merger Agreement, the Optionholder shall not (A) subject
to the next following sentence be able to transfer his or her rights to any payments under the Merger Agreement whether pursuant
to Section 2.9 or otherwise and (B) have an election whether to become a Participating Equityholder in the transfer of any payments
under the Merger Agreement. The Optionholder shall become a Participating Equityholder upon the determination of the Company Equityholder
Representative that there will be an Earn-Out Sale, provided that Company Stockholders that owned a majority of the voting power
of the outstanding capital stock of the Company immediately prior to the Effective Time become Participating Equityholders in such
Earn-Out Sale.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 6pt"><FONT STYLE="font-size: 10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Representations and Warranties of the Optionholder</B>. The Optionholder represents and warrants to the Company and the
Buyer that the statements contained in this <U>Section 8 </U>are true and correct as of the date hereof:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.85pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Ownership of Options</B>. The Optionholder is the sole record, legal and beneficial owner of all of the outstanding Options
set forth on the Schedule of Ownership, free and clear of all Liens, other than Permitted Liens pursuant to agreements between
the Optionholder and the Company and pursuant to applicable securities laws. The Optionholder has not granted any rights to purchase
any interests of any kind in such Options to any other Person. All ownership information set forth on the Schedule of Ownership
is accurate and complete.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.75pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Authority; Binding Nature of Agreement</B>. The Optionholder has the legal capacity to enter into and perform its obligations
under the terms of this Cancellation Agreement. The Optionholder has duly executed and delivered this Cancellation Agreement and
(assuming the due authorization, execution and delivery of this Cancellation Agreement by Buyer) this Cancellation Agreement constitutes
a legal, valid and binding obligation of the Optionholder.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 120; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.75pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>No Conflict</B>. Neither the execution of this Cancellation Agreement by the Optionholder nor the consummation of the
transactions contemplated hereby will result in a breach or violation of (i) the terms of any agreement by which the Optionholder
is bound or (ii) any decree, judgment, order or Law now in effect of any court or other Governmental Entity applicable to the Optionholder.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 96.65pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.65pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Non-Contravention; Consents</B>. No consent, notice, waiver, approval, order or authorization of, or registration, declaration
or filing with, any Governmental Entity or any third party, including a party to any contract with the Optionholder, is required
by or with respect to the Optionholder in connection with the execution and delivery of this Cancellation Agreement by the Optionholder
or the consummation of the transactions contemplated hereby except for such consents, notices, waivers, approvals, orders, authorizations,
registrations, declarations and filings as may be required under applicable securities laws or that the Optionholder has obtained.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.7pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Legal Proceedings; Orders</B>. There is no pending action, suit, proceeding, claim, arbitration or investigation, and,
to the Optionholder&rsquo;s actual knowledge, no Person has threatened to commence any action, suit, proceeding, claim, arbitration
or investigation against the Optionholder that challenges, or that would reasonably be expected to have the effect of preventing,
delaying, making illegal or otherwise interfering with, the Merger or any of the other transactions contemplated by the Merger
Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 10pt">9.</FONT></TD><TD STYLE="text-align: justify"><B>Additional Agreements and Acknowledgments</B>.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.9pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Reliance</B>. The Optionholder acknowledges that the Company, Buyer and Transitory Subsidiary will rely, and are entitled
to rely, on (a) the truth and accuracy of the Optionholder&rsquo;s representations and warranties set forth herein and (b) the
Optionholder&rsquo;s agreement to perform the obligations of the Optionholder set forth herein.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.75pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Advisors</B>. The Optionholder confirms that he or she has had the opportunity to ask representatives of the Company
questions with regard to all the agreements, consents and other provisions in this Cancellation Agreement. The Optionholder also
confirms that he or she has had a reasonable time and opportunity to consult with his or her financial, legal, tax and other advisors,
if desired, before signing this Cancellation Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.65pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Disclosure</B>. The Optionholder hereby agrees that all confidential and non- public information of the Company obtained
by Optionholder before or after the Effective Time, and including all confidential and non-public information provided to the Optionholder
by the Company Equityholder Representative, as well as the terms of this Cancellation Agreement, the Merger Agreement and the transactions
contemplated thereby, shall not be disclosed by him or her to any third party; <I>provided, however</I>, that (i) the Optionholder
may disclose such information or terms if required to do so by applicable Law (provided that Optionholder, to the extent legally
permitted, promptly notifies Buyer and the Company Equityholder Representative in advance of disclosing such information); (ii)
the Optionholder may disclose such information to a Governmental Entity of competent jurisdiction or arbitrator of competent jurisdiction
in connection with any dispute or proceeding relating to this Cancellation Agreement, the Merger Agreement or any of the transactions
contemplated thereby; (iii) following any public announcement of the acquisition of the Company by Buyer, the Optionholder may
disclose the terms of the Merger Agreement that are disclosed by Buyer in such public announcement or any subsequent public filing;
(iv) the Optionholder may disclose such information or terms to the extent they become generally available to the public other
than by virtue of a breach of this provision by the Optionholder or its Affiliates; and (v) the Optionholder may disclose such
information or terms to his or her professional advisers , in each case, who: (i) need to know such information; and (ii) agree
to keep it confidential and are subject to confidentiality obligations no less restrictive than those contained in this Cancellation
Agreement. The Optionholder shall be responsible for any breach of this <U>Section 9(c) </U>by any foregoing Persons as if such
Person were a party hereto.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 121; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.85pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Transfer and Encumbrance</B>. Between the date of the Merger Agreement and the Effective Time, and other than as set
forth in the Merger Agreement, the Optionholder agrees not to transfer, sell, exchange, pledge or otherwise dispose of or encumber
any of the Options.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.75pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>No Limitation on Actions of Optionholder as Director or Officer</B>. In the event the Optionholder is a director of the
Company, nothing in this <U>Section 9 </U>is intended or shall be construed to require the Optionholder not to take any action,
or in any way limit, any action that the Optionholder may take, to discharge the Optionholder&rsquo;s fiduciary duties as a director
or officer of the Company; <U>provided</U> that this <U>Section 9(e)</U> shall not be construed to expand the Company&rsquo;s or
such Optionholder&rsquo;s rights under <U>Section 11(c) </U>or any provision of the Merger Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.7pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Establishment of Foundation. </B>The Optionholder approves (i) the Company entering into a Memorandum of Understanding
with Buyer pursuant to which the Company and Buyer propose to consider establishing a charitable foundation (the &ldquo;<B><I>Foundation</I></B>&rdquo;)
with the objective of providing financial support for the foundational research and development of (1) tools and techniques that
support future drug development for Niemann- Pick Disease, Type C, (2) tools and techniques for early diagnosis of Niemann-Pick
disease, Type C, (3) understanding the disease and its impact through patient registries and (4) other matters as may be discussed
and agreed and (ii) the setting aside of $ [****] million in cash for the benefit of the Foundation and the deposit of such cash
amount in an escrow account to be administered by the Company Equityholder Representative under the guidance of the Advisory Group.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 78pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 10pt">10.</FONT></TD><TD STYLE="text-align: justify"><B>Releases</B>.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 76.5pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD>[****].</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 76.5pt; margin: 0pt 5.9pt 0pt 0"><FONT STYLE="font-size: 10pt">(b)
</FONT>This release is conditioned upon the consummation of the Merger as contemplated in the Merger Agreement, and shall become
null and void, and shall have no effect whatsoever, without any action on the part of any Person, upon termination of the Merger
Agreement for any reason.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 0"> <FONT STYLE="font-size: 10pt">11.</FONT> <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Miscellaneous Provisions</B>.</P>



<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 122; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.65pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Notices</B>. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i)
one (1) Business Day after being sent by registered or certified mail, return receipt requested, postage prepaid, (ii) one (1)
Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable nationwide overnight courier service
or (iii) on the date (or, the first Business Day following such receipt if the date of such receipt is not a Business Day) of transmission
by e-mail, subject to confirmation of receipt other than by means of automated reply, which the recipient shall provide promptly
upon receipt (it being understood that notice shall be deemed effective on the date (or first Business Day) following transmission
regardless of whether confirmation of receipt is provided on a subsequent date), in each case to the intended recipient as set
forth below:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 6pt 0pt 41pt">i.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if to the Buyer or the Transitory Subsidiary or (after the Effective Time) the Surviving Corporation, to:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 76.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 76.5pt">Sucampo Pharmaceuticals, Inc.</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 76.5pt">805 King Farm Boulevard, Suite 550</P>

<P STYLE="font-size: 10pt; margin: 0pt 266.9pt 0pt 76.5pt">Rockville, MD 20850</P>

<P STYLE="font-size: 10pt; margin: 0pt 266.9pt 0pt 76.5pt">Attention: General Counsel</P>

<P STYLE="font-size: 10pt; margin: 0pt 266.9pt 0pt 76.5pt">E-mail: N/A</P>

<P STYLE="font-size: 10pt; margin: 0pt 296.9pt 0pt 76.5pt">with a copy to:</P>

<P STYLE="font-size: 10pt; margin: 0pt 296.9pt 0pt 76.5pt">Cooley LLP</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 76.5pt">4401 Eastgate Mall</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 76.5pt">San Diego, CA 92121-1909</P>

<P STYLE="font-size: 10pt; margin: 0pt 2pt 0pt 76.5pt">Attention: Barbara Borden Christian Plaza</P>

<P STYLE="font-size: 10pt; margin: 0pt 2pt 0pt 76.5pt">Email: bborden@cooley.com &nbsp;cplaza@cooley.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45pt"></TD><TD STYLE="width: 27pt">ii.</TD><TD STYLE="padding-right: 156.6pt">if (prior to the Effective Time) to the Company, to: </TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 242.55pt 0pt 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 242.55pt 0pt 1in">Vtesse Inc.</P>

<P STYLE="font-size: 10pt; margin: 0pt 242.55pt 0pt 1in">910 Clopper Road, Suite 220S</P>

<P STYLE="font-size: 10pt; margin: 0pt 242.55pt 0pt 1in">Gaithersburg, MD 20878</P>

<P STYLE="font-size: 10pt; margin: 0pt 242.55pt 0pt 1in">Attention: Ben Machielse,
CEO</P>

<P STYLE="font-size: 10pt; margin: 0pt 242.55pt 0pt 1in">E-mail: ben@vtessepharma.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 242.55pt 0pt 1in">with a copy to:</P>

<P STYLE="font-size: 10pt; margin: 0pt 177pt 0pt 1in">Wilmer Cutler Pickering Hale and Dorr LLP 60</P>

<P STYLE="font-size: 10pt; margin: 0pt 177pt 0pt 1in">State Street</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 1in">Boston, Massachusetts 02109</P>

<P STYLE="font-size: 10pt; margin: 0pt 191.65pt 0pt 1in">Attention: Steven D. Singer, Gary R. Schall</P>

<P STYLE="font-size: 10pt; margin: 0pt 191.65pt 0pt 1in">E-mail: Steven.Singer@wilmerhale.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 1in">Gary.Schall@wilmerhale.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0pt 6pt 0pt 41pt">iii.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if
to Optionholder, at the address set forth below Optionholder&rsquo;s signature on the signature page hereto.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.7pt 0pt 5pt"></P>

<!-- Field: Page; Sequence: 123; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.7pt 0pt 5pt"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Interpretation</B>. When a reference is made in this Cancellation Agreement to Sections or Exhibits, such reference shall
be to a Section of or an Exhibit to this Cancellation Agreement unless otherwise indicated. The words &ldquo;include,&rdquo; &ldquo;includes&rdquo;
and &ldquo;including&rdquo; when used herein shall be deemed in each case to be followed by the words &ldquo;without limitation.&rdquo;
The phrases &ldquo;the date of this Cancellation Agreement,&rdquo; &ldquo;the date hereof,&rdquo; and terms of similar import,
unless the context otherwise requires, shall be deemed to refer to the date first above written.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.85pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Specific Performance; Injunctive Relief</B>. It is agreed that, in addition to any other remedies that may be available
to Buyer upon any such violation of this Cancellation Agreement, Buyer shall be entitled to seek to enforce such covenants and
agreements by specific performance, injunctive relief or by any other means available to Buyer at law or in equity.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.95pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Counterparts</B>. This Agreement may be executed in counterparts, all of which shall be considered one and the same instrument
and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties
hereto; it being understood that all parties need not sign the same counterpart.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.75pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Entire Agreement; Nonassignability; Parties in Interest</B>. This Agreement and the documents and instruments and other
agreements specifically referred to herein or delivered pursuant hereto or in connection with the Merger (including the Optionholder&rsquo;s
Investor Questionnaire, and Lock-Up Agreement (if applicable), (i) constitute the entire agreement among the parties with respect
to the subject matter hereof and supersede all prior agreements and understandings, both written and oral, among the parties with
respect to the subject matter hereof and (ii) are not intended to confer, and shall not be construed as conferring, upon any person
other than the parties hereto any rights or remedies hereunder. The provisions of this Cancellation Agreement shall survive the
Effective Time and the closing of the transactions contemplated by the Merger Agreement. Neither this Cancellation Agreement nor
any of the rights, interests, or obligations under this Cancellation Agreement may be assigned or delegated, in whole or in part,
by operation of law or otherwise, by either party without the prior written consent of the other party, and any such assignment
or delegation that is not consented to shall be null and void, except that the Buyer may assign this Cancellation Agreement to
any direct or indirect wholly-owned subsidiary of the Buyer without the prior consent of the Optionholder. Subject to the preceding
sentence, this Cancellation Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto
and their respective successors and assigns. The Transitory Subsidiary is an express third party beneficiary of this Cancellation
Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.65pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Amendment; Waiver</B>. Subject to the provisions of applicable law, the parties hereto may amend this Cancellation Agreement
at any time pursuant to an instrument in writing signed on behalf of each of the parties hereto. At any time, any party hereto
may, to the extent legally allowed, waive any inaccuracies in the representations and warranties made to such party contained herein
or in any document delivered pursuant hereto and waive compliance with any of the agreements or conditions for the benefit of such
party contained herein. Any agreement on the part of a party hereto to any such waiver shall be valid only if set forth in an instrument
in writing signed on behalf of such party. Without limiting the generality or effect of the preceding sentence, no delay in exercising
any right under this Cancellation Agreement shall constitute a waiver of such right, and no waiver of any breach or default shall
be deemed a waiver of any other breach or default of the same or any other provision in this Cancellation Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 124; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 96.65pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.75pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Severability</B>. In the event that any provision of this Cancellation Agreement, or the application thereof, becomes
or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Cancellation Agreement
shall continue in full force and effect and shall be interpreted so as reasonably to effect the intent of the parties hereto. The
parties hereto further agree to use their commercially reasonable efforts to replace such void or unenforceable provision of this
Cancellation Agreement with a valid and enforceable provision that shall achieve, to the extent possible, the economic, business
and other purposes of such void or unenforceable provision.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.9pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Remedies Cumulative</B>. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a
party shall be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party,
and the exercise by a party of any one remedy shall not preclude the exercise of any other remedy.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.7pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Governing Law; Exclusive Jurisdiction; Waiver of Jury Trial</B>. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware without reference to such state&rsquo;s principles of conflicts of law. Each
of the parties hereto irrevocably consents to the exclusive jurisdiction of any state or federal court located within the State
of Delaware, in connection with any matter based upon or arising out of this Cancellation Agreement or the matters contemplated
herein, agrees that process may be served upon them in any manner authorized by the laws of the State of Delaware for such persons
and waives and covenants not to assert or plead any objection which they might otherwise have to such jurisdiction and such process.
Each of the parties hereto irrevocably waives the right to trial by jury in connection with any matter based upon or arising out
of this Cancellation Agreement or the transactions contemplated hereby.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.65pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Additional Documents, Etc</B>. Without limiting the generality or effect of the foregoing or any other obligation of
the Optionholder hereunder, the Optionholder hereby authorizes the Buyer to deliver a copy of this Cancellation Agreement to the
Company and hereby agrees that each of the Company and the Buyer may rely upon such delivery as conclusively evidencing the consents,
waivers and terminations of the Optionholder referred to in <U>Section 9 </U>and <U>Section 10</U>, in each case for purposes of
all agreements and instruments to which such consents, waivers and/or terminations are applicable or relevant.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.85pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Rules of Construction</B>. The parties hereto agree that they have been (or have had the opportunity to be) represented
by counsel during the negotiation, preparation and execution of this Cancellation Agreement and, therefore, waive the application
of any law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document shall be construed
against the party drafting such agreement or document.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.65pt 0pt 6pt"></P>

<!-- Field: Page; Sequence: 125; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.65pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Effectiveness</B>. To the extent the Merger Agreement is terminated for any reason prior to Closing, this Cancellation
Agreement shall immediately and automatically terminate upon termination of the Merger Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.75pt 0pt 6pt"><FONT STYLE="font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Spousal Consent</B>. If applicable, and if required by the applicable Laws of a community property state, concurrently
with the execution and delivery of this Cancellation Agreement, the Optionholder shall deliver a copy of this Cancellation Agreement
executed by the spouse of such Optionholder.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 6pt 0pt 0"><B>[</B>REMAINDER OF PAGE INTENTIONALLY LEFT BLANK<B>]</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 126; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">IN WITNESS WHEREOF, the undersigned have caused this Cancellation Agreement
to be executed as of the<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>day of<U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
2017.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><U>O<FONT STYLE="font-size: 10pt">PTIONHOLDER</FONT>:</U></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><U>I<FONT STYLE="font-size: 10pt">F</FONT> O<FONT STYLE="font-size: 10pt">PTIONHOLDER</FONT>'<FONT STYLE="font-size: 10pt">S
</FONT>S<FONT STYLE="font-size: 10pt">POUSE</FONT> M<FONT STYLE="font-size: 10pt">UST</FONT> S<FONT STYLE="font-size: 10pt">IGN</FONT></U>:*</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="width: 29%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 29%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD></TD>
    <TD><I>Signature</I></TD>
    <TD>&nbsp;</TD>
    <TD><I></I></TD>
    <TD><I>Signature</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><I>Print Name</I></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><I>Print Name</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I></I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 2pt 0pt 0"><U>C<FONT STYLE="font-size: 10pt">ONTACT</FONT> I<FONT STYLE="font-size: 10pt">NFORMATION</FONT></U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><U>Address</U>:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><U>Email</U>:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 28%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><U> SSN</U>:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 0"><I>* If the Optionholder is married and holds Options
jointly with the Optionholder's spouse, both the Optionholder and his or her spouse must sign this Cancellation Agreement. The
community property states are Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Texas and Washington.</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I><I>Signature Page to Option Cancellation Agreement</I></I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 127; Options: NewSection; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><I></I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I></I></P>



<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0"><I></I></P>

<P STYLE="font-size: 10pt; margin: 0pt 237.95pt 0pt 0">ACCEPTED AND AGREED:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt"><U>COMPANY</U>:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt"><B>VTESSE INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">By:</TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; width: 28%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Name:&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><U>BUYER</U>:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" NOWRAP><B>S<FONT STYLE="font-size: 10pt">UCAMPO </FONT>P<FONT STYLE="font-size: 10pt">HARMACEUTICALS</FONT>,
I<FONT STYLE="font-size: 10pt">NC</FONT>.</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>By:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Name:&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 237.95pt 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>Signature Page to Option Cancellation Agreement</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 128; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; margin: 0pt 0"><I></I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><U>SCHEDULE OF OWNERSHIP</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">The following sets forth the Optionholder's outstanding,
unexercised stock options granted under the Stock Incentive Plan and the agreement(s) listed below (the &quot;<U>Option Agreement</U>&quot;),
as of the Closing Date.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: #E1E1E1">
    <TD STYLE="width: 26%; border: black 1pt solid">O<FONT STYLE="font-size: 10pt">PTION</FONT> A<FONT STYLE="font-size: 10pt">GREEMENT</FONT></TD>
    <TD STYLE="width: 22%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">G<FONT STYLE="font-size: 10pt">RANT</FONT> D<FONT STYLE="font-size: 10pt">ATE</FONT></TD>
    <TD STYLE="width: 22%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">E<FONT STYLE="font-size: 10pt">XERCISE</FONT> P<FONT STYLE="font-size: 10pt">RICE</FONT></TD>
    <TD STYLE="width: 30%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">O<FONT STYLE="font-size: 10pt">UTSTANDING</FONT> O<FONT STYLE="font-size: 10pt">PTIONS</FONT> (# <FONT STYLE="font-size: 10pt">OF SHARES</FONT>)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">______________________________________</P>

<P STYLE="font-size: 10pt; margin: 0pt 91.95pt 0pt 0"><B>[</B>Optionholder<B>]</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><I>[Schedule of Ownership to Option Cancellation
Agreement]</I></P>

<!-- Field: Page; Sequence: 129; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXHIBIT A </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>AGREEMENT AND PLAN OF MERGER</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 130; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit C-1</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Illustrative Closing Cash Consideration Statement</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>[Omitted pursuant to Item 601(b)(2) of
Regulation S-K]</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I></I></P>

<!-- Field: Page; Sequence: 131; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Exhibit C-2 Illustrative Allocation Schedule</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>[Omitted pursuant to Item 601(b)(2) of Regulation S-K]</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 132; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit D</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Form of Information Statement</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>[Omitted pursuant to Item 601(b)(2) of
Regulation S-K]</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 133; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit E</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Form of Certificate of Merger</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<!-- Field: Page; Sequence: 134; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0"><B>CERTIFICATE OF MERGER OF</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0"><B>SABER MERGER SUB, INC. WITH AND INTO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0"><B>VTESSE INC.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0"><B>April 3, 2017</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0">Pursuant to Section 251 of the General Corporation Law
of the State of Delaware (the &ldquo;<U>DGCL</U>&rdquo;), Vtesse Inc., a Delaware corporation, does hereby certify the following
information in connection with the merger of Saber Merger Sub, Inc., a Delaware corporation, with and into Vtesse Inc. (the &ldquo;<U>Merger</U>&rdquo;):</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><B>FIRST</B>: The name and state of incorporation of each of the
constituent corporations in the Merger (the &ldquo;<U>Constituent Corporations</U>&rdquo;) are as follows:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-decoration: underline"><B><U>Name</U></B></TD>
    <TD STYLE="width: 51%; text-decoration: underline"><B><U>State of Incorporation</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Vtesse Inc.</TD>
    <TD>Delaware</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Saber Merger Sub, Inc.</TD>
    <TD>Delaware</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.7pt 0pt 0"><B>SECOND</B>: The Agreement and Plan
of Merger, dated as of March 31, 2017, by and among Vtesse Inc., Sucampo Pharmaceuticals, Inc., a Delaware corporation, Saber Merger
Sub, Inc., and solely in such Person&rsquo;s capacity as the representative of Vtesse Inc.&rsquo;s equityholders, Fortis Advisors
LLC (the &ldquo;<U>Merger Agreement</U>&rdquo;), setting forth the terms and conditions of the Merger, has been approved, adopted,
executed and acknowledged by each of the Constituent Corporations in accordance with the requirements of Section 251 of the DGCL.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.95pt 0pt 0"><B>THIRD</B>: The name of the surviving
corporation in the Merger (the &ldquo;<U>Surviving Corporation</U>&rdquo;) shall be &ldquo;Vtesse Inc.&rdquo;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 0"><B>FOURTH</B>: The certificate of
incorporation of Vtesse Inc. as in effect immediately prior to the Merger shall be amended and restated in its entirety at the
effective time of the Merger as set forth in <B>Exhibit A</B> attached hereto and, as so amended and restated, shall be the certificate
of incorporation of the Surviving Corporation until thereafter amended as provided therein or by applicable law.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 0"><B>FIFTH</B>: The executed Merger Agreement is on file at
the principal place of business of the Surviving Corporation, the address of which is 805 King Farm Blvd #550, Rockville, MD 20850.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.95pt 0pt 0"><B>SIXTH</B>: A copy of the Merger
Agreement will be furnished by the Surviving Corporation, on request and without cost, to any stockholder of either Constituent
Corporation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 0"></P>

<!-- Field: Page; Sequence: 135; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 0"><B>SEVENTH</B>: The
Merger shall become effective immediately upon the filing of this Certificate of Merger with the Secretary of State of the State
of Delaware.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">(<I>Remainder of page intentionally left blank</I>)</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0"></P>

<!-- Field: Page; Sequence: 136; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 6pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">IN WITNESS WHEREOF, the undersigned has executed this Certificate of Merger on the date
first written above.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>VTESSE INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="width: 29%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name:&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title:</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 190pt 0pt 211.5pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 112.9pt 0pt 0; text-indent: 256.95pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 112.9pt 0pt 0; text-indent: 256.95pt"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 195.55pt 0pt 3.5in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">[<I>Signature Page to Delaware Certificate of Merger</I>]</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 137; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 4.5pt"><B>EXHIBIT A</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 4.5pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 4.5pt"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 4.5pt"><B>AMENDED AND RESTATED</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0 0pt 4.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0"><B>CERTIFICATE OF INCORPORATION </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0"><B>OF</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0"><B>VTESSE INC.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>I.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.7pt 0pt 0">The name of this corporation is <B>VTESSE INC.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>II.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.7pt 0pt 0">The registered office of the corporation
in the State of Delaware shall be 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, Delaware 19808 and
the name of the registered agent of the corporation in the State of Delaware at such address is Corporation Service Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>III.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 0">The purpose of this corporation is
to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>IV.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.8pt 0pt 0">This corporation is authorized to
issue only one class of stock, to be designated Common Stock. The total number of shares of Common Stock presently authorized is
100, each having a par value of</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">$0.001.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>V.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 4.5pt"><B>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>The management of the business and the conduct of the affairs of the corporation shall be vested in its Board of Directors.
The number of directors which shall constitute the whole Board of Directors shall be fixed by the Board of Directors in the manner
provided in the Bylaws.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 35.95pt; margin: 0pt 5.75pt 0pt 6pt"><B>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>The Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the corporation. The stockholders shall
also have power to adopt, amend or repeal the Bylaws of the corporation; provided, however, that, in addition to any vote of the
holders of any class or series of stock of the corporation required by law or by this Certificate of Incorporation, such action
by stockholders shall require the affirmative vote of the holders of at least a majority of the voting power of all of the then-outstanding
shares of the capital stock of the corporation entitled to vote generally in the election of directors, voting together as a single
class.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>VI.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 35.95pt; margin: 0pt 5.75pt 0pt 6pt"><B>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>The liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 36.05pt; margin: 0pt 5.7pt 0pt 5.95pt"><B></B></P>

<!-- Field: Page; Sequence: 138; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-indent: 36.05pt; margin: 0pt 5.7pt 0pt 5.95pt"><B>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>To the fullest extent permitted by applicable law, the corporation is authorized to provide indemnification of (and advancement
of expenses to) directors, officers and agents of the corporation (and any other persons to which applicable law permits the corporation
to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested
directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable
law is amended after approval by the stockholders of this Article VI to authorize corporate action further eliminating or limiting
the personal liability of directors, then the liability of a director to the corporation shall be eliminated or limited to the
fullest extent permitted by applicable law as so amended.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 36.05pt; margin: 0pt 5.7pt 0pt 5.95pt"><B>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>Any repeal or modification of this Article VI shall only be prospective and shall not affect the rights or protections or increase
the liability of any director under this Article VI in effect at the time of the alleged occurrence of any act or omission to act
giving rise to liability or indemnification.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>VII.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 0">The corporation reserves the right
to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter
prescribed by statute, and all rights conferred upon the stockholders herein are granted subject to this reservation.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0"></P>

<!-- Field: Page; Sequence: 139; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0"><B>Exhibit F</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0"><B>Form of Escrow Agreement</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 140; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ESCROW AGREEMENT</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.85pt 0pt 0">This Escrow Agreement dated this <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>day
of April, 2017 (the &ldquo;Escrow Agreement&rdquo;), is entered into by and among SUCAMPO PHARMACEUTICALS, INC., a
Delaware corporation (&ldquo;Buyer&rdquo;), VTESSE INC., a Delaware corporation (the &ldquo;Company&rdquo;), FORTIS ADVISORS
LLC, a Delaware limited liability company (the &ldquo;Company Equityholder Representative&rdquo; (on behalf of the Company
Equityholders)), and together with Buyer, the &ldquo;Parties,&rdquo; and individually, a &ldquo;Party&rdquo;), and WILMINGTON
TRUST, NATIONAL ASSOCIATION, a national association, as escrow agent (&ldquo;Escrow Agent&rdquo;).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">RECITALS</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.05pt; margin: 0pt 5.75pt 0pt 5.95pt">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Buyer and the Company Equityholder Representative are parties to the Agreement and Plan of Merger, dated as of March 31, 2017 (the
&ldquo;Merger Agreement&rdquo;), pursuant to which Buyer is acquiring the equity interests of the Company. Capitalized terms used
herein but not otherwise defined shall have the meanings set for the in the Merger Agreement; <U>provided</U> that, in accordance
with Section 2.1, the Escrow Agent is not charged with any knowledge of the terms and conditions of the Merger Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.05pt; margin: 0pt 6.1pt 0pt 5.95pt">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pursuant to the Merger Agreement, on the date of this Agreement, Buyer is placing in escrow certain funds and the Escrow Agent
agrees to hold and distribute such funds in accordance with the terms of this Escrow Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 5.8pt 0pt 5.95pt">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Schedule I sets forth the wire transfer instructions for Buyer, the Exchange Agent and the Company. Disbursements for the benefit
of the Company Equityholders shall be made to the Exchange Agent and the Company in accordance with the instructions relating to
disbursements contemplated hereby.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.85pt 0pt 0">In consideration of the promises and agreements of the
Parties and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties
and the Escrow Agent agree as follows:</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">ARTICLE 1</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">ESCROW DEPOSIT</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.85pt 0pt 0">Section 1.1. <U>Receipt of Escrow Property</U>. Upon
execution hereof, Buyer shall deliver to the Escrow Agent the amount of $[****] (including any earnings and income thereon, the
&ldquo;Escrow Property&rdquo;) in immediately available funds.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Section 1.2. <U>Investments</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 5.8pt 0pt 6pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Escrow Agent shall invest the Escrow Property, including any and all interest and investment income, in accordance with
the written instructions provided to the Escrow Agent and signed by Buyer and the Company Equityholder Representative. In the
absence of written investment instructions, the Escrow Agent shall deposit and invest the Escrow Property, including any and
all interest and investment income, in the M&amp;T Bank Corporate Deposit Account, which is further described herein on <B>Exhibit
A</B>. Any investment earnings and income on the Escrow Property shall become part of the Escrow Property, and shall be
disbursed in accordance with Section 1.3 or Section 1.5 of this Escrow Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 141; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.7pt 0pt 6pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Escrow Agent is hereby authorized and directed to sell or redeem any such investments as it deems necessary to make any payments
or distributions required under this Escrow Agreement. The Escrow Agent shall have no responsibility or liability for any loss
which may result from any investment or sale of investment made pursuant to this Escrow Agreement. The Escrow Agent is hereby authorized,
in making or disposing of any investment permitted by this Escrow Agreement, to deal with itself (in its individual capacity) or
with any one or more of its affiliates, whether it or any such affiliate is acting as agent of the Escrow Agent or for any third
person or dealing as principal for its own account. The Parties acknowledge that the Escrow Agent is not providing investment supervision,
recommendations, or advice.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 6pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Although the Parties recognize that they may obtain a broker confirmation or written statement containing comparable information
at no additional cost, the Parties hereby agree that confirmations of permitted investments are not required to be issued by the
Escrow Agent for each month in which a monthly statement is rendered.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Section 1.3. <U>Disbursements</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 36.05pt; margin: 0pt 0 0pt 5.95pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For purposes of this Agreement:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.85pt 0pt 6pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Final Order&rdquo; means a final and nonappealable judgment, order, award or determination of a court of competent jurisdiction,
which order, judgment, award or determination (an &ldquo;Order&rdquo;) is delivered to the Escrow Agent accompanied by a written
instruction from Buyer or the Company Equityholder Representative confirming that such Order is final and nonappealable, and Escrow
Agent shall be entitled to conclusively rely upon any such confirmation and instruction and shall have no responsibility to review
the Order to which such confirmation and instruction refers.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 1in; margin: 0pt 5.75pt 0pt 6pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Joint Written Direction&rdquo; means a written direction executed by Buyer and the Company Equityholder Representative and
directing the Escrow Agent to disburse all or a portion of the Escrow Property or to take or refrain from taking any other action
pursuant to this Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36.05pt; margin: 0pt 5.8pt 0pt 5.95pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On the date that is [****] months following the date of this Agreement, Parent and the Company Equityholder Representative shall
deliver a Joint Written Direction to the Escrow Agent instructing the Escrow Agent to disburse for the benefit of the Company Equityholders
the then-remaining amount of the Escrow Property, less any portion of the Escrow Property that is then subject to a claim.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 142; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.9pt 0pt 6pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Notwithstanding the foregoing, the Escrow Agent shall disburse all or any portion of the Escrow Property at any time and from time
to time upon receipt of, and in accordance with, a Joint Written Direction, or pursuant to a Final Order.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.8pt 0pt 6pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
With respect to any disbursements of the Escrow Property for the benefit of the Company Equityholders, the Company Equityholder
Representative (on behalf of the Company Equityholders) shall be responsible for providing the Escrow Agent with complete payment
instructions, including wiring instructions or an address to which a check shall be sent. Unless otherwise set forth in a Joint
Written Direction, such instructions of the Company Equityholder Representative shall provide for a portion of a disbursement to
be delivered to the Exchange Agent for further distribution to the Company Stockholders and the remainder of such disbursement
to be delivered to the Buyer or the Company for further distribution to the holders of Company Options (as of immediately prior
to the Effective Time).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 6pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In the event that Escrow Agent makes any payment to any other party pursuant to this Escrow Agreement and for any reason such payment
(or any portion thereof) is required to be returned to the Escrow Account or another party or is subsequently invalidated, declared
to be fraudulent or preferential, set aside and/or required to be repaid to a receiver, trustee or other party under any bankruptcy
or insolvency law, other federal or state law, common law or equitable doctrine, then the Parties shall instruct such recipient
to repay to the Escrow Agent upon written request the amount so paid to it.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.75pt 0pt 6pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Escrow Agent shall seek confirmation of such instructions by telephone call-back to the authorized person or persons of such
Party, and the Escrow Agent may rely upon the confirmations of anyone purporting to be the person or persons so designated provided
no call back is required if the Escrow Agent receives original instructions. The persons and telephone numbers for callbacks may
be changed only in a writing received and acknowledged by the Escrow Agent. The Parties agree that such security procedure is commercially
reasonable.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 6pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Escrow Agent will furnish monthly statements to the Parties setting forth the activity in the Account.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 0">Section 1.4. <U>Security Procedure for Funds
Transfer</U>. Concurrent with the execution of this Escrow Agreement, the Parties shall deliver to the Escrow Agent
authorized signers&rsquo; forms in the form of <U>Exhibit B-1 </U>and <U>Exhibit B-2 </U>to this Escrow Agreement. The Escrow
Agent shall confirm each funds transfer instruction received in the name of the Parties by confirming with an authorized
individual as evidenced in <U>Exhibit B- 1 </U>and <U>Exhibit B-2</U>. Once delivered to the Escrow Agent, <U>Exhibit B-1 </U>or <U>Exhibit
B-2</U> may be revised or rescinded only in writing signed by an authorized representative of the Party. Such revisions or
rescissions shall be effective only after actual receipt and following such period of time as may be necessary to afford the
Escrow Agent a reasonable opportunity to act on it. If a revised <U>Exhibit B-1 </U>or <U>Exhibit B-2</U> or a rescission of
an existing <U>Exhibit B-1</U> or <U>Exhibit B-2</U> is delivered to the Escrow Agent by an entity that is a
successor-in-interest to either party, such document shall be accompanied by additional documentation satisfactory to the
Escrow Agent showing that such entity has succeeded to the rights and responsibilities of the Parties. The Parties understand
that the Escrow Agent&rsquo;s inability to receive or confirm funds transfer instructions may result in a delay in
accomplishing such funds transfer, and agree that the Escrow Agent shall not be liable for any loss caused by any such
delay.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 143; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Section 1.5. <U>Income Tax Allocation and Reporting</U>.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 36.05pt; margin: 0pt 5.7pt 0pt 5.95pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Parties agree that, for tax reporting purposes, all interest and other income from investment of the Escrow Property shall,
as of the end of each calendar year and to the extent required by the Internal Revenue Code of 1986, as amended thereunder (the
&ldquo;Code&rdquo;), be reported as having been earned by Buyer, whether or not such income was disbursed during such calendar
year. The Escrow Agent is hereby instructed to distribute to Buyer, within thirty days after the end of each quarter (and immediately
prior to the final distribution of Escrow Property pursuant to this Agreement), [****] of any such interest or other income earned
in such quarter (or such shorter immediately preceding period) (and this sentence constitutes a Joint Written Direction for purposes
of Section 1.3(c)). The Escrow Agent shall be deemed the payor of any interest or other income paid upon investment of the Escrow
Property for purposes of performing tax reporting. With respect to any other payments made under this Escrow Agreement, the Escrow
Agent shall not be deemed the payor and shall have no responsibility for performing tax reporting. The Escrow Agent&rsquo;s function
of making such payments is solely ministerial and upon express direction of the Parties.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.8pt 0pt 6pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Parties shall provide the Escrow Agent with certified tax identification numbers by furnishing appropriate forms W-9 or W-8
and such other forms and documents that the Escrow Agent may request. The Parties understand that if such tax reporting documentation
is not provided and certified to the Escrow Agent, the Escrow Agent may be required by the Code, and the regulations promulgated
thereunder, to withhold a portion of any interest or other income earned on the investment of the Escrow Property.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.65pt 0pt 6pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To the extent that the Escrow Agent becomes liable for the payment of any taxes in respect of interest or other income derived
from the investment of the Escrow Property, the Escrow Agent shall satisfy such liability to the extent possible from the Escrow
Property. The Parties, jointly and severally, shall indemnify, defend and hold the Escrow Agent harmless from and against any tax,
late payment, interest, penalty or other cost or expense that may be assessed against the Escrow Agent on or with respect to the
Escrow Property and the investment thereof unless such tax, late payment, interest, penalty or other expense was directly caused
by the gross negligence or willful misconduct of the Escrow Agent (it being understood that, solely between the Parties, the liability
of the Parties described in this sentence shall be allocated in accordance with the Merger Agreement).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 144; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0">Section 1.6. <U>Termination</U>. Upon the disbursement
of all of the Escrow Property, this Escrow Agreement shall terminate and be of no further force and effect.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">ARTICLE 2</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">DUTIES OF THE ESCROW AGENT</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.75pt 0pt 0">Section 2.1. <U>Scope of Responsibility</U>. Notwithstanding
any provision to the contrary, the Escrow Agent is obligated only to perform the duties specifically set forth in this Escrow Agreement,
which shall be deemed purely ministerial in nature. Under no circumstances will the Escrow Agent be deemed to be a fiduciary to
any Party or any other person under this Escrow Agreement. The Escrow Agent will not be responsible or liable for the failure of
any Party to perform in accordance with this Escrow Agreement. The Escrow Agent shall neither be responsible for, nor chargeable
with, knowledge of the terms and conditions of any other agreement, including but not limited to the Merger Agreement, instrument,
or document other than this Escrow Agreement, whether or not an original or a copy of such agreement has been provided to the Escrow
Agent; and the Escrow Agent shall have no duty to know or inquire as to the performance or nonperformance of any provision of any
such agreement, instrument, or document. References in this Escrow Agreement to any other agreement, instrument, or document are
for the convenience of the Parties, and the Escrow Agent has no duties or obligations with respect thereto. This Escrow Agreement
sets forth all matters pertinent to the escrow contemplated hereunder, and no additional obligations of the Escrow Agent shall
be inferred or implied from the terms of this Escrow Agreement or any other agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.75pt 0pt 0">Section 2.2. <U>Attorneys and Agents</U>. The Escrow
Agent shall be entitled to rely on and shall not be liable for any action taken or omitted to be taken by the Escrow Agent in accordance
with the advice of counsel or other professionals retained or consulted by the Escrow Agent. The Escrow Agent shall be reimbursed
as set forth in Section 3.1 for any and all reasonable compensation (fees, expenses and other costs) paid and/or reimbursed to
outside counsel and/or outside professionals. The Escrow Agent may perform any and all of its duties through its agents, representatives,
attorneys, custodians, and/or nominees.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 0">Section 2.3. <U>Reliance</U>. The Escrow Agent shall not
be liable for any action taken or not taken by it in accordance with the written direction or consent of the Parties or their respective
agents, representatives, successors, or assigns. The Escrow Agent shall not be liable for acting or refraining from acting upon
any notice, request, consent, direction, requisition, certificate, order, affidavit, letter, or other paper or document believed
by it to be genuine and correct and to have been signed or sent by the proper person or persons, without further inquiry into the
person&rsquo;s or persons&rsquo; authority.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0">Section 2.4. <U>Right Not Duty Undertaken</U>. The permissive
rights of the Escrow Agent to do things enumerated in this Escrow Agreement shall not be construed as duties.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 96.6pt 0pt 0"></P>

<!-- Field: Page; Sequence: 145; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 96.6pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 96.6pt 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.85pt 0pt 0">Section 2.6. <U>No Financial Obligation</U>. No provision
of this Escrow Agreement shall require the Escrow Agent to risk or advance its own funds or otherwise incur any financial liability
or potential financial liability in the performance of its duties or the exercise of its rights under this Escrow Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">ARTICLE 3</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">PROVISIONS CONCERNING THE ESCROW AGENT</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 0">Section 3.1. <U>Indemnification</U>. The Buyer and Company
Equityholder Representative (on behalf of the Company Equityholders) hereby agree, jointly and severally, to indemnify the Escrow
Agent, its directors, officers, employees and agents (collectively, the &ldquo;Indemnified Parties&rdquo;), and hold the Indemnified
Parties harmless from any and against all liabilities, losses, actions, suits or proceedings at law or in equity, and any other
expenses, fees or charges of any character or nature, including, without limitation, attorney's fees and expenses, which an Indemnified
Party may incur or with which it may be threatened by reason of acting as or on behalf of Escrow Agent under this Agreement or
arising out of the existence of the Escrow Account, except to the extent the same shall be directly caused by Escrow Agent's gross
negligence or willful misconduct (it being understood that, solely between the Parties, the liability of the Parties described
in this sentence shall be allocated in accordance with the Merger Agreement). The Escrow Agent shall have a first lien against
the Escrow Account to secure the obligations of the Parties hereunder. The terms of Sections 1.5(c), 3.1 and 3.4 hereto shall survive
the termination of this Agreement and the resignation or removal of the Escrow Agent.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 0">Section 3.2. <U>Limitation of Liability</U>. THE ESCROW
AGENT SHALL NOT BE LIABLE, DIRECTLY OR INDIRECTLY, FOR ANY (I) DAMAGES, LOSSES OR EXPENSES ARISING OUT OF THE SERVICES PROVIDED
HEREUNDER, OTHER THAN DAMAGES, LOSSES OR EXPENSES WHICH HAVE BEEN FINALLY ADJUDICATED TO HAVE DIRECTLY RESULTED FROM THE ESCROW
AGENT&rsquo;S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, OR (II) SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES OR LOSSES OF ANY KIND
WHATSOEVER (INCLUDING WITHOUT LIMITATION LOST PROFITS), EVEN IF THE ESCROW AGENT HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES
OR DAMAGES AND REGARDLESS OF THE FORM OF ACTION.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.8pt 0pt 0">Section 3.3. <U>Resignation or Removal</U>. The
Escrow Agent may resign by furnishing written notice of its resignation to the Parties, and the Parties may remove the Escrow
Agent by furnishing to the Escrow Agent a joint written notice of its removal along with payment of all fees and expenses to
which it is entitled through the date of termination. Such resignation or removal, as the case may be, shall be effective
thirty (30) calendar days after the delivery of such notice or upon the earlier appointment of a successor, and the Escrow
Agent&rsquo;s sole responsibility thereafter shall be to safely keep the Escrow Property and to deliver the same to a
successor escrow agent as shall be appointed by the Parties, as evidenced by a joint written notice filed with the Escrow
Agent or in accordance with a court order. If the Parties have failed to appoint a successor escrow agent prior to the
expiration of thirty (30) calendar days following the delivery of such notice of resignation or removal, the Escrow Agent may
petition any court of competent jurisdiction for the appointment of a successor escrow agent or for other appropriate relief,
and any such resulting appointment shall be binding upon the Parties.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 146; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 0">Section 3.4. <U>Compensation</U>. The Escrow Agent shall
be entitled to compensation for its services as stated in the fee schedule attached hereto as Exhibit C, which compensation shall
be paid by Buyer. The fee agreed upon for the services rendered hereunder is intended as compensation for the Escrow Agent's services
as contemplated by this Escrow Agreement; provided, however, that in the event that the conditions for the disbursement of funds
under this Escrow Agreement are not fulfilled, or the Escrow Agent renders any service not contemplated in this Escrow Agreement
at the request of the Parties, or there is any assignment of interest in the subject matter of this Escrow Agreement, or any material
modification hereof, or if any material controversy arises hereunder, or the Escrow Agent is made a party to any litigation pertaining
to this Escrow Agreement or the subject matter hereof, then the Escrow Agent shall be compensated for such extraordinary services
and reimbursed for all reasonable out-of-pocket costs and expenses, including reasonable outside attorneys&rsquo; fees and expenses,
occasioned by any such delay, controversy, litigation or event. If any amount due to the Escrow Agent hereunder is not paid within
thirty (30) calendar days of the date due, the Escrow Agent in its sole discretion may charge interest on such amount up to five
percent (5%) per annum. The Escrow Agent shall have, and is hereby granted, a prior lien upon the Escrow Property with respect
to its unpaid fees, non-reimbursed expenses and unsatisfied indemnification rights, superior to the interests of any other persons
or entities and is hereby granted the right to set off and deduct any unpaid fees, non- reimbursed expenses and unsatisfied indemnification
rights from the Escrow Property.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.75pt 0pt 0">Section 3.5. <U>Disagreements</U>. If any
conflict, disagreement or dispute arises between, among, or involving any of the parties hereto concerning the meaning or
validity of any provision hereunder or concerning any other matter relating to this Escrow Agreement, or the Escrow Agent is
in doubt as to the action to be taken hereunder, the Escrow Agent shall be fully protected and may, at its option, retain the
Escrow Property until the Escrow Agent (i) receives a Final Order or a final non- appealable arbitration decision directing
delivery of the Escrow Property, (ii) receives a written agreement executed by each of the parties involved in such
disagreement or dispute directing delivery of the Escrow Property, in which event the Escrow Agent shall be authorized to
disburse the Escrow Property in accordance with such agreement, or (iii) files an interpleader action in any court of
competent jurisdiction, and upon the filing thereof, the Escrow Agent shall be relieved of all liability as to the Escrow
Property and shall be entitled to recover attorneys&rsquo; fees, expenses and other costs incurred in commencing and
maintaining any such interpleader action. The Parties hereto further agree to pursue any redress or recourse in connection
with such dispute without making the Escrow Agent a party to the same. The Escrow Agent shall be entitled to act on any such
agreement, court order, or arbitration decision without further question, inquiry, or consent.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 147; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.75pt 0pt 0">Section 3.6. <U>Merger or Consolidation</U>. Any corporation
or association into which the Escrow Agent may be converted or merged, or with which it may be consolidated, or to which it may
sell or transfer all or substantially all of its corporate trust business and assets as a whole or substantially as a whole, or
any corporation or association resulting from any such conversion, sale, merger, consolidation or transfer to which the Escrow
Agent is a party, shall be and become the successor escrow agent under this Escrow Agreement and shall have and succeed to the
rights, powers, duties, immunities and privileges as its predecessor, without the execution or filing of any instrument or paper
or the performance of any further act.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 0">Section 3.7. <U>Attachment of Escrow Property; Compliance
with Legal Orders</U>. In the event that any Escrow Property shall be attached, garnished or levied upon by any court order, or
the delivery thereof shall be stayed or enjoined by an order of a court, or any order, judgment or decree shall be made or entered
by any court order affecting the Escrow Property, the Escrow Agent is hereby expressly authorized, in its sole discretion, to respond
as it deems appropriate or to comply with all writs, orders or decrees so entered or issued, or which it is advised by legal counsel
of its own choosing is binding upon it, whether with or without jurisdiction. In the event that the Escrow Agent obeys or complies
with any such writ, order or decree it shall not be liable to any of the Parties or to any other person, firm or corporation, should,
by reason of such compliance notwithstanding, such writ, order or decree be subsequently reversed, modified, annulled, set aside
or vacated.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.75pt 0pt 0">Section 3.8 <U>Force Majeure</U>. The Escrow Agent shall
not be responsible or liable for any failure or delay in the performance of its obligation under this Escrow Agreement arising
out of or caused, directly or indirectly, by circumstances beyond its reasonable control, including, without limitation, acts of
God; earthquakes; fire; flood; wars; acts of terrorism; civil or military disturbances; sabotage; epidemic; riots; interruptions,
loss or malfunctions of utilities, computer (hardware or software) or communications services; accidents; labor disputes; acts
of civil or military authority or governmental action; it being understood that the Escrow Agent shall use commercially reasonable
efforts which are consistent with accepted practices in the banking industry to resume performance as soon as reasonably practicable
under the circumstances.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.75pt 0pt 0">Section 3.9 <U>Compliance with Legal Orders</U>. The
Escrow Agent shall receive and may conclusively rely upon an opinion of counsel to the effect that such order is final, non-appealable
and from a court of competent jurisdiction. The Escrow Agent shall be entitled to consult with legal counsel in the event that
a question or dispute arises with regard to the construction of any of the provisions hereof, and shall incur no liability and
shall be fully protected in acting in accordance with the advice or opinion of such counsel.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 148; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.65pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.65pt 0pt 0">Section 3.10 <U>No Financial Obligation</U>. The Escrow
Agent shall not be required to use its own funds in the performance of any of its obligations or duties or the exercise of any
of its rights or powers, and shall not be required to take any action which, in the Escrow Agent&rsquo;s sole and absolute judgment,
could involve it in expense or liability unless furnished with security and indemnity which it deems, in its sole and absolute
discretion, to be satisfactory.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0">ARTICLE 4</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0">MISCELLANEOUS</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.85pt 0pt 0">Section 4.1. <U>Successors and Assigns</U>. This Escrow
Agreement shall be binding on and inure to the benefit of the Parties and the Escrow Agent and their respective successors and
permitted assigns. No other persons shall have any rights under this Escrow Agreement. No assignment of the interest of any of
the Parties shall be binding unless and until written notice of such assignment shall be delivered to the other Party and the Escrow
Agent and shall require the prior written consent of the other Party and the Escrow Agent (such consent not to be unreasonably
withheld).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.85pt 0pt 0">Section 4.2. <U>Escheat</U>. The Parties are aware that
under applicable state law, property which is presumed abandoned may under certain circumstances escheat to the applicable state.
The Escrow Agent shall have no liability to the Parties, their respective heirs, legal representatives, successors and assigns,
or any other party, should any or all of the Escrow Property escheat by operation of law.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.85pt 0pt 0">Section 4.3. <U>Notices</U>. All notices, account statements,
requests, demands, and other communications required under this Escrow Agreement shall be in writing, in English, and shall be
deemed to have been duly given if delivered (i) personally, (ii) by facsimile transmission with written confirmation of receipt,
(iii) by overnight delivery with a reputable national overnight delivery service, or (iv) by mail or by certified mail, return
receipt requested, and postage prepaid, provided that notices to the Company Equityholder Representative shall be delivered solely
by facsimile transmission with written confirmation of receipt or email. If any notice is mailed, it shall be deemed given five
business days after the date such notice is deposited in the United States mail. If notice is given to a party, it shall be given
at the address for such party set forth below. It shall be the responsibility of the Parties to notify the Escrow Agent and the
other Party in writing of any name or address changes. In the case of communications delivered to the Escrow Agent, such communications
shall be deemed to have been given on the date received by the Escrow Agent.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 365.8pt 0pt 0">If to Buyer: with a copy to:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">If to Fortis Advisors LLC:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 149; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">If to the Escrow Agent:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.95pt 0pt 0">Section 4.4. <U>Governing Law</U>. This Escrow Agreement
shall be governed by and construed in accordance with the laws of the State of Delaware.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.8pt 0pt 0">Section 4.5. <U>Entire Agreement</U>. This Escrow Agreement
sets forth the entire agreement and understanding of the parties related to the Escrow Property; provided that, solely between
the Parties, nothing herein shall supersede the rights and obligations of the Parties (or the Company Equityholders) set forth
in the Merger Agreement with respect to the Escrow Property.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.85pt 0pt 0">Section 4.6. <U>Amendment</U>. This Escrow Agreement
may be amended, modified, superseded, rescinded, or canceled only by a written instrument executed by the Parties and the Escrow
Agent.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 0">Section 4.7. <U>Waivers</U>. The failure of any party
to this Escrow Agreement at any time or times to require performance of any provision under this Escrow Agreement shall in no manner
affect the right at a later time to enforce the same performance. A waiver by any party to this Escrow Agreement of any such condition
or breach of any term, covenant, representation, or warranty contained in this Escrow Agreement, in any one or more instances,
shall neither be construed as a further or continuing waiver of any such condition or breach nor a waiver of any other condition
or breach of any other term, covenant, representation, or warranty contained in this Escrow Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.75pt 0pt 0">Section 4.8. <U>Headings</U>. Section headings of this
Escrow Agreement have been inserted for convenience of reference only and shall in no way restrict or otherwise modify any of the
terms or provisions of this Escrow Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.8pt 0pt 0">Section 4.9. <U>Counterparts</U>. This Escrow Agreement
may be executed in one or more counterparts, each of which when executed shall be deemed to be an original, and such counterparts
shall together constitute one and the same instrument.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.75pt 0pt 0">Section 4.10. <U>Waiver of Jury Trial. </U><B>EACH OF
THE PARTIES HERETO EXPRESSLY WAIVES THE RIGHT TO TRIAL BY JURY IN RESOLVING ANY CLAIM OR COUNTERCLAIM RELATING TO OR ARISING OUT
OF THIS ESCROW AGREEMENT.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">[The remainder of this page left intentionally blank.]</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 150; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 5.9pt 0pt 0">IN
WITNESS WHEREOF, this Escrow Agreement has been duly executed as of the date first written above.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">SUCAMPO PHARMACEUTICALS, INC.,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">as Buyer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 3%">By:&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: &nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">FORTIS ADVISORS LLC, as Company</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Equityholder Representative</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>By:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: &nbsp;</TD>
    <TD>Richard Fink</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Managing Director</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">WILMINGTON TRUST, NATIONAL</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">ASSOCIATION, as Escrow Agent</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid"></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 5.9pt 0pt 229.5pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 229.5pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 229.5pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 225pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 225pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 5.9pt 0pt 0">[SIGNATURE PAGE TO ESCROW AGREEMENT]</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 151; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;<IMG SRC="wilmington.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><U>Schedule I</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><U>Wire Transfer Instructions</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><U>Buyer</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 374.75pt 0pt 0"><U>Bank Name: ABA</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 374.75pt 0pt 0"><U>Number: Account</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 374.75pt 0pt 0"><U>Name: Account</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 374.75pt 0pt 0"><U>Number:</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><U>Exchange Agent</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 374.75pt 0pt 0"><U>Bank Name: ABA</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 374.75pt 0pt 0"><U>Number: Account</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 374.75pt 0pt 0"><U>Name: Account</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 374.75pt 0pt 0"><U>Number:</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><U>Company</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 374.75pt 0pt 0"><U>Bank Name: ABA</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 374.75pt 0pt 0"><U>Number: Account</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 374.75pt 0pt 0"><U>Name: Account</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 374.75pt 0pt 0"><U>Number:</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 152; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;<IMG SRC="wilmington.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3pt 0pt 0"><U>EXHIBIT A</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Agency and Custody Account Direction For Cash Balances</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Manufacturers &amp; Traders Trust Company Deposit Accounts</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.7pt 0pt 0">Direction to use the following Manufacturers &amp; Traders
Trust Company (also known as M&amp;T Bank) Deposit Account for Cash Balances for the escrow account or accounts (the &ldquo;Account&rdquo;)
established under the Escrow Agreement to which this Exhibit A is attached.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.6pt 0pt 0">You are hereby directed to deposit, as indicated below,
or as the Parties shall direct further in writing from time to time, all cash in the Account in the following deposit account of
M&amp;T Bank:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>M&amp;T Corporate Deposit Account</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.75pt 0pt 0">The Parties acknowledge that amounts on deposit in the
M&amp;T Bank Deposit Account are insured, subject to the applicable rules and regulations of the Federal Deposit Insurance Corporation
(FDIC), in the basic FDIC insurance amount of $250,000 per depositor, per issued bank. This includes principal and accrued interest
up to a total of $250,000.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Parties acknowledge that they have full power to direct investments
of the Account.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.8pt 0pt 0">The Parties understand that they may change this direction
at any time and that it shall continue in effect until revoked or modified by me by written notice to you.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 153; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;<IMG SRC="wilmington.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><U>EXHIBIT B-1</U></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CERTIFICATE AS TO AUTHORIZED REPRESENTATIVES</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">OF BUYER</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.7pt 0pt 0">SUCAMPO PHARMACEUTICALS, INC. (the &ldquo;Buyer&rdquo;)
hereby designates each of the following persons as its Authorized Representatives for purposes of this Agreement, and confirms
that the title, contact information and specimen signature of each such person as set forth below is true and correct. Each such
Authorized Representative is authorized to initiate and approve transactions of all types for the Escrow Account(s) established
under the Agreement to which this Exhibit B-1 is attached, on behalf of the Buyer.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B> (print):</FONT></TD>
    <TD STYLE="width: 74%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Specimen Signature:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Title:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Telephone Number</B></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">(required):</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 4.95pt 0pt 0"><I>If more than one, list all applicable telephone numbers.</I></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>E-mail</B> (required):</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 4.95pt 0pt 0"><I>If more than one, list all applicable&#9;email addresses.</I></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B> (print):</FONT></TD>
    <TD STYLE="width: 74%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Specimen Signature:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Title:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Telephone Number</B></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">(required):</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 4.95pt 0pt 0"><I>If more than one, list all applicable telephone numbers.</I></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>E-mail</B> (required):</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 4.9pt 0pt 0"><I>If more than one, list all applicable&#9;email addresses.</I></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 154; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;<IMG SRC="wilmington.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>COMPLETE BELOW TO UPDATE EXHIBIT B-1</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.75pt 0pt 0">If Buyer wishes to update this Exhibit B-1, Buyer must
complete, sign and send to Escrow Agent an updated copy of this Exhibit B-1 with such changes. Any updated Exhibit B-1 shall be
effective once signed by Buyer and Escrow Agent and shall entirely supersede and replace any prior Exhibit B-1 to this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">SUCAMPO PHARMACEUTICALS, INC.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 3%">By:&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Date:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 320.45pt 0pt 0"><U></U></P>

<P STYLE="font-size: 10pt; margin: 0pt 320.45pt 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 427.35pt 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 427.35pt 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">WILMINGTON TRUST, NATIONAL ASSOCIATION (as Escrow Agent)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 3%">By:&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Date:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 155; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><IMG SRC="wilmington.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><U>EXHIBIT B-2</U></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">CERTIFICATE AS TO AUTHORIZED REPRESENTATIVES</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">OF SELLER</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.65pt 0pt 0">Fortis Advisors LLC (the &ldquo;Company Equityholder
Representative&rdquo;) designates each of the following persons as its Authorized Representatives for purposes of this Agreement,
and confirms that the title, contact information and specimen signature of each such person as set forth below is true and correct.
Each such Authorized Representative is authorized to initiate and approve transactions of all types for the Escrow Account(s) established
under the Agreement to which this Exhibit B-2 is attached, on behalf of the Company Equityholder Representative.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B> (print):</FONT></TD>
    <TD STYLE="width: 74%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Specimen Signature:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Title:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Telephone Number</B></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">(required):</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 4.95pt 0pt 0"><I>If more than one, list all applicable telephone numbers.</I></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>E-mail</B> (required):</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 4.95pt 0pt 0"><I>If more than one, list all applicable&#9;email addresses.</I></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B> (print):</FONT></TD>
    <TD STYLE="width: 74%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Specimen Signature:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Title:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Telephone Number</B></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">(required):</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 4.95pt 0pt 0"><I>If more than one, list all applicable telephone numbers.</I></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>E-mail</B> (required):</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 4.95pt 0pt 0"><I>If more than one, list all applicable&#9;email addresses.</I></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 156; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><IMG SRC="wilmington.jpg" ALT="">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; border: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B> (print):</FONT></TD>
    <TD STYLE="width: 74%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Specimen Signature:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Title:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Telephone Number</B></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">(required):</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 4.95pt 0pt 0"><I>If more than one, list all applicable telephone numbers.</I></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>E-mail</B> (required):</P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 4.95pt 0pt 0"><I>If more than one, list all applicable&#9;email addresses.</I></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>COMPLETE BELOW TO UPDATE EXHIBIT B-2</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.65pt 0pt 0">If the Company Equityholder Representative wishes to
update this Exhibit B-2, the Company Equityholder Representative must complete, sign and send to Escrow Agent an updated copy of
this Exhibit B-2 with such changes. Any updated Exhibit B-2 shall be effective once signed by the Company Equityholder Representative
and Escrow Agent and shall entirely supersede and replace any prior Exhibit B-2 to this Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">FORTIS ADVISORS LLC</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 3%">By:&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Date:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">WILMINGTON TRUST, NATIONAL ASSOCIATION (as Escrow Agent)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 3%">By:&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Date:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 157; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><IMG SRC="wilmington.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 2.5pt 0pt 0"><U>Exhibit C</U></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 2.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 2.5pt 0pt 0"><B>Fees of Escrow Agent</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Acceptance Fee:</U></B></FONT></TD>
    <TD STYLE="width: 45%; text-align: right"><FONT STYLE="font-size: 10pt"><B>$</B>[****]</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 27.3pt 0pt 0">Initial Fees as they relate to Wilmington Trust acting
in the capacity of Escrow Agent &ndash; includes review of the Escrow Agreement; acceptance of the Escrow appointment; setting
up of Escrow Account(s) and accounting records; and coordination of receipt of funds for deposit to the Escrow Account(s).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Acceptance Fee payable at time of Escrow Agreement execution</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 68%; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Escrow Agent Annual Administration Fee:</U></B></FONT></TD>
    <TD STYLE="width: 32%; text-align: right"><FONT STYLE="font-size: 10pt"><B>$</B>[****]</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 14.6pt 0pt 0">For ordinary administrative services by Escrow Agent &ndash; includes daily
routine account management; investment transactions; cash transaction processing (including wire and check processing); monitoring
claim notices pursuant to the agreement; disbursement of funds in accordance with the agreement; and mailing of trust account statements
to all applicable parties. These fees cover a full year, or any part thereof, and thus are not pro-rated in the year of termination.
The annual fee is billed in advance and payable prior to that years&rsquo; service.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 14.6pt 0pt 0"><B><I>Wilmington Trust&rsquo;s bid is based on the following assumptions:</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.95pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 14.6pt">Number of Escrow Accounts to be established: [****]</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.95pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 14.6pt">Estimated Term: [****]</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.95pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 14.6pt">Amount of Escrow: $[****]</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.95pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 14.6pt">Estimated number of cash transactions: [****]</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 14.6pt">Investment in M&amp;T Deposit Products</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 61%; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Out-of-Pocket Expenses:</U></B></FONT></TD>
    <TD STYLE="width: 39%; text-align: right"><FONT STYLE="font-size: 10pt"><B>[&bull;]</B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 158; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit G-1</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Form of Investor Questionnaire</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<!-- Field: Page; Sequence: 159; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>INVESTOR QUESTIONNAIRE</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.9pt 0pt 0">This Questionnaire is being distributed to certain individuals
and entities which may be offered the opportunity to acquire shares of Class A Common Stock (the &ldquo;<B><I>Securities</I></B>&rdquo;)
of Sucampo Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;). The purpose of this Questionnaire
is to assure the Company that all such offers and purchases will meet the standards imposed by the Securities Act of 1933, as amended
(the &ldquo;<B><I>Securities Act</I></B>&rdquo;), and applicable state securities laws.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">The undersigned agrees that this information may be
provided by the Company to its legal and financial advisors (including Cooley LLP), and the Company may rely on the information
set forth in this Questionnaire for purposes of complying with all applicable securities laws and may present this Questionnaire
to such advisors as the Company reasonably deems appropriate if called upon to establish its compliance with such securities laws.
<B>The undersigned represents that the information contained herein is complete and accurate and will notify the Company of any
material change in any of such information prior to the undersigned&rsquo;s acquisition of the Securities.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Certain Definitions:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.9pt 0pt 31.5pt">For purposes of this Questionnaire, &ldquo;<B><I>income</I></B>&rdquo;
means adjusted gross income, as reported for federal income tax purposes, increased by the following amounts: (a) the amount of
any tax exempt interest income received, (b) the amount of losses claimed as a limited partner in a limited partnership, (c) any
deduction claimed for depletion, (d) amounts contributed to an IRA or Keogh retirement plan, (e) alimony paid, and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0.15in 0pt 31.5pt">(f) any amounts by which income from long-term capital
gains has been reduced in arriving at adjusted gross income pursuant to the provisions of Section 1202 of the Internal Revenue
Code of 1986, as amended (the &ldquo;<B><I>Code</I></B>&rdquo;).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 31.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.7pt 0pt 31.5pt">For purposes of this Questionnaire, &ldquo;<B><I>net
worth</I></B>&rdquo; means the excess of total assets, excluding your primary residence, at fair market value over total liabilities,
including your mortgage or any other liability secured by your primary residence only if and to the extent that it exceeds the
value of your primary residence. Net worth should include the value of any other shares of stock or options held by you and your
spouse and any personal property owned by you or your spouse (e.g. furniture, jewelry, other valuables, etc.).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD NOWRAP STYLE="width: 100%; border: Black 1pt solid; text-align: center; background-color: Silver"><B>FOR INDIVIDUAL INVESTORS</B></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Accredited Investor Certification.</B> The undersigned makes one of the following
representations regarding its income or net worth and certain related matters <B><I>and has checked the applicable representation</I>:</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">[ ] The undersigned&rsquo;s income during each of the
last two years exceeded $200,000 or, if the undersigned is married, the joint income of the undersigned and the undersigned&rsquo;s
spouse during each of the last two years exceed $300,000, and the undersigned reasonably expects the undersigned&rsquo;s income,
from all sources during this year, will exceed $200,000 or, if the undersigned is married, the joint income of undersigned and
the undersigned&rsquo;s spouse from all sources during this year will exceed $300,000.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">[ ] The undersigned&rsquo;s net
worth, including the net worth of the undersigned&rsquo;s spouse, is in excess of $1,000,000 (excluding the value of the undersigned&rsquo;s
primary residence).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">[ ] The undersigned
cannot make any of the representations set forth above.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 160; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD NOWRAP STYLE="width: 100%; border: Black 1pt solid; text-align: center; background-color: Silver"><B></B>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>FOR ENTITY INVESTORS</B></P>



<B></B></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Accredited Investor Certification. </B>The undersigned makes one of the following
representations regarding its net worth and certain related matters <B><I>and has checked the applicable representation</I>:</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">[ ] The undersigned is a trust with
total assets in excess of $5,000,000 whose purchase is directed by a person with such knowledge and experience in financial and
business matters that such person is capable of evaluating the merits and risks of the prospective investment.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">[ ] The undersigned is a bank, insurance company, investment
company registered under the United States Investment Company Act of 1940, as amended (the &ldquo;Companies Act&rdquo;), a broker
or dealer registered pursuant to Section 15 of the United States Securities Exchange Act of 1934, as amended, a business development
company, a Small Business Investment Company licensed by the United States Small Business Administration, a plan with total assets
in excess of $5,000,000 established and maintained by a state for the benefit of its employees, or a private business development
company as defined in Section 202(a)(22) of the United States Investment Advisers Act of 1940, as amended.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">[ ] The undersigned is an employee
benefit plan and <I>either </I>all investment decisions are made by a bank, savings and loan association, insurance company, or
registered investment advisor, <I>or</I> the undersigned has total assets in excess of $5,000,000 <I>or</I>, if such plan is a
self-directed plan, investment decisions are made solely by persons who are accredited investors.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">[ ] The undersigned is a corporation, partnership, business
trust, not formed for the purpose of acquiring the Securities, or an organization described in Section 501(c)(3) of the Internal
Revenue Code, in each case with total assets in excess of $5,000,000.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">[ ] The undersigned is an entity
in which <B>all </B>of the equity owners (in the case of a revocable living trust, its grantor(s)) qualify under any of the above
subparagraphs, or, if an individual, each such individual has a net worth, either individually or upon a joint basis with such
individual&rsquo;s spouse, in excess of $1,000,000 (within the meaning of such terms as used in the definition of &ldquo;<B><I>accredited
investor</I></B>&rdquo; contained in Rule 501 under the Securities Act), <I>or</I> has had an individual income in excess of $200,000
for each of the two most recent years, or a joint income with such individual&rsquo;s spouse in excess of $300,000 in each of those
years, and has a reasonable expectation of reaching the same income level in the current year.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">[ ] The undersigned
cannot make any of the representations set forth above.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0"></P>

<!-- Field: Page; Sequence: 161; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 40pt"><B>IN WITNESS WHEREOF</B>, the undersigned has executed this Investor Questionnaire as
of the date written</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Name of Investor</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Signature)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Name of Signing Party (Please Print)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Title of Signing Party (Please Print)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Date Signed</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0"></P>

<!-- Field: Page; Sequence: 162; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0"><B>Exhibit G-2</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Form of Letter of Transmittal</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 163; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>LETTER OF TRANSMITTAL</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>To accompany certificates of common stock, $0.001 par
value per share, of Vtesse Inc., and </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Series A Preferred Stock, $0.001 par value per share,
of Vtesse Inc.</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 33pt 0pt 0"><I>The undersigned represents that I (we) have full authority
to surrender without restriction the certificate(s) for exchange. You are hereby authorized and instructed to prepare in the name
of and deliver to the address indicated below (unless otherwise instructed in the boxes in the following page) a check representing
a cash payment or a wire transfer to an account identified by the undersigned, and, if the undersigned is an &ldquo;accredited
investor&rdquo; (as set forth in the Investor Questionnaire), a certificate representing shares of Sucampo Pharmaceuticals, Inc.
Class A common stock for shares tendered pursuant to this Letter of Transmittal.</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 54.75pt 0pt 0">Method of delivery of the certificate(s) is at the option
and risk of the owner thereof. <I>See Instruction 1.</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 54.9pt 0pt 0">Mail or deliver this Letter of Transmittal, or a facsimile,
together with the certificate(s) representing your shares, to:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;<IMG SRC="ast.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><U>If delivering by mail:</U></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">American Stock Transfer &amp; Trust Company, LLC Operations
        Center</P>
        <P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Attn: Reorganization Department</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">P.O. Box 2042</P>
        <P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">New York, New York 10272-2042</P></TD>
    <TD STYLE="width: 50%">
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><U>If delivering by hand or courier:</U></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">American Stock Transfer &amp; Trust Company, LLC Operations
        Center</P>
        <P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Attn: Reorganization Department 6201 15th Avenue</P>
        <P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Brooklyn, New York 11219</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 54.9pt 0pt 0">For assistance call (877) 248-6417 or (718) 921-8317</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 30.5pt 0pt 0">Pursuant to the merger of Saber Merger Sub, Inc., a wholly owned subsidiary
of Sucampo Pharmaceuticals, Inc., with and into Vtesse Inc., the undersigned encloses herewith and surrenders the following certificate(s)
representing shares of Company stock:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 2.5pt 0pt 4in"></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 2.5pt 0pt 4in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt"><B>DESCRIPTION OF SHARES SURRENDERED</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt"><B><I>(Please fill in. Attach separate schedule if needed)</I></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; border-right: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"></P></TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 27%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-indent: 10pt">
        Certificate No(s) / Class<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"></P></TD>
    <TD STYLE="width: 24%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid; text-indent: 10pt">Number of Shares<P STYLE="font-size: 10pt; margin: 0pt 0"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Name(s) and Address of Registered Holder(s)</B></P>



</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center">If there is any error in the name or address shown below,
please make the necessary corrections</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-indent: 10pt"><B>TOTAL SHARES OF COMMON &nbsp;</B><FONT STYLE="font-family: Wingdings">F</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 10pt"><FONT STYLE="font-size: 10pt"><B>TOTAL SHARES OF SERIES A <BR>
PREFERRED &nbsp;</B></FONT><FONT STYLE="font-family: Wingdings">F</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 30.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 30.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 30.5pt 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 11.05pt 0pt 0"></P>



<P STYLE="font-size: 10pt; margin: 0pt 30.5pt 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 30.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 30.5pt 0pt 0"></P>

<!-- Field: Page; Sequence: 164; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 30.5pt 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: #F2F2F2">
    <TD COLSPAN="3" STYLE="border: black 1pt solid"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-size: 10pt"><B>Check this box if your certificate(s) has been lost, stolen, misplaced or mutilated. See Instruction 5.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-size: 10pt">SPECIAL PAYMENT INSTRUCTIONS</FONT></TD>
    <TD ROWSPAN="2" STYLE="width: 2%; border-right: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid; border-right: black 1pt solid"><FONT STYLE="font-size: 10pt">SPECIAL DELIVERY INSTRUCTIONS</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 5.2pt 0pt 0">Complete <B>ONLY</B> if the check is to be issued in a name which differs from
        the name on the surrendered certificate(s). Issue to:</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 11.5pt 0pt 0">Name: _______________________________________________________________</P>
        <P STYLE="font-size: 10pt; margin: 0pt 11.5pt 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 11.5pt 0pt 0">Address: _____________________________________________________________</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">____________________________________________________________________</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">____________________________________________________________________</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">____________________________________________________________________</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Please also complete Form W-9 AND</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 9.55pt 0pt 0">see instructions regarding signature guarantee. <I>See
        Instructions 3, 4, 6 and 7</I>)</P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 8.8pt 0pt 0">Complete <B>ONLY </B>if check is to be mailed to some address other than the
        address reflected above. <I>See Instructions 4</I>. Mail to:</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">Name: ____________________________________________________</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">Address: __________________________________________________</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">_________________________________________________________</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">_________________________________________________________</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">_________________________________________________________</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 8.95pt 0pt 0">Please check here if address change is permanent.</P>
        <P STYLE="font-size: 10pt; margin: 0pt 8.95pt 0pt 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>YOU MUST SIGN IN THE BOX BELOW AND FILL OUT AND SIGN THE FORM W-9 ATTACHED HERETO</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 289.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 289.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; border: Black 1pt solid; text-align: center"><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SIGNATURE(S) REQUIRED</B></P>


</TD>
    <TD ROWSPAN="2" STYLE="width: 2%; border-right: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 45%"><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SIGNATURE(S) GUARANTEED (IF REQUIRED)</B></P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 5.2pt 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 5.2pt 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Must be signed by the registered holder(s) EXACTLY as name(s)
appear(s) on stock certificate(s). If signature is by a trustee, executor, administrator, guardian, attorney-in-fact, officer
for a corporation acting in a fiduciary or representative capacity, or other person, please set forth full title. <I>See
Instructions 2, 3 and 7</I>.</P>



<P STYLE="font-size: 10pt; margin: 0pt 5.2pt 0pt 0"></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">_______________________________________________________________</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Registered Holder</P>



<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">_______________________________________________________________</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Registered Holder</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">_______________________________________________________________</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Title, if any</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Date ________________</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Phone No: ________________________</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid">
        <P STYLE="font-size: 10pt; margin: 0pt 8.8pt 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 8.8pt 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Unless the shares are tendered by the registered holder(s) of
the common stock, or for the account of a participant in the Securities Transfer Agent&rsquo;s Medallion Program
(&ldquo;STAMP&rdquo;), Stock Exchange Medallion Program (&ldquo;SEMP&rdquo;) or New York Stock Exchange Medallion Signature
Program (&ldquo;MSP&rdquo;) (an &ldquo;Eligible Institution&rdquo;), the signature(s) must be guaranteed by an Eligible
Institution. <I>See Instruction 3.</I></P>



<P STYLE="font-size: 10pt; margin: 0pt 8.8pt 0pt 0"></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">____________________________________________________</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Authorized Signature</P>



<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">___________________________________________________</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Name of Firm</P>
        <P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">___________________________________________________</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Address of Firm - Please Print</P>



<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0"></P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 289.5pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 289.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 289.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 289.5pt"></P>

<!-- Field: Page; Sequence: 165; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 289.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><U>INSTRUCTIONS FOR SURRENDERING CERTIFICATES</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(<I>Please read carefully the instructions below</I>)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.6pt 0pt 6pt">1.&nbsp; <B><I>Required Documents</I></B>.
Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 31, 2017, by and among Sucampo Pharmaceuticals, Inc.
(&ldquo;Buyer&rdquo;), Vtesse Inc. (&ldquo;Company&rdquo;) and the other persons and entities parties thereto (the &ldquo;Merger
Agreement&rdquo;), in order to receive your merger consideration under the Merger Agreement, you must properly complete, duly execute
(as applicable) and deliver this Letter of Transmittal (and the documents required hereby), together with your Company share certificate(s),
and an Investor Questionnaire and, if you are an &ldquo;accredited investor&rdquo; (as described in the Investor Questionnaire),
the attached Lock-Up Agreement. As set forth in more detail in the Merger Agreement, you will receive, in exchange for your shares
of common stock of the Company or Series A Preferred Stock of the Company, cash and, if you are an &ldquo;accredited investor&rdquo;
(as set forth in such Investor Questionnaire), shares of Class A common stock of Buyer, in each case, at the times and subject
to the terms and conditions set forth in the Merger Agreement. You have been provided with a copy of the Merger Agreement (as an
attachment to the Information Statement the Company provided to you in connection with the Merger). Capitalized terms used herein
and not otherwise defined shall have the meanings given to them in the Merger Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.75pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.75pt 0pt 6pt">2.&nbsp; <B><I>Method of Delivery</I></B>:
Your old certificate(s) and the Letter of Transmittal must be sent or delivered to American Stock Transfer &amp; Trust Company
(the &ldquo;Exchange Agent&rdquo;). <I><U>Do not send your certificates to Vtesse Inc. or Sucampo Pharmaceuticals, Inc.</U></I>
The method of delivery of certificates to be surrendered to the Exchange Agent at the address set forth on the front of this Letter
of Transmittal is at the option and risk of the surrendering stockholder. Delivery will be deemed effective only when received.
If you submit this Letter of Transmittal by facsimile, you must also send or deliver your certificate(s) in order to receive payment.
<B>If the certificate(s) are sent by mail, registered mail with return receipt requested and proper insurance is suggested.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.65pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.65pt 0pt 6pt">3.&nbsp; <B><I>Payment in the Same
Name</I></B>: If the check and stock certificate are issued in the same name as the surrendered certificate is registered, the
Letter of Transmittal should be completed and signed exactly as the surrendered certificate is registered. <I><U>Do not sign the
stock certificate(s</U>)</I>. <U>Signature guarantees are not required </U>if the certificate(s) surrendered herewith are submitted
by the registered owner of such shares who has not completed the section entitled &ldquo;Special Payment Instructions&rdquo; or
are for the account of an Eligible Institution. If any of the shares surrendered hereby are owned by two or more joint owners,
all such owners must sign this Letter of Transmittal exactly as written on the face of the certificate(s). If any shares are registered
in different names on several certificates, it will be necessary to complete, sign and submit as many separate Letters of Transmittal
as there are different registrations. Letters of Transmittal executed by trustees, executors, administrators, guardians, attorneys-
in-fact, officers of corporations, or others acting in a fiduciary capacity who are not identified as such in the registration
must be accompanied by proper evidence of the signer's authority to act.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.7pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.7pt 0pt 6pt">4.&nbsp; <B><I>Payment in Different
Name</I></B><I>:</I> If the section entitled &ldquo;Special Payment Instructions&rdquo; is completed, then signatures on this Letter
of Transmittal must be guaranteed by a firm that is a bank, broker, dealer, credit union, savings association or other entity that
is an Eligible Institution. If the surrendered certificates are registered in the name of a person other than the signer of this
Letter of Transmittal, or if payment is to be made to a person other than the signer of this Letter of Transmittal, or if the payment
is to be made to a person other than the registered owner(s), then the surrendered certificates must be endorsed or accompanied
by duly executed stock powers, in either case signed exactly as the name(s) of the registered owners appear on such certificate(s)
or stock power(s), with the signatures on the certificate(s) or stock power(s) guaranteed by an Eligible Institution as provided
herein.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.75pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.75pt 0pt 6pt">5.&nbsp; <B><I>Special Payment
and Delivery Instructions</I></B>: Indicate the name in which and address to which the check and stock certificate are to be sent
if different from the name and/or address of the person(s) signing this Letter of Transmittal. If Special Payment Instructions
have been completed, a Form W-9 must also be completed for the person named therein, and that person will be considered the record
owner.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.65pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.65pt 0pt 6pt">6.&nbsp; <B><I>Letter of Transmittal
Required; Surrender of Certificate(s; Lost Certificate(s</I></B><I>)</I>: You will not receive your check or wire transfer and
stock certificate unless and until you deliver this Letter of Transmittal, properly completed and duly executed, to the Exchange
Agent, together with the certificate(s) evidencing your Company shares and any required accompanying evidences of authority. <B>If
your certificate(s) has been lost, stolen, misplaced or destroyed, contact the Exchange Agent for instructions at (877) 248-6417
or (718) 921-8317 prior to submitting your certificates for exchange. </B>Any Company stockholder who has lost certificates should
make arrangements (which may include the posting of a bond or other satisfactory indemnification and an affidavit of loss) to replace
lost certificates. Such arrangements should be made with Exchange Agent.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.6pt 0pt 6pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.6pt 0pt 6pt">7.&nbsp; <B><I>Form
W-9</I></B>: Under U.S. federal income tax law, a non-exempt stockholder that is a U.S. person (as defined in the enclosed
instructions to IRS Form W-9) is required to provide the Exchange Agent with such stockholder's correct Taxpayer
Identification Number (&ldquo;TIN&rdquo;) on the enclosed IRS Form W-9, along with certain other information If the
certificate(s) are in more than one name or are not in the name of the actual owner, consult the enclosed instructions to IRS
Form W-9 for additional guidance on which number to report. <I>Failure to provide the information on the form may subject the
surrendering stockholder to 28% backup withholding. </I>If you do not have a TIN, but have applied for one, write
&ldquo;Applied For&rdquo; in the space for the TIN as directed in the instructions to the enclosed IRS Form W-9. If a TIN has
been applied for and the Exchange Agent is not provided with a TIN before payment is made, the Exchange Agent will withhold
28% on all payments to such surrendering stockholders of any consideration due for their former shares. Please review the
instructions to the Form W-9 for additional details on what TIN to give the Exchange Agent. If a stockholder is not a U.S.
person (as defined in the instructions to the enclosed IRS Form W-9), such stockholder is required to provide the Exchange
Agent with an appropriate IRS Form W-8. The appropriate IRS Form W-8 and the instructions thereto may be obtained from the
IRS at http://www.irs.gov.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.65pt 0pt 6pt"></P>

<!-- Field: Page; Sequence: 166; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.65pt 0pt 6pt">8.&nbsp;&nbsp;&nbsp; <B><I>Stock
Transfer Taxes.</I></B> If payment is to be made to any person other than the registered holder, or if surrendered certificates
are registered in the name of any person other than the person(s) signing the Letter of Transmittal, the amount of any stock transfer
taxes (whether imposed on the registered holder or such person) payable as a result of the transfer to such person will be deducted
from the payment for such securities if satisfactory evidence of the payment of such taxes, or exemption therefrom, is not submitted.
Except as provided in this Instruction 8, it will not be necessary for transfer tax stamps to be affixed to the certificates listed
in the Letter of Transmittal.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.65pt 0pt 6pt">All questions as to the validity, form and eligibility
of any surrender of certificates will be determined by the Exchange Agent and Buyer and such determination shall be final and binding.
Exchange Agent and the Company reserve the right to waive any irregularities or defects in the surrender of any certificates. A
surrender will not be deemed to have been made until all irregularities have been cured or waived.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.6pt 0pt 6pt">9.&nbsp;&nbsp; <B><I>Indemnification;
Joinder</I></B>. You hereby acknowledge that you have read and understand the Merger Agreement, including Article II and Article
VIII of the Merger Agreement with respect to the payment arrangements, the Escrow Fund, the Company Equityholder Representative
Expense Amount, the Illustrative Allocation Statement, the determination of the number of shares of Buyer Common Stock to be issued,
conditions and provisions relating to the receipt and transfer of Buyer Common Stock (including the lock-up requirements and the
fact that the shares of Buyer Common Stock are not registered), conditions and provisions relating to the receipt and transfer
of Future Contingent Payments (including provisions related to opting into a potential sale of rights to Future Contingent Payments),
indemnification obligations of you and other matters set forth therein, in each case described therein, and hereby agree to be
bound by all terms of such provisions thereunder. You hereby acknowledge the appointment of the Company Equityholder Representative
as set forth in Section 2.4 of the Merger Agreement and hereby agree to and ratify such appointment in all respects. You agree
that by the execution and delivery of this Letter of Transmittal, you shall be, and hereby agree to be, bound by Article II and
Article VIII of the Merger Agreement, including the relevant terms defined in Article X of the Merger Agreement, solely to the
extent such Articles are applicable to you as a Company Stockholder, as if a signatory to the Merger Agreement, and you shall comply
with, and be subject to, all of the terms, conditions, covenants, agreements and obligations applicable to you as a Company Stockholder
set forth in Article II, Article VIII and Article X of the Merger Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.65pt 0pt 6pt">10. <B><I>Escrow; Expense Amount;
Future Payments</I></B>. You understand, agree to and acknowledge the following: (a) Buyer has or shall deliver to the Escrow Agent,
as a contribution to the Escrow Fund, the Escrow Amount (in an aggregate amount of $ [****]), which shall serve as partial security
for your indemnification obligations pursuant to Article VIII of the Merger Agreement and obligations with respect to the Final
Closing Cash Consideration Adjustment pursuant to Section 2.6(b)(iv) of the Merger Agreement; (b) Buyer has or shall deliver to
the Company Equityholder Representative the Company Equityholder Representative Expense Amount (in an aggregate amount of $2,352,000),
which shall serve as a partial source of payment for expenses incurred by the Company Equityholder Representative pursuant to Section
2.4 of the Merger Agreement; (c) the receipt of any Future Contingent Payments by you, if any, including any Final Closing Cash
Consideration Adjustment, any portion of the Escrow Fund, any Company Equityholder Representative Account Payment, any Earn-Out
Consideration and any Priority Review Voucher Payment, are not guaranteed and are subject to the terms and conditions set forth
in the Merger Agreement and are subject to setoff with respect to the Company Stockholder&rsquo;s obligations under Section 2.6(b)(iv)
and Article VIII of the Merger Agreement; and (d) you shall be entitled to your share of any Future Contingent Payments, if any,
in the proportions described in the Allocation Schedule and only as and when such amount or amounts are payable to the Company
Stockholder in accordance with the provisions of the Merger Agreement and the Escrow Agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 7.25pt; margin: 0pt 5.65pt 0pt 5.95pt">11. <B><I>Representations
and Warranties</I></B>. You represent and warrant to Buyer and the Exchange Agent that: (a) you are the sole record, legal
and beneficial owner of all of the outstanding shares of Company Stock set forth in this Letter of Transmittal, free and
clear of all Liens, other than Permitted Liens pursuant to agreements between you and the Company and pursuant to applicable
securities laws; (b) you have not granted any rights to purchase any interests of any kind in such shares of Company Stock to
any other Person; (c) such Company Stock (or other shares of Company Stock transmitted under a separate Letter of
Transmittal) constitutes all Company Stock owned of record, legally or beneficially by you, and, except for any Company
Options owned by you, you have no other rights to acquire Company Stock; (d) all ownership information set forth in this
Letter of Transmittal is accurate and complete; (e) you have the legal capacity (or, if you are an entity, the full power and
authority) to enter into and perform your obligations under the terms of this Letter of Transmittal; (f) If you are an entity
other than a natural person, (i) you are duly incorporated, validly existing and in good standing under the laws of your
jurisdiction of organization; and (ii) the execution and delivery of this Letter of Transmittal by you and the consummation
by you of the transactions contemplated hereby have been duly authorized by all necessary action, if any, on the part of you
and your directors, officers, stockholders, members or other Persons whose approval is required in order for this Letter of
Transmittal to be valid and enforceable against you, subject to, (A) laws of general application relating to bankruptcy,
insolvency and the relief of debtors, and (B) rules of law governing specific performance, injunctive relief and other
equitable remedies; and (g) you have duly executed and delivered this Letter of Transmittal and this Letter of Transmittal
constitutes a legal, valid and binding obligation of you.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 167; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.55pt 0pt 5pt">12.&nbsp; <B><I>Additional Agreements
and Acknowledgements</I></B>. You acknowledge and understand that a Company Stockholder who does not vote in favor of the Merger
may, under certain circumstances, exercise dissenter&rsquo;s rights under Section 262 of the Delaware General Corporation Law (&ldquo;DGCL&rdquo;)
by following procedures prescribed under such Section. By executing this Letter of Transmittal, you affirmatively agree not to
exercise any statutory rights of appraisal or any dissenters&rsquo; rights that you may have (whether under Section 262 of the
DGCL or otherwise) or could potentially have or acquire in connection with the Merger. You acknowledge that the Company, Buyer
and Transitory Subsidiary will rely, and are entitled to rely, on (a) the truth and accuracy of your representations and warranties
set forth herein and (b) your agreement to perform your obligations as set forth herein. Buyer is an express third party beneficiary
of your representations, warranties, covenants and agreements set forth herein. You confirm that you have had the opportunity to
ask representatives of the Company questions with regard to all the agreements, consents and other provisions in this Letter of
Transmittal. You also confirm that you have had a reasonable time and opportunity to consult with your financial, legal, tax and
other advisors, if desired, before signing this Letter of Transmittal. You hereby agree that all confidential and non-public information
of the Company obtained by you before or after the Effective Time, and including all confidential and non-public information provided
to you by the Company Equityholder Representative, as well as the terms of this Letter of Transmittal, the Merger Agreement and
the transactions contemplated thereby, shall not be disclosed by you to any third party; <I>provided, however</I>, that: (a) you
may disclose such information or terms if required to do so by applicable Law (provided that you, to the extent legally permitted,
promptly notify Buyer and the Company Equityholder Representative in advance of disclosing such information); (b) you may disclose
such information to a Governmental Entity of competent jurisdiction or arbitrator of competent jurisdiction in connection with
any dispute or proceeding relating to this Letter of Transmittal, the Merger Agreement or any of the transactions contemplated
thereby; (c) if you are an investment fund, you may disclose the terms of this Letter of Transmittal and the Merger Agreement,
the return on your investment, and other summary terms of the Merger to your current investors or prospective investors and, as
applicable, to your limited partners to the extent permitted under Section 2.8(f) of the Merger Agreement; (d) following any public
announcement of the acquisition of the Company by Buyer, you may disclose the terms of the Merger Agreement that are disclosed
by Buyer in such public announcement or any subsequent public filing; (e) you may disclose such information or terms to the extent
they become generally available to the public other than by virtue of a breach of this provision by you or your Affiliates; and
(f) you may disclose such information or terms to your professional advisers and, if you are not a natural person, to your Affiliates
and your and their partners, members, managers members, directors, officers, employees and representatives, in each case, who:
(i) need to know such information; and (ii) agree to keep it confidential and are subject to confidentiality obligations no less
restrictive than those contained in this Letter of Transmittal. You shall be responsible for any breach of this paragraph by any
of the foregoing persons as if such person were a party hereto. You hereby agree that, except as may be requested by Buyer, you
will not revoke or rescind any written consent you may have given or may in the future give relating to approval of the Merger
and the Merger Agreement or any resolution contained therein and further agree not to vote in favor or adopt any resolutions rescinding
or revoking any such consent or any resolution contained therein or otherwise precluding or rescinding approval of the Merger or
the adoption of the Merger Agreement. If applicable, and if required by the applicable Laws of a community property state, concurrently
with the execution and delivery of this Letter of Transmittal, you are delivering to Buyer and the Exchange Agent an executed copy
of the Spousal Consent attached hereto.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.1in; margin: 0pt 5.55pt 0pt 5pt">13. <B><I>Release</I></B>. [****].</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 168; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: Red">&nbsp;<IMG SRC="w9_1.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red">&nbsp;</P>

<!-- Field: Page; Sequence: 169; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: Red">&nbsp;<IMG SRC="w9_2.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red">&nbsp;</P>

<!-- Field: Page; Sequence: 170; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: Red"><IMG SRC="w9_3.jpg" ALT="">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red"></P>

<!-- Field: Page; Sequence: 171; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: Red"><IMG SRC="w9_4.jpg" ALT="">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red"></P>

<!-- Field: Page; Sequence: 172; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; color: Red"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0.05pt 0pt 0"><B>SPOUSAL CONSENT</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.65pt 0pt 0">I&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
spouse of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, have read and approve the foregoing Letter of Transmittal (the <B>&ldquo;<I>Letter of
Transmittal</I>&rdquo;</B>), the written consent of the Company Stockholder referred to therein (the <B>&ldquo;<I>Consent</I>&rdquo;</B>)
and the form of release referred to therein (the <B>&ldquo;<I>Release</I>&rdquo;</B>). In consideration of the terms and
conditions as set forth in the Letter of Transmittal and the matters set forth in the Consent, I hereby appoint my spouse as
my attorney-in-fact with respect to the exercise of any rights and the performance of any obligations under the Letter of
Transmittal and the Consent (including, without limitation, the execution and delivery of the Release), and agree to be bound
by the provisions of the Letter of Transmittal, the Consent and the Release insofar as I may have any rights or obligations
in the Letter of Transmittal or in the Consent under the community property laws of the State of California or similar laws
relating to marital or community property in effect in the state of our residence as of the date of the Agreement or the
Consent or the Release.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 328.5pt">Date:<U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2017</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 224.75pt 0pt 0">Signature of Spouse <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U></U></P>

<P STYLE="font-size: 10pt; margin: 0pt 224.75pt 0pt 0">Printed Name of Spouse <U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></U></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 85.85pt 0pt 0"></P>

<!-- Field: Page; Sequence: 173; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit G-3</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Form of Lock-Up Agreement</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 174; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>LOCK-UP AGREEMENT</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.95pt 0pt 0">This Lock-Up Agreement,
dated<U> </U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 (this &ldquo;<U>Agreement</U>&rdquo;), by and between the undersigned holder (the &ldquo;<U>Company
Equityholder</U>&rdquo;) and Sucampo Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<U>Buyer</U>&rdquo;), is being
executed and delivered in accordance with the Agreement and Plan of Merger, dated as of March 31, 2017 (the &ldquo;<U>Merger
Agreement</U>&rdquo;), by and among the Buyer, Saber Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary
of the Buyer (&ldquo;<U>Transitory Subsidiary</U>&rdquo;), Vtesse Inc., a Delaware corporation (the
&ldquo;<U>Company</U>&rdquo;), and Fortis Advisors LLC, as the representative of the Company Equityholders (the
&ldquo;<U>Company Equityholder Representative</U>&rdquo;), pursuant to which the Buyer is acquiring the Company by means of a
merger of Transitory Subsidiary with and into the Company, with the Company continuing as the surviving corporation and a
wholly-owned subsidiary of the Buyer, pursuant to the terms and subject to the conditions provided for in the Merger
Agreement (the &ldquo;<U>Merger</U>&rdquo; and the date the Merger is consummated, the &ldquo;<U>Closing
Date</U>&rdquo;).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.95pt 0pt 0">WHEREAS, the Company Equityholder
is or was a stockholder, and/or a holder of stock options to purchase common stock, in each case of the Company as of immediately
prior to the consummation of the Merger and, as such, will benefit from the transactions contemplated by the Merger Agreement;
and</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 5.95pt 0pt 0">WHEREAS, the execution and delivery
of this Agreement by the Company Equityholder is a condition to the Company Equityholder&rsquo;s receipt of a portion of the merger
consideration provided for in the Merger Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 6pt; margin: 0pt 5.95pt 0pt 0">NOW, THEREFORE, for good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged and intending to be legally bound, the parties hereto
agree as follows:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 6pt"></TD><TD STYLE="width: 35pt">1.</TD><TD><U>Lock-Up</U>.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(a)</TD><TD STYLE="text-align: justify; padding-right: 5.7pt">The Company Equityholder shall not offer, sell, lease, contract to sell,
pledge, assign, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly, the shares of
Class A common stock, par value $0.01 per share, of the Buyer (&ldquo;<U>Buyer Common Stock</U>&rdquo;) issued to the Company Equityholder
pursuant to the Merger Agreement and set forth under the Company Equityholder&rsquo;s signature on the signature page hereto (the
&ldquo;<U>Locked-Up Shares</U>&rdquo;) until the date that is [****] after the Closing Date (the &ldquo;<U>Lock-Up Period</U>&rdquo;).
The foregoing restriction is expressly agreed to preclude the Company Equityholder from engaging in any hedging or other transaction,
including any short sale or any purchase, sale or grant of any right (including any put or call option) with respect to any of
the Locked-Up Shares or with respect to any security that includes, relates to, or derives any significant part of its value from
the Locked-Up Shares.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify; padding-right: 5.7pt">Notwithstanding the provisions of <U>Section</U> <FONT STYLE="font-size: 10pt">1(a),</FONT>
during the Lock-Up Period the Company Equityholder may transfer all or a portion of the Locked-Up Shares (i) as a bona fide gift
or gifts, provided that the donee or donees thereof agree in writing to be bound by the restrictions set forth in this <U>Section</U>
<FONT STYLE="font-size: 10pt">1,</FONT> (ii) to any trust</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.8pt 0pt 0.75in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.8pt 0pt 0.75in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.8pt 0pt 0.75in"></P>

<!-- Field: Page; Sequence: 175; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.8pt 0pt 80pt">for the direct or indirect benefit of the Company
Equityholder and/or the immediate family of the Company Equityholder; <U>provided</U> that the trustee of the trust agrees in writing
to be bound by the restrictions set forth in this <U>Section</U> 1; <U>provided</U>, <U>further</U> that any such transfer shall
not involve a disposition for value,</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.8pt 0pt 80pt">(iii) to the Company Equityholder&rsquo;s affiliates
(including, if applicable, commonly controlled or managed investment funds and the limited partners, members and stockholders of
such investment funds, <U>provided </U>that neither Seller nor the Surviving Corporation shall have any responsibility for obtaining
information or documents from any such Person in connection with the Form S-3); and <U>provided</U>, <U>further</U>, that the Company
Equityholder&rsquo;s affiliates agree in writing to be bound by the restrictions set forth in this <U>Section </U>1, (iv) pursuant
to a tender or exchange offer recommended by the Buyer&rsquo;s board of directors, (v) by will, other testamentary document or
intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the Company Equityholder;
<U>provided </U>that such legal representative, heir, beneficiary or member agrees in writing to be bound by the restrictions set
forth in this <U>Section </U>1, (vi) by operation of law, including pursuant to a qualified domestic relations order or in connection
with a divorce settlement; <U>provided </U>that the transferee agrees in writing to be bound by the restrictions set forth in this
<U>Section </U>1, or (vii) pursuant to a merger, stock sale, consolidation or other transaction recommended by the Buyer&rsquo;s
board of directors. For purposes hereof, &ldquo;<U>immediate family</U>&rdquo; shall mean any relationship by blood, marriage or
adoption, not more remote than first cousin, and &ldquo;<U>affiliate</U>&rdquo; shall mean, as applied to any entity, any other
entity directly or indirectly controlling, controlled by, or under direct or indirect common control with, such entity (for purposes
hereof, &ldquo;<U>control</U>&rdquo; (including, with correlative meanings, the terms &ldquo;<U>controlling</U>,&rdquo; &ldquo;<U>controlled
by</U>&rdquo; and &ldquo;<U>under common control with</U>&rdquo;), as applied to any entity, means the possession, directly or
indirectly, of the power to direct or cause the direction of the management and policies of such entity, whether through the ownership
of voting securities, by contract or otherwise).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(c)</TD><TD STYLE="text-align: justify; padding-right: 5.75pt">Any discretionary waiver or termination, whether made before or after the
date hereof, of the restrictions pursuant to a Lock-Up Agreement by another Company Equityholder shall apply pro rata and on the
same terms to the undersigned based on the number of Lock-Up Shares held by the undersigned relative to the holdings of all of
the Company Equityholders. The Buyer shall provide the undersigned with prompt notice of any discretionary waiver or termination
of the restrictions pursuant to a Lock-Up Agreement by the Buyer of another Company Equityholder; <I>provided </I>that the failure
to provide such notice shall not give rise to any claim or liability against the Buyer.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(d)</TD><TD STYLE="text-align: justify; padding-right: 5.75pt">The Company Equityholder consents to the entry of stop transfer instructions
with the Buyer&rsquo;s transfer agent and registrar against the transfer of the Locked-Up Shares except in compliance with the
restrictions set forth in this <U>Section</U> <FONT STYLE="font-size: 10pt">1</FONT>.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 36pt">(e)</TD><TD STYLE="text-align: justify; padding-right: 5.95pt">Each Company Equityholder acknowledges that the Locked-Up Shares bear the
following legend evidencing the lock-up restrictions set forth in this <U>Section</U> <FONT STYLE="font-size: 10pt">1</FONT> (which
legend shall be removed at the end of the applicable Lock-Up Period):</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.8pt 0pt 58.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.8pt 0pt 58.5pt"></P>

<!-- Field: Page; Sequence: 176; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.8pt 0pt 80pt">&ldquo;THESE SHARES OF COMMON STOCK ARE SUBJECT TO
THE TERMS OF A LOCK-UP AGREEMENT BETWEEN THE HOLDER AND THE ISSUER. THESE SHARES MAY NOT BE SOLD, TRANSFERRED, PLEDGED, GIFTED
OR OTHERWISE DISPOSED OF OTHER THAN IN ACCORDANCE WITH THE TERMS OF SUCH AGREEMENT, AND ANY ATTEMPT TO DO SO SHALL BE VOID.&rdquo;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 36pt">2.</TD><TD STYLE="padding-right: 6pt"><U>Representations and Warranties</U>. The Company Equityholder hereby represents and warrants to
the Buyer as follows:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41pt"></TD><TD STYLE="width: 36pt">(a)</TD><TD STYLE="text-align: justify; padding-right: 5.65pt"><U>Authorization</U>. The Company Equityholder has all requisite power and
authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated
hereby. This Agreement has been duly and validly executed and delivered by the Company Equityholder and is a legal, valid and binding
obligation of the Company Equityholder, enforceable against it in accordance with its terms, subject to bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors&rsquo;
rights and to general equity principles.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify; padding-right: 5.75pt"><U>Accredited Investor</U>. The Company Equityholder is an accredited investor
as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder (the &ldquo;<U>Securities Act</U>&rdquo;). The Company Equityholder confirms that the representations, warranties
and information set forth in the Company Equityholder&rsquo;s Accredited Investor Questionnaire (which the Company Equityholder
is delivering to Buyer concurrently with the execution and delivery of this Agreement) are true are correct.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41pt"></TD><TD STYLE="width: 36pt">(c)</TD><TD STYLE="text-align: justify; padding-right: 5.95pt"><U>No General Solicitation</U>. The Company Equityholder has not, and if
applicable, none of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including,
through a broker or finder (a) engaged in any general solicitation, or (b) published any advertisement, in each case, in connection
with the issuance of the Buyer Common Stock.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41pt"></TD><TD STYLE="width: 36.1pt">(d)</TD><TD STYLE="text-align: justify; padding-right: 6pt"><U>Investment in Buyer Common Stock</U>.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify; padding-right: 5.75pt">The Company Equityholder: (1) is receiving the Buyer Common Stock in the
Merger for investment purposes only for its own account and not with any view toward a distribution thereof, except as otherwise
provided in <U>Section 1</U>; (2) has no contract, undertaking, agreement or arrangement with any other person or entity to transfer
to such person or entity or any other person or entity any shares of the Buyer Common Stock received in the Merger; and (3) has
no present plans or intention to enter into any such contract, undertaking, agreement or arrangement with respect to any of the
foregoing.</TD></TR>                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 5.75pt">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify; padding-right: 5.8pt">The Company Equityholder, in making its investment in the Buyer Common Stock:
(1) has relied solely upon its own investigation and the representations and warranties of Buyer set forth in the Merger Agreement,
(2) has considered and evaluated the risks and merits of investing in the Buyer Common Stock, and has determined that the Buyer
Common Stock is a suitable investment for it; (3) has received and reviewed all information it deems necessary or appropriate with
respect to the Buyer Common Stock; (4) can bear the economic risk of its investment in the Buyer Common Stock and can afford a
complete loss of its entire investment in the Buyer Common Stock; and (5) is knowledgeable and experienced in evaluating investments
and experienced in financial and business matters, and is capable of considering and evaluating the merits and risks of investing
in the Buyer Common Stock.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 177; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77pt"></TD><TD STYLE="width: 36pt">(iii)</TD><TD STYLE="text-align: justify; padding-right: 5.75pt">The Company Equityholder has been advised by the Company to consult with
the Company Equityholder&rsquo;s own legal, financial and tax advisors concerning the receipt of Buyer Common Stock. The Company
Equityholder has reviewed the risks and merits of an investment in the Buyer Common Stock with the Company Equityholder&rsquo;s
tax, legal and investment counsel to the extent the Company Equityholder has deemed advisable or appropriate. The Company Equityholder
acknowledges that none of Buyer, the Company, their affiliates or any person on behalf of any such persons has or is making any
representation or warranty, express or implied, to the Company Equityholder with respect to the tax implications of any aspect
of this Agreement, the issuance of the Buyer Common Stock to the Company Equityholder, the Merger or the Merger Agreement.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77pt"></TD><TD STYLE="width: 36pt">(iv)</TD><TD STYLE="text-align: justify; padding-right: 5.85pt">The Company Equityholder understands that the representations, warranties,
statements, covenants and agreements set forth herein and in the Company Equityholder&rsquo;s Accredited Investor Questionnaire
have been and will be relied upon by Buyer as the basis for claiming exemptions from the registration requirements of federal and
state securities laws for the issuance of Buyer Common Stock.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41pt"></TD><TD STYLE="width: 36pt">(e)</TD><TD STYLE="text-align: justify; padding-right: 5.75pt"><U>Unregistered Securities</U>. The Company Equityholder acknowledges that
the shares of Buyer Common Stock it is receiving in the Merger have not been registered for resale (in accordance with, and subject
to the terms and conditions of, the Merger Agreement) under the Securities Act, and any applicable state or foreign securities
laws and that such shares of the Buyer Common Stock may not be sold, transferred, offered for sale, pledged, hypothecated or otherwise
disposed of unless such transfer, sale, assignment, pledge, hypothecation or other disposition is pursuant to (i) the terms of
an effective registration statement under the Securities Act and registration under any applicable state or foreign securities
laws or (ii) pursuant to an exemption from registration under the Securities Act and any applicable state or foreign securities
laws, and any stop transfer restrictions applicable to such shares of Buyer Common Stock shall be removed at such time that Buyer
is no longer required to maintain the effectiveness of the Registration Statement covering such shares in accordance with Section
6.7 of the Merger Agreement. The Company Equityholder acknowledges that all or a portion of the shares of Buyer Common Stock it
is receiving in the Merger may be shares of treasury stock held by the Buyer.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 178; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->172<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 36pt">3.</TD><TD STYLE="padding-right: 5.95pt"><U>Binding Effect</U>. This Agreement shall be binding upon the parties hereto and each of their
heirs, beneficiaries, legal representatives, successors and assigns, as applicable.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 36pt">4.</TD><TD STYLE="padding-right: 5.75pt"><U>Governing Law</U>. The provisions of this Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware (excluding any conflict of law rule or principle that would refer to the laws
of another jurisdiction).</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 36pt">5.</TD><TD STYLE="padding-right: 5.85pt"><U>Severability</U>. In the event that any provision of this Agreement, or the application thereof,
becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement
will continue in full force and effect and the application of such provision to other persons or circumstances will be interpreted
so as reasonably to effect the intent of the applicable parties.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5pt"></TD><TD STYLE="width: 36pt">6.</TD><TD STYLE="padding-right: 5.85pt"><U>Counterparts</U>. This Agreement may be executed in a number of identical counterparts (including
by PDF or other electronic transmission), all of which shall constitute one agreement.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">* * * * *</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 179; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->173<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">IN WITNESS WHEREOF, the parties hereto have executed and delivered this Agreement as
of the date first written above.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><B>SIGNATURE LINE FOR INDIVIDUAL HOLDERS:</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name: </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><B>SIGNATURE LINE FOR ENTITY HOLDERS:</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; width: 3%">By:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 42%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name: </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title: </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Number of Shares of Buyer Common Stock:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><B>SUCAMPO PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>By: </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name: </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title: </TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 180; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->174<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[<I>Lock-Up Agreement</I>]</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 181; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->175<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0"><B>Schedule 1.1(b)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0"><B>Key Stockholders</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0"><B>[</B><I>Omitted pursuant to Item 601(b)(2) of Regulation
S-K</I>]</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0"></P>

<!-- Field: Page; Sequence: 182; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->176<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 3.5pt 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Schedule 2.8(b)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Current Phase 3 Clinical Trial</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>[</B><I>Omitted pursuant to Item 601(b)(2) of Regulation
S-K</I>]</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 183; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->177<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Schedule 7.1(g)</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Required Consents</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>[</B><I>Omitted pursuant to Item 601(b)(2) of Regulation S-K</I>]</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 184; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->178<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Schedule 11.7 Additional Disclosures</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>[</B><I>Omitted pursuant to Item 601(b)(2) of Regulation S-K</I>]</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 185; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->179<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Company Disclosure Schedule</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>[</B><I>Omitted pursuant to Item 601(b)(2) of Regulation S-K</I>]</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 186; Value: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->180<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Buyer Disclosure Schedule</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>[</B><I>Omitted pursuant to Item 601(b)(2) of Regulation S-K</I>]</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>[Signature Page to Agreement and Plan of Merger]</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Confidential and Proprietary&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT.
THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
